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ABSTRACT
The primary function of the heart is to pump blood at a sufficient rate to ensure perfusion of all the
organs. This vital task is achieved in large part by controlling the rate of cardiac contractions, which are
initiated by cells in the sinoatrial node, the "pacemaker" of the heart. The oscillation rate of these
spontaneously active cells is tightly regulated by the sympathetic and parasympathetic branches of the
autonomic nervous system.
Our understanding of sinoatrial node cell function has been greatly advanced by experimental and
modeling efforts that quantitatively describe the numerous ionic currents responsible for the cell's
spontaneous depolarization and generation of the action potential. Several models have also explored the
effect of sympathetic and parasympathetic activity on specific ion channels and have reproduced the
classic slowing and acceleration phenomena. However, a complete model of this interaction does not
exist: current models lack the ability to simulate simultaneous sympathetic and parasympathetic activation
or to reproduce heart rate dynamics in response to time-varying autonomic inputs.
We addressed this need by constructing a bottom-up model of sinoatrial node cell regulation by the
autonomic nervous system, with a focus on reproducing the full range of heart rates observed under
simultaneous sympathetic and parasympathetic nerve stimulation, as well as the dynamic heart rate
response to steps in sympathetic or parasympathetic stimulation rate.
In constructing our model, we consolidate a large body of experimental data in a consistent mathematical
framework. The model comprises 57 nonlinear coupled ordinary differential equations based on first-
principles and the current mechanistic understanding of the component reactions, fits well all the
experimental data used to build the model, and reproduces high-level features of the system that were not
explicitly fit when building the model. The detailed nature of the model also allows numerous
conclusions to be drawn about the mechanisms of heart rate control. A better understanding of these
mechanisms in health and disease may enable the development of better diagnostics for cardiovascular
disease and more targeted drug design. We also identified a number of limitations in the present model
that can be refined through further experimental and numerical efforts.
Thesis Supervisor: Richard J. Cohen
Title: Whitaker Professor in Biomedical Engineering
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Glossary:
This glossary contains abbreviations used throughout the text. For a list of parameter values, see Table 22.
AC adenylate cyclase
ACh acetylcholine
AChE acetylcholinesterase
ANS autonomic nervous system
AP action potential
bpm beats per minute
BS Blood stream (compartment for neurotransmitter diffusion)
ECM extracellular matrix
EJS extrajunctional space
GAP GTPase activating protein
G, Inhibitory G-protein
GPCR G-protein coupled receptor (j-adrenergic and M2 muscarinic receptors)
Gs Stimulatory G-protein
HH Hodgkin and Huxley
HR heart rate
HRV heart rate variability
IbCa Ca' dependent background current
IbNa Na dependent background current
IcaL L-type Ca2 current
ICa,T T-type Ca2 current
If Hyperpolarization-activated "funny" current
IK,ACh Acetylcholine-activated K+ current
'Kr Rapidly activating delayed rectifier K_ current
1Ks Slowly activating delayed rectifier K+ current
INaK Na*-K* pump current
INCX Na±-Ca2 exchanger current
Iso isoproterenol (P adrenergic agonist)
ill Sustained non-selective current
IUSa Sustained 4-aminopyridine-sensitive current
Ita Transient outward 4-aminopyridine-sensitive current
MDP Maximum diastolic potential (measured from 0, larger value means more negative)
NE norepinephrine
NJ neuroeffector junction
NT neurotransmitter
PDE phosphodiesterase
PKA phosphokinase A
RGS Regulator of G-protein signaling
SAN sinoatrial node
SANC sinoatrial node cell
U Enzyme activity unit: pmol substrate catalyzed/min/active site, at 25'C unless specified
P-AR P-adrenergic receptor
1 INTRODUCTION
This thesis is concerned with the regulation of heart rate (HR) by the autonomic nervous system (ANS).
The importance of HR regulation is easy to grasp: it is one of the major mechanisms by which the
cardiovascular system ensures sufficient blood flow, which in turn is necessary for an organism's
continued survival. On the other hand, the mechanisms involved in this process are very complicated: we
have a fairly good qualitative understanding of the molecular signals, but a comprehensive quantitative
model does not yet exist.
A quantitative description of the mechanisms of autonomic nervous system regulation of HR has
implications for both basic-science and application development. Viewed through the lens of a scientist, a
quantitative model of this complicated system summarizes our collective understanding of the chemical
and biological processes at play. Due to the number of components and the level of detail required to
build a quantitative model, this is not an easy task. For example, G-proteins and phosphokinase A are
both involved in the signal transduction cascade from autonomic nervous system activity to HR (more
detail on this below). However the G-protein scientific literature is vast and separate from the equally
broad and specific body of work describing phosphokinase A. To delve into the depths of each subject
area and extract the necessary information requires mastering the specific terminology adopted by each
field, understanding the pertinent chemical reaction mechanisms, and often re-analyzing historic
experimental data. However, summarizing this knowledge in a unified mathematical model leads not only
to a better understanding of each component system, but also the nature of their interaction. Equally as
important, when a quantitative model built upon the current understanding of the system falls short of
reproducing documented phenomena, the model becomes a useful tool for identifying areas that we do not
understand and which can be refined through further experimentation.
From the standpoint of a biomedical engineer who aspires to use an understanding of biology to design
new diagnostics or therapies, a quantitative model similarly allows him to understand the problem and
focus in on the possible solutions. A model of HR control by the autonomic nervous system is particularly
useful because heart disease is the leading cause of death in the US (191) and worldwide (2), and changes
in autonomic control of HR occur early in the onset of disease (119). Furthermore, cardiac autonomic
changes are not restricted to heart disease and have also been observed in a number of health conditions
and lifestyle choices (hypertension (172, 268), diabetes (226, 239, 243, 268), obesity (150, 268),
schizophrenia (12), gastroesophageal reflux disease (204), physical exercise (45, 302, 335), mental strain
(337), diet (235), and others (303)). A quantitative model of HR regulation by the autonomic nervous
system allows a researcher to identify the biological changes that lead to specific disease manifestations
and develop targeted diagnostics based on statistical properties of the heart rate signal, or on biomarkers
for the process of interest. For example, the algorithms for estimating heart rate variability (HRV),
although mostly based on a simple quantitative description of the autonomic nervous system (the
parasympathetic system changes HR quickly whereas sympathetic changes are slow), have been useful
for diagnosing disease and tracking its progression. Examples include: screening for diabetic neuropathy
(173) and heart failure (366), assessing the degree of sleep apnea (267), predicting orthostatic intolerance
(258), and others (10). A more detailed model would enable improvements in such estimation algorithms.
In addition, a very detailed model of the type presented in this thesis also allows more targeted design of
therapies in the form of specific receptor, enzyme, or ion channel inhibitors/stimulators.
In this thesis, we specify the numerical details of HR regulation by the autonomic nervous system. We
show that the model reproduces low-level (specific chemical reactions that are sub-components of the
complete system) and high-level (HR changes due to ANS stimulation) experimental data.
1.1 Model overview
To help orient the reader with regard to the general anatomy, see Figure 1. Our focus is at the level of the
sinoatrial node cell and sympathetic and parasympathetic nerve varicosities shown on the right. We can
think of this system in three parts: 1) extracellular signals, 2) intracellular signals, and 3) the effect of the
ANS signal cascade on the sinoatrial node cell (see Figure 2, Figure 3, and Figure 4, respectively).
Sinoatrial
Parasympathetic node
nerves (Vagus) ------ Symp. Para.
Sympathetic ------- aricosity varicosity
n ervesc
Receptors
Na+
Ca' Second Ion
messenger channels
---- - Sinoatrial node cell
The brain communicates with the The sympathetic and Sinoatrial node cell function is defined
heart through the sympathetic parasympathetic nerves affect by ionic currents. Ion channel properties
and parasympathetic branches of the cells in the sinoatrial node, are controlled by the ANS through a
the autonomic nervous system where the heart beat is initiated second messenger cascade
Figure 1. High-level hierarchical view of HR control by the ANS. The color scheme green =
sympathetic/stimulatory and red = parasympathetic/inhibitory is maintained wherever possible. Brain/heart
illustration from (116), heart image from (159).
The extracellular side of the system concerns neurotransmitter and receptor dynamics. As shown in
Figure 2, sympathetic nerve varicosities store and release the sympathetic neurotransmitter
which synthesizes the ubiquitous second messenger cAMP. cAMP exists in equilibrium between the
generating process of adenylate cyclase and its destruction by phosphodiesterase. cAMP also activates
phosphokinase A. The second messengers regulated by these processes (inhibitory G-protein py subunit,
cAMP and PKA) modify the properties of ion channels and pumps in the sinoatrial node cell, and thereby
affect the cell's beating rate.
Activated Activated
0-adrenergic receptor Adenylate Cyclase M2-muscarinic receptor
GO
G acAM P Gla*I
IF J
Stimulatory G-protein PDE Inhibitory G-protein
* UPKA *
[WGTPIon channels and pumps 0 GDP
Figure 3. Intracellular components of autonomic nervous system-sinoatrial node cell interaction. *: activated form, -:
inhibited form, Gsa*: activated stimulatory G-protein a subunit, Gia*: activated inhibitory G-protein a subunit, Gp.1:free inhibitory G-protein py subunit, cAMP: cyclic adenosine monophosphate, PDE: phosphodiesterase, PKA:
phosphokinase A.
Finally, a summary of the entire system with a focus on the intrinsic components of the sinoatrial node
cell are shown in Figure 4. This figure illustrates the complexity of the sinoatrial node cell: the membrane
contains a plurality of ion channels, exchangers, and pumps; the intracellular space is divided into three
compartments: the cytosol, submembrane space, and sarcoplasmic reticulum (SR), which communicate
through ionic fluxes due to diffusion, active transport, and gated channels. These features define the basal
activity of the sinoatrial node cell in the absence of autonomic nervous system stimulation. The major
components under autonomic control are also shown in the figure, with the signaling cascade flowing as:
neurotransmitter release -- receptor activation -+ G-protein activation -- modulation of adenylate
cyclase cAMP synthesis rate -+ establishment of a cAMP equilibrium between synthesis by adenylate
cyclase and destruction by phosphodiesterase -+ activation of phosphokinase A. All three second
messengers (G-protein, cAMP, PKA) modulate ion channel and pump properties, and thus control heart
rate. This figure summarizes most of the components in our model; some elements were left out for the
sake of clarity, but are described in full detail in the body of the thesis.
norepinephrine (NE). Norepinephrine interacts with p-adrenergic receptors within the neuroeffector
junction (NJ) and in the extrajunctional space (EJS), and is cleared by three mechanisms: diffusive
transport, reuptake into the nerve varicosity, and absorption into the sinoatrial node cell. An analogous
process occurs on the parasympathetic side: parasympathetic varicosities release the neurotransmitter
acetylcholine (ACh), which binds M2 muscarinic receptors on the cell membrane. Acetylcholine is
cleared by two processes: diffusive transport, and hydrolysis by the membrane-bound enzyme
acetylcholinesterase. Both neurotransmitters are synthesized in their respective nerves.
Blood Stream
'C,!
Norepinephrine Extracellular Matrix * Acetylcholine Extrajunctional space
e ynthesis *Synthesis
NE reuptake ' Pain .
-- -- *L -- - - - - - - AOL -- -- - _. N-- - -
0 Diffusion "N Diffusion > NJ
Cell mmrn
NEla bsorptio -adrenergic Acetylcholinesterase M2-muscarinicNE absorption receptor receptor
Junctional receptors Extrajunctional receptors Junctional receptors
Figure 2: Extracellular components of autonomic nervous system-sinoatrial node cell interaction. NE:
norepinephrine, NJ: neuroeffector junction, Symp.: sympathetic varicosity, Para.: parasympathetic varicosity.
The extracellular signals from the sympathetic and parasympathetic nerves are transduced across the cell
membrane by the p-adrenergic and M2 muscarinic receptors, respectively. The intracellular processes are
shown in Figure 3. We model five major intracellular players:
1) G-proteins
2) Adenylate cyclase (AC)
3) cAMP
4) Phosphodiesterase (PDE)
5) Phosphokinase A (PKA)
p-adrenergic and M2 muscarinic receptors are activated by binding their respective neurotransmitters, and
once activated, they catalyze the subsequent activation of stimulatory or inhibitory G-proteins,
respectively. The activated G-protein a subunits bind and modulate the activity of adenylate cyclase,
Blood stream
Symp. Para.
Varicosity Extracellular Varicosity
Norepinephrine e matrix e 0 * Acetylcholine
IK,ACh
if
IKs
IbCa 'bNa sto sus NaK
Exchanger Ca2+ P Calmodulin 4W Troponin i Calsequestrin
channel ATPase -- Activation -- Inhibition s * Gi* Ga G1
Figure 4. Full illustration of sinoatrial node cell model components, with a summary of autonomic nervous system
interaction. NJ: neuroeffector junction, EJS: extrajunctional space, p-AR: p-adrenergic receptor, M2: M2 muscarinic
receptor, AC: adenylate cyclase, Gs: stimulatory G protein (not activated), Gsa*: activated stimulatory G-protein a
subunit, GI: inhibitory G protein (not activated), G10*: activated inhibitory G-protein a subunit, Gpyi: free inhibitory
G-protein py subunit, PDE: phosphodiesterase, PKA: phosphokinase A, PLB: phospholamban, IcaL: L-type Ca 2
current, INCX: Na*/Ca 2 exchanger current, IcaT: T-type Ca2 current, Ibca: background Ca2 current, IbNa: background
Na+ current, I,,: sustained inward current, Io: 4-aminopyridine sensitive transient outward current, Is: 4-
aminopyridine sensitive sustained current, INaK: Na*/K* exchanger current, IK,: rapidly activating delayed rectifier K+
current, IKs: slowly activating delayed rectifier K* current, If. hyperpolarization-activated "funny" current, IKACh:
acetylcholine-activated K+ current, [Ca 2 ]Sub: Ca2 concentration in the subspace, [Ca 2 ];: Ca2 concentration in the
cytosol, jSR: junctional sarcoplasmic reticulum, nSR: network sarcoplasmic reticulum,jp: Ca> uptake flux,j,.: Ca2
transfer from nSR to jSR, ISRCaRel: Ca> flux out of jSR, jCadif Ca> flux due to diffusion, RyR: ryanodine receptor,
SERCAII: sarcoplasmic reticulum Ca> pump, [Ca2 +]jSR: Ca> concentration in the jSR, [Ca+]nlSR: Ca> concentration
in the nSR.
1.2 Background on sinoatrial node cell models
This thesis is a natural outgrowth of the advancements in numerical modeling of excitable cells. In this
section, we provide a brief historical overview to help place the current work in context. We also
introduce the three recent models that serve as the basis for our work and against which we compare our
model in terms of mathematical definition and performance.
The field of excitable cell modeling took the stage following the groundbreaking work of Hodgkin and
Huxley (HH) in 1952 (151). This first quantitative model of action potential (AP) generation in the squid
giant axon, soon inspired scientists to turn their attention to the spontaneously active cells of the heart.
The first model of heart automaticity developed by Noble in 1960 (253), was very similar to the HH
model: it contained the three original currents (sodium INa, potassium IK, and "leak" IL, see Figure 5) with
a slight modification of the potassium current which allowed for sustained, periodic AP generation. In
retrospect, this model was more of a proof of concept showing that "pacemaking" could be simulated
using the Hodgkin-Huxley formalism; the finer detail of the ionic currents actually responsible for
automaticity and AP shape evolved through subsequent modeling efforts that were based on experimental
measurements of individual currents in mammalian (usually rabbit) sinoatrial node cells (SANCs). For
more detailed reviews on SANC models see Wilders et al. (360) and the more recent (359), as well as the
excellent review of major ionic currents responsible for SANC automaticity by Mangoni and Nargeot
(231).
A Outside ,o B
mV.
+4i + 
_ _ 
__
0 0-5 1 5 2
Inside (se)
Figure 5 A. Original illustration of the squid giant axon model by Hodgkin and Huxley showing the two time-
varying currents INa and 1K, and the passive "leak" current IL (figure from (151)). I: total transmembrane current,
CM: membrane electric capacitance, E: transmembrane potential, RNa, RK and RL: resistance of sodium, potassium
and leak channels, ENa, EK, and EL: electrochemical driving force of sodium, potassium and leak current B.
Simulated transmembrane membrane potential from the Noble model showing sustained, periodic oscillations
(figure from (253)).
We bring attention to three models in particular, which serve as the inspiration and foundation for the
further development described in this thesis:
* "Dokos Model" - developed by Dokos et al. in 1996 (96)
e "Demir Model" - developed by Demir et al. in 1999 (81)
e "Maltsev Model" - developed by Maltsev and Lakatta in 2010 (227)
A schematic comparison of these three models against the "complete" model presented in this thesis is
shown in Figure 6. The specific virtues and limitations of each model are discussed below.
Complete * Dokos Model
Demir Model - Maltsev Model
*0 03on
S4
Figure 6. Comparison of the complete model presented in this thesis versus the Dokos (96), Demir (81), and Maltsev
(227) models. See Figure 4 for a labeled version of the full system. Unique aspects of each model are discussed in
the text.
The Maltsev model is the most complete SANC model to date. It features:
* Mathematical descriptions of almost all ionic currents that have been identified in the SANC
(231).
* Subcellular compartmentalization and Ca 2+ buffering developed by Kurata et al. (198).
* Spontaneous Ca 2 release. The existence and importance for pacemaking of this "Ca2+ clock"
were recently elucidated (199, 200, 229, 338, 340-344).
" A simple implementation of some of the functional changes that occur in response to adrenergic
and cholinergic stimulation. As shown in Figure 6, the Maltsev model does not include explicit
descriptions of neurotransmitter release from the autonomic nerves, receptor activation, or any of
the second messengers. Rather, acetylcholine concentration acts directly on specific ion channels.
The description of sympathetic control is even more abstract, and is only defined for "maximal
adrenergic stimulation." Because of this limited description, we show it with dashed lines in
Figure 6.
We chose this model as the baseline cell model: note that the intracellular compartments, ion channels,
and pumps are identical in the complete and Maltsev models. To this baseline model we add the
components necessary for dynamic heart rate regulation by the autonomic nervous system. In fact, this is
one of the limitations of the Maltsev model pointed out by the authors:
"Our present model does not describe the kinetics of the evolution of the responses to 8-
AR [/-adrenergic receptor] and ChR [Cholinergic receptor] stimulation. Additional
experimental data that define the transient state kinetics of cAMP, PKA and CaMKII
signaling in spontaneously firing SANCs are required for systems modeling of
biochemistry kinetics to simulate the transitions." - Maltsev and Lakatta 2010 (227)
The authors point out the lack of explicit data on second messenger evolution in response to adrenergic
and cholinergic stimulation; we circumvented this issue by developing detailed "bottom-up" models of
the major molecular players based on in-vitro experimental data (see Section 1.5) and tying these into the
Maltsev model to bridge autonomic nervous system activity to changes in sinoatrial node cell function.
The Dokos model is unique in its detailed description of acetylcholine release from the parasympathetic
nerves. However, no sympathetic effects are modeled, and the baseline sinoatrial node cell model is
incomplete (lacks submembrane compartment, spontaneous Ca 2+ release from the sarcoplasmic reticulum,
and Ca2 buffering; see Figure 6). Also, the downstream treatment of acetylcholine-mediated effects is
similar to that in the Maltsev model: acetylcholine directly modifies ion channel properties (see Figure 6).
This framework is incorrect because it is known that NTs bind receptors on the cell surface and initiate a
second messenger cascade, which in turn interacts with the ion channels and influences their activity (see
Figure 4). The consequences of this model choice are 1) the dynamic response to ACh is assumed to be
rate-limited at the point of ACh release and not anywhere downstream, which is a questionable
assumption given the complexity of the downstream processes and 2) this model does not provide a venue
for adrenergic/cholinergic interaction, which occurs (in large part) postsynaptically, through opposing
influences on cAMP generation. Despite these limitations in the description of the mechanisms, the model
successfully reproduces a number of experimentally observed phenomena. Its treatment of vagal release
of acetylcholine was also a major influence in how we described neurotransmitter release in our complete
model (for example, the idea of explicitly modeling the extrajunctional space originated in the Dokos
model).
The Demir model features the most detailed description of intracellular second messengers, and includes
responses to the adrenergic agonist isoproterenol (Iso) (see Figure 6). Its more explicit nature is this
model's main virtue: for example, the second messenger cAMP is explicitly modeled, and it modulates
ion channel properties. This allows the model to reproduce the individual effects of adrenergic (bath
applied) and cholinergic (bath applied and neural) stimulation, as well as some interaction between these
two stimuli when applied simultaneously. Its major shortcomings however, are the arbitrary form of some
of the functions: for example, the description of phosphodiesterase activity is based entirely on a single
data point (the baseline concentration of cAMP), and is reasonable but arbitrary outside the baseline
range. Also, since the model only includes bath application of Iso, it cannot simulate responses to
dynamic adrenergic stimulation.
Taken together, these three models identified the important membrane and intracellular players and
thereby set the stage for developing a truly unified molecular-level model of autonomic nervous system
control of heart rate. In this thesis we take the next step, by describing explicit relationships between
molecules that are known to interact with each other. We provide a thorough model framework based on
the current understanding of the signaling cascade from sympathetic and parasympathetic nerve activity
to the final end effectors (ion channels and Ca 2 clock). To determine model parameters, we use available
data from a variety of sources and rather than disregarding values that seem disparate, we consider the
actual experimental methods used to obtain at the measurements and explain the inconsistencies
mechanistically in an attempt to use the most accurate parameter values.
1.3 Aims
General aim:
* Build a sinoatrial node cell model capable of reproducing dynamic heart rate changes in response
to simultaneous sympathetic and parasympathetic stimulation.
Specific aims:
1) Build a model of sinoatrial node cell regulation by the autonomic nervous system which is
mechanistically motivated and can accurately reproduce both steady-state and dynamic
experimental data. The components of the model are:
a. Neurotransmitter release from sympathetic and parasympathetic nerves and
neurotransmitter clearance mechanisms
b. Binding of neurotransmitter to -adrenergic and M2 muscarinic receptors
c. Intrinsic and receptor-mediated activation of stimulatory and inhibitory G-proteins
d. Activation/inhibition of adenylate cyclase by activated G-proteins
e. cAMP hydrolysis by phosphodiesterase
f. Activation of phosphokinase A by cAMP
g. Changes in ion channel and pump function due to second messengers
2) Use the model to understand the critical steps along the signaling cascade and to explore the
mechanisms underlying high-level phenomena that have been observed experimentally
a. Identify the molecular origin of the disparity between sympathetically- and
parasympathetically-mediated changes in heart rate
b. Identify major ionic currents responsible for sinoatrial node cell beating rate
c. Reproduce impulse response functions describing the effects of sympathetic and
parasympathetic nerve stimulation on heart rate
3) Identify model components that require further refinement or experimental study
1.4 Summary of accomplishments
This thesis is very lengthy and dense, and the major contributions of the work are distributed over a
number of chapters. To help guide the reader, we provide a summary here.
1) We provide a full mathematical specification of all the components shown in Figure 4
a. The 57 state variables (Table 21) are described by a system of coupled nonlinear ordinary
differential equations (section 9.5.2)
b. The majority of model parameters (Table 22) are rigorously derived from experimental
data from numerous sources. Experimental values are organized in tables (Table 1-Table
6, Table 8, Table 9, Table 17, Table 20)
c. The neurotransmitter release model can be used independently to calculate average
neurotransmitter concentration as a function of sympathetic or parasympathetic nerve
stimulation frequency (Figure 26). This allows comparison of data collected under nerve
stimulation versus bath application of known neurotransmitter concentration.
2) The biological origin of the slow rate of sympathetically mediated changes in heart rate occurs at
the level of the p-adrenergic receptors (Figure 24), whereas M2-muscarinic rate is limited
downstream, by second messenger kinetics
3) Our model fits all of the steady-state "training data" used to build it, including heart rate
responses to simultaneous sympathetic and parasympathetic nerve stimulation (Figure 105)
4) Our model reproduces behaviors that were not explicitly fit when building the model ("test data")
a. Sympathetic and parasympathetic impulse response functions (Figure 113)
b. Phase response curves (sensitivity to stimulus time over the course of an action potential)
for parasympathetic stimulation (Figure 111)
5) Our model produces more accurate action potential shapes and eliminates a major limitation of
the Maltsev model wherein heart rates below 100 bpm could not be reliably simulated (Figure 97,
Figure 102)
6) We show that ion channel kinetics can be a subtle but powerful determinant of sinoatrial node cell
beating rate, and that the effect of classic "pacemaker currents" is not as potent as previously
believed (Figure 107)
7) We describe a feasible hypothesis to explain quantitative differences between experimental data
collected on isolated sinoatrial node cells versus whole sinoatrial node tissue (Figure 89, Figure
105k)
1.5 Thesis organization
This thesis describes a very complicated biological system in great detail. Experimental data from
numerous sources are gathered and the merits of specific experimental protocols are discussed to
determine the most suitable values. All assumptions are explicitly stated, and in many cases, the validity
of the assumptions is discussed at length. This thesis is therefore a valuable record of all the experimental
data we considered and the thought process involved in building the model. It will also be a useful guide
for future work on the model, which can re-examine the more questionable assumptions or experimental
values. On the other hand, it is very dense and hard to follow on a first read.
This is a necessary compromise; to present a large amount of information, one must choose between
length andfocus. A work that re-introduces the same important concept multiple times gently reminds the
reader of the topic and allows him to keep going forward. This approach has the drawback of length.
Given the amount of information in this thesis, and the detailed nature of some of the concepts, we
reasoned that the extra length would be prohibitive. We chose instead to use specific language ("jargon")
and describe concepts only on a first presentation for the sake of succinctness. This format demands great
focus from the reader, to note and remember particular definitions on a first read. However, for a reader
who is familiar with the concepts, this format should not be overly taxing and should allow a faster
conveyance of ideas.
We separate the thesis into chapters that describe components of the signal transduction cascade (see
Figure 7). To highlight the important concepts and results of each chapter, a high-level summary is
provided at the beginning of the chapter. The remainder of each chapter reads like a mini-review that
gives the pertinent background information, presents the new material, and discusses the proposed model
in the context of the experimental data or previous published models. The content of each chapter is:
Chapter 2: Neurotransmitter Release from Autonomic Nerves. Describes the geometry of
the SANC and nerve varicosities; release, diffusion, hydrolysis, uptake, and
clearance of NT; and the abundance and kinetics of p-AR and M2 muscarinic
receptors.
Chapter 3: G-Proteins (EC 3.6.5.1) and Adenylate Cyclase (EC 4.6.1.1). Describes the
intrinsic properties of stimulatory and inhibitory G-proteins, their activation by
P-AR and M2 muscarinic receptors, and their influence on AC.
* Chapter 2:
Neurotransmitter release
Chapter 3:
G-proteins and adenylate cyclase
Chapter 4:
Phosphodiesterase
}Chapter 5:
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Figure 7 Thesis chapter organization in terms of the signal transduction cascade.
Chapter 4: Phosphodiesterase (EC 3.1.4). Describes the function of PDE, its modulation
by various regulators, and specifies a detailed and a reduced model pertaining
to cAMP regulation in the SANC.
Chapter 5: Phosphokinase-A (EC 2.7.11.11). Describes the structure and cellular roles of
PKA, and its activation by cAMP in a minimal model.
Chapter 6: Modification of Ion Channels and Calcium-Cycling Machinery by Second
Messengers. Combines the components from Chapters 2-5 with the Maltsev
model; uses experimental data on the effects of ACh, NE, and nerve
stimulation to find best-fit parameters for the direct effects of second
messengers on ion channels and Ca2+ clock (most of the fitting/optimization is
described in this chapter). Compares the ANS-mediated changes in the new
model against the Maltsev, Dokos, and Demir models.
Chapter 7: Model Properties. Describes high-level features of the model and compares
performance against published results from other modeling studies or
experiments.
Chapter 8: Conclusion and Future Work. Summarizes the model and the conclusions that
it enables us to draw about the physiological system. Proposes future work to
address the model's major limitations and potential other uses of the model for
answering interesting questions.
Chapter 9: Appendix. Provides full model specification and more detail on model
construction.
2 NEUROTRANSMITTER RELEASE FROM AUTONOMIC NERVES
2.1 Overview
This chapter describes the processes involved in norepinephrine and acetylcholine storage and release
from sympathetic and parasympathetic nerve varicosities, respectively, their clearance from the
extracellular spaces and their interaction (binding/unbinding) with p-adrenergic and M2 muscarinic
receptors. This part of the system is highlighted in Figure 8.
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Figure 8. High level illustration of neurotransmitter release in the context
Figure 4 (see original figure for key).
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of the entire model originally shown in
Anatomy
e Our model focuses on the local interaction between sympathetic and parasympathetic nerve
varicosities and a single sinoatrial node cell
e The autonomic nervous system anatomy is complicated, with many opportunities for
sympathetic-parasympathetic interaction prior to the termination at the sinoatrial node
* The sinoatrial node is a collection of heterogeneous cells with dissimilar properties; we attempt to
describe the function of the entire mode using the specific properties of a single cell
Model features
* Neurotransmitter storage
o ACh and NE are stored in hundreds of vesicles inside on the order of ten adrenergic and
cholinergic varicosities per sinoatrial node cell
o Vesicle and varicosity dimensions are based on microanatomical measurements
o Amount of NE and ACh in each vesicle are based on experimental measurements
o The blood stream is modeled as a separate compartment with a fixed neurotransmitter
concentration, based on experimental measurements
o Both neurotransmitters are synthesized in the respective nerves, at rates high enough to
preclude vesicle depletion for stimulation frequencies at or below 7 Hz (experimental
observation). Synthesis equations are based on current understanding of pertinent
mechanisms.
" Neurotransmitter release
o For numerical tractability, we model a single adrenergic and a single cholinergic "lumped
varicosity"
o Each sympathetic or parasympathetic stimulus releases neurotransmitter from a small
percentage of the available vesicles into the space immediately below the varicosity,
called the neuroeffector junction
e Neurotransmitter clearance
o Norepinephrine is cleared by three mechanisms: neuronal reuptake, absorption by
sinoatrial node cells, and diffusive transport and eventual clearance by the blood stream
(see Figure 9). The model reproduces experimentally measured clearance ratios.
- Neuronal reuptake occurs through a high affinity norepinephrine transporter,
modeled using standard Michaelis-Menten kinetics, measured norepinephrine
affinity, and necessary abundance (maximal uptake rate) needed to produce
clearance of 86% of released norepinephrine by reuptake (experimental value).
- Cell absorption occurs through a low affinity transporter, modeled using
standard Michaelis-Menten kinetics, measured affinity, and necessary abundance
(maximal absorption rate) to produce clearance of 5% of released norepinephrine
by this route (experimental value).
- Diffusion is modeled using rate constants theoretically/numerically deduced
from microanatomical measurements of adrenergic varicosity-sinoatrial node cell
geometry and experimentally measured norepinephrine diffusivity in the
appropriate media. Overall diffusion into the bloodstream reproduces the
measured clearance of 9% of released norepinephrine by this route.
o Acetylcholine is cleared by two mechanisms: hydrolysis by sinoatrial node cell
membrane-bound acetylcholinesterase and diffusive transport similar to that for
norepinephrine (see Figure 9)
- Hydrolysis is modeled using acetylcholinesterase properties: Michaelis-Menten
kinetics, acetylcholine affinity, hydrolytic turnover rate, and enzyme abundance
are all derived from measured values. Overall hydrolysis rate matches
experimental measurements.
- Diffusion is modeled using the same framework as for norepinephrine, with rate
constants derived from the actual cholinergic varicosity-sinoatrial node cell
geometry and measured diffusivities.
* Interaction with receptors
o Acetylcholine and norepinephrine bind M2 muscarinic and p-adrenergic receptors,
respectively.
o The abundances and spatial distribution of both receptors are based on experimental
measurements
o The kinetics of the binding/unbinding reactions are based on measured affinities and
dissociation rates
NE Clearance ACh Clearance
Neuronal reuptake (86%) Choline
uptake
Diffusion (9%) Diffusion (5%) 00
Cell absorption (5%) Hydrolysis (95%) Choline
Acetylcholinesterase
Figure 9. Modes of norepinephrine (NE) and acetylcholine (ACh) clearance. Left: norepinephrine is cleared by
neuronal reuptake, diffusion to the blood stream, and cell absorption, with the indicated ratios. Right: acetylcholine
is cleared by acetylcholinesterase-mediated hydrolysis and diffusion to the blood stream with the indicated ratios.
Results:
e The rate disparity between sympathetic and parasympathetic effects on heart rate begins at the
level of the p-adrenergic and M2-muscarinic receptors: p-adrenergic receptors respond slowly to
norepinephrine release, requiring -20 seconds to reach 95% of steady-state value. M2-muscarinic
receptors only require < Is to reach 95% of steady-state value (see Figure 24).
* Acetylcholine hydrolysis by acetylcholinesterase has a large effect on the rate at which
acetylcholine is removed following cessation of stimulation. The rate of norepinephrine removal
following cessation of stimulation is not greatly affected by neuronal reuptake. The overall
receptor activation by neurotransmitter binding is greatly increased by blockage of acetylcholine
hydrolysis and norepinephrine reuptake (for respective receptors). See Figure 25.
* The relationship between the rate of sympathetic or parasympathetic nerve stimulation and the
equivalent amount of neurotransmitter released is quantified using a power law (see Figure 26)
* The extracellular matrix can act as a buffer: if an experiment is done on non-isolated cells (with
the extracellular matrix intact), and neurotransmitter concentration is maintained in the cell
bathing solution, the actual "effective" neurotransmitter concentration at the cell membrane will
be about 1.5 orders of magnitude less due to the local clearance mechanisms (neuronal reuptake
for norepinephrine, hydrolysis for acetylcholine), see Figure 27. This has implications for
properly interpreting experimental data based on preparation.
" A direct pathway of parasympathetically-mediated inhibition of p-adrenergic receptor activation
is described (necessary to reproduce heart rate data)
2.2 Introduction
2.2.1 Anatomy: from the brain to the sinoatrial node, via the autonomic nervous system
The sinoatrial node (SAN) of the heart is populated by spontaneously depolarizing cells that initiate
cardiac contraction and therefore act as the pacemaker of the heart. The rate of depolarization is
modulated by the sympathetic and parasympathetic branches of the autonomic nervous system.
Sympathetic and parasympathetic signals travel from the brainstem to the heart through the sympathetic
and vagus nerves, respectively. These nerves do not synapse directly on the cells in the SAN, but rather,
they first interact with intracardiac ganglia (reviews: (197, 219)).
The existence of intracardiac parasympathetic ganglia is generally accepted, and has been visualized with
cholinesterase staining (284), see Figure 10. Intracardiac parasympathetic ganglia spread across a
significant portion of the base of the heart and postganglionic parasympathetic neurons project primarily
to the sinoatrial and atrioventricular nodes, with minimal innervation of the atrial and ventricular
myocardium (review: (219)).
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Figure 10 Chick heart stained for cholinesterase activity, indicating the distribution of intracardiac parasympathetic
ganglia. Figure taken from (284).
It is unclear whether intracardiac sympathetic ganglia exist however, as there are data that both support
(241) and refute (252) their existence. It is known however that sympathetic fibers innervate a more
diffuse area of the myocardium, including not only the sinoatrial node, but also the working myocardium
of the atria and ventricles (review: (324)). In birds, it has been shown that sympathetic fibers contribute to
the intracardiac parasympathetic ganglia (324), so even if there are no adrenergic ganglion cells in the
heart, the sympathetic nerves may still be a part of the intracardiac ganglion network.
The role of the intracardiac ganglia is also an evolving concept. Previously, the ganglia were thought of as
distribution points for parasympathetic nerves (127, 197), but more recently, the idea of a highly
interconnected and sophisticated intracardiac ganglion network, or "heart brain" has gained prominence
(9, 197, 277, 278). Thus, the intracardiac ganglia may, and likely do, provide a venue for sympathetic-
parasympathetic interactions. Furthermore, some sympathetic fibers from the stellate ganglion join the
vagus nerve and travel to the heart in close physical contact (171, 324). The proximity of these axons
opens doors for mutual excitation of these two, usually opposing, branches.
Finally, the end effector cells (SANCs) are not homogeneous. It is known that cells in the SA node differ
with respect to ionic current densities and innervation (32, 94, 368). It has also been observed that the
leading pacemaker site shifts with autonomic stimulation (153, 261, 328, 352). Because the cell that
depolarizes the fastest initiates cardiac contraction, we include the effects of heterogeneity by modeling a
cell with the weakest parasympathetic innervation, and the strongest sympathetic innervation. This is
manifested through tight adrenergic neuroeffector junctions (NJs) and wide cholinergic NJs (more detail
on this in section 2.3.1).
There are many opportunities for interaction between the two branches of the ANS, and presynaptic
mechanisms of accentuated antagonism and reciprocal excitation have been proposed (review: (210)).
Also, following the idea of cotransmission, wherein a neuron releases more than a single type of NT, it is
possible that sympathetic and parasympathetic fibers can independently produce a variety of effects (for a
review, see Burnstock 2009 (47)). We appreciate that such interactions may exist, but focus our efforts by
assuming that the major molecular players are ACh and NE, and that they are released independently of
each other. Under these assumptions, we construct a model where downstream interactions (through
cAMP production) are responsible for reproducing the majority of observed behaviors. This approach
worked well for moderate vagal stimulation; however, to reproduce HR effects at high rates of vagal
stimulation, we found it necessary to include a mechanism of direct inhibition of sympathetic activity as
suggested by Levy (210) and Loffelholz and Pappano (219), described in section 2.5.10.
Our model focuses on the sympathetic and parasympathetic neuroeffector junctions, where we assume
that stimulation of the nerve causes a release of neurotransmitter into the neuroeffector junction, which in
turn exerts changes on sinoatrial node cell activity.
2.2.2 Previous models of neurotransmitter release
Several models of neurotransmitter release, diffusion and hydrolysis have been published. They range
from the highly theoretical development by Purves (276), to more empirical/experimental approaches
used by Warner and Cox (349), Celler (56), Dexter et al. (86), and Dokos et al. (96). Here we provide a
succinct, high-level overview; for a detailed evaluation of each model, see Appendix section 9.3.
The Purves equation has been used in a number of models including those by Pott and Pusch (275),
Osterrieder et al.(265), and Demir et al. (81). The appeal of the Purves formulation is that it has a closed
form:
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Where C is the concentration of the molecule at time t and radial distance x away from the source, M is
the number of moles of ACh released at time 0, D is the diffusion coefficient, and kh is the rate of
hydrolysis. The equation was obtained by solving diffusion equations under various assumptions in order
to calculate the time course of neurotransmitter concentration following its release from a pipette some
distance away from the cell of interest (276). This approach is mathematically rigorous and suitable for
explaining in-vitro data, but is not well suited for the in-vivo system (see 2.5.2 for Discussion).
In our model, we use the compartmental approach similar to (56, 86, 96, 349). The advantages of this
framework are 1) we can use actual measurements/anatomy to define the geometry of each compartment,
2) the reactions within each compartment are relatively simple 3) the rate constants for each reaction have
been measured and are fairly well characterized, and 4) similar frameworks can be used for ACh and NE
although they are cleared from the system in different ways. The main disadvantage is that the solution is
not closed-form, but rather involves the numerical integration of a system of differential equations. This is
not a major drawback however, since the SANC model is already implemented in this fashion.
2.3 Model Development
2.3.1 Geometry
The physical configuration of a SANC and the pertinent compartments for neurotransmitter diffusion are
schematized in Figure 11. The dimensions of model components are based on the detailed study of guinea
pig SAN anatomy by Choate et al. (65), modified to reflect rabbit data whenever available. The guinea
pig SAN is about 6-8 cells thick and is bordered on either side by a 15-20 pm thick layer of connective
tissue and epithelial cells (65). Light micrographs of rabbit and guinea pig SAN show that the former is
about twice as thick (262). This difference is likely due to a larger cell diameter of rabbit SANCs rather
than a greater number of cells: in their model of the rabbit SANC, Kurata et al. (198) used a cylindrical
cell with a diameter of 8 ptm and a length of 70 pm, whereas Choate et al. observed cells with 4-5 Pm
diameters and lengths up to 27 ptm in the guinea pig (65). Given this apparent species difference, and that
the present model is an extension of the Maltsev model (227), which in turn was built upon the Kurata
model, we use the larger cell. The cell volume and surface area are calculated assuming that the cells are
attached end-to-end, 8 cells thick, with 20 pim of extracellular matrix (ECM) on either side. The ECM is a
compartment for diffusion of neurotransmitter released from a single cell, so the pertinent ECM volume is
divided by the number of cells that influence that compartment (4 cells). A complete list of parameter
values can be found in Table 22.
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Figure 11 Neurotransmitter diffusion compartments: BS: blood stream, ECM: extracellular matrix, Adr. V:
adrenergic varicosity, Chol. V: cholinergic varicosity, EJS: extrajunctional space, NJ-NE: adrenergic neuroeffector
junction, NJ-ACh: cholinergic neuroeffector junction, SANC: sinoatrial node cell. Upon release from the adrenergic
and cholinergic varicosities, ncurotransmitter fills the neuroeffector junctions, diffuses into the EJS and ECM, and is
cleared from the system once it reaches the blood stream.
Adrenergic and cholinergic varicosity dimensions and their location relative to SANCs were thoroughly
characterized by Choate et al. (65) as summarized in Figure 12. We model varicosities as oblate spheroids
(a reasonable representation, see Fig 2 in (65)) with major and minor axis dimensions shown in Figure 12
that reproduce the measured varicosity volume and surface area.
Choate et al. estimate that 0.2% of SANC membrane area is involved in close apposition with adrenergic
and cholinergic varicosities. Using the measured average areas of close apposition per varicosity and the
fraction of adrenergic and cholinergic varicosities that make close appositions (0.75 cholinergic, 0.25
adrenergic), we calculate that there are about 13.5 cholinergic and 4.5 adrenergic varicosities per SANC
(non-integer numbers are acceptable, as some varicosities were noted to make contacts with 2 or even 3
cells (65)).
Cholinergic and adrenergic varicosities contain hundreds of spherical, membrane-bound vesicles filled
with neurotransmitter (65). Upon depolarization of the varicosity by an excitatory spike traveling down
the nerve fiber, Ca 2 influx at the varicosity causes one or more vesicles to fuse with the cell membrane
and release their contents into the neuroeffector junction. Typically, each excitatory spike arriving at the
varicosity causes the release of a fixed amount of neurotransmitter, a "quantum". For a review of
autonomic signal transmission, see Burnstock 2009 (47).
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Figure 12 Summary of adrenergic and cholinergic varicosities in guinea pig sinoatrial node, from (65). The major
and minor axis diameters of the varicosities illustrated at the bottom were chosen in order to fit the measured surface
area and varicosity volumes in a least squares sense: for an oblate spheroid with major axis radius a and minor axis
radius b, the volume is Vos=4/37ta2b and the surface area is A os-2R(a 2+b2/sin(ae)log(1+sin(ae)/cos(ae)),
ae=arcos(b/a). The values of a and b were chosen to minimize the root sum squared error between calculated and
measured volume and surface area using fminsearch in Matlab.
Following the information in Figure 12, and the observation that large vesicles are rarely found in the area
of the varicosity closest to the neuroeffector junction and therefore do not participate in fusion with the
varicosity membrane (65), we model the typical cholinergic and adrenergic varicosities as containing a
maximum of 450 and 150 vesicles, respectively.
The neurotransmitter contents of a single vesicle define the size of a quantum. For cholinergic vesicles,
the number of ACh molecules per vesicle has been measured in various tissues and varies with tissue
type. Whittaker estimates an ACh concentration of at least 200 mM (356) in vesicles from mammalian
brain, which equates to 4,020-7,800 molecules per small vesicle (dimensions as in Figure 12) and matches
the 6,000 ACh molecules/vesicle mentioned in a recent review (355). In a model of cholinergic synapses
of the chick ciliary ganglion a value of 5,000 ACh molecules per vesicle was assumed (68); the same
value was also used in a previous model of the mammalian neuromuscular junction (15). On the other
hand, values as low as 1,600 ACh molecules /vesicle in sympathetic ganglia (295) to 58,000-246,000
ACh/vesicle in the specialized electromotor synaptic vesicles in Torpedo marmorata (electric ray) (354,
355). Functionally, the size of a quantum is estimated to be from a few hundred (124) to 50,000 (97, 184,
232) ACh molecules. It has also been noted however, that a quantum interacts with an area of membrane
that presents as many ACh receptors and AChE binding sites as there are ACh molecules (19, 232). In our
model of the cholinergic neuroeffector junction, we estimate ~3500 binding sites (M2 receptors and
AChE combined, details below), so a cholinergic quantum of 5,000 ACh molecules matches not only the
measured size of ACh quanta and vesicle contents, but also satisfies this idea of ligand-receptor
correspondence.
Quantal size has also been measured for adrenergic vesicles. In bovine adrenal medullary cells, the NE
concentration in vesicles is measured to be 360 mM (273), which equates to about 7,200-14,000
molecules per small vesicle. This estimate is in line with measurements in the sympathetic adrenergic
varicosities in rat vas deferens (15,000 NE/vesicle (78)). In sympathetic nerves of the rabbit pulmonary
artery, a quantum is estimated to be about 2,000 molecules of NE (24). This value is smaller than the
contents of a single vesicle, an inconsistency that the authors explain by proposing two hypotheses: either
one vesicle is only released every 7 or 8 pulses (which would be the case if the number of vesicles is
nearly depleted), or there is partial release from a vesicle (the explanation favored by the authors based on
reports by Burnstock (48, 49)). We model an adrenergic quantum as 20,000 molecules of NE. This figure
is in agreement with the measured vesicular contents cited above, as well as with the total NE content of
rabbit SAN tissue: 2.04-3.58 pg/g wet tissue (8, 320), which converts to 25-45x 106 NE molecules per
SANC using cell dimensions in our model (see Appendix section 9.2 for unit conversions). At 20,000
molecules /vesicle, and using the total number of vesicles per varicosity, and total number of adrenergic
varicosities per SANC in our model, we obtain a similar value of 65x 106 NE molecules. This quantal size
also allows us to reproduce the observation that sympathetic nerve stimulation at 10 Hz produces a
maximal adrenergic effect and 10% liganded p-ARs (162).
Neurotransmitter is released into the neuroeffector junction, the compartment between a varicosity and
the cell membrane (see Figure 11). In our model, the volume of this compartment is determined by the
neuroeffector junction height (distance from the varicosity to the SANC membrane). All varicosities that
make close contacts have a neuroeffector junction height of less than 100 nm, with cholinergic
varicosities tending to be closer (average height of 75 nm) than adrenergic (minimum height 90 nm) (65).
To capture the phenomenon of pacemaker shift (153, 261, 328, 352) wherein the leading pacemaker site
changes position based on sympathetic and parasympathetic drive, we choose to model a cell with the
weakest cholinergic innervation and the strongest adrenergic innervation. This idea is motivated by the
fact that the SA node contains a heterogeneous population of cells, and the cell which depolarizes the
fastest is the one that initiates the heart beat (153, 368). Thus, we model the cholinergic neuroeffector
junction height as 100 nm (the largest height that still provided close apposition), and the adrenergic as 90
nm (an estimate of the smallest height). However, as Toda and Shimamoto observed (328), pacemaker
shift was more prominent in response to bath application of NE rather than sympathetic nerve stimulation,
therefore in the physiological system, this phenomenon may not be significant. The neuroeffector junction
height allows us to compute the adrenergic and cholinergic neuroeffector junction volumes by
numerically integrating the space between the oblate spheroid varicosity and the cylindrical SANC,
values shown in Table 22.
Neurotransmitter quickly diffuses to fill the entire area beneath a varicosity, and more slowly expands
into the surrounding space (see section 2.3.2). For this reason, we consider the neuroeffector junction to
have a footprint equal to the entire area beneath a varicosity rather than the measured area of close
contact. Thus, although the contact area accounts for only 0.2% of total cell surface area (65), the
combined neuroeffector junction area is about 1.5% of total cell surface area. Following the nomenclature
of Dokos et al. (96) in their formulation of ACh release, we refer to the space outside the neuroeffector
junction as the extrajunctional space (EJS). The EJS occupies 98.5% of the cell surface area and has a
height of 100 nm based on microscope images of the guinea pig sinoatrial node (65), which we assume is
similar in rabbit.
To simplify the model, we consider an aggregate cholinergic and adrenergic varicosity and neuroeffector
junction. Thus, rather than having 13.5 individual cholinergic varicosities, we model only one, where the
total number of vesicles is 13.5x450=6075, and the neuroeffector junction volume is similarly multiplied
by the number of varicosities to yield the total cholinergic neuroeffector junction volume. When
simulating vesicle release, we require an integer number of vesicles to be released from each varicosity,
thus release is always a multiple of 13.5. Adrenergic varicosities are treated similarly, containing
4.5x 150=675 vesicles and releasing multiples of 4.5 vesicles with each stimulus.
2.3.2 Neurotransmitter release and diffusion
We model neurotransmitter release using the same release rate constant k, = 0.01 used in the Dokos model
(96). This constant implies that 1% of the vesicles release their neurotransmitter contents into the
neuroeffector junction in response to each stimulus. The quantal nature of this process is captured in
implementation by not allowing fractions of a vesicle to be released at a time. The functional implication
is that vesicle depletion causes the sporadic release of full quanta, rather than a smoother "analog"
decrease in released neurotransmitter.
Upon vesicle fusion with the varicosity membrane, neurotransmitter diffuses throughout the neuroeffector
junction, EJS, ECM, and is eventually cleared by the bloodstream. For computational simplicity and
compatibility with the Maltsev SANC model, we model diffusion between compartments using rate
constants to describe the transport between each pair of adjacent compartments (as was done by Dokos et
al. (96)). These rate constants were obtained through molecular Monte-Carlo simulations using measured
diffusivities of ACh and NE and the 3-dimensional geometry of each compartment. The diffusivity of
ACh and NE measured in a variety of media are summarized in Table 1. The diffusion coefficient of ACh
in solution is similar to that in the synaptic cleft, and is on the range 5.38-7.75 x10-6 cm2 /s (93, 99, 201,
290). The diffusion coefficient for NE in solution was measured as 7.0 x 10~6 cm 2/s (118). Since ACh and
NE are of similar molecular weight and both are positively charged (283, 301), we conclude that the
diffusivity of ACh and NE in the neuroeffector junction and EJS is 7 x 10-6 cm2/s.
Table 1 Measured
Source
diffusion coefficients for ACh and NE.
Molecule Medium
[g/mol]
Temperature
(OC)
D measured
(x 10-6 cm 2/s)
D at 37'C
(x 10-6 cm2/s)
Sattarahmady
et al. 2010
(290)
Land 1984
(201)
Dionne 1976
(93)
Krnjevi6 and
Mitchell 1960
(196)
Eccles and
Jaeger 1958
(99)
ACh
[146]
Solution
Lizard NJ
Solution
Rat diaphragm
Agar gel
Synaptic cleft
Rice et al. Rat brain 37 0.77 0.771985 (283)Rabri
Gerhardt and
Adams 1982 NE Solution 25 5.5 7.0
(118) [169]
Bevan and
Torok 1970 Rabbit aorta media 37 0.729 0.729
(25)
Krnjevid and Mitchell noted a Qio of about 1.2 (2% per degree); this value was used to correct measured values to
37'C (196). See section 9.1 for a note on temperature corrections.
4.74
4
6.11
6.38
5.38
7.75
2.0
13.7
1.4
9.8
7.6
The diffusion of ACh through connective tissue is about 7 times less than in gel (196). Similarly, the
diffusion of NE through connective tissue is about 9 times less than in solution (25, 283). This large
difference is postulated to be due to electrostatic interactions between these positively charged molecules
and areas of negative charge in the extracellular matrix (ECM) (25, 283). Thus, we estimate the diffusion
coefficient of ACh and NE through ECM to be 0.8 x 10-6 cm 2/s.
To determine the appropriate rate constants for the diffusive transport between compartments, we used
the numerical approach detailed below. We considered the three intersections: neuroeffector junction to
EJS, EJS to ECM, and ECM to BS (refer to Figure 11 for illustration). We looked to molecular Monte-
Carlo simulations because of the ease with which they can be implemented, and the unlimited flexibility
they provide with regard to specifying the problem geometry. Before launching into the details, we
provide a brief summary: owing to the proximity of the varicosity and the cell, diffusion through the
neuroeffector junction is rapid. Our simulations indicate that all of the released molecules make contact
with the cell membrane within 50 pis of release, a result in line with a more detailed finite element
simulation of ACh diffusion in the neuromuscular junction showing that the time to peak postsynaptic
detection is on the order of tens of ps (313). Since the fastest processes within the SANC occur on the
timescale of milliseconds, we assume that diffusion within the neuroeffector junction is instantaneous for
both ACh and NE. The diffusion rate constant between the neuroeffector junction and EJS compartments
is rapid with a rate on the order of 10,000 /s, whereas the diffusion rate constant from the EJS to the ECM
is slower at 20 /s, and clearance from the ECM slower still at 0.4/s due to the thickness of and lower
diffusivity within the ECM.
- Diffusion out of the neuroeffector junction:
Assuming the concentration of neurotransmitter within the neuroeffector junction is homogeneous, we ran
three sets of simulations to compute the best diffusion rate out of the neuroeffector junction:
1) Idealized 2D system - to verify molecular Monte-Carlo simulation versus analytic 2D solution
2) Idealized 3D system - to verify correspondence of simulation and numerical approximation
3) Actual 3D system - to obtain the best approximate solution given actual model geometry
Each simulation was run with two sets of initial conditions: a) point source in the space immediately
below the varicosity, centered on the varicosity in the xy plane, and b) uniform distribution of particles
across the underside of the varicosity. These two conditions were used to obtain the slowest (a) and
"average" (b) diffusion out of the varicosity since vesicles can in theory be released at any point on the
underside of the varicosity. These geometries and initial conditions are shown in Figure 13.
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Figure 13 Illustration of three diffusion models and two initial conditions. Left column: point source initial
condition, where a quantum (5000) of molecules are located at x=0, y-0, and immediately below the bottom edge of
the varicosity. Right column: uniformly distributed initial condition, where a quantum of particles is uniformly
distributed over the bottom of the varicosity. Model 1: the cell is a plane at 0 elevation (solid line in figures) and
diffusion is restricted to the plane of the neuroeffector junction (shown with horizontal dashed line). The varicosity
is a cylinder whose cross-section is shown. Model 2: geometry identical to model 1, but diffusion in the z direction
is not restricted for z>0. Models 1 and 2 use a single diffusion constant (appropriate for the neuroeffector junction)
for all regions of space. Model 3: cell is a cylinder with center at z=0 and radius 4 gm. The varicosity is an oblate
spheroid with dimensions appropriate for the type of varicosity (see Figure 12). Diffusion is allowed in all
dimensions but diffusing molecules cannot enter the space occupied by the cell or the varicosity. Diffusion constants
for the neuroeffector junction, EJS, and ECM regions were used as appropriate.
Simulations were run for 1 ms, and the concentration of molecules within the neuroeffector junction was
tracked on this interval. Physical contact of molecules with the cell surface in the neuroeffector junction
was also tracked in order to assess how quickly molecules diffused from the varicosity to the cell
membrane (Figure 14). For an illustration of the various systems at 50 gs, see Figure 15.
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Figure 14 Diffusion of molecules from the varicosity to the cell membrane is very rapid. The cumulative fraction of
molecules that make at least one contact with the cell surface in the NJ is plotted as a function of time (3D diffusion,
actual geometry). Top line: point source initial condition, bottom line: uniform initial condition. In the first case, all
of the molecules contact the cell membrane before escaping the neuroeffector junction; in the second case, about
50% of the molecules contact the cell membrane while the remainder escapes into the EJS without contacting the
cell.
The average concentration in the cholinergic neuroeffector junction as a function of time is shown in
Figure 16 (adrenergic neuroeffector junction simulations look similar and are omitted for succinctness).
The first panel contains the results of the 2D system, where the analytic concentration gradient for M
moles of matter with diffusion coefficient D deposited at the origin and allowed to diffuse radially (r is
the radial distance from the origin) within a plane of height h is given by:
M
C(r,t)= -e 4D'
h4xctD
If the neuroeffector junction is modeled as a disk with radius R, we obtain the average concentration by
integrating this profile:
C(t)= 2 M e 24 Dt xrh dr
x R 2 h 0 h4fftD
R2 \hK (2)= 1 -e 4Dt
R 2 h
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Figure 15 Simulations at 50 pts showing that molecules diffuse across the neuroeffector junction space very quickly,
and illustrating the diffusive behavior of the three models. Same figure layout as Figure 13.
The analytic solution shown in Figure 16 is Equation (2) evaluated for M=5000/6x 1023 mol, R=0.69 pm,
h=O.1 prm, and D=7x 1 06 cm 2/s, with units appropriately converted to give final concentration in mM.
Note that the analytic solution is almost perfectly replicated by the 2D Monte-Carlo simulation, validating
the implementation. The implementation is identical in all three simulations; the only aspect that differs is
the particular geometry, as explained above. Each panel contains three curves: simulation results with the
point and uniform initial condition, and an approximate solution.
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Figure 16 Concentration in neuroeffector junction as a function of time for the six Monte-Carlo simulations as well
as an explicit analytic solution in two dimensions and numerical approximations for all three models. Dimensions of
the cholinergic varicosity are used in these figures. Legend in top plot refers to all three plots.
The approximate solution for each scenario was obtained as follows. The concentration within the
neuroeffector junction is assumed to be homogeneous and the spatial gradient is assumed to be
established instantaneously. In two dimensions, the steady state concentration gradient surrounding a disk
of radius R with concentration C falls as 1/r; scaling this relationship in order to obtain a concentration of
C at distance R yields the equation C(r)=CR/r. Given this concentration profile, we can calculate the flux
J through the sides of the disk (flux leaving the neuroeffector junction is positive):
dC DJ=-D- =-Cdr r=R R
Since J has units of mol/time/area, we multiply by the surface area through which the diffusion happens
(for this idealized geometry the neuroeffector junction is a cylinder with open surface area 2rRh) and
divide by the volume of the neuroeffector junction (2tR2h) to obtain the rate of change in mol/time
(negative sign appears again because flux leaving the neuroeffector junction is positive):
dC A D 2zRh 2D
=-_J-=-_-C - = - C
dt V R 7R R2 h R2
Using the values of R=0.69 ptm and D=7x1 0-6 cm 2/s, and correcting units appropriately, we obtain the rate
constant r-2,940/s, implying that the concentration in the neuroeffector junction as a function of time can
be approximated as C(t)=Coe-". This approximation is plotted in the top panel of Figure 16. In three
dimensions (still using idealized geometry), the spatial gradient outside the disk is C(r)=CR2/r 2, which
gives
dC 4D
- = - C
dt R2
and yields the approximate rate constant of r-5,880/s, which is plotted in the middle panel of Figure 16.
Finally, using the actual geometry and numerically integrated values for the surface area through which
the flux flows (the actual area was scaled by a factor of 0.7 to calculate an "effective diffusive area") and
for the volume of the neuroeffector junction, we obtain estimated rate constants of kdNjNE 8 ,8 00/s for the
adrenergic neuroeffector junction and kdNJ,Ach= 7 ,800s/S for the cholinergic varicosities (the cholinergic rate
is plotted in the third panel of Figure 16).
To test model sensitivity to the neuroeffector junction diffusion rate, we ran the neurotransmitter release
simulation with rates that are 50% faster and 50% slower (these simulations use our full neurotransmitter
release model with receptor binding and various clearance mechanisms detailed below). The results are
shown in Figure 17. The M2 muscarinic receptor occupancy was virtually unaffected by the change. The
slower neuroeffector junction diffusion rate seemed to favor more p-adrenergic receptor activation,
however adjusting the reuptake rate to reproduce the desired NE clearance fractions (86% reuptaken, 9%
diffused, 5% absorbed, see section 2.3.6) made the receptor occupancy unaffected by neuroeffector
junction diffusion rate. For the model, we use the baseline diffusive transport rate constants of
kdNJ,N= 8 ,8 0 0 /s for the adrenergic and kdNJAch= 7 ,8 0 0 /s for the cholinergic varicosities.
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Figure 17. Model sensitivity to neuroeffector junction diffusion rate constants. A. p-adrenergic receptor occupancy
is plotted as a function of time for 10 Hz sympathetic stimulation from 1 to 10 seconds. Black and gray lines were
obtained using slow and fast kdNJNE as indicated in legend in B. *: maximum reuptake rate constant (vm.,x9 for slow
and vmn/1.9 for fast kdNJNE) was adjusted to maintain -86% NE reuptake despite change in kdNJ,NE. B. M2
muscarinic receptor occupancy as a function of time for 10 Hz vagal stimulation at two scalings of baseline kdNE,ACh
as indicated in legend. Due to fast M2 muscarinic receptor kinetics, receptor occupancy fluctuates between 10-90%
for each neurotransmitter release; for clarity, we show a smoothed version using a centered 0.2s-wide rectangular
window.
- Diffusion out of EJS and ECM:
The EJS is a 100 nm thick shell surrounding the SANC. We assume that diffusion within this shell
happens very quickly so that the entire EJS can be considered as a single compartment with no local
concentration gradients. This assumption is reasonable given the fast diffusion rate constants between the
neuroeffector junction and extrajunctional space (above), and the assumption that a number of varicosities
are uniformly distributed over the sinoatrial node cell membrane. We do however test this assumption
(that neurotransmitter instantly diffuses throughout the extrajunctional space) to see the effect on the
diffusive rate constant between the extrajunctional space and ECM.
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Figure 18. Innervation of sinoatrial node. A. Cross section showing two autonomic nerves running through the
tissue. ECM: extracellular matrix, SAN: sinoatrial node. B. Figure from (46) showing an autonomic nerve (white)
running along the surface of smooth muscle in rat intestine (darker vertical cells).
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To estimate the rates of concentration change for the EJS and ECM, we constructed a molecular Monte-
Carlo simulation of a cross section of cell, EJS and ECM as shown in Figure 19. We ran simulations with
two initial conditions:
Initial condition 1: Molecules distributed evenly across the whole EJS: using the assumption of rapid
diffusion throughout the EJS and uniform coverage by autonomic varicosities. Such uniform
coverage is expected if autonomic nerves run through the sinoatrial node tissue as shown in
Figure 18A.
Initial condition 2: Molecules distributed evenly through only the top half of the EJS: relaxed
assumption of rapid diffusion throughout the EJS and assuming instead that the autonomic
varicosities primarily run along the epicardial side of the sinoatrial node (as in Figure 18B) and
the released neurotransmitter stays more localized to the site of release.
Only the top half of the EJS can directly communicate with the ECM. The top surface of the ECM is in
contact with the bloodstream, and this boundary was modeled as an absorber under the assumption that
the bloodstream irreversibly washes away the neurotransmitter. As shown in Figure 20, the number of
molecules within the EJS initially decays very rapidly (rate constant >1000/s, virtually instant), followed
by a slower rate constant which is 30/s for initial condition 1 and -20/s for initial condition 2. The rate
constant of decay of the concentration from the ECM is the same regardless of initial condition, and is
0.3-0.4/s, as shown in Figure 20. This rate constant is also supported by an analytic approximation
(similar to what was done for the neuroeffector junction), wherein we assume that the spatial
concentration gradient within the ECM rapidly reaches steady state. Since the neurotransmitter originates
at the SANC and exits into the bloodstream, these two sides of the ECM can be thought of as having a
fixed concentration thereby giving a linear concentration within the ECM at steady state (a linear profile
was indeed seen in the Monte-Carlo simulation). A mean ECM concentration of C implies that the flux
out of the ECM (x is the distance away from the cell, through the ECM) is
dC 2D
dx hECM hECM
where hECM is the height of the ECM. As above, we multiply by the diffusive area and divide by the
volume of the ECM to obtain the rate of change of concentration in the ECM:
dC A 2D A 2D
-J-=-- -C = C
dt V hECM AhECM hECM
which evaluates to a rate constant of 0.4/s using D=0.8x 10-6 cm2/s, hEcA 2 0 gm. This value is close to
that observed in the Monte-Carlo simulations (see Figure 20), so it is the value we adopt for the model.
Initial Condition 2
0 5 -5
Distance (sm)
0
Distance (pm)
25
20
15
10
5
0
, -5
5 -10 0 10
Distance (gm)
Figure 19 Illustration of physical setup for molecular Monte-Carlo simulation of diffusion out of the EJS. Initial
condition 1: Cell: sinoatrial node cell cross section with radius 4 pm. EJS: extrajunctional space, ECM: extracellular
matrix immediately above cell. Initial condition 2: Molecules are initially distributed only in the top half of the EJS.
System at Is: sample molecule distribution at Is for initial condition 1; 2 was similar. The molecules stuck at the top
have been captured by the bloodstream.
Given the large difference between the fast and slow time constants for the EJS, we ran the
neurotransmitter release model with two rate constants: 20/s and 1000/s. As shown in Figure 21, although
the rate constants differ by 2 orders of magnitude, the amount of bound receptor is not affected to that
degree (neurotransmitter concentrations in both compartments followed similar trends, not shown),
implying that the model is fairly insensitive to this parameter. Because adrenergic and cholinergic
varicosities may be located at any depth in the tissue (Figure 18A, and ref (65), although the majority are
on the epicardial side (262)), we adopt the slower time constant kdEJs-20/s.
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Figure 20 Time course of Monte-Carlo simulation in extrajunctional space and extracellular matrix. A. NECM:
number of molecules in the extracellular matrix with time, NEJS: number of molecules in the extrajunctional space
with time. Slower lines are from initial condition 1 and the faster lines are from initial condition 2. B. Black lines:
number of molecules in the extrajunctional space is plotted on a logarithmic y-axis for the first 0.1 seconds of the
simulation in A. Colored lines: linear fits to logarithmic data, slopes as indicated on the figure (ri: initial condition 1,
r2 : initial condition 2). C. Black lines: number of molecules in the extracellular matrix for last 0.5 seconds of
simulation, logarithmic y axis. Colored lines: linear fits to the data, slopes as indicated. Both initial conditions
yielded the same decay rate.
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Figure 21. Slow (20/s) versus fast (1000/s) rate constants for EJS-ECM diffusion produce a small difference in
receptor binding NE or ACh. A. p-adrenergic receptor occupancy as a function of time for 10 Hz sympathetic
stimulation between 1 and 10 s. Black and gray lines are for kdEis values as indicated in the legend in B. B. M2
muscarinic receptor occupancy for 10 Hz vagal stimulation between 1 and 10 s. Due to fast M2 muscarinic receptor
kinetics, receptor occupancy fluctuates between 10-90% for each neurotransmitter release; for visual clarity, we
show a smoothed version using a centered 0.2s-wide rectangular window. The orders of magnitude difference in
diffusion out of the EJS produces <5% difference in p-adrenergic receptor occupancy and ~25% difference in M2
muscarinic receptor occupancy. The slow diffusion rate constant favors lower p-AR and M2 muscarinic occupancy
(by allowing more time for the membrane-localized clearance mechanisms of NE reuptake/absorption and ACh
hydrolysis by AChE).
Our model includes a blood stream (BS) compartment into which the NTs ACh and NE eventually
diffuse. The BS also contains a baseline concentration of these NTs which diffuses into the system and
may affect HR (thus, we have the capability to model changes in HR due to intravenously applied
neurotransmitter; this feature was not used in the present study, where the focus was on in-vivo activity).
ACh in plasma has been measured to range from 0.2 nM (goat) to 15 nM (swine), with 3.1 nM being the
concentration in human (117, 185). For our rabbit model, we assume the intermediate value of [ACh]BS
3 nM, and that this value is constant.
The plasma concentration of NE is subject to more variability, since plasma concentration is determined
by "spillover" from sympathetic nerves and sympathetic stimulation of the adrenal glands (see section
2.3.6). Thus, for high sympathetic tone, the NE content in the blood stream may be significantly higher
than baseline. For example, for humans in the supine position, plasma NE has been measured on the range
1.3-1.6 nM (21, 79, 83, 107, 109). In the standing position (higher sympathetic tone), this concentration
roughly doubles to 2.8-3.1 nM (21, 83), and higher levels of activity such as exercise may significantly
increase the plasma NE concentration. The plasma NE concentration has also been measured in rabbits, at
around 2.6-2.9 nM (133). For our model, we follow the example of Warner and Cox 1962 and assume
that the concentration in blood is constant (349). We assume a value near that measured for rabbits at
baseline, [NEBS = 3 nM.
p-adrenergic M2-muscarinic
2.3.3 M2 muscarinic receptor binding/activation by A Ch
The M2 muscarinic receptor is the major ACh receptor in mammalian hearts (137, 156, 157).
Measurements of M2 muscarinic receptor density in cardiac tissue are summarized in Table 2.
Unfortunately, we were unable to find data for rabbits, and the human vs. canine data imply inter-species
or tissue-specific variability. It is interesting to note that the high receptor density in dogs may explain the
pronounced respiratory sinus arrhythmia (RSA) seen in these mammals (182), since RSA comes about
from an inhibition of parasympathetic outflow during inspiration (183) and the M2 muscarinic receptor
density effectively sets the gain of the system in transducing parasympathetic variation to changes in HR.
During inspiration, HR in dogs increases by about 58% relative to the HR during exhalation (estimated
from data in (182)), whereas in humans this increase is around 12-25% depending on respiration rate
(100). For comparison, rats experience RSA of about 6% (30). We were unable to find any RSA
measurements on rabbits, so we assume moderate RSA on the order of humans and rats, and therefore
conclude that the average M2 muscarinic receptor density in rabbit atrium is about 8 receptors/pim 2. In
terms of variability across tissue type, the M2 muscarinic receptor density of the SA node has been
measured to be -5 times that of the atrium (17), so we set the average M2 muscarinic receptor density in
rabbit SA node to 40 receptors/ptm 2. We convert this average receptor density to neuroeffector junction-
and EJS-specific densities that give a 45 times greater density in the neuroeffector junction. The large
difference is thought to exist because local receptor concentration is proportional to local neurotransmitter
concentration. This hypothesis is supported by data in the neuromuscular junction and autonomic
neuroeffector junction showing that receptor density is highest near the site of neurotransmitter release
(232), that receptor clusters migrate over time to follow the displacement of autonomic varicosities (47),
and that muscarinic M2 receptor density matches the density of innervation (16, 19, 135). As an estimate
of local concentration differences, we compare the volumes of the neuroeffector junction versus the EJS
to obtain the value of 45-fold greater receptor density in the cholinergic neuroeffector junction than the
EJS (in the frog neuromuscular junction, this ratio is 500 (232)). The result of this scaling is that roughly
34% of the M2 receptors are confined to the neuroeffector junction despite the small fraction of SANC
surface area dedicated to the neuroeffector junction. This figure is supported by measurements of
acetylcholinesterase (AChE), which is also present in the cell membrane and aggregates in the
neuroeffector junction such that 45% of total AChE activity occurs there (134, 286). Due to the fast
diffusion within the neuroeffector junction and EJS, the concentration of M2 receptors in these
compartments is computed using the volume of each compartment (rather than confining them to the 2-
dimensional membrane) to arrive at the total receptor concentrations in Table 22.
Table 2 Measured M2 Muscarinic and p-adrenergic receptor density in various mammals.
CalculatedMeasured Density densityteSource Receptor Anatomy (fmol/mg protein) density
(receptors/pgm2)
Dunlap et al. 2003 M2 Canine SAN 250 17.5
(98) M2 Canine RAA 300 21.0
Brodde et al. 1998 M2 Human RA <20 YO 130 9.1
(43) M2 Human RA 20-50 YO 110 7.7
Giessler et al. 1999 M2 Human RA 115 8.1
(119) p-Adr HurnanRA 70 4.9
Bristow et al. 1992 p-Adr Human LV 87.7 6.1
(42) p-Adr Human RV 102.1 7.1
Muntz et al. 1988 3-Adr RatV 25
(248)
Bristow et al. 1986 P-Adr HumanLV 88 6.2
(40)
Fowler et al. 1986 P-Adr Failing Human RV l.91
(115)
Karliner et al. 1985 9-Adr Rat V*, no serum -- 2.48
(174) Rat V , in serum -- 6.96
Bristow et al. 1984 P-Adr HumanLV 62.1 4.3
(39)
McKean 1988 p-Adr Guinea pig RV 154.6 10.8
(234) p-Adr Muskrat RV 99.8 7.0
Zola et al. 1988 p-Adr Rabbit LV 119 8.3(373)
See section 9.2 for details on unit conversion. * rat ventricle cells cultured in serum-free or serum containing
solution. t 1732 fmol receptor/gram wet weight, converted using 1 g/mL, see section 9.2 for source of this value.
Detailed data on M2 receptor kinetics could not be found, so the binding and dissociation rates are
formulated based on the average dwell time of ACh in a receptor and estimates of affinity and Hill
coefficient. Katz and Miledi estimate the average dwell time as -1 ms at 23 'C (184), which yields a
dissociation rate constant of kff M of 2,100 /s (temperature corrected to 37 C). Following the example of
Demir et al. (81), we deduce the Michaelis-Menten coefficient KMM from the dose-response relationship
curve for ACh-activated potassium current (IK,ACh) measured by DiFrancesco et al. (88) and Inomata et al.
(160). IK,ACh can be used as a surrogate for ACh-receptor binding because this current is stimulated
directly by the G-protein py subunit which in turn is activated by the M2 muscarinic receptor (358). The
Hill coefficient nm was set to 0.7 to reflect the existence of high and low affinity receptors. A Hill
coefficient less than unity was also needed in order to replicate the wide dynamic range of ACh
modulation (see Chapter 6). These parameters set the binding rate to:
[ ACh] j""
kn, M= K )ki.
We use the actual binding and dissociation rate coefficients rather than steady-state occupancy functions
because the amount of ACh released into the neuroeffector junction is on the same order as the number of
M2 receptors. This means that binding causes significant neurotransmitter depletion in the physiological
system, so the usual assumption of constant ligand concentration used to arrive at steady-state
occupancies is invalid.
2.3.4 ACh hydrolysis by acetylcholinesterase
Acetylcholinesterase (EC 3.1.1.7) is a membrane-bound enzyme that rapidly breaks down ACh. This
reaction involves three steps, binding, hydrolysis and unbinding (286):
E+ACh " '-E-ACh '2 - E.Ch k, >E+Ch
where E is the enzyme (AChE), and Ch is choline. Under the common enzyme kinetics assumption of
rapid equilibrium, we can encapsulate the intermediate states and model the rate of hydrolysis as
E + ACh r (ACh,E) >E+Ch
where the rate of hydrolysis ru(ACh,E) is a function of ACh concentration and AChE density expressed in
standard Michaelis-Menten form:
rH(A Ch, E)= ka, AChE E [Ach][ACh] + KapPAChE
- A [ACh]
vmax AChE [ACh]+KappAChE
Where kcatAChE is the turnover number (ACh molecules hydrolyzed per second per active site) Kapp,AChE is
the apparent Michaelis-Menten constant, E is the number of AChE active sites, and v,ma is the maximal
hydrolysis rate (ACh molecules hydrolyzed per second).
Kapp,AChE has been measured in human erythrocytes and electric eel (106, 287, 312, 361). For human
erythrocyte, the range is 45-200 pM (106, 169, 312) and 100 ptM for electric eel (287, 361); we use the
intermediate value of Kapp,AChE=lO IM-
kcatAChE has also been measured in human erythrocyte and electric eel. At 25 'C electric eel AChE has a
turnover number of 12,300-16,000/s (287, 361), and human erythrocyte AChE is about half as fast at
6,700/s (125). For our estimate of rabbit AChE, we choose a value close to that reported for human
erythrocytes since both are mammals and the electric organ of the electric eel is highly specialized and
may contain an equally specialized AChE. Furthermore, a kca, of 7000/s at 25 'C was used in a model by
Szegletes et al. (312). After temperature correction to 37 'C, kcat,AChE 13,000/s.
AChE is plentiful in SAN and its activity is often used to identify the pacemaker anatomically (175).
Since AChE density overlaps the density of M2 muscarinic receptors (135), we again make the argument
that AChE density varies with local ACh concentration, in other words, that it is proportional to M2
muscarinic receptor density. Using a proportionality factor of unity gives an AChE density of -1200
AChE sites/pm 2 in the neuroeffector junction, which is close to that measured in the frog neuromuscular
junction (2000-2600 sites/pm 2, (232)). The AChE density in the EJS is smaller, at 27 /pim 2. To check the
absolute value of these figures, we convert the AChE density to catalytic units per mg protein (0.46 U/mg,
for conversions see section 9.2). This value agrees well with the total AChE rate measured in the rat
diaphragm at 37'C (0.48-0.6 U/mg protein, (134)), with 40% of the activity localized to the
neuromuscular junction. In our model, about 35% of the AChE is located within the neuroeffector
junction and since the neuroeffector junction sees a higher ACh concentration than the EJS, these figures
agree closely. Furthermore, the overall AChE hydrolysis rate we observe using our model is close to that
measured in a number of systems (see discussion in section 2.5.2) produces ACh profiles similar to those
generated by the Dokos model (data not shown), and reproduces the shift in ACh-activated potassium
current (IKACh) in response to AChE inhibition ((264), see Figure 89). The value of kcat,AChE and the
AChE densities described above are multiplied and scaled by the area of the neuroeffector junction and
the extrajunctional space to yield the maximal velocities of ACh hydrolysis by AChE in these two
compartments: VmaNJ,A ChE525 amol/s and Vma EJSA Ch E =1014 amol/s.
2.3.5 8-adrenergic receptor binding/activation by NE
Cardiac myocytes contain pi-adrenergic and p2-adrenergic receptors, with Pi being about 3 times as
plentiful as 32 (42, 307). Evidence regarding the role of Pi and/or p2 receptors in the regulation of cAMP
is inconsistent: studies show the involvement of both Pi and p2 (41, 139), only P1 (155, 372), and only p2
(345). A recent study showed that both Pi and p2 adrenergic receptors effect increases in cAMP, but these
changes are physically segregated within the cell: p2-induced cAMP remains near the cell membrane
whereas si creates a more far-reaching signal (251). There is also evidence that P2 receptors may activate
both the stimulatory and inhibitory G-proteins whereas P1I acts only through the stimulatory pathway (71).
Since their functional differences are unclear, we consider only the total p-adrenergic receptor population.
Data on the p-adrenergic receptor density in a number of species are presented in Table 2. From these
numbers we estimate that the p-adrenergic receptor density in rabbit atrium is about 6 receptors/pim 2.
Similar to the M2 muscarinic receptor case, the p-adrenergic receptor density of SA node is about 3 times
that of the right atrium (17), giving an average p-adrenergic receptor density in rabbit SA node of 20
receptors/pm2 . Using the same reasoning as for the M2 muscarinic receptor, we compute the ratio of ~200
for P adrenergic receptors in the neuroeffector junction to that in the EJS. This computation results in
about 39% of the total P adrenergic receptor population being confined to the neuroeffector junction, a
figure similar to that for the cholinergic case.
p-adrenergic receptor kinetics are defined in the same way as for the M2 muscarinic receptors. The half-
binding ligand concentration KMy has been measured in various ways, and a wide range of values have
been reported depending on the cellular origin of the receptor and the specific ligand. Interestingly,
norepinephrine (NE) is not the most commonly used p-adrenergic agonist in these studies (experimental
compounds include DHA (51), ICYP (115), Iso (142, 245, 309), CGP 12177 (80),
iodohydroxybenzylpindolol (224), epinephrine (306)), however some studies reported data from which
NE binding kinetics could be deduced (6, 51, 136, 205-207, 223), and are summarized in Table 3. An
explanation for the widely varying KMf8 values is that P adrenergic receptors exist in a high-affinity and a
low-affinity state, with the difference in affinities being roughly 10-fold (307). The NE- adrenergic
receptor affinity is set to KMp of 1.5 pM with a Hill coefficient np of 0.7, and the overall rate is dictated by
a kffgg of 0.15 /s at 37 'C. The dissociation rate is significantly slower than that of the M2 muscarinic
receptor, however it is on the right order of magnitude when compared to the rate measured for the more
potent (205, 345) p-adrenergic agonist Iso (kffIs= 0.067/s in human polymorphonuclear lymphocytes
(245)).
Table 3 -adrenergic receptor kinetic data for binding NE.
Source Cell Type Temperature KD ([IM) k., (/(mM s)) kff (/s)(0C0
Stiles et al. 1983 (308) Human LV -- 0.95 -- --
Bylund and Snyder 1976 Rat brain 0.8
(51)
Harden 1976 (136) Rat V -- 2.5-25 -- --
Lefkowitz 1975 (205) Canine V -- 3-8 -- --
Alexander et al. 1975 (6) Canine V -- 10 -- --
Lefkowitz and Haber 1971 Canine V 37 0.8 150a 0.12b
(206)
Maguire 1974 (223) Rat glioma 37 -- 77C --
Lefkowitz et al. 1972 Canine V 37 4.3 5 8 -9 6d 0.25-0.4b(207)
a -50% binding is reached by ~15 minutes in 5nM [NE], b -Calculated from KD reported in paper and kon calculated
here, ' -50% binding happens in ~30 minutes in 5nM [NE]; however maximal rate of cAMP production is seen
within <5 seconds of 50 nM or 10 pM NE application., d -Complete binding happens in ~2 hours at 5nM [NE],
assuming that this is 3-5 time constants yields the calculated k,, range.
2.3.6 NE clearance through reuptake and absorption
In addition to diffusive transport and clearance by the bloodstream, NE is removed through reuptake by
the sympathetic nerve varicosities and absorption by end-effector cells (for review, see (102)). NE is
rapidly reuptaken by a NE transporter (NET) in sympathetic nerve terminals (102, 161). This rate is
believed to be fast enough to clear the volume immediately surrounding sympathetic varicosities on the
order of milliseconds, the entire extracellular space of the heart in 10 seconds (161). The NET is a high-
affinity transporter, with a measured KM of 0.27 tM and a maximal uptake rate Vmax of 1.18 nmol/min
per gram of heart tissue in rat heart (161).
[NE]
" "
m
" [NE ]+ Km
NE is also absorbed by tissues, although significantly less NE is removed through this route compared to
neuronal reuptake (161). NE absorption is a low-affinity, but high rate process, with a measured KM of
252 ptM and a maximal rate V.ax of 100 nmol/min per gram of heart tissue in rat heart (163).
We set the affinities to their measured values (KDn=0.27gM for neuronal reuptake, KDa=252pM for
absorption), and chose maximal rates of neuronal reuptake and effector cell absorption to reproduce
measurements of the fraction of NE removed by each mechanism. In humans, spillover of NE from the
heart into the circulation is 11 ng/min, and NE clearance by the heart (presumably through absorption and
subsequent metabolism) is 22 mL/min, which equates to 6 ng/min (109). In rats, the rate of NE reuptake
is 9.7 times the spillover rate, which yields 107 ng/min (104). Using these values, we conclude that of all
the NE released from sympathetic varicosities, 86% is reuptaken by the nerve, 9% spills over into the
circulation, and 5% is absorbed and metabolized by the myocardial cells, figures which are in agreement
with the general scheme presented by Eisenhofer (102) and the observation that less than 10% of the
released NE is spilled over into plasma (103). The maximal rate of neuronal reuptake is vmx,n=1 8.7 amol/s
and only occurs in the neuroeffector junction. Cellular absorption is divided into neuroeffector junction
and EJS rates: vmax,NJ,a=0. 3 7 4 amol/s, vm,EJSa=l 15.566 amol/s. The total absorption rate was set to satisfy
clearance rates, and neuroeffector junction vs. EJS fractions were calculated assuming uniform absorption
across the cell membrane and the ratio of cell surface area dedicated to adrenergic neuroeffector junction
versus EJS. These values reproduce the observed clearance ratios, and are valid on a range of sympathetic
stimulation frequencies (see Figure 22).
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Figure 22 Our model reproduces NE clearance ratios observed experimentally. A. Percent of sympathetically-
released NE absorbed, diffused into the bloodstream, or reuptaken by the varicosity. The range of values is for
sympathetic stimulation frequencies 2-10 Hz. B. Illustration taken from a review by Eisenhofer (102), showing the
flow and relative absorption of NE. In this figure, 90% of NE is reuptaken, 3% is absorbed by cells, and 7% diffuses
into the blood stream; the numbers we used are based on particular measurements so they are slightly different. To
compute the percentages in A, we simulated 60 seconds of sympathetic stimulation at 2, 4, 6, and 10 Hz. This
duration is long enough to allow the system to come to steady state. The total amount of NE absorbed, reuptaken,
and diffused was computed in the space of time between the last two stimuli, and the results are expressed as
percentages of the sum total.
2.3.7 Neurotransmitter synthesis
Both ACh and NE are synthesized in the nerves from which they are secreted ((218) for ACh, (162) for
NE).
The synthesis of ACh is catalyzed by the enzyme choline acetyltransferase, which assists the reaction of
choline and acetyl-CoA (218). Choline (Ch) is taken up from the extracellular space (218), and acetyl is
obtained from the surrounding tissue (334). As pointed out by Loffelholz, the [Ch] in the blood stream
(~5-15 pM in various mammals (140, 218, 291)) is an order of magnitude greater than the half-maximal
concentration for high affinity Ch uptake (which is on the range 0.5-2 gM) and therefore ensures
sufficient ACh synthesis to prevent depletion under physiological conditions (167, 218). However, even
when the Ch source is removed by isolating the heart, the [ACh] store cannot be exhausted by
physiological vagal stimulation. This has been demonstrated in isolated chicken, rabbit, cat, and guinea
pig hearts, which maintained a steady-state ACh release at 29 -58% of the initial value during 20 minutes
of 20 Hz stimulation (87, 218). In this setting, the primary source of Ch is from the hydrolysis of released
ACh as well as from metabolism of choline-containing compounds (phospholipids,
glycerophosphocholine, phosphorylated choline) in the tissue (218). In our model, these aspects are
described as follows: we include two sources of Ch for ACh synthesis - a "constant" source from the
blood stream/tissue, and a vagal stimulation-dependent source from the hydrolysis of ACh. Thus, the
number of vesicles in the varicosity is recharged by both a constant rate process that works to maintain
the maximum number of vesicles (with time constant TACh), as well as at a rate proportional to ACh
hydrolysis (khNJ and UEJsxkhEJs). Each varicosity releases an integer number of vesicles with the arrival of
each stimulus, as indicated by the last term in equation (3). In the last term, Istim is a stimulatory impulse
which is infinitesimal in time, but integrates to 1 around the time of the stimulus t, (Dirac delta function at
ts). In implementation, this is realized by running the numerical ODE integrator (ode15s in Matlab)
between sets of stimulation times, and adjusting the initial condition according to how many varicosities
are released at each stimulus as described in the last term of equation (3). For descriptions of the other
variables in this equation, see Table 22.
from constant store all ACh hydrolyzed in NJ is absorbed a portion of ACh hydrolyzed in EJS is absorbed
dNAch NMuaACh- NvACh khNJ[ACh]NJ VNJACh 6x 5  khEJS ACh]EJS VEJS 6 x 10 5
dt - TACh + QACh +UEJS QACh
Nva Chk var,ACh
1
stim
L var ,A Chs
integer number of vesicles released per varicosity per stimulus
We assume that all of the Ch created in the neuroeffector junction is uptaken due to its proximity to the
varicosity, and we use measurements from the frog neuromuscular junction to determine the value of the
time constant rAch and the uptaken fraction of Ch produced in the EJS UEJS. In the frog neuromuscular
junction, it has been observed that 6 minutes of 10 Hz stimulation caused end plate potentials to drop to
21% of initial value in intact preparations, 10% in preparations with blocked AChE, and 2% in
preparations with blocked high-affinity active transport (194). Our model can reproduce these values if
rACh=100s, and UEJS=0.3 (see Figure 23). Due to differences between the neuromuscular junction and the
cardiac neuroeffector junction, these measurements are not necessarily appropriate for our model. Using
the parameter values from above, 20 Hz vagal stimulation causes steady state release that is -10% of
maximum, which contrasts the 29-58% seen in perfused hearts (87, 218). Furthermore, these parameter
values also cause decreases in ACh released during 1-minute stimulation at 7Hz; but this is not evident in
the data of Brack et al. in perfused rabbit heart (33). To correct these discrepancies we found it necessary
to decrease rAch to 5s, and increase UEJS to 0.5.
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Figure 23 A. TACh and UEJS values were chosen to allow 7 Hz stimulation for 1 minute without a drop in ACh release
(black lines). Here we also show the replication of an experiment where ACh release was monitored for the control
system, for a system with inhibition of AChE (and therefore, no uptake of Ch from hydrolysis), and with blockage
of Ch transport from the bloodstream (TAch=oo). The gray lines show the model reproduction of the results of this
experiment (see text for details). B. TNE was chosen to allow stimulation at 10 Hz without depletion. We show the
NE release as a function of time for TNE= 3Os and rNE= 3 5 s to illustrate that depletion does not occur with the faster
time constant but does occur if the time constant is slowed.
NE is synthesized in sympathetic nerve varicosities (105) in the following reaction (162):
L-tyrosine -+ L-DOPA -+ dopamine -- L-norepinephrine
Following synthesis, NE is stored in release vesicles through a dynamic process that allows NE to leak
out into the cytoplasm (where the majority of NE metabolism occurs) and is replaced back into the
vesicles through active pumping (105).
Since reuptake of NE from the synaptic cleft reclaims the majority of the neurotransmitter, and since most
sympathetic nerve activity happens at slow rates (typically -1-2 Hz, rarely exceeding 10 Hz (162)), it is
unlikely that vesicles become depleted. In a recent review, Eisenhofer points out that even if NE release
increases 10-fold due to exercise, the rate of NE synthesis only needs to increase 3.2 times due to the
"gearing down" afforded by the high rate of reuptake (105). Finally, Warner and Cox successfully used a
constant neurotransmitter supply in their model of HR control in the dog (349). For these reasons, we
model the number of NE vesicles as:
synthesis from blood stream reuptake from NJ integer number of vesicles released per varicosity per stimulus
dNsNE _ NvMax,NE - Nv, NE 5N, 1 NvNE r t
dt QNE NE NarNE N
where rNE is set to a value small enough (rNE= 3 0s) to ensure no depletion at 10 Hz (see Figure 23).
2.3.8 Direct inhibition of/i-AR activation by ACh
Levy (210) discusses the possibilities for "mutual inhibition" and "mutual excitation" of the two branches
of the ANS. We constructed our model by first assuming that there were no direct effects of one branch
on the other; however, when we attempted to reproduce HR data collected by Brack et al. (33), we
noticed that our model produced higher HRs than measured for high vagal stimulation rates (7 Hz) and
moderate to high sympathetic stimulation rates (2-10 Hz). Thus, we include a path of direct p-AR
inhibition at these high vagal rates. A perusal of the literature did not provide a clear mechanism for this
interaction; both presynaptic (ACh inhibits the amount of NE released from adrenergic varicosities) and
postsynaptic (regulatory machinery activated by M2 receptors deactivates p-AR) mechanisms seem
plausible. Given the complexity of intracellular processes, we model this interaction postsynaptically by
introducing a variable X as a surrogate for vagal activity/M2 activation. This variable is essentially a
delayed version of the activated M2-muscarinic receptor concentration inside the cell (M2*). It was
necessary to introduce the -rx-3 s time constant in order to smooth out the pulsatile nature of M2
activation (see Figure 25). The inactivating effect of X on p* (the activated p-AR concentration inside the
cell) is modeled using a standard Hill equation, with parameters chosen to reproduce the HR data of
Brack et al. (33)
M2* =([AChM]NJ VNJACh +[ AChM ]EJS EJS to
dX M2* -X
dt rX
* = ([NE I8]NJ NJNE + [NE/3] EJS EJS) yto x M,max X nM *
X +K.
2.4 Results
The complete equations describing the phenomena of neurotransmitter release, diffusion, clearance, and
receptor binding can be found in the Appendix, section 9.5. Here, we summarize model performance.
As the function of neurotransmitter release is to transduce activity in sympathetic and vagus nerves to
activation of p-AR and M2 muscarinic receptors, we show the steady state receptor activation and time to
maximum activation as a function of nerve stimulation frequency in Figure 24. Regarding receptor
occupancy (panel A), three differences between sympathetic and vagal stimulation can be appreciated: 1)
neurotransmitter depletion is more pronounced in the sympathetic branch, 2) the disparity between
receptor activation in the neuroeffector junction and EJS is greater for sympathetic stimulation, and 3) the
maximal percent of receptors that can be activated with nerve stimulation is greater for M2 receptors.
The SS values reflect neurotransmitter depletion from the varicosity, whereas the peak values show the
maximum attainable occupancy for a particular stimulation frequency, assuming that the varicosities
contain the maximum number of vesicles at the start of stimulation. The depletion effect is drastic for
sympathetic stimulation, with receptor occupancy reaching a maximum of ~15% activation at 10 Hz
stimulation and not increasing beyond that. This occurs because each adrenergic varicosity contains a
maximum of 150 vesicles, and k,=0.01 means that 1% of available vesicles are released with each
stimulus. Once the number of vesicles is depleted to below 100, no vesicles are released despite
increasing stimulation rates (quantal release does not allow for fractions of a vesicle). In this regime, the
rate of NE release is limited by the rate of synthesis which is a constant, rather than the rate of
stimulation, so the receptor occupancy function is also a constant. A depletion effect is also present for
vagal stimulation, causing a widening gap between steady-state and peak receptor activation for
stimulation frequencies beyond 7 Hz. The M2 SS curve drops in a stepwise manner because quantal
release permits only integer-valued numbers of vesicles to be released with each stimulus. Since each
varicosity contains 450 vesicles, and 1% are released for each stimulus, this allows the release of 4 (for f
<10 Hz), 3 (for 10 Hz<f<30Hz), 2 (for 30 Hz<f<100 Hz), or 1 (for f>100 Hz) vesicle with each stimulus,
resulting in the stair-step appearance of the M2 SS curve.
For M2 receptors, the neuroeffector junction/EJS occupancy is only slightly different from the total;
however p-AR occupancy in the EJS is significantly greater than that in the neuroeffector junction. This
difference arises due to the high rate of NE reuptake by sympathetic nerve varicosities from the
adrenergic neuroeffector junction, which is absent from the EJS. The hydrolysis of ACh by AChE on the
other hand, affects both the neuroeffector junction and EJS more equally.
The maximum p-AR occupancy does not exceed 30% with increasing rates of stimulation, but M2
muscarinic receptors approach 100% occupancy. This phenomenon arises for two reasons: the smaller
number of vesicles present in the adrenergic varicosities which results in lower maximal neurotransmitter
release despite high stimulation frequency, and the high rate of NE clearance by the reuptake process
compared to the relatively sluggish rate of NE-(p-AR) binding, which results in NE being removed from
the neuroeffector junction before having sufficient time to bind the receptors.
More information on the kinetics of p-AR and M2 muscarinic receptor activation is provided in Figure
24B and Figure 25. M2 receptors activate very quickly: the first stimulus always resulted in greater than
half-maximal receptor activation, and 0.95 of peak value is reached within -1 second over the physiologic
range of stimulations (< 10Hz). P-AR are significantly slower, with half-times of about 4s, and requiring
10-20s to reach 0.95 of peak value on the physiologic range of stimulations.
Sample time courses of p-AR and M2 muscarinic activation by 6 Hz stimulation are shown in Figure 25.
The difference in responsiveness of these two receptors to nerve stimulation is apparent, and is manifested
in two ways. Not only is the approach to peak value faster for the M2 muscarinic receptor (panel A), but
the response to each individual stimulus elicits a rapid binding (to ~80% of total receptors) followed by a
fast decay (to ~15%) before the following stimulus (panel B). This phenomenon does not occur with the
p-AR, which undergoes a more monotonic rise in total binding. Deactivation kinetics also differ, wherein
the M2 muscarinic receptor undergoes a rapid (12/s) decay from 27% to 15%, followed by a slower
(0.86/s) decay toward baseline value (panel C). The p-AR on the other hand, follows an approximately
single-exponential decay with a slow rate (0. 14/s).
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Figure 24. Receptor sensitivity and rate of activation (model simulation). A. The solid lines show the percent of total
receptors occupied/bound by neurotransmitter. Each family of receptor shows two curves, a steady-state (SS) and
peak, as labeled. The occupancies for the neuroeffector junction and EJS receptor populations are also shown
individually by dotted and dashed lines as indicated in the figure. B. The rates of activation from a baseline level of
~0 to the peak values indicated in A. did not follow an exponential rise, so we show the time required to reach 0.5
and 0.95 of peak value. Missing values indicate frequencies where the first stimulus surpassed either the 0.5 or 0.95
point.
To better understand the effect of ACh hydrolysis and NE reuptake and absorption, simulations were run
using the system state at the end of stimulation as the initial condition, and setting the various clearance
rates to 0. The effect of eliminating AChE hydrolysis is drastic, eliminating the rapid decay phase, and
slowing the slow decay by a factor of 5 (from 0.86/s to 0.17/s). The rapid decay phase is actually replaced
by a temporary increase in receptor activation (see Figure 25C), because the ACh liberated from bound
receptors (the last stimulation peak) is made available for re-binding receptors rather than being
hydrolyzed. The second effect of AChE blockade is that the baseline receptor occupancy due to the BS
concentration of ACh increases to the expected 0.00307/(0.00307+0.307)=3.8% (this is simply the Hill
equation describing M2 muscarinic receptor occupancy evaluated at AChBS=3 nM [ACh]). The effects of
eliminating NE reuptake and/or absorption are not as drastic: the effect on rate of clearance is virtually
unaffected by the absence of absorption, and only decreases from by 21% when reuptake is eliminated.
The combined effect of reuptake and absorption blockade is a slowing of the deactivation rate by 36%.
The biggest effect of these clearance pathways is on the baseline p-AR occupancy, which also rises to the
expected 0.0030-7/(0.0030-7+1.50.7)=1 .3% in the absence of both reuptake and absorption. The reason that
the M2 deactivation rate is more strongly affected by elimination of hydrolysis is also due to the rapid
kinetics of M2 muscarinic receptors: binding/unbinding of these receptors is rapid enough that receptor
occupancy is in equilibrium with the local ACh concentration, so the rate of ACh removal is the limiting
process. For p-AR however, the rate limiting process is not the local NE concentration, but rather the
binding/unbinding rates, so its rate of deactivation is not affected nearly as strongly by blockage of
reuptake and absorption. As we pointed out though, the maximal receptor occupancy would be affected
by elimination of these clearance pathways for both M2 muscarinic receptors and -AR (running the same
simulation with AChE rate set to 0 resulted in average M2 occupancy of 80% during stimulation and
setting reuptake and absorption rates to 0 resulted in 40% peak p-AR activation, data not shown).
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Figure 25 Sample time courses of -AR and M2 muscarinic receptor activation and deactivation (model simulation,
note logarithmic axis for receptor occupancy). Gray lines show actual percentage of total receptors bound to
neurotransmitter for 6 Hz stimulation as indicated. Solid black lines show average receptor occupancy between
adjacent stimuli. Dashed lines show alternate simulations, where ACh hydrolysis (H), NE reuptake (R), NE
absorption (A), and NE reuptake and absorption (RA) were blocked after cessation of stimulation, to study the
clearance processes. The numbers indicate the decay rate constant (/s) for each intervention. Rate constants were
calculated by fitting the linear part (on log scale) of the decay curves. All panels share the same y-axis. A. Full
simulation, showing receptor activation from 5 to 30 seconds, and subsequent deactivation due to unbinding and
neurotransmitter clearance. B. Enlarged view of the activation process. C. Enlarged view of the deactivation process
and deactivation rates for the baseline simulations.
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Figure 26. Relationship between stimulation frequency and the neurotransmitter concentration (in the neuroeffector
junction and EJS) necessary to produce an equivalent total receptor activation (model simulation). Solid lines show
the equivalent neurotransmitter concentration for matching steady-state receptor occupancy and dashed lines show
neurotransmitter concentrations required for peak receptor occupancy. For frequencies where neurotransmitter
depletion was not encountered (<7 Hz), the relationship is well described by a power law, as indicated in the figure,
where f is the stimulation frequency in Hz.
For the range of physiological stimulation frequencies, the neurotransmitter concentration required to
elicit an equivalent activated receptor fraction is related to stimulation frequency by a power law (Figure
26). For frequencies beyond 7 Hz, the peak attainable M2 muscarinic occupancy continues to obey the
power law, whereas peak p-AR, and the SS occupancy of both receptors drops off from this relationship
due to the depletion phenomena discussed above. In this figure, the equivalent neurotransmitter
concentration is assumed to be present in the local environment of the receptors (neuroeffector junction
and EJS), which appears possible in isolated SANC preparations (see the discussion in section 6.3). If the
various neurotransmitter clearance mechanisms present in-vivo are not eliminated by thorough isolation
of cells (as in experiments done on tissue slices), and neurotransmitter concentration is fixed at some
distance from the cell membrane, a drastic shift in apparent affinity is observed. Figure 27 illustrates this
effect: the expected affinities are observed for M2 muscarinic and p-AR for neurotransmitter
concentrations in the neuroeffector junction/EJS, but both are shifted to the right by a factor of roughly 20
when neurotransmitter concentration is maintained in the BS. This occurs because the ECM acts as a
diffusion barrier, allowing clearance processes at the cell membrane (ACh hydrolysis, NE reuptake and
absorption) to decrease the local neurotransmitter concentration. The M2 curve is shifted to the right
without a significant change in slope because AChE is a relatively low-affinity process, with an apparent
affinity of 100 pM. The same is true for the effect of only NE absorption on p-AR (affinity 252 pM).
However, since the majority of NE is cleared by reuptake, and this process is fairly high-affinity (0.27
jM), it saturates around 10 pM NE and that is why we see the steepening in the p-AR curve for high BS
NE concentrations.
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Figure 27. Clearance processes (hydrolysis, reuptake, absorption) reduce the effectiveness of neurotransmitter
concentration in the BS (model simulation). Solid lines show the receptor occupancy when neurotransmitter
concentration in the neuroeffector junction and EJS is set to the indicated values. Dashed lines show the occupancy
for neurotransmitter concentrations in the BS. The dotted line shows the p-AR occupancy for neurotransmitter
applied in the BS but with reuptake rate set to 0.
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Figure 28. Direct inhibition of p-adrenergic activity by the cholinergic system occurs sharply and maximally reduces
effective p* to 10% of uninhibited value (model simulation). A. Steady state p3* for the indicated values of
sympathetic stimulation (SS) and simultaneous vagal (V) stimulation as shown on the x axis. B. Sample time course
of p* activation and inhibition for dual sympathetic and vagal stimulation as shown by the bars at the bottom of the
figure. The rate of 8* inhibition indicated next to the curve was computed by a linear fit to the log of the data
between 35.5 and 37.5s. The value ofXis also shown, multiplied by 0.1 in order to be visible using the y-scale in A.
The pulsatile nature of the neural stimulation contributes to the thickness of the lines, similar to but less drastic than
Figure 25.
The direct-inhibitory effect of high vagal stimulation rates is shown in Figure 28. Panel A shows the
sharp onset of inhibition around 5 Hz vagal stimulation, and reaches maximum inhibition by 15 Hz. The
inhibition is multiplicative, reducing the effective #* concentration by a maximum of 90%, independent of
60
the sympathetic stimulation frequency. Panel B shows the time course of $* activation and inactivation,
showing the same activation dynamics as discussed for p-adrenergic receptors in Figure 24 and Figure 25.
The X-mediated inactivation lags by about 4 seconds, which is the time required for X to approach its
steady-state value. Due to the sharpness of the inhibition curve, virtually no effect is seen for X< 1 5nM,
but beyond this point inhibition becomes apparent and proceeds with a rate similar to that of 8* activation.
2.5 Discussion
We constructed a detailed model of neurotransmitter release from vagus and sympathetic nerve
varicosities to describe the transduction of neural impulses originating in the brain to changes in p-AR
and M2 muscarinic receptor activation on rabbit SANCs. Our model combines elements from the Dokos
(96) and Demir (81) models of ACh release, and includes a number of novel elements. We focus this
discussion on a comparison of these two models; a more general discussion of past ACh release and
diffusion models can be found in Appendix section 9.3.
2.5.1 A Ch model compartments and receptor populations
The full diagram of our ACh release model is shown in Figure 29. It features six compartments: the
number of cholinergic vesicles (N,Ach), ACh concentrations in the neuroeffector junction, EJS, and ECM
([A Ch]NJ, [A Ch]EJs, and [A ChIECM), and bound M2 muscarinic receptors in the neuroeffector junction and
EJS ([A ChM]NJ and [A ChM]EJs). What it shares in common with the Dokos model are three
compartments: the main vesicle store, ACh concentration in the neuroeffector junction, and ACh
concentration in the EJS, where the latter two compartments communicate through diffusion and ACh is
released from the main store into the neuroeffector junction. The Dokos model does not explicitly model
the activation of M2 muscarinic receptors by ACh, and it does not include any M2 muscarinic receptors in
the EJS. The Demir model on the other hand, includes two populations of receptors: what they term
"junctional" and "extrajunctional" receptors, which directly activate different ion channels following the
example of Edwards et al. (101). These two populations were included to reproduce the differences in
SANC responses to bath application of ACh vs. neuronal release, as recorded by Campbell et al. (53) in
the guinea pig. Our model is similar in that M2 muscarinic receptors exist in both the neuroeffector
junction and EJS, but we model these two populations as activating the same second messenger cascade
through G-proteins (see Chapter 3). We chose this approach because it is known that M2-muscarinic
receptors are localized in the sympathetic neuroeffector junction, and the kinetic mechanisms of M2-
muscarinic receptor activation and interaction with inhibitory G-proteins have been experimentally
described. This approach does not require us to postulate the existence of some other "junctional" receptor
type with undocumented properties, as was done by Demir et al. (81). Furthermore, we were able to
reproduce the experimental data concerning the modulation of ion channel properties by ACh (both
vagally-released and bath-applied) using our model (see Chapter 6), without the need for an additional
junctional receptor type. On the other hand, the Demir model assumption of different intracellular effects
of junctional vs. extrajunctional receptors may be justified from the point of view of subcellular
compartmentalization (see section 6.7). Thus, perhaps both groups of receptors are M2 muscarinic and
they activate the same type of inhibitory G-proteins, but because they are tethered to different locations in
the cell membrane, they may hold sway over different populations of ion channels. Modeling such
interactions explicitly would require more experimental data to describe the areas/volumes of influence,
the mechanisms by which second messengers are localized, and the physical distribution of ion channel
types on the cell membrane. Finally, we also include the ECM and BS compartments (included in neither
the Dokos or Demir models), which is not only anatomically justified, but limits the rate of ACh
clearance through diffusion to a reasonable value (see below) and provides an explanation for the
apparent ACh affinity difference observed in isolated cells vs. whole tissue (see Figure 27 and section
2.5.4).
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Figure 29. Reaction diagram for ACh release, diffusion, clearance, binding, and synthesis. Solid lines delineate
compartments that are explicitly modeled, dashed lines show compartments that have been lumped together either
because diffusion between them is instantaneous ([A Ch]NJ and [ACh]i, [ACh]EJs and [ACh] 2) or because it is not
necessary to model them explicitly (all [Ch]; [ACh]BS exists as a parameter but does not change with time). The six
compartments are described by six differential equations, see section 9.5.2; for a key of abbreviations see Table 22.
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2.5.2 ACh diffusion and hydrolysis
Our model is similar to the Dokos model in that diffusion across the neuroeffector junction is assumed to
be instantaneous; an assumption that we justified with molecular Monte-Carlo simulations and
experimentally-measured physical parameters. A similar method was applied to calculate the diffusion
coefficients between the neuroeffector junction and EJS, EJS and ECM, and ECM and BS compartments,
which yielded reasonable M2 muscarinic receptor activation and ACh clearance profiles (see Figure 25).
We modeled ACh hydrolysis based on the experimental characterization of AChE affinity, maximal
catalytic rate, and density. While the Demir and Dokos models both included hydrolysis terms, their
models were more arbitrary: Dokos chose a hydrolysis rate of 14/s in order to produce desired ACh
profiles, and Demir assumed a rate of 50/s, which appeared as a parameter in the Purves equation for ACh
diffusion. Several models (81, 265, 275) use the Purves equation (276) to account for diffusion of ACh
across the neuroeffector junction, but it is not an appropriate model for the in-vivo system. This equation
(equation (1)) assumes that diffusion happens in an infinite sphere surrounding the point source (usually
the tip of a pipette), with hydrolysis occurring in the diffusive medium (276). For the models of
Osterrieder et al. (265) and Pott and Pusch (275), where ACh was released onto target cells from a
micropipette some 30-100 microns away, it is important to account for diffusion, because using the values
of Osterrieder et al. with D=8 x 10-6cm2/s, x=100 x 104 cm, and k=5/s , the concentration at the specified
distance takes about 650 ms to reach its peak (265). A similar value is obtained for the time to peak using
the parameters from Pott and Pusch (275). Demir et al. used a much smaller distance of 75 nm (81),
which is more appropriate for the width of the neuroeffector junction. However, their assumed diffusion
constant (D=5.1469 x 10- 11cm2/s) is five orders of magnitude smaller than the measured value (see Table
1). Thus, the reason that ACh diffusion was not instantaneous in these models is that either the distance
from source to cell is much farther or the assumed diffusion coefficient is too small. Furthermore, the
assumption of the Purves model that diffusion happens in an infinite sphere would tend to overestimate
the delay in the neuroeffector junction, which is more like two parallel plates with diffusion only
occurring in a single dimension from one plate to the other, rather than in all radial directions from the
source.
As support for our bottom-up approach, we point out that the M2-muscarinic receptor deactivation
process occurred at two rates with AChE intact: 12/s and 0.87/s (Figure 25C). With AChE inhibition, a
single rate of 0.17/s was observed and is credited to the rate of diffusion into the BS. This value is in line
with the experimentally measured rate of ACh "washout" in perfused chick heart (0.069/s (214)).
Furthermore, these figures imply that ACh hydrolysis occurs at two rates, a fast rate close to 12/s that is
similar to the 14/s used by Dokos et al (96), and 0.7/s, which is close to the values experimentally
measured or assumed in a number of models (see "Hydrolysis" column in Table 20).
2.5.3 A Ch synthesis
Our model of ACh synthesis is based on the current mechanistic understanding of this process, where
ACh is synthesized in the nerve varicosities from Ch that enters the nerve after being created by
hydrolysis of ACh or from the surrounding tissue (ECM) and BS. The Dokos model is similar in that all
of the ACh hydrolyzed in the neuroeffector junction re-enters the varicosity, and there is a second source
of ACh from the BS. The Demir model on the other hand, includes ACh depletion (see equation 13 in
(81)), but does not specify any mechanism of synthesis. The downside of this specification is that long
stimulus trains lose potency very quickly, and indeed, the data shown by Demir et al. usually uses 6- or 9-
pulse stimulus trains. Since our aim was to model in-vivo parasympathetic activity with sustained ACh
release, mechanisms of ACh synthesis are crucial. Our model shows reasonable ACh depletion as a
function of stimulation rate and synthesis, supported by experimental data (Figure 23, Figure 24).
2.5.4 ACh-M2 affinity
Neither the Dokos nor Demir model includes explicit M2 muscarinic receptor activation. We model M2
activation by ACh using a standard Hill equation, with an experimentally measured affinity (KMM), and a
Hill coefficient nM needed to reproduce downstream data. We use the value KmA4-0. 3 pM, based on the
half-activation concentration of IKACh measured by DiFrancesco et al. (88). As pointed out by the authors,
this value is similar to that measured in another isolated cell preparation by Breitwieser and Szabo (0.16
ptM) but much lower than that measured in whole SA node tissue by Osterrieder et al. (1.7 pM) (38, 88,
264). We suspect that Osterrieder et al. observed a lower affinity because of they used tissue slices rather
than isolated cells. As we show in Figure 27, the effect of neurotransmitter applied in the BS
compartment of our model yields lower apparent affinities for both receptors; since whole SAN tissue
would likely have some components of the ECM intact, it is likely that the local ACh concentration at the
cell membrane was lower than Osterrieder et al. expected due to the activity of AChE. In further support
of this argument is data from the same study, where the IK,ACh affinity for ACh was measured in the
presence of the AChE inhibitor neostigmine (see Figure 30). This data yielded a half-activation value in
line with the observations in isolated cells (88, 160, 264). This issue is discussed further in our IKACh
activation model (section 6.3). On the other hand, Lazareno and Birdsall mention a much lower KD of I
nM for ACh with M2 muscarinic receptors (see bottom of right column, page 363 in (203)). This
extremely high affinity would have caused receptor saturation for ACh concentrations in the high jM
range, and would not have allowed us to reproduce the measured ACh effects on IKACh, ICaL, If and P,,
(see Chapter 6).
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Figure 30 AChE inhibitor neostigmine shifts the apparent activation curve for IKACh to the left in experiments done
on whole SAN tissue. X axis shows the log [ACh], and the y axis shows the peak IKACh current elicited during
voltage clamp to -40 mV. Figure taken from Fig 1 in (264).
2.5.5 NE model compartments and receptor populations
Our NE release model is shown in Figure 31. It features six compartments, just like the ACh model: the
number of adrenergic vesicles (NNE), NE concentrations in the neuroeffector junction, EJS, and ECM
([NE]NJ, [NEiEJS, and [NE]ECM ), and bound p-AR in the neuroeffector junction and EJS ([NEp]NJ and
[NEp3]EJS). It is difficult to compare his model with those of Dokos and Demir because they did not
include neural release of NE. In fact, Dokos did not model adrenergic effects at all, and Demir only
modeled bath application of the adrenergic agonist Iso. In effect, the Demir model includes a single
compartment with a constant Iso concentration; it interacts with the cell by affecting cAMP production,
which in turn affects ion channel properties. Our model, on the other hand, includes the compartments
that have been observed in micro-anatomical studies, and the interaction of neurotransmitter between
compartments is based on the same first principles and physical measurements used for the ACh model.
This illustrates the main advantage of the "bottom-up" modeling approach we undertook. While the
functional effects of ACh and NE on the SANC are very different, going down to the molecular level
allowed us to build a general framework (diffusion-connected compartments) of simple reactions
(binding, diffusion, active transport, hydrolysis) that is the same for both. Furthermore, we were able to
use experimental data on the kinetics of these simple reactions and were rewarded by observing the
expected high-level phenomena.
As detailed as our model is, some details were not included. On the topic of different receptor
populations, we model junctional and extrajunctional p-AR, and although the current model does not
differentiate the two in terms of intracellular effects, it leaves the doors open for future refinement as data
on receptor/channel/second messenger localization becomes available. We also did not differentiate
between p1 and p2 receptors for reasons mentioned in section 2.3.5. These two simplifications of our
model may prove to be important, since new data is emphasizing more and more the importance of
subcellular compartmentalization on signal transduction (see section 6.7).
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Figure 31. Reaction diagram for NE release, diffusion, clearance, binding, and synthesis. Solid lines delineate
compartments that are explicitly modeled, dashed lines show compartments that have been lumped together either
because diffusion between them is instantaneous ([NE]NJ and [NE] 1, [NEEJS and [NE]2) or because they are assumed
to be constant with time ([NEIBS). The six compartments are described by six differential equations, see section
9.5.2; for a key of abbreviations see Table 22.
2.5.6 NE diffusion and clearance
Since the Demir model simulated bath applications of Iso, no dynamic processes were included. We
followed the same approach as for ACh: calculating diffusion coefficients based on diffusivities and
compartment geometry, and using a mechanistic model for NE clearance through neural reuptake, cell
absorption and diffusion. We chose the maximal rates of NE reuptake and absorption in order to replicate
the experimentally observed clearance ratios (Figure 22). The maximal reuptake rate we chose (v,an=18.5
amol/s/cell) can be converted to a rate of 1.12 x 107 molecules/s/cell, whereas the measured rate of 1.180
nmol/min/g tissue (161) converts to 4.15x104 molecules/s/cell (for conversions, see section 9.2).
Similarly, the maximal cellular absorption rate in our model is equivalent to 6.96x 107 molecules/s/cell,
whereas the measured rate of 100 nmol/min/gram tissue (163) converts to 3.52x 106 molecules/s/cell. In
both cases, we use faster reuptake and absorption rates than measured. This could be due to species
NNE
--- A
differences between rabbit and rat (measurements were in rat), experimental error, or perhaps our
diffusion rate for NE is too fast. Since the diffusion rate was calculated rigorously and matches data fairly
well, and since the reuptake rate we used is 1000 times faster than the measured value, while the
absorption rate is only 10 times faster, we do not think that the discrepancy is due to an incorrect diffusion
rate. We mention this issue for completeness and conclude that further experimental data would be
needed to better quantify these NE clearance mechanisms.
2.5.7 NE synthesis
Our NE replenishment model describes two processes: reuptake of NE from the neuroeffector junction,
and synthesis of NE from L-tyrosine (not explicitly modeled) in the BS. We chose the simplest synthesis
model, wherein the varicosity attempts to maintain the maximal level of NE-filled vesicles. This process
is described with a time constant that was set to a value small enough to allow stimulation without
depletion in the physiologic range (<10 Hz) (162). It is unclear whether NE depletion is a physiologic
process that needs to be accounted for however, since the model of dog HR by Warner and Cox
successfully reproduced experimental data using a fixed NE store (349).
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Figure 32. Iso is a more potent -adrenergic activator than NE. Figure taken from Waelbroeck et al. (345). The y-
axis shows the rate of AC activity as a measure of P-AR activation, since AC is activated by P-AR-activated
stimulatory G-proteins (for detail, see section 3.3).
2.5.8 NE-fl-AR affinity
While the Demir model does not include explicit p-AR binding, they use a term with an affinity for Iso of
0.14 RM in their cAMP specification (81). Since Iso binds p-AR with higher affinity than NE (about a
factor of 10-100, see Figure 32), this value is in fairly good agreement with the 1.5 pM affinity for NE
that we use. The Hill coefficient we use is not unity however, which implies cooperative binding. Since p-
ARs only have a single site for ligand binding, this reaction should in theory have a Hill coefficient of 1.
Non-unity Hill coefficients are often used in modeling as an empirical tool rather than to imply a specific
mechanism, and it is in this spirit that we use it. As we pointed out, p-ARs can exist in low- and high-
affinity states (307), so we use the Hill coefficient to represent the sum of these two affinities, which has
the effect of decreasing the total slope of activation.
2.5.9 M2, AChE, and f-AR dynamics
We assume that the abundances of M2-muscarinic receptors, AChE, and p-AR do not change with time.
This is in line with the Dokos model and Demir model. However, it is not true, as AChE has been shown
to change with half times of 12 hours -3 days (195) M2 muscarinic receptors desensitize by being
removed from the cell membrane (333), and p-AR are known to desensitize due to phosphorylation with
half times on the order of 10 minutes (31). Because these half-times are rather long compared to
reasonable stimulation protocols of the neurotransmitter release model, we assume that receptor and
enzyme concentrations are constant. Furthermore, this data further supports our use of non-unity Hill
coefficients for M2 and p-AR binding, as desensitization processes would cause shifts in affinity or total
rate with time.
2.5.10 Direct inhibition of l-adrenergic activity by vagal stimulation
Neither the Dokos nor Demir models include direct inhibition of p-AR effectiveness. We found this
interaction necessary only under high vagal stimulation rates and non-zero sympathetic stimulation. In
contrast, Dokos et al. did not model sympathetic effects, and Demir et al. did not study the effect of
simultaneous p-adrenergic and cholinergic stimulation. Thus, these studies did not model this cholinergic-
p-adrenergic interaction because it was outside their modeling aims. As we briefly mentioned in the
description of X, we only added this term when it became necessary to reproduce HR data. Although
Levy (210) proposes various opportunities for presynaptic interaction that would result in modified NE
release due to vagal activity, we model the interaction as an intracellular process. This approach seemed
more reasonable because it does not force us to commit to a particular mechanistic explanation: the
reduction in p* could be the result of reduced NE release, reduced p-AR abundance, reduced p-AR
affinity for NE, reduced p-AR affinity for G-protein, reduced catalytic rate of p-AR for activating G-
protein, or any combination of the above. Many of these changes may be mediated by intracellular
modifications of p-ARs such as phosphorylation, which most likely cause conformational changes in the
protein, and may lead to the functional changes mentioned above. The fact that our model indicates the
necessity for direct cholinergic-adrenergic interaction, and the mechanistic uncertainty surrounding this
issue both point to the need for further experimentation and better understanding of this phenomenon.
2.6 Conclusion
We created a novel model of neurotransmitter release and M2-muscarinic and p-AR activation in the
rabbit SANC based on the current mechanistic understanding and experimental kinetic data. The model
reproduces macro-phenomena such as the fast activation of M2 muscarinic receptors, and the slow
activation of p-AR. ACh diffusion and hydrolysis rates reproduce experimental values, as do the rates of
NE neural reuptake, absorption, and diffusion. It is also interesting to note that the ACh hydrolysis is
responsible for both reduced M2 receptor activation and fast rate of deactivation following cessation of
stimulation, while NE clearance mechanisms also decrease the peak p-AR activation but only slightly
affect the rate of deactivation. Furthermore, the rate limiting step in sympathetic modulation of HR
appears to be receptor activation, because the observed time constants for p-AR activation are on par with
HR changes elicited by sympathetic nerve stimulation. This is not the case for M2 muscarinic receptors,
which have an almost instantaneous activation, so the rate limiting steps for parasympathetic HR
modulation actually emerge intracellularly, through the more sluggish second messenger cascade. We
also proposed a plausible inhibitory effect of cholinergic activity on p-ARs, which is supported by
experimental observations, and allowed us to reproduce experimental HR data over the full range of
physiological vagal and sympathetic stimulation (Figure 105 gj,k).
No model is complete without a list of limitations. In our case, the limitations stem from uncertainty in
the experimental measurements of rate constants and other physical parameters, and simplifying
assumptions (diffusion being modeled as a single rate constant, that junctional and extrajunctional
receptors are identical, quantal release). We also assume that cell membrane-localized receptors are static,
in the sense that their numbers or affinities do not evolve with time. However, the explicit nature of our
model framework allows relatively easy changes to these assumptions as more experimental data
becomes available.
In all, our neurotransmitter release model was rigorously developed and compares favorably with existing
models, setting the stage for quantifying the intracellular processes that ultimately affect SANC properties
and HR.

3 G-PROTEINS (EC 3.6.5.1) AND ADENYLATE CYCLASE (EC 4.6.1.1)
3.1 Overview
This chapter describes the intrinsic GTP turnover cycle of G-proteins, the facilitation of this process by
activated (ligand-bound) p-adrenergic and M2 muscarinic receptors, the properties of adenylate cyclase,
and the nature of the interaction between activated G-proteins and adenylate cyclase as highlighted in
Figure 33.
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Figure 33. High level illustration of G-protein activation and modulation of adenylate cyclase in the context of the
entire model originally shown in Figure 4 (see original figure for key).
G-proteins
* G-proteins are heterotrimers, consisting of a, p, and y subunits
e The stimulatory (Gs) and inhibitory (G1) G-proteins differ in a subunit only
e Stimulatory and inhibitory G-proteins have a similar activation mechanism: the a subunit is
activated when it binds GTP and dissociates from the py subunits (which stay bound). Activated a
and free py subunits serve as second messengers inside the cell. The a subunit has an intrinsic
catalytic ability, hydrolyzing GTP to GDP and inactivating itself. The activation steps are
catalyzed by liganded p-adrenergic (for stimulatory G-proteins) and M2 muscarinic (for
inhibitory G-proteins) receptors. See Figure 34.
" The rate coefficients for each component reaction are derived through detailed re-analysis and
reproduction of historic G-protein data/experiments, summarized in Figure 65.
* Both G-protein models reproduce the measured steady-state GTP turnover rates at baseline and
with adrenergic or cholinergic stimulation (see Figure 66). G-protein abundances are based on
experimentally measured values
" The activation of G-proteins by activated P-adrenergic and M2 muscarinic receptors is modeled
using standard Michaelis-Menten kinetics, and measured receptor-G-protein affinities and
maximal catalytic velocities.
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Figure 34. The G-protein activation-inactivation cycle. G *: activated a subunit, must be dissociated from py and
bound to GTP in order to be activated. The other three -protein states are inactive and do not interact with adenylate
cyclase (AC). Activated p-adrenergic or M2 muscarinic receptors catalyze the GTP-binding and subunit dissociation
steps.
Adenylate Cyclase
" Adenylate cyclase synthesizes the second messenger cAMP
" The abundance of adenylate cyclase, and its baseline, stimulated, and inhibited rates of cAMP
production are based on experimental measurements
e Adenylate cyclase activity is modulated by competitive binding of activated stimulatory or
inhibitory G-proteins
6 r Ga Gov
Results
e G-protein activation is not rate-limiting for either sympathetic or parasympathetic effects (see
Figure 67 compared to receptor activation in Figure 24)
" Modulation of adenylate cyclase rate through binding with activated G-proteins is the main venue
for sympathetic-parasympathetic interactions (see Figure 69)
3.2 Introduction
G-proteins link the activation of p-AR and M2 muscarinic receptors on the cell's surface to the generation
of intracellular second messengers. Because their main role is to activate G-proteins, the M2 muscarinic
and P-AR of the heart belong to the family of G-protein coupled receptors (GPCRs). For a review of
GPCR structure and function, consult Gilman 1987 and Taylor 1990 (323). Here, we present a brief
summary.
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Figure 35 G-protein structure and atomic weights of its subunits. G-proteins are heterotrimeric, consisting of three
distinct subunits: a, P, and y. In the early literature, before these names were adopted, the subunits were referred to
by their molecular weight. It is now understood that the Ga subunit is the business-end of this protein, as it binds the
guanine-nucleotide GTP, hydrolyzes it to GDP, and the type of a subunit specifies its end-effector and ultimate role.
Binding of GTP causes the dissociation of the Ga from the py subunits, and both parts effect changes within the cell.
The py subunit is tethered to the cell membrane, while the dissociated Ga subunits are free to diffuse throughout the
cytoplasm. References: a (66), b (257), c (122), d(315), e (36),f(29). Image from Wall 1995 (346) and Jena Library
of Biological Images (PDB 1gg2).
Three major components exist in the GPCR signal transduction cascade: the receptor, G-protein (see
Figure 35), and end effector. Each of these components exists in a basal (low activity) form as well as an
activated form (denoted by * in figures). In Figure 36, we diagram the process of G-protein activation: A
GPCR (A) is activated when it binds ligand (B), in this case, ACh or NE. The activated GPCR catalyzes
the activation of the G-protein, by facilitating its release of GDP and binding to GTP (C). The activated
G-protein a subunit then dissociates from the GPCR and the membrane-tethered Gpy subunit (D) and can
bind the end effector. Figure 36 A-D illustrate the activation of the stimulatory G-protein (Gs) by p-
adrenergic receptors. M2 muscarinic receptors follow a similar G-protein activation mechanism, however
they are linked to an inhibitory G-protein (G1) (E). It is also of note that while the GPCR is activated (D
and E), it can catalyze GDP-GTP exchange for a number of GDP-Gsap (6-8 per active receptor (35)).
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Figure 36 Activation of stimulatory Gsa and inhibitory Gia G-proteins by p-adrenergic and M2 muscarinic receptors,
respectively. See text for description of steps A-E.
Activated G-proteins regulate AC. For a detailed review of AC function and regulation, see Patel et al.
2001 and Iyengar 1993 (164, 269). Briefly, ten isoforms of mammalian AC have been identified:
membrane-localized AC I-AC IX and one soluble form (for reviews see (164, 269)). The major isoforms
in cardiac tissue are AC V and VI (164, 269), and AC serves a critical function in SANC as over-
expression of AC VI was recently shown to confer pacemaking ability to ventricular cells (288). All AC
subtypes catalyze the conversion of ATP to cAMP, but some differences in regulation by the G proteins
exist. For this reason we limit our discussion to AC V and AC VI, to which we refer simply as AC.
Modulation of the catalytic rate of AC by activated G proteins is illustrated in Figure 37. In its basal state,
AC catalyzes the production of cAMP from ATP (A). Binding of activated Gsa* stimulates cAMP
production by stabilizing the AC dimer (B), while binding of activated GIa* destabilizes the dimer and
virtually abolishes its activity (C) (164, 269). There is also evidence that the py subunits can directly
stimulate or inhibit some AC subtypes (67, 178, 315), however for AC V and AC VI only an indirect
effect is believed to occur through sequestration of Gsa (D) ((256, 282), reviews: (164, 269, 310)).
Activation by Gsa > Indirect Inhibition by GOy
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Figure 37 The baseline catalytic rate of AC (A) is increased by Gsa (B) and reduced by Gia (C), through direct
binding with a regulatory site. Two distinct sites exist, one for Gia and another for Gsa; since binding by either
induces conformational changes that may alter the unoccupied binding site (269), we conclude that only one G-
protein can bind at a time. Activation of Gai also increases available Gpy which indirectly "inhibits" AC by
competing for Gsa (D). Some experimental results have been interpreted to mean that Gp, can also directly inhibit or
activate AC; we assume that this direct action of Gp, does not occur, and rather that the effects of Gpy on AC activity
are through buffering Gs or G1 as espoused by Gilman (122).
G-proteins have an intrinsic control to limit the duration of their signal, as shown in Figure 38. The G,
subunits of both stimulatory and inhibitory proteins are GTPases, which hydrolyze GTP to GDP,
releasing Pi and inactivating themselves (B). The inactivated G-protein has a reduced affinity for AC, and
therefore unbinds and is reunited with a Gpy subunit (C).
ATP cAMP ATP cAMP
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Figure 38 Regulation of AC activity by activated Ga subunits (A) of both Gs and G1 terminates when the Ga
hydrolyzes the bound GTP (B), thereby decreasing its affinity for AC and increasing its affinity for Gpy (C).
In the following sections, we quantify the intrinsic GTP turnover cycle of stimulatory and inhibitory G-
proteins, their activation by p-AR and M2 muscarinic receptors, and their interaction with AC.
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Unfortunately, the G-protein literature does not report explicitly the rate constants needed to describe the
intrinsic GTP turnover of G proteins. We derive these rate constants by re-analysis of the pertinent
experimental data. In most cases, the data we analyzed were digitized from figures in published papers so
we include the original figure and the digitized versions to show that digitization was done properly.
3.3 The Stimulatory G-protein Gs
In this section we detail the intrinsic function of Gs; we leave the activation of Gs through interaction with
p-AR for section 3.5. First, we consider the abundance of stimulatory G-protein in mammalian cells. A
number of measurements are listed in Table 4, from which we conclude a reasonable value for G-protein
abundance of 2x 106 molecules, which for the sake of all the reactions, we consider dissolved in the entire
cytoplasmic volume of the SANC to yield a total concentration Gsr=2 pM. Although the py subunits are
tethered to the cell membrane, this assumption is justified by the fast rate of diffusion estimated to occur
within the SANC (see section 9.4).
Table 4 Abundance of G-protein in mammalian and insect cell membranes.
Measured amount
Source System (pmol/mg membrane Number per cell
protein)
Neubig et al. 1985 Human platelet G1  25.8 3.1x10 6
Mosser et al. 2002 Insect Sf9 G1  50* 6.Ox106
Rabbit liver G1  42' 5.Ox106Bokoch et al. 1984
Rabbit liver Gs 17.51 2.1x10 6
Ransnas et al. 1992 Mouse S49 Gs 19.3 2.3x 106
* from a maximum amount of GTPyS binding to membranes of 50 pmol/mg protein. I reported value is 300 nmol G1
per 7,082 mg protein. I purification of G1 yielded 1.05 mg (5% recovery of original amount) and Gs yielded
0.347mg (4% recovery). Assuming comparable molecular weight of G1 and Gs, the ratio of the original abundances
is (1.05/0.05)/(0.347/0.04)=2.4, we used this ratio to calculate pmol Gs from the reported value for G1.
The kinetics of stimulatory G-protein were probed by Northup et al. in 1982-1983 (255-257). Below, we
reproduce the model and summarize pertinent experiments for determining the rate constants.
The stimulatory G-protein has the following characteristics:
1. Gs, is activated by binding GTP and dissociation from Gpy (255-257)
a. Dissociation is promoted by binding of GTP or F- and Al3 (256, 257)
b. Gs, is deactivated by GTP hydrolysis or binding Gp, (256)
2. Gs contains a single GTP binding site (255)
a. Under physiologic [Mg>], GTP binding to dissociated Gs" is irreversible ((255) Fig 4)
b. GTP binding activates Gsa by promoting dissociation from py subunits and increasing
affinity for effector (AC)
3. GTP is in rapid equilibrium with Gs,, followed by a rate-limiting Gsa-Gpy dissociation step (255)
The Gs activation model presented by Northup et al. (256) is reproduced below. We consider free, GDP-
bound Gsa to be inactivated in the sense that its affinity for AC is very low. This idea is supported by the
observation that GTP binding produces a conformational change in the Gs, effector-binding site and that
this conformational change increases affinity (70, 300). This model is consistent with the data and models
presented by both Northup et al. (256) and Brandt and Ross (36). We go into the details of each reaction
(A-F) below.
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Figure 39 Overall state diagram for activation of stimulatory G protein and subsequent activation of AC. States are
numbered 1-6 and reactions are specified by letters A-F.
3.3.1 A. Guanine nucleotide exchange/hydrolysis, Gsafly
Reaction A is a reduction of the full model that includes an intermediate state where Gss,5 is not bound to
nucleotide (similar to Fig. 9 in (35)):
a c
1I
kcat
Figure 40 Diagram for reaction A in Figure 39, showing the intermediate state.
The simplest reaction to consider is the binding of GTP, described by rate constants c and d. This reaction
is considered to be in rapid equilibrium (c+d is large) (35, 255), with a dissociation constant Kd=0. 1 tM
(35). This value is smaller than what was measured by Northup et al. (1.3gM) (255); we choose the
smaller value because Northup et al. conducted experiments in solution and mention that the affinities
they observed were an order of magnitude less than what is seen in plasma membranes. Brandt and Ross
(35) used phospholipid vesicles to simulate the presence of a plasma membrane, and they report the value
of 0.1 pM. Another simplifying circumstance is that the physiological plasma concentration of GTP in
cells (~25-100gM) (38, 281) is significantly higher than the measured dissociation constant for GTP.
Thus, the reaction is essentially irreversible and rapid, allowing us to ignore the intermediate state and
yielding the A reaction illustrated in Figure 39.
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Figure 41 Rate of GDP dissociation in the presence or absence of Gpy, taken from (36). Gs, was pretreated with [a-32P]GTP, which quickly hydrolyzes to [C- 32 P]GDP; the figure shows the amount of bound 32P under three
conditions: 1 contained isolated Gs, and a very low concentration of the detergent Lubrol; 2 contained isolated Gsa
as well as buffer with heat-denatured Gpy and a high concentration of Lubrol; 3 contained isolated Gs, and buffer
with active Gpy and a high concentration of Lubrol. The dissociations proceeded with rates indicated on the figure.
From lines 1 and 2, the presence of a higher Lubrol concentration seems to decrease the GDP dissociation rate by
-40%.
The leftmost reaction, described by rates a and b concerns the dissociation of GDP. This has classically
been considered the rate limiting step in the activation of G-protein and in the full-cycle hydrolysis of
GTP (see Introduction in (35) for a summary, (122) for review). The dissociation rate of GDP is reported
by Brandt and Ross to be 1.3-1.7/min at 30 'C (Fig 6 in (36)) but other data in the same paper show fast
and slow dissociation rates of 0.7-1.1 /min and 0.1-0.2 /min, respectively (Figs 5 and 7 in (36), the latter
is reproduced in Figure 41). The authors' interpretation of the data may have been confounded by their
hypothesis that GTP association (rather than GDP dissociation) is the rate limiting step, and they note that
this rate limiting step proceeds at 0.43/min at 30'C (36). This is on the same order as the GDP
dissociation rate measured for G1 (0.3/min at 22-24'C (38)) and Go (0.03-0.3 /min at 20'C (146-148)). It
is also similar to the 0.2/min GDP dissociation rate in the presence of Go, shown in Figure 41. We
conclude that a is approximately 0.4/min, to match not only the apparent GDP dissociation rate, but also
the overall GTP hydrolysis rate in which this is the rate limiting step (see Table 6). A further
simplification can be made because the intermediate is rapidly converted to the GTP bound form: as soon
as a GDP is released, a GTP takes its place virtually irreversibly. Therefore the rate of GDP binding is
very low, and b can be ignored. The only remaining way that GsasyGDP can be created is through
hydrolysis of GTP, which happens with rate kcat=10/min (see Table 5). The overall reaction A is:
~ 0. 4 *t
Figure 42 Reduced form of Figure 40, showing rate constants in units of /min. Simplifying circumstances are the
rapid equilibrium and abundance of GTP, which make both dissociation of GDP and binding of GTP essentially
irreversible.
The equality of the models presented in Figure 40 and Figure 42 was tested by assuming that [GTP]
[GDP] = 50 pM. The [GTP] value falls within the measured range (38, 281) and the [GDP] is actually a
'worst case' assumption because a high [GDP] would shift the reaction to the left and most stringently
tests the idea that the dissociation of GDP is irreversible. The Kd for GTP is 0.1 pM, and for GDP it is
0.3pM (using the value of 3 pM reported in (255), and decreasing an order of magnitude to compensate
for the lack of plasma membrane as was done for GTP). Since Kd= a/b for GDP, and a=1 /min, then
b=3.3/min/pM GDP. At 50 pM, this rate is b=167/min. Doing similarly for GTP, where Kd=d/c, we see
that c=10d /min/pM GTP, so at 50 pM, this is c=500d/min. The value of d has not been measured, but is
expected to be large to satisfy rapid equilibrium. Even if we assume a relatively low value of d=10/min,
the models of Figure 40 and Figure 42 produce very similar results, as shown in Figure 43:
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Figure 43 Comparison of full and reduced model for reaction A. Parameters described above were used, with solid
lines representing the solutions to the full model and points showing the reduced model. The initial condition on the
system was that all of the G protein was bound to GTP, lines as labeled. At its maximal value, the intermediate state
accounted for less than 0.2% of total G protein abundance.
Table 5 Measured values of kcat for Gs and G1, temperature corrected using a Qio of 1.7. kcat
the catalysis of GTP to GDP as shown in Figure 40.
System Temperature Measured value(OC) (/mm)
is the rate constant for
Value at 37'C
(/min)
Cassel et al. 1977 (54) Turkey Gs* 37 15 15
Brandt and Ross 1985 Rabbit Gs 30 8.3 12(36)
Brandt and Ross 1986 Rabbit Gs 30 4 6(35)
Graziano et al. 1989 Rabbit Gs 20 3.2-4.5 8-11(128)
Linder et al. 1990 (213) Recombinant Rat 20 1.8 -2 .7 ' 4-7olfactory G1
Kleuss et al. 1994 (189) Recombinant Rat 20 3.4 8
olfactory G1
* The study was done before the role of G-proteins in AC activation was known, so G protein type was not specified.
The reported rate is the rate of GTP hydrolysis, which the authors presumed to be due to GTPase activity of AC. t
values obtained using solution with the detergent Lubrol PX which decreases the catalytic rate of G-proteins (35,
36).
Source
Table 6 Measured values of kh for Gs and G1, temperature corrected using a Qio of 1.7. kh describes the hydrolysis
rate of GTP, thus it includes the full cycle of GTP--GDP catalysis and the rate-limiting step of GDP release.
Measured value Value at 37'C
Study System Temperature (/min) (/min)
Sevilla et al. 1976 (292) Turkey Gs 37 0.7 0.7
Brandt et al. 1983 (34) Rabbit Gs 30 1-1.5* 1.4-2.2*
Cerione et al. 1984 (58) Human Gs 30 0.3 0.4
Brandt and Ross 1985 Rabbit Gs 30 0.2-0.41' O.3-0.6(36)
Graziano et al. 1989 Recombinant 20 0.13-0.34 0.3-0.8(128) Rabbit Gs
Sunyer et al. 1984 Human G, 32.5 0.011 0.011(311)
Milligan et al. 1985 Bovine G1  37 0.3 0.3(240)
Katada et al. 1986 Rat brain G, 30 0.16-.34 0.2-0.5(181)
Linder et al. 1990 (213) Recombinant 30 .03-.11 0.04-0.11Rat olfactory G1
Kleuss et al. 1994 (189) Recombinant 30 0.026 0.04Rat olfactory G,
Gilman 1987 (122) Gs, G1, Go 30-37 0.3 0.3-0.4
maximum observed kh with Iso-stimulated p-adrenergic receptors. Cerione et al. 1984 also report a turnover
number of 2/min with high activated p-adrenergic receptor concentrations. t Brandt and Ross also report kh values
>1.5/min, but at extremely high Mg2+ concentrations (>100 mM (34), compared to physiological Mg2+ of 2.5 mM
(198)). 1 values obtained using solution with the detergent Lubrol PX which decreases the catalytic rate of G-
proteins (35).
3.3.2 B. G-protein dissociation (GDP)
Reaction B describes the dissociation of the Gsa and Gp7 subunits, while GsQ is bound to GDP. While the
dissociation reaction happens in a single step, reassociation most likely occurs through an intermediate
state illustrated in Figure 44.
To obtain the function for e and the rate constant f, we consult binding studies reported by Northup et al.
(256, 257). In these experiments, A3 and F~ were used to activate Gsa (dissociate it from Gpy) and various
concentrations of free Gp subunit were added while observing the rate of inactivation of Gsa. At this time,
the y subunit had not yet been identified, so its presence was not specified. Judging by the molecular
weight of the p subunit reported in the study however, it seems like no y was present. We therefore
assume that the y subunit only marginally affects the interaction between Gsa and Gs.
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Figure 44 Schematic of reaction B, including an intermediate state (left) the presence of which is supported by data.
The implicit association rate (e) is illustrated because we reduce the transition through the intermediate state to a
function of [Gpy] and treat this as the concentration-dependent rate e. Dissociation rate (f) is also included for
completeness, although it turns out to be negligible.
Figure 45A shows the time course of Al3 and F- activated Gsa subunit activity (measured as the rate of
production of cAMP by AC) in the absence (top line) or presence of 1p g/mL (30 nM) of Go subunit. The
rate constants (slopes) of the two reactions are 0.01/min and 0.8 /min, and these rates equal the rate of Gsa
deactivation through thermal denaturation or unbinding of A1F4 and through binding Gs, respectively.
Figure 45B shows that the deactivation of Gsa follows Michaelis-Menten kinetics:
V(#)= V.. L] (4)[/9]+ K,
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Figure 45 Binding experiment of Gsa and Gp subunits. Figure A is from (256) and B is from (257). The 35K subunit
refers to the Gp subunit. A was performed at 21 C, B was at 20'C.
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Figure 46 summarizes the process for obtaining the constants v,, and K from the data in Figure 45.
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Figure 46 Michaelis-Menten fit to the data digitized from Figure 45B. The data are plotted with [GP] on the x axis
(converted using molar weight 35 kDa) and deactivation rate (not half-time as in Figure 45; converted as
rlog(2 )/t/a) on the y axis. The deactivation rate was shifted down by 0.08/min to be 0 at the origin in order to
cancel the rate of Gsa denaturation in the absence of Gs. The constants for the inactivation rate in Eq (4) were
obtained by fitting the data in a least squares sense (1 sqcurve f it in Matlab).
Considering all the data presented above, we conclude that rate e is a function of free Go, concentration as
quantified by equation (4) with parameters shown in Figure 46 for 20'C. Using a Qio of 1.7 to convert
v, to 37'C yields
V(p)=3.7 (5)[#6]+30nM
Since the deactivation reaction appears to go to completion (see Figure 45A), rate f is assumed to be
insignificant when compared to e. Therefore, the overall reaction is:
[G,]3.7[GOnM
[G, ] +30nM
Figure 47 Complete reaction diagram for reaction B, showing the actual association rate as a function of [Gpy].
3.3.3 C. G-protein dissociation (GTP)
Reaction C is similar to B, except that Gsa is bound to GTP. GTP has a stabilizing effect on Gsa so the
balance of this reaction is shifted toward the dissociated state (256). The simplified diagram for this
reaction is shown in Figure 48.
g [h
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Figure 48 Schematic of reaction C, with explicit association (g) and dissociation (h) rates.
To quantify this reaction, we refer to experimental data from Northup et al. (256), reproduced in Figure
49. Since GTPS is non-hydrolyzable, the Gsa-GTPyS subunits are very stable and show no deactivation
over 200 minutes. Addition of 20 pg/mL (0.6 pM) of free Gp subunits induces a slow deactivation of Gsa.
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Figure 49 Deactivation of Gsa-GTPYS by free Gp subunit. A is from (256); the top line shows relative cAMP
production rate for the system with Gs, activated by GTPyS in the absence of Gp, and the bottom line shows the
deactivation process with 20 pg/mL of Gs, at 21 C. B is from (255); the data shows cAMP production rate as a
function of time for the indicated combinations of G-protein (G/F) and free Gp subunit (35K Subunit). Experiments
done at 30'C.
The binding/dissociation reaction between Gp and Gsa-GTPyS as schematized in Figure 48 can be fit by
the equation
a(t) =s +(1 -- s)e- (6)
r=g+h; s=h/(g+h) (7)
which describes a first-order reaction with rate r that reaches a steady state value s. The data and fit of
equation (6) are shown in Figure 50.
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Figure 50 Exponential decay fit to the binding reaction between Gp and Gs,-GTPyS ('data' were digitized from
Figure 49A). The parameters for equation (6) were obtained by a least-squares fit to the data, using 1sqcurvef it
in Matlab.
The data in Figure 50 give h(600 nM)= 0.006 /min and g(600 nM)=0.009 /min at 21 C, which converts to
h(600 nM)=0.014/min and g(600 nM)=0.02/min at 370C. The data in Figure 49B confirm this estimate at
600 nM Gp and add another data point for 6 nM Gs, allowing us to establish a trend. Figure 51 shows the
digitized data from Figure 49B and the parameters of the exponential fits. From these data, we see that the
two experiments with -600 nM Gp have a rate of 0.03/min at 30'C, which is 0.04/min at 370 C, and agrees
with the sum of h(600 nM)+g(600 nM) = 0.034/min obtained from Figure 50. Assuming that 6 nM GP is a
low enough concentration that Gs, is almost completely dissociated, Figure 51 implies h(6 nM)=0. 14/min
and g(6 nM)~0/min at 30'C, or h(6nM)=0.20/min and g(6nM)~ 0 at 370C. This information is
summarized in Table 7.
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Figure 51 Inhibitory effect of Gp subunit on the rate of activation of Gsa by GTP.S. Data from Figure 49B were
digitized (symbols) and fit with exponential functions of the form a(l-e-) (dashed lines). Least squares fit
parameters are shown on the figure. The red lines show model reproductions of the two conditions with 6 nM Gap
and 0 nM (top) or 600 nM (bottom) additional Go. We did not reproduce the middle curve because this experiment
involved the 100-fold dilution of the solution before measurement of Ga activity which could have introduced an
error due to imprecision in the dilution procedure as well as promoting dissociation of Ga from Gy due to the
lowered concentration.
It is expected that the association rate (g) increases with increasing Gp concentration, and this is most
likely due to an intermediate state in the Gsa-Gp binding process as shown for reaction B. As Northup et
al. point out, and as we quantify in Table 7, the P subunit has an inhibitory effect on the rate of Gsa
activation (h) (255). This observation cannot be explained simply through the increase in g, because the
overall rate of activation or inactivation is actually r-g+h. As we see from the values in Table 7, h
decreases with increasing P subunit concentration. The overall behavior of this system can be explained
by a number of models, but the simplest one is diagrammed in Figure 52. Enough proof does not exist to
insist that this is indeed the molecular mechanism, but it does serve the purpose of providing a
mathematical form for the rate functions g and h.
Table 7 Association and dissociation rate constants as a function of Gp concentration, at 370 C.
[Gp] nM h (/min) g (/min)
6 0.19 ~0
600 0.014 0.02
g h4MMV
K
Figure 52 Potential mechanism for explaining the dependence of rates g and h on Gpy concentration. The increase in
g with increasing Gpy is explained by the existence of an intermediate state, similar to the reaction in Figure 44. The
decrease in h with increasing Gpy can be explained by an alternate state, were an extra Gp. unit stabilizes the
Gsapy-GTP complex. This reaction is presumed to be in rapid equilibrium with Michaelis-Menten coefficient Km2.
Because of the stabilizing effect of the second Gpy subunit, this state does not dissociate with an appreciable rate and
therefore limits the amount of GsQsy-GTP available to dissociate with rate h.
The mechanism for activation and deactivation of Gsa shown in Figure 52 is summarized by the two
functions for g and h shown in Figure 53.
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Figure 53 Reaction C with first-order rate functions based on the data in Figure 49, scaled to 370 C. This model
(adjusted for temperature to 30'C) was used to generate the red lines in Figure 51.
To reproduce the data in Figure 51, we numerically integrated the following differential equation,
obtained from the reaction in Figure 53:
da* a* +J8xtra *. + /'-extra *dt =0.23T 1- a*+p" (ar -a* 0.02T ,/a*+a ,8,p+" a*
Where T=1.77/1O is the temperature correction to reduce the rate to 30'C, a* is the concentration of
activated Gsa subunit (0 nM initial condition), ar-6 is the total concentration of Gsa (nM), and pex,,= 0 or
600 is the concentration of additional Gp subunit (nM).
The activation and deactivation rates as functions of [Gp,] are shown in Figure 54.
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Figure 54 Free Gpy subunits decrease the activation rate and increase the deactivation rate of Gs-GTP.
3.3.4 D. Thermal inactivation of Gsa
Activated Gs, undergoes thermal denaturation with a rate of -0.01-0.08/min, estimated from the data in
Figure 45. Given this very low rate, and assuming that total Gsa abundance is actively regulated by the
cell, we choose to exclude this reaction.
Similarly, Northup et al. report a half-time of 4 hours at 21 C for thermal inactivation of dissociated
Gsa-GTPyS (state 5 in Figure 39) in the absence of Mg2l (256). This converts to a rate of 0.007/min at
37*C. For reasons discussed above, we also do not include this reaction.
3.3.5 E. Guanine nucleotide exchange/hydrolysis, dissociated Gsa
Reaction E is similar to reaction A discussed above, with the only difference being that these reactions
concern the dissociated form of Gsa. Following the same reasoning as in reaction A, the two pertinent
rates are the rate of GDP dissociation (i) and the rate of GTP hydrolysis (j):
Figure 55 Guanine nucleotide exchange (i) and GTP hydrolysis (j) reactions for free and AC-bound Gsa.
Rate i can be obtained from Figure 41, which shows that the GDP dissociation rate for isolated Gs, is
approximately 1.1 /min at 30 *C (1.6 /min at 37 C). Furthermore, the GDP dissociation rate for isolated
Gsa is about 4 times faster than the rate for Gsap (comparing lines 2 and 3 in Figure 41; also stated in the
text of (36)). Given the rate of 0.4/min we calculated for GDP dissociation from Gs.sy, we conclude that
rate i is 1.6 /min. We assume that py subunit does not affect the catalytic ability of Gsa, so the catalytic
rate (j) of activated Gs, is 10 /min (Table 5).
We model the activation of AC by Gs* as an instantaneous process (see section 3.6) meaning that a
fraction of Gs0 * is bound to AC* at any time. We do not include an explicit model of guanine nucleotide
exchange and hydrolysis for Gsa bound to AC, which is equivalent to assuming that binding of AC does
not affect these processes. Brandt and Ross showed that interaction with AC does not stimulate the
GTPase activity of Gs, (34), and they hypothesized that this interaction may decelerate the GTPase rate in
order to prolong AC activation but were unable to present experimental data to this end (36).
Furthermore, Cassel et al. (54) computed the decay of AC activity due to GTP hydrolysis to be 15/min at
37 0C, which is close to the assumed GTP hydrolysis rate in this model. Thus, we conclude that the GTP
hydrolysis rate of AC-bound Gsa is 10 /min. We assume that AC does not bind dissociated Gsa-GDP, so
we do not need to consider how the rate of nucleotide exchange is affected by AC.
3.3.6 F. Gsa -AC binding kinetics
The affinity of Gsa* for AC was chosen to replicate data describing the cAMP synthesis rate and
concentration as a function of Iso and ACh in Chapter 6. For completeness, here we report data of direct
measurements of Gs, affinity for AC, and point out the inconsistency in the reported values.
Northup et al. report that activated GsaGTPYS is in rapid equilibrium with AC, with dissociation constant
KD=3 pM (256). The authors contrast this value with the significantly higher KD observed in cyc
membranes (240 pM), but conclude that the lower value is more representative of the actual interaction
between pure AC and activated Gsa (256). Interestingly, the KD obtained by calculating the slope of the
Hofstee plot of the data from Northup et al. (reproduced in Figure 56A) is 0.3 pM, not 3 pM as the body
of the paper states. This prompted us to digitize and re-plot the given data with bound GTPyS
concentration on the x axis (Figure 56B, see caption for procedure). Fitting this rescaled data gave higher
dissociation constants, of 14-19 pM, as indicated in the figure. In this analysis, it is reasonable to equate
bound GTPS concentration to activated Gsa concentration because the binding of non-hydrolyzable GTP
analogs to Gs, is irreversible (255), and at these low concentrations, the dissociation reaction is essentially
irreversible as well (see Figure 53). Therefore, bound GTPYS is equivalent to dissociated/activated Gsa.
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Figure 56 Original (A) and re-plot (B) of the data from (256) used for determining AC-Gsa dissociation constant KD.
The re-plot uses the same y-axis values, but the x axis was processed to yield bound GTPyS concentration by
dividing the x values from (A) by the y values from (A) and then scaling these concentrations by a constant in order
to reproduce the reported range of 1.5-97pM GTPYS bound (from original figure caption). These scaling constants
were -40 and -70. The data were fit with standard Michaelis-Menten functions with the parameters shown in B.
For a summary figure showing all the rates calculated above, see Figure 65.
3.4 The Inhibitory G-protein G1
As with Gs, here we discuss the intrinsic properties of G1 and leave activation of G1 by M2 muscarinic
receptors for section 3.5. The abundance of G1 is shown in Table 4. From these data, we conclude that
there are 10 X106 G1 molecules per rabbit SANC. The value we chose for Gs matches that found in rabbit
liver and mouse S49 lymphoma cells, however we choose a G1 value higher than that measured in human
platelet and rabbit liver cells in order to achieve a high G1:Gs abundance ratio of 5. We assume that a high
abundance ratio is likely present in SANC cells (compared to the cells in Table 4) because strong
cholinergic stimulation can abolish spontaneous depolarization and the overabundance of G1 is considered
to make the indirect Gs inhibition pathway more powerful. As with Gs, We assume that G1 is dissolved in
the entire SANC cytoplasmic volume, giving a total concentration of Gir- 10 pM.
The kinetics of inhibitory G-protein were studied by Katada et al., Bokoch et al., and Sunyer et al. in 1984
(29, 177, 178, 180, 311). The mechanisms of isolated G1 protein activation are very similar to what was
discussed for Gs, and are summarized below. It helps remove some confusion if we point out that the
initial studies (177, 178) were misinterpreted because they were conducted in membranes containing both
Gs and G1, and the combined effect of these two proteins was ascribed to the activity of G1 only. The later
study however (180), was conducted in cyc~ mutant cells that lack fully-functional Gs, and the
independent effect of G1 was clearly understood.
The inhibitory G-protein has the following characteristics:
1. Gia is activated by binding GTP and dissociation from Gp, (177, 178, 180)
a. Dissociation is promoted by binding of GTP or F and Al"_ (177, 178, 180)
b. Gia is deactivated by GTP hydrolysis or binding Gy (178)
2. Gia contains a single GTP binding site (28, 29, 177)
a. Under physiologic [Mg>], GTP binding to dissociated G is irreversible (29, 180)
b. GTP binding activates G1a by promoting dissociation from py subunits and increasing
affinity for effector (AC) (177, 178, 180)
3. GTP is in rapid equilibrium with G12, followed by a rate-limiting Gia-Gpy dissociation step (178)
The fact that the mechanism of G1 activation is identical to that of Gs, we reproduce below the Gs
activation framework, with the difference that activated G1 inhibits (rather than activates) AC. Note that
the Gp, subunit is identical to that used in the Gs figures; this is so because the py subunits of G1 and Gs
are identical both functionally and in terms of amino acid composition (178). The interchangeability of py
subunits is the mechanism of Gs/G1 interaction, and the main culprit in the difficulty with interpreting
experimental results from systems that contain both forms of the G-protein (177, 180).
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Figure 57 Overall state diagram for activation of inhibitory G protein and subsequent inhibition of AC.
3.4.1 A. Guanine nucleotide exchange/hydrolysis, Gial
The generally accepted mechanism of guanine nucleotide exchange in G1 is the same as that for Gs: GDP
dissociation is rate-limiting, followed by fast and irreversible binding of GTP (29, 178, 189, 213). This
model of slow dissociation followed by fast binding is supported by experimental data showing that the
rate of GTPS binding is insensitive to GTPS concentration (Fig 8 in (29)). The irreversibility of GTP
binding at physiologic GTP concentration is supported by the high affinity of G1 for GTP, with a KD of 25
nM (29) to 40nM (311). Also, experiments in the presence of Mg 2+ show irreversible binding of GTPyS to
G1 ((29) Fig 9).
Similar to Gsa, Gia hydrolyzes GTP with an intrinsic catalytic rate kcat (see Table 5) that is higher than the
rate of GDP dissociation, thus GDP dissociation limits the full-cycle GTP hydrolysis rate (189, 213) (see
Table 6). These properties imply that the rate of GDP dissociation, GTP binding, and overall GTP
hydrolysis are equal, and that the only mechanism for generating G1a-GDP is through hydrolysis of bound
GTP.
The measured values for the rate limiting step (GDP dissociation) differ by an order of magnitude
depending on the particular G-protein source or experimental conditions. On the low end are GDP
dissociation values on the order of 0.04 /min at 37 'C (29, 189, 213, 311), and on the high end are values
on the order 0.1-0.4 /min at 37 'C (29, 178, 181, 240). It is interesting to note that Bokoch et al. show an
order of magnitude different GTPyS binding rates in the same paper (Fig 8 shows an initial rate of
-0.1/min whereas Fig 10 shows -0.01/min) using the same G1 protein (from rabbit liver), under similar
G1, Mg2+ and GTP7 S concentrations but different buffers (Tris-HCl vs. sodium Hepes, respectively) and
Na* concentrations (0 vs. 100 mM, respectively) (29). Milligan and Klee state that Na* can either
accelerate or retard GTPase activity, depending on the source of G1 (240). On the other hand, Katada et al.
report GTPyS binding rates of -0.05/min and -0.1-0.4 /min at 30 'C using the same buffer solutions (Tris-
HCl with 100mM Nat) but G1 protein from different sources (rabbit liver (177) vs. rat brain (181)). The
reported GTP catalytic rate kcat is more consistent however, with values 4-8/min at 37 'C (189, 213) (see
Table 5).
Given this information, we adopt the faster GDP dissociation/GTP binding/ GTP hydrolysis rate constant
of 0.4/min. We choose this higher value for two reasons: 1) an excess or dearth of a number of substances
can alter enzyme function, so it is likely that various in vitro experiments may have been conducted in a
suboptimal chemical environment and therefore give an underestimate of the enzyme's native, in-vivo
performance. 2) The rate of 0.4 /min is the same as that measured for GDP dissociation from Gsa, and
despite dissimilar actions on the end effector, it is reasonable to assume that the guanine nucleotide
binding site in this protein family is highly conserved and therefore exhibits similar kinetics. Similar
arguments apply to choosing the catalytic rate kat of 10/min, which is close to the rates explicitly
measured for Gia (Table 5).
3.4.2 B. G-protein dissociation (GDP)
Unfortunately, we were unable to find data of the form shown in Figure 45 for G1. The only data we found
that could be used to quantify this reaction is shown in Figure 58. The denaturation of Gia can be modeled
by the reaction shown in Figure 59. In this scheme, free G1a denatures with rate a, and is stabilized
through interaction with other Gia subunits or components in the buffer with rate b and binds Gpy subunits
with rate c (rate c is a function of Gp, concentration). The portion of non-denatured GIQ subunit at time t
is:
aactive (t) b+c a e-("**"' (8)
a+b+c a+b+c
Since the 'control' reaction in Figure 58A was done in the absence of py subunits (c=O), we can use it to
calculate rates a and b; this result is shown in Figure 61A, with the calculated rates a and b displayed on
the figure.
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Figure 58 Rate of Gia denaturation in the absence of py subunits at 30 'C. A is from Fig 15a and B is from Fig 16a in
(181). In A, isolated a4 1 subunits were monitored for GTPase activity in Mg2+-free buffer (control), and
combinations of added py subunits and Mg2' as indicated. The decline in GTPase activity is ascribed to thermal
denaturation of Gia. In B, isolated a41 and c3, were evaluated for ADP-ribosylation as a measure of intact (non-
denatured) protein. Isolated a subunits were incubated with py subunits of various concentrations, and ADP-
ribosylation was evaluated at 60 minutes. We use the data for a41 subunit because its mass (41 kDa) is closest to that
measured for G1; the a39 subunit is hypothesized to be a different type of G-protein, Go (181).
a b OtI
Figure 59 Gia denaturation and binding of py. An extra state (right) is added to represent aggregated or otherwise
stabilized Gi which is not prone to denaturation. We do not include a dissociation rate because it is very slow, as
can be seen from the top line in Figure 58A showing that in the presence of py subunits, G, does not denature at all
over 40 minutes.
After obtaining rates a and b from Figure 58A, we use Figure 58B to determine the function for rate c as a
concentration of py subunit. Equation (8) still applies for this data since we are using the same model, but
we can further simplify it by noting that the only time-dependent term is e -(a+b+c)t, which for a-b=0.04/min
and t=60 min (the data in Figure 58B were collected at 60 min) is less than 0.01 which is negligible.
Ignoring the time-dependent term allows us to solve equation (8) for c at each Py concentration given in
Figure 58B:
a.ctive (a + b) - b
C (AV) - I- active 9
The rates c calculated according to equation (9) are well fit by a 3-parameter logistic function (for data
and fit see Figure 60):
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1+e([f)r-276)40(
where py concentration is in nM.
Ga - py binding rate
15
9 From data
------ Logistic fit /
10
4
0 .00 1 1
0 100 200 300 400 500
[@y] (nM)
Figure 60 Rate c calculated from data of Figure 58B and equation (9), as well as the logistic function fit of equation
(10).
Using this form for rate c, and rates a and b as calculated previously allows us to reproduce the data from
Figure 58B, as shown in Figure 61B.
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Figure 61 Data digitized from Figure 58 and fit with model of Figure 59. Both of these figures contain data at 30 'C.
Correcting the function in equation (10) to 37 0C gives the model for Gia association with Gpy in:
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Figure 62 Summary of reaction B showing Gpy-dependent reassociation rate for GDP-bound G1, and Gpy at 37 0C.
The dissociation rate is negligible.
Notes on this rate: the data we used to calculate the association rate were obtained in the absence of Mg 2+
and guanine nucleotides. Mg 2+ has been shown to promote subunit dissociation (29), so the association
rate calculated above may be an overestimate (cells have a nonzero Mg 2+ concentration). Guanine
nucleotides tend to stabilize free Ga (181), and this increased stability may imply a lower affinity for Gpy,
so the above function may be an overestimate of Gp, affinity. Together, these two observations imply that
the above association rate may need to be scaled down and shifted to the right; we did not find this change
necessary to fit the available data.
3.4.3 C. G-protein dissociation (GTP)
We are unable to find any data that would allow us to quantify reaction C. Thus, we adopt a minimal
model, where the dissociation occurs at a constant rate and association rate is negligible. This rate does
not alter the baseline GTP turnover rate, but does affect the baseline AC rate. We set this rate to 1 /min.
3.4.4 D. Thermal inactivation of Gia
Here we discuss the denaturation of the three possible Gia configurations: unliganded G12, Gia-GTP, and
GJ-GDP. In the absence of py subunits, unliganded Gia subunits appear to denature with rate 0.04 /min
(a4 1 subunit in (181) Fig 15A, reproduced in Figure 58A), but due to the high affinity for GTP, the
amount of unliganded Gia is expected to be negligible. Katada et al. (181) show that GTP has a stabilizing
effect on G1 and effectively prevent its denaturation at GTP concentrations above 10 pM, a condition that
is met in the GTP-rich SANC. Since GTP protects GiQ from denaturation, it is not unreasonable to assume
that GDP also confers some degree of stability so the denaturation rate for GDP-bound Gia is expected to
be lower than 0.04 /min. Gp, subunits also confer significant stability to Gia (181), and their presence in
the physiological environment therefore limits the loss of G1, to heat denaturation.
Finally, we also assume that the cell actively synthesizes Gia at a rate sufficient to maintain total
abundance, so we choose not to include this reaction, as we did for Gs.
3.4.5 E. Guanine nucleotide exchange/hydrolysis, dissociated Gia
The rate of GTP hydrolysis was measured for free Gia subunits as well as Gia in the presence of Gpy, and
the data are reproduced in Figure 63. This figure shows a Lineweaver-Burk plot of GTP hydrolysis rate as
a function of GTP concentration for two GI, proteins a 4 1 and a39 (the subscript indicates the molecular
weight). Since a41 was shown to be an inhibitor of AC activity whereas a39 was not (181), we look to the
a41 data and see that the GTP hydrolysis rate for the free unit is 1/3 as fast as the Gpy bound unit.
Converting these rates from 30 'C to 37 'C gives rates of approximately 0.1 /min for free Gia and 0.4 /min
for Gpy-bound G1a. The latter agrees with the GDP dissociation rate in reaction A, so we adopt the slower
0.1 /min rate for the GDP dissociation rate for reaction E. It is interesting to note that Gsa releases GDP
more readily when it is activated, whereas Gia releases GDP faster when bound by Gpy. This observation
has also been made by Bokoch et al. (29), noting that the py subunit "promotes dissociation of nucleotide"
from the Ga subunit. The greater affinity of free Gia for GDP may explain the greater stability of Gia to
thermal denaturation (29) and provides a mechanism for prolonging the activated state of Gs, but limiting
the duration of the inhibiting effects of G1.
Figure 63 Effect of fy subunits on GTP hydrolysis rate of Ga subunits at 30 'C, taken from (181). For the G1, types
tested, the GTP hydrolysis rate (set by the rate limiting GDP dissociation) is 2-3 times faster in the presence of Py
than for isolated G1 . The maximal hydrolysis velocities (inverse of y-intercept) are shown for each condition. GTP
dissociation coefficients (inverse of negative x-intercept) are 0.2-0.8 pM.
As for Gs, we assume that the catalytic rate of GTP hydrolysis remains unaltered by being in solution or
bound to AC, so kcat=IO/min.
3.4.6 F. Gia -AC binding kinetics
The affinity of G1 * for AC was chosen to fit data on cAMP synthesis rate and concentration as a function
of Iso and ACh in Chapter 6. As we did for GS, here we report some direct measurements of Gia*-AC
affinity.
We assume that activated Gia binds AC rapidly, like Gsa. This view is supported by experiments showing
that the time course of GTP' S binding to G1 is directly proportional to the inhibition of AC activity
without a delay (Fig 3 in (177)). Katada et al. (178) state that G1 binds AC with a lower apparent affinity
than does Gs, and the experimental data shown in Figure 64 allow the calculation of KD=60-90 nM for the
Gi,-AC reaction. These values are indeed higher than the KD for Gsa-AC reported by the same group,
which was in the picomolar range (256). We assume that the affinity of Gia-GDP for AC is very low so
we do not consider binding of these molecules.
The overall model with all the rates for G1 activation is shown in Figure 65.
3.5 Activation by GPCRs
3.5.1 Mechanism of GPCR-G-protein interaction
The kinetics of G-protein interaction with GPCRs has been modeled in two ways. The collision coupling
model of Tolkovsky and Levitzki (329) assumes that G-protein and GPCRs freely diffuse through the
membrane, and that an instantaneous collision (or finite-duration encounter (305)) between an activated
GPCR and a G-protein activates the G protein. The other class of models are standard enzyme models
with a rapid binding/unbinding of G-protein and GPCR, followed by an irreversible activation of G-
protein (244). These two types of models have different kinetic mechanisms, but share the feature of rapid
equilibrium, where the rate of G-protein activation instantly changes as a function of activated GPCR
population. Estimates for encounter frequency are on the order of 100-350/min (225, 305), so compared
to the slower downstream rates of G, activation (on the order of 1/min), the assumption of rapid G-
protein-GPCR equilibrium is justified.
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Figure 64 Effect of G, and G, subunits on AC modulation; both figures taken from (178). X axis is in pmol/assay
tube, assay tubes contained 50tL of buffer and membrane. A shows that half-inactivation of AC occurs at ~3
pmol/assay tube (solid symbols A; disregard empty symbols since they represent py subunit). B shows half-
inactivation occurring -4.5 pmol/assay tube for both wild-type and cyc- cells. Dividing by assay tube volume gives
the concentrations as 60 and 90 nM, respectively.
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Since Gp, is necessary for interaction with GPCRs (114), we do not model the binding of free Ga with
GPCR. Also, since both guanine nucleotide exchange and G protein subunit dissociation are facilitated by
interaction with a liganded GPCR ((34, 35), for review see (122)), we bypass the 'intermediate' state (state
2 in both Figure 39 and Figure 57) and introduce a direct GPCR mediated rate from state 1 to state 5 (see
Figure 65). Due to the rapid equilibrium between GPCRs and G-proteins discussed above, the GPCR-
mediated rates of G-protein activation can reasonably be modeled using instantaneous functions of G-
protein concentration. In fact, GPCRs are known to catalyze the activation of a number of G proteins
while themselves activated by hormone (122). We use the standard enzyme kinetics form (equation (11))
where the maximal rate V,ax is related to the amount of liganded p-adrenergic (B*) or M2 muscarinic
receptor (M2*) and Gapy is treated as substrate with the specified dissociation constants. Note that in the Rfp
equation, we also include a second term for activation of Gs by unliganded p-AR. This term has a lower
vmax,/3o and a higher KGSO, and was necessary in order to raise the baseline Gsa* concentration and allow the
reproduction of data showing AC to be about 50% activated at steady state (see fig 4b in (320)) while still
allowing full activation by NE stimulation and full inactivation by ACh stimulation.
[GsapyGDP] [ GsarGDP
R 3,=*(]pvI G GDP] +(6r -(Q Li*]) v po [ GDP]
8 (Gsa*7 GDP] + KGS (Gsafr GDP] + KGSO
G,,,GDP ,M =(M 2 jvmaxM (Gur  +KG
3.5.2 Parameters for GPCR-G-protein interaction
We could not locate references that explicitly report the parameters for the model in equation (11), so we
convert published measurements related to the quantities of interest. From the model and experimental
measurements done in mouse S49 cells by Stickle and Barber (305), where the encounter frequency was
fE-100/min and an average encounter duration of 0.2 seconds, we calculate that KGS is 3[Gs] where [Gs] is
the baseline concentration of Gs in the cell:
K koff koff [ Gs ]ko [ Gs] 1/ 0.2K =k f [G|=3[ GsGS kon kon [ Gs E 100/60
We assume that [Gs] is not significantly depleted by binding, a valid assumption given that the Gs
abundance is two orders of magnitude greater than the abundance of p-AR (our estimate of Gs abundance
is 2x10 6 /cell, and p-AR abundance is ~3.5x1 04 /cell).
To obtain a similar estimate for G1, we look to experiments done on insect Sf9 cells by Mosser et al.
(244), which show that addition of ACh increases the portion of M2-G binding from 0.07 to 0.26. These
values imply KGI is 13[G1] for unliganded M2 muscarinic receptors and 3[G1] for ACh-bound M2
muscarinic receptors by the following formula, where P is the portion of receptors bound for a given [G1]:
[G, ] 1-PP = 
->I KGI = I [G,[G,]+KGI [
In purely theoretical models, values on the range 1-30 x[G] have been assumed/computed (225, 259).
Thus, we regard the estimates of 3[G] for liganded GPCRs and 13[G] for unliganded GPCRs reasonable,
giving KGS 6 MM, KGSo=2 6 gM, and KGJ 309M.
It is estimated that a liganded P adrenergic receptor can catalyze the activation of 10 Gs proteins over the
course of a few seconds (122). Setting vmax./1f0/s gives an overall GTP turnover by Gs of 2.1/min
(turnover is calculated as mol GTP hydrolyzed per mol of Gs per minute). This value is in line with the
measurements made by Brandt et al. (34), who measured GTP turnover of 1-1.5 /min for Iso-stimulated
vesicles (containing p-adrenergic receptors) at 30'C. Correcting these rates to 37 'C, we obtain GTP
turnover of 1.4-2.2/min. Setting vmax,2=10/s gives a maximally M2-stimulated GTP turnover of 1.3/min
for G1, which is approximately 3x the baseline value of 0.4/min, and 1.4x the total baseline GTP turnover
of 0.9/min. These values are in accordance with data (130, 149, 177, 178). The effect of hormone on
platelet membranes (Fig 6 in (177)) and S49 cells (Fig lb in (178)) increased the activation of G1 by a
factor of 3. The M2-muscarinic receptor agonist carbachol increased GTP hydrolysis rate by a factor of 2
in reconstituted phospholipid vesicles (Fig 3 in (130)), and by a factor of 1.7 in porcine atrial membranes
(Fig 2 in (149)).
The rate vatfpO=1.54/s was chosen in order to generate a high enough GsaGTP concentration at baseline to
allow for an AC rate of about 50% of maximum, as shown by Taniguchi et al. (see Fig 4b in (320)).
3.6 A C and its modulation by Gs and G1
AC catalyzes the conversion of ATP to cAMP (reviews: (164, 269)). From studies of purified AC (Table
8), the basal turnover number is on the order of 1/s, and it increases roughly 10-100 fold upon activation
(85, 292, 353). AC activated by forskolin or Gsa yields turnover numbers on the range from 5-91/s, with
AC I and II being on the lower end with rates 5-18/s (316, 322, 364), and AC V and VI (the isoforms of
interest to us) on the higher end with rates 54-91/s (85, 271). We adopt the baseline rate vAc-1/s and
GsaGTP-stimulated rate vAc.=100/s. Experiments on the inhibition of AC rate by activated Gia show 12-
50% inhibition: Fig 6 in (178) shows 12% inhibition, Fig 1 in (240) shows 25% maximal AC inhibition
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by G1, Figs 1 and 2 in (178) and Fig 4 inset in (180) show ~50% inhibition. We set the GiaGTP-bound AC
rate to vAC =0.5/s, noting that the absolute value is not critical since the major inhibitory effect is
obtained by competing AC away from Gs. We treat these three AC rates as constants, which is
appropriate under the assumption that the substrate ([ATP] ~ 9-11 mM in perfused rat heart, converted
from 4-5 pimol/g wet tissue (187, 260), see section 9.2 for conversion) concentration in the cell is actively
maintained and therefore does not fluctuate significantly with time.
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Table 8 Basal and activated turnover rates (mol cAMP/mol AC/s) of purified AC.
Temp. Reported value Turnover Turnover atSource AC type (0C) (pmol/min/mg) (/s)* 37C
(/s)
Takai et al. 1974 (314) Brevibacterium 33 30 23 28liquefaciens
Sevilla et al. 1976 Turkey erythrocyte 37 -- 2t 2f
(292) 15-20 15-20
Pfeuffer et al. 1985 Rabbit myocardium 30 15 37.5 54
(271)
Smigel 1986 (297) Bovine brain 30 10 20 29
Tang et al. 1991 (316) I 30 5 9.2 13
Taussig et al 1993 I 30 7 12.4 18
(322) II 2 3.5 5
Yan et al. 1996 (364) IC1 + IIC 2  30 -- 8.2 12
Dessauer et al. 1997 IIC2+VC1 30 0.61 0.6' 0.91
(85) 63 63 91
* Conversion from pmol/min/mg was converted to mol cAMP produced/mol AC/second (turnover) by
dividing the reported values by the molecular weight of AC provided in the paper. The following weights
were used: Takai et al. (46 kDa), Pfeuffer et al.(150 kDa), Smigel (120 kDa), Tang et al.(110 kDa),
Taussig et al.(106 kDa), Dessauer et al.(60 kDa, since activity is reported per mg of one of the AC
subunits which we assume is half the weight of the whole protein).
t basal activity, in the absence of activating substances like Gs, or Forskolin, all other rates are activated
Experiments done on crude membranes (Table 9) allow us to estimate the basal and maximally activated
rates of cAMP generation per cell. These measurements are made in different tissues in a number of
species, but the cAMP production rates per cell are fairly consistent. Basal rates are on the order of
10,000 cAMP molecules/s/cell whereas maximal rates are 10-100 times higher, in agreement with
observations on purified AC ((85, 177, 353) (shows 30x increase due to Gs)). We assume a total AC
abundance of 6,000 per cell (ACr--6.25 nM), which gives baseline and maximal cAMP synthesis rates in
line with the data in Table 9.
Because AC can bind either Gsa or Ga at a time (see Figure 37 caption), the two reactions are
competitive. We use a simple, phenomenological model based on competitive binding of Gs and G1
parameterized by and apparent dissociation constants KsAc and KrAc and Hill Coefficients nsAc and nAc.
This gives the concise form for AC, AC* and AC-, which are weighted by their respective cAMP
velocities to produce the overall velocity vAc, Tal:
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Table 9 Basal and maximal rates of cAMP production in mammalian cells
Reported value
Tem (pmol/min
/mg)
cAMP rate
(x10 5 molecules
/s/cell) *
cAMP rate at
3 70C
(x10 5 molecules
/s/cell)
Lefkowitz and
Levey 1972b
(208)
Sevilla et al.
1976 (292)
Spiegel et al.
1976 (299)
Waelbroeck et
al. 1983 (345)
Fowler et al.
1986 (115)
Bristow et al.
1989 (41)
Cat LV
Turkey
erythrocyte
Turkey
erythrocyte
Human adult LV
Human fetus LV
Human R auricle
Human R auricle
Rat LV
Rat LV
Human LV
Human LV
Human RV
Human RV
Human LV
60'
160
1,200
292
225
350
37 50'175
35'
100
8.5-14.l1'
136-224T
30 5.7-10.9'
97.8-162t
AC- =ACT
Source Cell type
1.2'
3.2
1.2'
3.2
5.8
4.5
7
1 t
3.5
0.7'
2
0. 17-0.3'
2.7-4.51
0.11-0.2f
2.0-3.21
8.6
4.5
7
it
3.5
0.7'
2
0.2-0.4'
3.9-6.51
0.2-0.3'
2.9-4.61
12.4
* cAMP rate calculated by multiplying pmol/min/mg membrane protein values by mg of membrane protein in the
model cell (see section 9.2 for conversion constants) and converting minutes to seconds and moles to number of
molecules. t basal rate, in the absence of p-adrenergic agonists or AC activators like forskolin. t rates in presence of
Iso and forskolin; Iso alone only stimulated 15-16% of this amount of cAMP production
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The parameters for the binding reaction were chosen in order to reproduce AC rate and cAMP
concentration data in response to adrenergic and cholinergic stimulation (see Chapter 6). This procedure
provided the values KsAc- 4 5.9 nM, nsAc- 1, KjAc- 2 13.9 nM, nAc;-l.74. The Hill coefficients are close to
unity, which is expected for binding of single molecules. The affinities agree with the qualitative
observation that Gs binding is higher affinity than G, (178). Quantitatively, our KsAc value is higher than
the reported values (3-240 pM, see section 3.3.6), while our KAc value is reasonably close to the values
we estimated from experimental data (60-90 nM, see section 3.4.6).
The overall model for G-protein activation and modulation of AC is shown in Figure 65; the full list of
instantaneous and differential equations is in section 9.5.2.
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3.7 [G, [ 3n k,, 0.23 1 G +60nM[G,,+30nM T[G,]+6n
'~I~1.6,
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Figure 65 Entire G protein - AC model. The rate functions and constants shown were deduced from detailed in-vitro
experimental data. In the final model implementation, all G-protein rates were scaled by a constant factor in order to
match higher-level kinetic data. See section 6.7 for details.
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3.7 Results
We showed some results in sections 3.3 and 3.4 in the form of reproductions of experimental data by
isolated reactions in our Gs and G1 models. In this section, we show the characteristics of the Gs, G1 and
AC system when coupled with the neurotransmitter release model of Chapter 2.
Figure 66 shows snapshots of the Gs, G1, and AC system at steady state, at 0.1 pM ACh, baseline, and 0.1
pM NE. The baseline system is in the absence of ACh or NE perturbations; the concentrations are not 0
however, due to the nonzero concentrations in the BS. The fixed ACh and NE concentrations were chosen
to correspond to ~10 Hz stimulation, as the maximal physiological effect. In all three situations, the bulk
of G-protein resides in the heterotrimeric, GDP-bound state (GpyGDP). Upon activation by ACh, the
percentage of activated G1 increases from near 0% to 4%, causing the G1-mediated GTP turnover to
almost double from 0.4 to 0.7/min. ACh causes a negligible change in the GTP turnover rate of Gs and
activated amount of Gs (a very slight deactivation due to the increased concentration of fy subunits
causes the GsapyGDP state to increase by a fraction of a percent). The effect of ACh on AC rate is large
however, causing a shift from 41% activated at baseline to only 17% with ACh, and a matching 2.3-fold
decrease in cAMP synthesis rate. Adrenergic stimulation tells the opposite story, with a significant rise in
activated Gs, from 2% at baseline to 6%, and a similar near-doubling of Gs-mediated GTP hydrolysis rate
that we saw with G1 and ACh. The relatively high baseline AC rate increased 1.6-fold in response to the
1.7-fold increase in the percent activated AC*. The most striking feature of these data is the high
sensitivity of the system, where only small fractions of total Gs and G1 (< 10%) need to be activated for
maximal adrenergic and cholinergic effects. These results are supported by experimental measurements
indicating 90-97% of Gs in the GDP-bound states (36), and baseline and stimulated GTP turnover rates on
the order of 0.4 /min and 1 /min (Table 6, (34, 130, 149, 177, 178). A difference between the activation
response of Gs and G1 is that G1 activation results in increased GJQGTP with the other states remaining
virtually unchanged, whereas activation of Gs greatly increases both dissociated states: GsaGTP and
GsGDP.
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Figure 66. The percent of Gs and G1 found in GDP/GTP/p7- bound forms match experimental observations; small
changes in activated G-protein abundance lead to large changes in AC activation. State diagrams are shown for three
conditions: 0.1 pM ACh, baseline (minor effect of BS concentrations of NE and ACh), and 0.1 iM NE. Each
condition shows the same diagram, where each box shows the distribution of a species (Gs, G1, and AC) in terms of
percentages. The boxes are arranged in a geometric pattern similar to Figure 65: for the G-proteins, the top left is
GpGDP, top right is GapyGTP, bottom left is G GDP, and bottom right is the activated form GaGTP; for AC, the
left box is activated AC*, the middle is AC, and the right is inhibited AC-. The percent of each species that is in the
activated form is shown in bold. The horizontal arrows beneath the G-protein boxes show the GTP turnover due to
Gs and G1, respectively. The arrow beneath AC shows the overall AC rate, vAc ToaI.
The concentration of activated Gs and G1 as a function of nerve stimulation frequency are shown in Figure
67A. Nerve stimulation causes peak GIaGTP concentration to rise from 0.05 pM to over 0.8 ptM, and
while the steady-state concentration manifests the same depletion phenomena as M2-muscarinic receptor
activation, the difference between steady-state and peak is not great. GsaGTP increases from a baseline
value of 0.035 RM to a modest 0.18 [tM peak and 0.12 pM steady-state concentration. The lower GsaGTP
concentrations, despite greater fractional activation (see Figure 66), are a result of the 5-fold greater G1
abundance in the rabbit SANC. We also see the drastic effect of NE depletion on the difference between
the peak and SS values, as we saw with p-AR activation. The kinetics of Gs and G1 activation are shown
in Figure 67B. Gs activation is about an order of magnitude slower than G1, with G1 taking a fraction of a
second to reach half of its peak value and virtually reaching the peak within one second, while Gs requires
about 5 seconds to climb half-way and about 20 seconds to reach the peak. These rates are similar to those
of the M2-muscarinic and p-AR activations we showed in Figure 24.
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Figure 67. Gs and G1 sensitivity and rate of activation (model simulation). A. Steady-state (SS) and peak
concentrations of Gs and G1 are shown as functions of sympathetic and vagal stimulation frequency, respectively. B.
The rates of activation from a baseline level (>0 RM for both Gs and G1) to the peak values indicated in A. did not
follow an exponential rise, so we show the time required to reach 0.5 and 0.95 of peak value. Missing values
indicate frequencies where the first stimulus surpassed either the 0.5 or 0.95 point.
Despite our faithful reproduction of the Gs-deactivating effect of py subunits (Figure 51), the effect is
very small for our in-vivo model, as seen in Figure 68. With increasing ACh, GiOGTP concentration rises
more than one order of magnitude and liberates the same amount of py subunits, but these free py subunits
only cause a minimal decrease in GsaGTP from 0.033 to 0.031 pM. This is an unexpected result given the
potency of py subunits in deactivating GsQGTP in-vitro (255, 256); but it is an important observation, as it
implies that the direct pathway of AC inhibition is more important than the indirect (Figure 37). On the
other end of this spectrum, increasing NE concentration causes a similar order of magnitude increase in
GsaGTP concentration, but there is no inhibitory effect on GiaGTP.
The effects of G-protein activations on AC is summarized in Figure 69. Starting at the baseline AC rate in
the middle of the figure, addition of ACh in the absence of sympathetic stimulation (SS=O Hz) causes a
sigmoidal decline in vAcTta1 to a minimum value of about 2 pM/min. Concurrent sympathetic stimulation
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(SS=2, 5, 10 Hz) increases the AC rate, but only at low cAMP concentrations. Note that for ACh>0.1 IM,
all the SS lines fuse into one, showing the ineffectiveness of sympathetic stimulation at high ACh
concentrations. This effect arises due to the direct inhibition pathway described in section 2.3.8 and
Figure 28. Looking at the NE-stimulated side of Figure 69, we see the expected sigmoidal increase in
vAc Total in the absence of concurrent vagal stimulation (VS=O Hz). The effect of vagal stimulation at 2 and
5 Hz is simply to shift the curve down, as the AC available to bind GsQGTP is competed away by GIQGTP.
At the high vagal stimulation rate of 7 Hz, we again start to see the effect of direct cholinergic inhibition
on p-adrenergic activation, as the curve is not only shifted down more drastically, but it is also shifted to
the right such that the physiologically-achievable NE concentration range (up to 0.1 pM) results in
minimal activation of AC.
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Figure 68. Cholinergic activation results in a GIGTP-dominated cellular environment, while adrenergic activation
causes GsGTP dominance; the in-vivo effect of py inhibition of GsaGTP is small (model simulation). Note that the
ACh scale is reversed, so the left side of the plot shows the maximal cholinergic effect, the middle shows 'baseline'
(both neurotransmitter concentrations at 0) and the right side shows the maximal adrenergic effect. The solid line
and dashed line are Gs and G, as labeled. Ncurotransmitter concentrations were clamped in the neuroeffector
junction and EJS (no effect of reuptake / absorption / hydrolysis).
3.8 Discussion
We constructed models of Gs and G, activation from the basic reactions of guanine nucleotide exchange
(both intrinsic and GPCR-mediated), hydrolysis, and dissociation. Our model of AC activation and
inhibition is similarly based on a simple competitive binding with activated Gs, and G1a. In building these
models, we made what we consider to be the most reasonable assumptions; below, we summarize some of
the possibly contentious points.
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Figure 69. AC rate is modulated by both sympathetic and parasympathetic activity (model simulation). Note the
reverse ACh scale; showing maximal cholinergic effect on the left and maximal adrenergic effect on the right. In the
ACh regime, four sets of simulations were done, with simultaneous sympathetic stimulation (SS) at 0, 2, 5, and 10
Hz as labeled. In the NE regime, simultaneous vagal stimulation (VS) frequencies are similarly indicated. The
baseline panel shows the AC rate in the absence of neurotransmitter. neurotransmitter concentrations were clamped
in the neuroeffector junction and EJS (no effect of reuptake / absorption / hydrolysis).
We model GaGTP as entering the cytoplasm following its dissociation from py. This issue has been
debated: Taylor (323) argued that it is unlikely because the resulting dilution would lower the
effectiveness of the activated subunits in interacting with membrane-bound proteins like AC. On the other
hand, a number of studies support the mechanism diagrammed in Figure 36, with a membrane-tethered py
and freely-diffusible G, (27, 122, 281, 282). Our model produces activated G, and Gs concentrations in
the 0.1-1 pM range (Figure 67, Figure 68), and AC-binding affinities in the nM range, close to what was
experimentally observed (178, 256). However, we found it necessary to speed-up all our G-protein
reactions by a factor of 20 (see section 6.7 for details) in order to reproduce the half-time of py-mediated
activation of the IKACh channel. We argue that this speed-up represents the localization of G-proteins to
specific cellular domains (166, 250), or interaction with regulators of G-protein signaling (RGS) or
GTPase activating proteins (GAPs) which can speed up GTP hydrolysis rates by a factor of 50 (23, 327).
In future refinement of this model, it would be prudent to revisit the assumption of G-protein dilution in
the entire cytoplasmic volume, since reducing the volume in which reactions occur would result in faster
rates and may provide a mechanistic explanation for the 20-fold speedup we currently use.
For dissociation of either Gsa or Gia from Gy, a concentration of at least 1 piM Mg2+ is necessary (180,
256, 281). We do not model the dependence of G-protein subunit dissociation on Mg2+ because according
to the SANC model of Kurata et al., physiologic Mg2 concentration is 2.5 mM (198). Experimentally, the
109
effect of Mg2 ' and GTP is sometimes simulated by Al" and F-, which can mimic the y-phosphate of GTP
and cause G, activation (122, 300).
In the G-protein literature, the activation of G-proteins by GTP and dissociation from py is not explicitly
described in terms of these two processes: is GTP necessary and sufficient to activate Ga, regardless of
whether py is attached or dissociated? Or, is GTP binding necessary, but only as a mechanism for
dissociating the a and Py subunits? In our model, we consider only the GTP-bound and dissociated Ga
subunit as "activated". This decision is supported by a review that summarizes the structure of Ga and Gpy
subunits and points out that the same residues of Ga are responsible for binding effector and Gp, (70).
Thus, GapyGTP cannot interact with AC since the py is in the way. When Ga binds GTP, these residues
undergo a conformational change and become less suitable for binding py, and more suitable for
interacting with AC (300). This is why we also consider GaGDP as inactive; although this conformation
does not have the physical barrier or py; it also lacks the high enough affinity to bind AC. If we removed
this assumption (that both GTP and dissociation are necessary) from our model, the inhibitory activity of
GI would not be greatly affected because ACh causes a much greater activation of GiaGTP than any other
potentially active state (see Figure 66). On the other hand, if GsaGDP were considered an active species;
the effect of NE would be much greater than it currently is, owing to the significant increase in not only
GsaGTP, but also GsQGDP (see Figure 66). We did not find the adrenergic activation of AC to be
problematic in reproducing experimental data on SANC modulation by NE and Iso, so we are fairly
confident that our decision on this issue is correct.
For determining the rates of GTP hydrolysis by Gs and G1, we presented measurements from a number of
studies in Table 5 and Table 6. The kh value we chose (~0.4 /min) is close to what is generally accepted
(122). The ka, measurements show a bit of variance though: the Gs measurements were made using rabbit
proteins (35, 36, 128), and tend to have larger values than the G1 measurements, which coincidentally
were made using rat protein (189) or recombinant G-protein from cDNA of unspecified origin (213). In
our model of the rabbit SANC, we use a single kcar value of 10 /min for both Gs and G1 based on the
reported values for rabbit Gs. A single catalytic rate is generally considered sufficient to summarize this
property across G-protein subtypes (122). A much higher rate was reported by Breitwieser and Szabo,
who estimate kca,=135/min in bullfrog cardiac myocytes (38). These authors obtained this estimate
through observation of IK,ACh and argue that hydrolysis rates in vivo are larger than in solubilized systems.
We concluded that this value is questionable because it was obtained using hydrolysis-resistant GTP
analogues and nanomolar concentrations of ACh to derive a linear relationship between ACh
concentration and IKACh activation rate, and then extrapolated this relationship to 160 nM ACh, at which
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concentration the rates of hydrolysis and IK,ACh activation are equal. The authors also mention that under
control conditions, nanomolar ACh concentrations failed to activate IK,ACh, and activation only occurred
after the addition of non-hydrolyzable GTP. Because of the multiple system perturbations, the use of non-
hydrolyzable GTP analogues to estimate GTP hydrolysis rate, and the linear extrapolation, we find this
data questionable. However; the authors do bring up a valid point by questioning the applicability of in-
vitro G-protein kinetics to in-vivo systems. For example, it has been noted that Gsa* bound to AC
hydrolyzes GTP more rapidly than free Gsa*, implying that interaction with AC and other GAPs may
happen in-vivo but would not be observed in-vitro if the appropriate components are not explicitly
included (see (269) for a review).Most of our G-protein kinetic constants were derived from in-vitro
experiments, so it is possible that the natural system behaves more rapidly (this also partly validates the
20x speedup we had to apply to the G-protein kinetics).
We modeled modulation of AC by Gs and G1. There is also evidence showing that both cardiac AC
isoforms are inhibited by adenosine, PKA, and Ca 2 (164, 179, 269). We do not include these effects
because their mechanisms are not as well-understood as those of G-protein interaction, and because they
did not seem necessary in order to reproduce high-level SANC data.
GPCRs desensitize when exposed to ligand for an extended period (see Chapter 2 in (37)). Three
processes have been identified: 1) GPCRs can be phosphorylated, and as a result, their affinity for the G-
protein decreases. In an elegant negative feedback mechanism, G, subunits have been implicated in
stimulating GPCR kinases and contributing to GPCR phosphorylation (170, 190) 2) GPCRs are removed
from the external membrane and sequestered within the cell; however the effect of sequestration on
GPCR activity is unclear as there has been recent evidence that even sequestered p-adrenergic receptors
can continue to stimulate/inhibit their end effectors (see (165) for review, (52, 110, 247)). 3) The number
of potentially active GPCRs is reduced either by destruction of sequestered receptors or transcriptional
downregulation. We do not include these processes in our model because they happen on longer
timescales (phosphorylation and sequestration on the order of minutes, downregulation on the order of
hours (see Chapter 2 in (37)) and the mechanisms and effects are not fully understood. However, we
mention these processes here as a potential limitation of the model and as an issue to be addressed when it
is better understood.
It has also been shown that although p-adrenergic receptors typically cause a stimulatory effect, high
ligand concentrations cause activation of inhibitory G-proteins in cardiac myocytes (217). This is thought
to be a protective mechanism to guard against catecholamine overstimulation, and it seems to be
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modulated by the p-adrenergic receptor phosphorylation mechanism mentioned above and takes on the
order of 3 minutes before any effect is seen (217). Because of this long delay, and since we are modeling
a physiological system where catecholamine overstimulation should not be an issue, we do not include
this mechanism in our model.
The completed model, with all the assumptions mentioned above, produces Gs and G1 activation profiles
and rates very similar to those of the M2 muscarinic and p-AR. We had anticipated that the "indirect
inhibition" of AC, through removal of activated GsQGTP by high concentrations of free py would be a
powerful effect and a possible mechanism of direct cholinergic inactivation of the adrenergic system. Our
model did not show this to be the case, as the effect of ACh on reducing GSaGTP concentration was
minimal (see Figure 68).
The major cholinergic/adrenergic interaction occurs through the opposite effects of these two branches on
the overall AC rate. As seen in Figure 69, independent ACh or NE decrease or increase AC rate in a
sigmoidal manner, similar to the model used by Demir et al. (81), with the main difference being that our
model explicitly includes the activation of G-proteins, and that all the rate constants and affinities are
supported by experimental data. Furthermore, we show that concurrent stimulation of adrenergic and
cholinergic branches likewise produces reasonable effects: sympathetic stimulation can stimulate AC rate
despite inhibition by ACh (but only at low ACh concentrations), and vagal stimulation can inhibit AC
despite activation by adrenergic agonists. The powerful effect of direct cholinergic inhibition of the
adrenergic system is also seen, since sympathetic stimulation has almost no effect on AC rate for ACh
concentrations >0.1 pM.
3.9 Conclusion
We developed a G-protein and AC model by studying in detail the major reactions that define these
molecules. The stimulatory and inhibitory G-proteins are characterized by GTP-binding, dissociation, and
GTP hydrolysis, where the first two reactions are catalyzed by interaction with liganded GPCRs (M2-
muscarinic receptors and p-ARs). The activation of GPCRs through the release of neurotransmitter by the
sympathetic and parasympathetic nerve varicosities speeds the activation of respective G-proteins, which
interact with AC and either stimulate or inhibit its rate. AC generates cAMP, which is an important
second messenger in the cell, and modulates many cellular functions.
Our model was constructed in a bottom-up manner in order to utilize all of the available experimental
data. This approach generated reaction rates that are more than just model parameters: the parameters in
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our model all have specific meanings because they represent actual reactions. This is different from other
high-level models where parameters are sometimes arbitrarily placed in order to reproduce a desired
behavior, and a large uncertainty surrounds their actual value and meaning. Due to the explicit nature of
our model, new experimental data can more easily be incorporated to improve the accuracy of any one
reaction, or to replace entire mechanisms if necessary. It also lets us make some basic-science
conclusions: for example, illustrating the importance of subcellular compartmentalization, or the
ineffectiveness of py-mediated inhibition of GsLGTP.
Despite being very thorough, our model contains a number of limitations arising from the simplifying
assumptions we made. The biggest limitation of our model is that we did not include
compartmentalization of G-proteins, GPCRs, and AC. More data on this topic is becoming available
however, and we suspect that future models that incorporate second messenger localization will have
much better performance and will shed new light on the real molecular mechanisms driving the processes
within the cell. Another limitation of our model is that we did not consider interactions with regulatory
proteins like RGS and GAPs, and this likely contributed to the need for a 'speedup factor' of undetermined
molecular origin. Finally, we did not include the long-term processes of receptor desensitization, or the
co-stimulation of both the stimulatory and inhibitory G-proteins by the same GPCR family.
Despite all these potential limitations, the model in its current state produces reasonable Gs and G1
activation dynamics and cAMP synthesis rates. It also shows the relative effectiveness of simultaneous
adrenergic and cholinergic stimulation, and sets the stage for computing downstream second messenger
activation and ion channel modifications that ultimately result in changes in HR.
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4 PHOSPHODIESTERASE (EC 3.1.4)
4.1 Overview
This chapter describes the hydrolysis of cAMP by the enzyme phosphodiesterase. We provide two
models: 1) a full model with two distinct phosphodiesterase types and explicit modulation of hydrolysis
rate by Ca2'-calmodulin and cGMP, 2) a reduced model that is described by a single equation and
provides the overall cAMP hydrolysis rate appropriate for the specific chemical environment of the
sinoatrial node cell.
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Figure 70. High level illustration of phosphodiesterase (PDE)-mediated hydrolysis of cAMP
entire model originally shown in Figure 4 (see original figure for key).
in the context of the
Full Model
e Sinoatrial node cells contain two phosphodiesterase types: PDE1 and PDE3, both of which exist
in soluble or membrane-localized forms
e PDE1 is activated by Ca 2 -calmodulin and cGMP, and it hydrolyzes both cGMP and cAMP (see
Figure 72)
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* PDE3 hydrolyzes only cAMP; cGMP competitively inhibits this activity (see Figure 72)
" The PDE subtype distributions between cytosolic and membrane-localized fractions, affinities,
and catalytic rates are from experimental measurements and the proposed mechanisms are based
on the structure of the protein and reproduce experimental data
Reduced model
* The overall cAMP hydrolysis rate by the full model was evaluated at extremes of Ca2+
calmodulin and cGMP concentration encountered by a sinoatrial node cell and this relationship is
well-described by a Hill function
" The reduced model is similar to the phosphodiesterase model used by Demir et al. (81), but more
rigorously derived and with more accurate absolute hydrolysis rate which agrees well with
another published phosphodiesterase model
e We use the reduced phosphodiesterase model in our overall model of autonomic nervous system
regulation of sinoatrial node cell function
Results
* The phosphodiesterase model in conjunction with the adenylate cyclase and G-protein models
produces a baseline cAMP concentration of 3 jiM, in line with experimental values
* Maximal parasympathetic and sympathetic stimulation produce cAMP concentrations on the
range 0.3-10 ptM
* The rate of cAMP change (through the combined activity of phosphodiesterase and adenylate
cyclase) is rate limiting for parasympathetic stimulation, changing the time required to reach 95%
of steady-state value from ~1 s to 4-5 s. This process is not rate limiting for sympathetic
stimulation. See Figure 77
4.2 Introduction
cAMP is hydrolyzed by enzymes called phosphodiesterases (PDEs). For recent reviews of PDE types,
function, and regulation, see (72, 263); here we provide a high-level summary and focus on the
characteristics pertinent to our rabbit SANC model. PDEs are classified based on properties of their
catalytic domains (class I, II, III), with all mammalian PDEs belonging to class I. This class houses 11
families (PDE 1 -PDE 11), and each family has multiple variants generated through a variety of promoters
and alternate splicing. The PDE families differ in cyclic nucleotide selectivity (cAMP or cGMP),
regulatory effects (stimulation/inhibition by cAMP/cGMP, phosphorylation, etc.), and localization on the
species, organ, and intracellular levels. The effects of PDEs are broad, through downstream effects of
cAMP regulation, but also through direct interaction with receptors, ion channels, and various other
intracellular proteins (see Fig. 4 in (72)). It has also been recently shown that PDEs act in specific
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compartments of cardiac myocytes, and that this localization has important implications for their function
(for review, see (176)). We recognize that insufficient data exists to formulate a complete PDE model so
we focus on the main features: cAMP and cGMP hydrolysis and regulation by cGMP and Ca2-
calmodulin (Ca-CaM). This approach follows the example of Demir et al. (81), where an even simpler
model featuring only hydrolysis of cAMP was used with success. In our model, as in the Demir model,
the main purpose of PDEs is to allow for a steady-state cyclic nucleotide concentration despite ongoing
synthesis by AC and negligible membrane permeability to cAMP (285, 363).
PDEs contain two important structural domains: a single catalytic site which can bind cAMP and cGMP
with varying affinities, and regulatory sites that bind Ca -calmodulin (Ca-CaM) or cGMP, or serve as
phosphorylation targets for kinases (for a review see (72)). The presence of a single catalytic site that can
bind either cyclic nucleotide implies that cAMP and cGMP may competitively inhibit the other's
hydrolysis depending on their relative affinities for the catalytic site. This indeed seems to be the case, as
measurement shows good agreement between K and Km (317). Binding of regulatory entities may alter
the selectivity of the catalytic site or the maximal catalytic rate (62).
PDEs have a profound effect on cardiac contractility, so the bulk of investigation has focused on the
effects of PDE inhibitors in ventricular cells (for review see (263)). These studies indicate that PDE3 is
the major family found in mammalian cardiac myocytes, it exists in membrane-bound and soluble forms
(the membrane bound form is mainly confined to sarcoplasmic reticulum, SR), and the majority of cAMP
hydrolysis happens in the cytosol (263). PDE3 hydrolyzes both cAMP and cGMP, has a high affinity for
cAMP (KM<1pM in rabbit, <0.3pM in human) and has a maximal hydrolysis rate for cAMP that is 5-10
times higher than for cGMP, and is inhibited by cGMP with a K, <1p M (263). In addition to PDE3, rabbit
ventricular myocytes have been found to contain PDE1 and PDE2, and human ventricular myocytes
contain PDEl-4 (263, 317). From PDE inhibitor studies on rabbit ventricular myocytes, Shahid and
Nicholson conclude that under physiological conditions, cAMP levels are controlled mainly by PDEI and
PDE3, while cGMP is regulated by PDEl and PDE2 (293).
A number studies in rabbit SA node cells were also conducted (317-320, 328, 342, 352, 363). These
studies support the general observations from cardiac myocytes but also illustrate that PDE1 and PDE3
are the main families responsible for cAMP and cGMP hydrolysis in the rabbit SANC. Figure 71 shows
the cAMP and cGMP hydrolysis rates in the supernatant fraction (soluble proteins) of rabbit SAN
homogenate in various fractions of a protein separation column at low (0.4 pM) and high (100 pM, inset)
substrate concentrations (317). The peaks of hydrolytic activity (labeled FI-FIII) indicate distinct PDE
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Figure 71 The dominant cAMP and cGMP hydrolyzing PDE families in cytosol are fractions Fl and FIII; these
fractions correspond to PDE1 and PDE3, respectively. Figure from (317), cGMP (e) hydrolysis and cAMP
hydrolysis (o) are indicated as a function of elution fraction. At low substrate concentrations (main figure), cAMP
hydrolysis is split between PDEl and PDE3 (twice as much hydrolysis by PDE3 as PDEl, judging by areas under
peaks), whereas PDE1 dominates at high concentrations (inset). cGMP is hydrolyzed by PDEl only, at both low and
high substrate concentrations. PDE2 was shown to hydrolyze cGMP 4x faster in the presence of saturating amounts
of Ca-CaM, but even as such, its contribution is less than that of PDEL. Direct information is not available for the
dominant families in the sarcolemmal fractions, but cyclic nucleotide specificity and total hydrolysis rates (317), as
well as the presence of a transmembrane domain in PDE3 (see Fig 1 in (72)) imply that PDE3 is localized to the
sarcolemma.
families, and the numbering convention is in line with that used in ventricular myocyte experiments (FI
corresponds to PDE1, FII to PDE2, etc.) (77, 293). Furthermore, the defining characteristics of each PDE
family (PDE1 is Ca-CaM stimulated, PDE3 is cGMP inhibited (263, 293)) match with those seen in the
corresponding fractions in Figure 71. This figure illustrates that at both high and low concentrations, the
majority of cGMP hydrolysis is due to PDE1. Alternatively, cAMP is hydrolyzed by both PDE1 and
PDE3 at low substrate concentration, but PDE1 dominates at high substrate concentrations (implying a
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lower affinity but higher Vmax of PDEI for cAMP). We assume that these two families represent the bulk
of cyclic nucleotide hydrolysis in the cytosol and membrane, but allow for different abundances in these
two regions. Below we use pertinent experimental measurements to build a model of PDE1 and PDE3
activity in the rabbit SANC.
4.3 PDE Model
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Figure 72 Schematic of PDE1 and PDE3 activity and regulation by cGMP and Ca-CaM. The catalytic site of both
PDE 1 and PDE3 can bind cAMP and cGMP, which compete with each other (catalytic site reactions shown going
left-right). PDE 1 also has a regulatory site that can bind cGMP or Ca-CAM and lead to faster catalytic rates
(regulatory reactions shown going up-down).
The overall model of PDEl and PDE3 activity is diagrammed in Figure 72. This model is supported by
PDE structure and is the minimal model needed to reproduce all the functional observations quantified by
Taniguchi et al. in the rabbit SAN (317, 320). The catalytic site of PDE1 and PDE3 can bind both cAMP
and cGMP with affinities Km and K for PDE 1, respectively, and KM3 and K 3 for PDE3. PDE 1 also has a
regulatory site which can bind either Ca-CaM or cGMP with affinities Kc and KA, respectively. Both of
these regulators have been shown to increase the hydrolysis rate of cAMP or cGMP (317). To keep the
model simple, we assume that Ca-CaM and cGMP bind the same regulatory site competitively, and that
this binding only affects the catalytic rates (a-f in Figure 72) and not the substrate affinities (KM and K).
We make these assumptions because insufficient data exist to permit estimation of the additional
parameters required by a more general model where both cGMP and Ca-CaM can be bound at the same
time. A final detail which is not represented in Figure 72 is that the PDEs are distributed between the
membrane and the cytoplasm; this distribution is specified by the fraction of PDE1 and PDE3 in the
membrane Mi and M3, respectively. The parameter values are set as described in Table 11.
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Table 10 Cyclic nucleotide hydrolysis data from (317), at 30 'C and 0.4 pM substrate concentration.
Total
Soluble
Membrane-bound
cAMP hydrolysis
(pmol/min/mg protein)
32±1 (100%)
9±1 (28%)
26±2 (81%)
cGMP hydrolysis
(pmol/min/mg protein)
120±10 (100%)
60± 10 (50%)
80± 10 (67%)
Table 11 PDE complete model parameters for rabbit SANC model at 37'C.
Parameter Source
K=8.3 pM
KI=2 gM
Km3=0.8 pM
K,3=0.1 pM
M1=0.5
Affinities reported by Taniguchi et al. (317)
PDE1 is the only PDE that hydrolyzes cGMP (see Figure 71), and
was measured to be roughly equal between the cytosolic and
fractions at low cGMP concentration (see Table 10).
M3=0.8
a=17.4 pM/min
g-12 pM/min
b=54 pM/min
KA=0.3 pM
c=35 pM/min
Kc-2 pM
d=130 jiM/min
e=130 pM/min
f-180 pM/min
cGMP hydrolysis
membrane-bound
In the absence of cGMP and Ca-CaM, and at 0.4 pM cAMP: 1) total cAMP hydrolysis
has been measured as 4.8 pM/min (see Table 12). 2) -0.75 of the total cAMP
hydrolysis happens in the membrane-bound fraction (see Table 10). 3) in the cytosolic
fraction, cAMP hydrolysis by PDE3 is about 2x that by PDE1 (see Figure 71). These
three observations allow us to write three equations, which can be solved for M3 , a, and
g.
a (0.4 / (0.4+ K, )) + g (0.4 / (0.4 +K13)) 4.8
aM, (0.4 / (0.4 + KM )) + gM (0.4 / (0.4 + KM3 ))= 0.75-4.8
2a(1- M )(0.4 /(0.4+ K ))= g(1 -AM3 )(0.4/(0.4 + KM3 ))
These values reproduce the data in Figure 73B (b=3.l a) (see reproduction in Figure
74). The Hill coefficient for this reaction is 2
A saturating concentration of Ca-CaM causes cAMP hydrolysis rate to double, c=2a
(317)
This dissociation constant and a Hill coefficient of 2 reproduce the data in Figure 73A,
see reproduction in Figure 74A. We assume that the affinity of PDE1 for Ca-CaM is
the same as that of PDE2, since only data for PDE2 are available.
In the absence of cAMP and Ca-CaM, and at 0.4 pM cGMP, total cGMP hydrolysis
rate is 22 jM/min (see Table 12): d(0.4 /(0.4+ K,))= 22
Taniguchi et al. report standard Michaelis-Menten kinetics for cGMP hydrolysis by
PDE1 (317); this implies that cGMP binding the regulatory site does not affect cGMP
hydrolysis rate, so e=d.
A saturating concentration of Ca-CaM causes cGMP hydrolysis rate to increase by 1.4-
fold,f=1.4d (317)
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Table 12 Measured hydrolysis rates at 0.4 ptM substrate concentration, 30'C, rabbit SANC homogenate.
Nucleotide Reported hydrolysis rate, 30 'C Converted hydrolysis rate, 37C Source
(pmol/min/mg protein) (pM/min)*
19.9 3.6 (320)
cAMP 27 4.8 (317)
32 5.7 (317)
cGMP 120 22 (317)
see section 9.2 for unit conversions
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Figure 73 Modulation of PDE2 and PDE1 by Ca-CaM and cGMP. Figures from (317). A. rate of cGMP hydrolysis
([cGMP]=0.4 ptM) by PDE2 is shown as a function of saturating amounts of calmodulin (the "activator of the rabbit
brain" referred to by Taniguchi et al. (317) is a protein first purified by Cheung (62) and later shown to be
calmodulin by Means and Dedman (236)) and the indicated concentration of Ca2+. The effect of saturating
concentration of Ca 2 and varying amounts of calmodulin produced a similar curve. cGMP hydrolysis by PDE2 was
most sensitive to Ca-CaM activation (4x baseline); the effect on cAMP and cGMP hydrolysis by PDEl was 2x and
l.4x baseline, respectively (317). B) rate of cAMP hydrolysis ([cAMP]=0.4 iM) by PDE1 as a function of cGMP
concentration. All measurements at 30'C.
The PDE1 and PDE3 models are specified by equations (l 2 ).fGMP,fCaM andfhse, are the fractions of PDE1
activated by cGMP or Ca-CaM, and at baseline, respectively. veAMPI and VcGMPJ are the hydrolysis
velocities of cAMP and cGMP by PDEl (soluble plus membrane-bound), and veAmp3 is the hydrolysis
velocity of cAMP by PDE3 (soluble plus membrane-bound). To obtain only the membrane-bound PDE
activity, the total activities in these equations can be multiplied by Mi or M 3 (or 1 -Mi and 1 -M 3 for soluble
portion).
fcGMP =[cGMP]2 / cGMP]2 + K( + [CaM] 2 / K)
fCaM = CaM]2 / ([CaM]2 + K (1+[CGMP]2 / K))
fbase 1 - fcGP - fCaM
vCAMPI=(afbase+bfcGMP+ CfCaM) [cAMP][CA MP]+ Km (1+ [cGMP]/K) (12 )
GMP =(df fC f [cGMP]
v1 base +cGMP +CaM )[cGMP] + K, (1 +[cAMP]/ Km)
= 
[cAMP]
[cA MP]+KM3 1+ cGMP|/ K, 3 )
4.4 Model Reduction:
The full model presented above contains many details that were necessary in order to quantify its
properties based on the available experimental data. For purposes of cAMP regulation within a SANC
model however, that level of complexity is unnecessary. We therefore reduce the complete model to a
total PDE rate by calculating the actual PDE rate according to the full model at fixed cGMP and Ca-CaM
concentrations and fitting that relationship with a Hill function. We used extreme cGMP concentrations
measured in the SANC at rest and with maximal ACh stimulation (318), and extreme Ca-CaM
concentrations based on their values in the Maltsev model. The resulting cAMP hydrolysis rates were
well-fit by a single Hill function (see Figure 76) of the form in equation (13):
VPDE VPDEmx [cAMP]"PDE / ([CAMP]nPDE + K nPDE (13)
4.5 Results
As we can see in Figure 74, Figure 75, and Table 13, this model reproduces the following features of the
experimental system:
1) Activation of PDE1 by Ca-CaM (2x activation of cAMP hydrolysis is shown in Figure 74A; cGMP
hydrolysis increased by 1.4x, as reported by Taniguchi et al. (317), not shown).
2) Activation of PDE 1 by low concentrations of cGMP; competitive inhibition by high concentrations of
cGMP (Figure 74B)
3) Competitive inhibition of PDE3 by cGMP (Figure 75C).
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4) Distribution of cAMP and cGMP hydrolysis in the cytosolic and membrane fractions of SANC
homogenate (Table 13)
Ca/CaM activation of PDE1 cGMP activation/inhibition of PDE1
0.8 -A BM_ 0
E0.80
0.60
_n cn 0.6
20.4 0.4
0.2 S PDE2 data (scaled) 2- 0.2 0 Data (scaled)
PDE1 Model (cAMP) PDE1 Model
0 0-
102 100 10 10 100 10
[Ca-CaM] ( M) [cGMP] (MM)
Figure 74 Reproduction of data from Figure 73 using complete PDE1 model. The line in A was generated with
[cAMP]=0.4 pM, [cGMP]=0 pM, and [Ca-CaM] as indicated; only the cytosolic activity of PDEl is shown. The
data points in A were digitized from (317) and vertically shifted and scaled to lie on top of the model line (shifting
and scaling was necessary because the units and baseline rate of the data were different from the model). The line in
B was generated with [cAMP]=0.4 pM, [cGMP] as indicated, and [Ca-CaM]=0 pM; only the cytosolic activity of
PDE1 is shown. The data points were scaled to line up with the model (scaling necessary since units of data and
model are different).
Figure 74 shows the data that were used to determine the values of parameters Kc, KA, and b. The model
is justified not only by the excellent fits to the data, but also by the molecular structure of PDE 1, which
contains two regulatory sites (72). The presence of multiple regulatory sites supports cooperative binding
(the model uses a Hill coefficient of 2, present as the exponents in equations (12)), which was necessary
to replicate the steep up-slopes. The model-generated distribution of PDE activity between the soluble
and membrane-bound fractions is shown in Table 13, which can be compared to the data collected by
Taniguchi et al. (317) and reproduced in Table 10. The absolute value of the hydrolysis rates is different
between the two tables because of disparate units and temperatures, but the percent of cAMP and cGMP
hydrolysis occurring in the soluble versus membrane-bound fractions match closely. The values in Table
13 were generated by using equations (12) with the substrate concentration indicated in the table, the
presence of a single cyclic nucleotide at a time, and no Ca-CaM. The parameters Mi and M3 were used to
separate the total PDE1 and PDE3 hydrolysis velocities into soluble and membrane-bound portions. As
indicated in the table footnotes, about twice as much cAMP is hydrolyzed by PDE3 compared to PDE 1 in
the soluble fraction (see Figure 71), and PDE3 dominates cAMP hydrolysis in the membrane-bound
fraction at low [cAMP].
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Table 13 Cyclic nucleotide hydrolysis model results at 37 'C and 0.4 pM substrate concentration.
cAMP hydrolysis
(pM/min)
cGMP hydrolysis
(gM/min)
Total 4.8 (100%) 22 (100%)
Soluble 1.2* (25%) 11(50%)
Membrane-bound 3.6k (75%) 11(50%)
* 0.4 due to PDE1, 0.8 due to PDE3. t 0.4 due to PDE1, 3.2 due to PDE3
PDE1 activity as a function of cAMP, Ca-CaM, cGMP
40
100 101
[cAMP] (pM)
PDE3 activity as a function of cAMP and cGMP
100 101
[cAMP] (pM)
10-1
Figure 75 cAMP and cGMP hydrolysis rates by PDE 1 and PDE3. In all panels, [cAMP] is on the abscissa, and three
[Ca-CaM] and [cGMP] are shown as separate lines. The [Ca-CaM] are indicated in the legend of panel A; the
nonzero values were picked because they are the mean [Ca-CaM] in the cytoplasm and sub-membrane space
produced by the Maltsev model during steady-state oscillation. [cGMP] are indicated next to each curve (pM). The
nonzero [cGMP] are the mean (0.075 pM) and maximum (0.4 pM) concentrations in rabbit SANC at rest and after
maximal ACh stimulation, respectively (318). Panels B and C show processes that are insensitive to Ca-CaM so they
only include the effect of cGMP. A. cAMP hydrolysis rate by PDEl. B. cGMP hydrolysis rate by PDE1. C. cAMP
hydrolysis rate by PDE3.
The summary of PDE1 and PDE3 activity is shown in Figure 75. This figure shows the activation of
PDEl-mediated cAMP hydrolysis by both Ca-CaM and low concentrations of cGMP. The results in
Figure 75A point to an interesting consequence of this dual regulation: Ca-CaM tunes the sensitivity of
PDE 1 to cGMP, wherein the effect of increasing [cGMP] is large in the absence of Ca-CaM, but becomes
negligible as [Ca-CaM] increases. At the physiological [cGMP] shown in this figure, we appreciate that
hydrolysis of cAMP by PDE1 is only stimulated due to the rather low affinity of the PDE1 catalytic site
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for cGMP which makes competitive inhibition negligible. On the other hand, PDE3-mediated cAMP
hydrolysis is significantly inhibited by physiological [cGMP]. cGMP hydrolysis by PDEI is inhibited by
cAMP in the physiologic [cAMP] range (1-10 pM), as shown in panel B.
Figure 76 shows the total PDE rate under extreme cGMP and Ca-CaM concentrations. The cGMP
concentrations are the values at baseline and maximal ACh stimulation as in Figure 75. The Ca-CaM
concentrations were calculated by taking the average Ca-CaM concentrations in the subspace and cytosol
for the baseline Maltsev model (6.2 and 5 piM, respectively), and scaling them by 0.75 and 1.4 to
represent extremes during cholinergic and p-adrenergic stimulation (Ca-CaM changes proportional to
intracellular Ca 2 , and fig 7 in (227) shows the submembrane space Ca concentration changes by these
ratios from the baseline value upon application of Iso and ACh).
Total PDE Hydrolytic Rate
50
Low cGMP, Low Ca-CaM
40 ........ Low cGMP, High Ca-CaM
High cGMP, Low Ca-CaM
30 ........ High cGMP, High Ca-CaM
-- 
- Best Fit
a 20 Fit Params:
KM = 6.95 VM
O 10 n = 0.9
v max 48 M/min
0
10 100 101 102
[cAMP] (jiM)
Figure 76 Total PDE hydrolysis at extreme cGMP and Ca-CaM concentrations along with best fit. Low and high
cGMP (0.075, 0.4 pM) are each paired with low Ca-CaM (3.8 pM in cytosol, 4.7 pM in submembrane space) or
high Ca-CaM (7 pM in cytosol and 8.7 pM in the submembrane space). Parameters were obtained by least-squares
fitting (1sqcurvef it in Matlab) to all four curves on the displayed cAMP range and are shown on the figure.
The independent effects of vagal and sympathetic stimulation on cAMP rate are shown in Figure 77.
Sympathetic stimulation causes an increase in cAMP from the baseline value of 3pM to ~10 pM, with a
small difference between the peak and SS value emerging for stimulation frequencies >10 Hz. Vagal
stimulation lowers cAMP concentration from the baseline value to -0.3, and virtually no difference
between the steady-state and peak values. The rates of cAMP change tell a similar story as what we saw
with p-AR and M2-muscarinic receptor activation, and Gs and G1 activation. The sympathetic effect is
still slower than the vagal, with a half-time on the order of 7s and a 0.95 time around 20 seconds. These
rates are about the same as what we saw for Gs activation in Figure 67. The vagal effect remains faster,
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with a half-time on the order of 1-2s and 0.95 time on the order of 4-5s, a slight slowing from the -0.5s
and 1-2s times, respectively, for G1 activation (Figure 67).
The effect of simultaneous sympathetic and vagal stimulation can be seen in Figure 78. This figure is
similar to the figure of AC rate Figure 69, but reflects the equilibrium cAMP concentrations that result
from its synthesis by AC and its destruction by PDE. In the absence of simultaneous SS or VS (0 lines),
we see the expected sigmoidal decrease in cAMP with ACh, and a sigmoidal increase with NE.
Sympathetic stimulation in the presence of moderate ACh concentrations (<0.1 pM) causes cAMP to
increase rather effectively, but higher ACh concentrations render this effect virtually negligible.
Simultaneous vagal stimulation during NE application produces the expected effect, reducing cAMP with
increasing concentrations, and two differences from the ACh/SS simulations: VS reduces cAMP across
the whole NE range, and it becomes more powerful with increasing VS (0-5 Hz VS causes a downward
shift in the cAMP curves, whereas 7 Hz also shifts the curve to the right).
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10- S PeakSSS
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0 .1 . . . . ... 
. . . .
100-
10 S0.95E
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V 0.95
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Stim Freq. (Hz)
Figure 77 cAMP sensitivity and rate of activation/inactivation (model simulation). A. Steady-state (SS) and peak
cAMP concentrations are shown as functions of sympathetic (S) and vagal (V) stimulation frequency, respectively.
B. The rates of activation from a baseline level (-3 ptM cAMP) to the peak/min values indicated in A. did not follow
an exponential time course, so we show the time required to reach 0.5 and 0.95 of peak value. Missing values
indicate frequencies where the first stimulus surpassed either the 0.5 or 0.95 point.
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Figure 78 cAMP concentration is modulated by both sympathetic and parasympathetic activity (model simulation).
Note the reverse ACh scale; showing maximal cholinergic effect on the left and maximal adrenergic effect on the
right. In the ACh regime, four sets of simulations were done, with simultaneous sympathetic stimulation (SS) at 0, 2,
5, and 10 Hz as labeled. In the NE regime, simultaneous vagal stimulation (VS) frequencies are similarly indicated.
The baseline panel shows the cAMP concentration in the absence of neurotransmitter. neurotransmitter
concentrations were clamped in the neuroeffector junction and EJS (no effect of reuptake / absorption / hydrolysis).
4.6 Discussion
We developed a PDE model for the SANC which uses measured affinities, regulation by cGMP and Ca-
CaM, and hydrolysis rates (total, and their distribution between the cytosol and submembrane space). The
complete model was then reduced to a simple relationship between cAMP concentration and hydrolysis
rate, similar to the PDE model used by Demir et al. (81). We use the reduced PDE model together with
our AC model in order to produce steady-state cAMP concentrations that show the expected increase with
adrenergic stimulation and decrease with cholinergic stimulation (Figure 77 and Figure 78). The baseline
cAMP concentration produced by our model is 3pM. This value falls within the range of measured cAMP
concentrations listed in Table 14. Furthermore, the maximum cAMP value generated by the model under
maximal adrenergic stimulation (~17 pM) matches the cAMP concentration (18 jM) obtained by
blocking PDE activity in rabbit SANC (342). In our model, complete blockage of PDE would result in
infinite cAMP concentration because PDE is the only mechanism for removing cAMP synthesized by
AC; we say these numbers match because they at least give us confidence that maximal cAMP
concentration should be on the order of 10 pM since unopposed cAMP production in the real cell
produces a concentration of 18 pM. Of course, there are experimental considerations such as incomplete
blockage of PDE, or whether the system reached steady state (it appears that PDE inhibition proceeded
for 5 minutes before cAMP was measured), but this data point is good enough to provide some support
for the overall order of magnitude of cAMP concentrations produced by our model.
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Table 14 cAMP measurements in mammalian cells. For unit conversions, see section 9.2
Source System cAMP Measurement Concentration estimate(pmol/mg protein) (pM)
Webb et al. 2001 (350) A7r5* 100 12.4Cultured VSMC 44 5.4
Vinogradova et al. 2006 (341) Rabbit SANC 100 12.4
Vinogradova et al. 2008 (342) Rabbit SANC 20 2.5
Taniguchi 1977 (320) Rabbit SANC 40.6 5
* Arterial smooth muscle cell line. t rat aortic vascular smooth muscle cell
Our model also produced rates of cAMP change that are reasonable: for sympathetic-mediated changes,
the rate limiting factor is still the activation of p-ARs; however a slight decrease in activation rate was
seen for vagally-mediated changes. This implies that the rate of AC synthesis/breakdown starts to be a
rate-determining step in the parasympathetic modulation of HR.
Finally, our model compares favorably with another published PDE model. The maximal baseline cAMP
hydrolysis rate in our model is 48 pM/min (reduced model total PDE rate). This value is in agreement
with the value used by Banks et al.: 8 x 10~6 mol/min/kg tissue, which converts to ~17 pM/min per cell
using the mass and cytoplasmic volume of one SANC model cell (11). The cAMP affinity used by Banks
et al. (1 AM) is also close to that in our model. On the other hand, the Demir et al. model used a much
higher maximal rate of 20 pM/s (per second!) (81). This value appears to have been picked arbitrarily in
order to counterbalance the large baseline cAMP generation rate of 8 pM/s and to reproduce the desired
steady-state [cAMP] of 3 MM. As the purpose of PDE in the Demir et al. model was to maintain cAMP
homeostasis, the absolute value of the maximal rates were not critical. However, since our model is based
on actual experimental data describing PDE kinetics we maintain that our parameters are more correct in
an absolute sense. We also note that the maximal PDE rate of 48 MM/min is greater than the maximal AC
rate that our model generates (<35/min, Figure 69), which ensures that cAMP concentration cannot
increase without bound.
Despite developing a detailed PDE model and using it to reproduce experimental data as well as
believable cellular cAMP concentrations, we made a number of simplifying assumptions that need to be
discussed. For example, our complete PDE model was not built to reproduce cGMP hydrolysis rate at
high substrate concentration (100 MM cGMP). Taniguchi et al. show that at such a high concentration, the
cGMP hydrolysis rate is significantly faster (1,470 pmol/min/mg protein) than at 0.4 MM [cGMP] (see
Table 12) (317). This implies the presence of a low-affinity, high catalytic rate PDE. We did not include
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this species because physiologic cGMP concentration, even under maximal ACh stimulation, does not
exceed 1 tM (318).
In our SANC model, we do not explicitly include cGMP concentration, synthesis, or hydrolysis. This
decision was made in order to simplify this already complex system and because we reasoned that the
effect of this exclusion would not be significant. cGMP changes have been documented in response to
cholinergic stimulation of rabbit SANCs (318), and cGMP affects the rate of cAMP hydrolysis by PDE
(see complete model developed here, Figure 72). However, the minimal and maximal cGMP
concentrations (0.075 and 0.4 pM (318)) do not have a large effect on PDE rate in our model (Figure
75,Figure 76). As we show in Figure 75, the regulatory effect of cGMP on PDE is made negligible by the
presence of relatively high Ca-CaM concentrations in the rabbit SANC. Furthermore, including an
explicit cGMP synthesis and hydrolysis system would have required the introduction of a number of rate
constants and affinities that would come with their own uncertainties attached (especially because the
cGMP system does not seem as well-understood as the AC/cAMP system). Finally, the Demir model also
considered cGMP concentration to be constant and did not mention that any limitations were caused by
this assumption. We do concede however, that if the effect of cGMP on the cAMP balance is not
negligible, its exclusion in our model would tend to underestimate the effects of vagal stimulation on
cAMP concentration.
We excluded PDE2/4 from this model because the FII peak, which corresponds to PDE2 and PDE4 (see
Fig. 5 and 6 in(293)), had very low hydrolytic rate for both cAMP and cGMP according to Taniguchi et
al. (317). Another discrepancy between the rabbit SANC and rabbit ventricular PDE1 is that the effect of
Ca-CaM is significantly greater in the ventricle (16x activation (293)) than the SAN (2x activation (317)).
We replicated the rabbit SANC data and explain the difference as arising from cell-type specific PDE
differences; however, the possibility remains that differing experimental conditions or calmodulin quality
may be the true cause of this disparity.
Of the two PDE types we model, PDE1 and PDE3 differ in a number of ways: PDEl has a higher Vma
than PDE3 but a lower affinity for cAMP, and PDE3 is more selectively localized to the membrane.
Furthermore, membrane-bound PDE3 is localized to the SR in humans (221), a prime location for
regulating the cycling of Ca2+ that has recently been shown to have a major impact on SANC oscillation
rate (227). In fact, PDE inhibition studies in human and rabbit cardiac myocytes show a clear impact of
PDE3 on HR and contractility (168, 263, 266). A similar result was seen in rabbit SANC, where
inhibition of PDE3 increased Ca2 cycling and spontaneous firing rate (342). These properties and
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observations imply specific and different purposes for PDE1 and PDE3: the former is suited for
regulating bulk [cAMP] in the cytoplasm and may have an effect on PKA activation and downstream
effects on ion channels ("membrane clock"), whereas the latter exerts specific control over the cAMP
effects on the SR and Ca 2+ cycling ("calcium clock"). For now, this is just a hypothesis, and more
experimental data and a focused modeling study would be required to elucidate the unique roles (if any)
played by the different PDE families.
The biggest limitation of the PDE model as presented here, is that we do not consider
compartmentalization of PDE and cAMP in the cell. There has been much evidence pointing to the
potential functional implications of local cAMP pools which are created because localized PDE creates
diffusion barriers or otherwise limits the spread of cAMP from the site of synthesis ((13, 14, 188, 251),
see (72, 321, 365) for reviews). We did not model all this complexity due to insufficient data regarding
the size of these microdomains and unknown mechanisms of how PDE accomplishes this cAMP-
localization task. Beavo et al. also argued that (18) compartmentalization of cAMP was not necessary in
order to reproduce its functional effects. However, we did find a need to abstractly incorporate the effect
of compartmentalization, by including a cAMP speedup factor of 10 (see section 6.7). This rate was
necessary in order to reproduce high-level vagal and sympathetic stimulation data, and implies that the
molecular rates of cAMP synthesis and degradation as we have modeled them here are not necessarily
applicable when we consider cAMP to be diffused and equal within the entire cytosol. From our
experience with this model, the compartmentalization of second messengers is a feature that must be
included in future versions, when it is better understood mechanistically and functionally.
4.7 Conclusion
We constructed a detailed model of PDE 1 and PDE3 activity in the rabbit SANC, based on experimental
data that reported specific affinities, hydrolysis rates, and subcellular distribution of the enzyme. We used
a number of simplifying assumptions to reduce the model to a simple relationship that was appropriate for
the rabbit SANC, and verified that it works together with our AC model to generate reasonable cAMP
concentrations in response to adrenergic and cholinergic stimulation.
Our PDE model converts cAMP synthesis rate to steady-state cAMP concentration (the synthesis rate
equals the hydrolysis rate at steady-state), and compares favorably to previous PDE models. However, it
also has a number of limitations: it assumes a constant cGMP concentration, when cGMP is known to
change with cholinergic stimulation; it does not model all the PDE families known to exist in cardiac cells
and which may have distinct effects on cAMP concentration in specific locations; it assumes an even
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distribution of PDE throughout the cell and therefore does not create localized cAMP pools or
differentially regulate membrane from cytosolic components. Despite these limitations, our model is able
to reproduce the phenomena of HR regulation by the ANS. However, in the quest for a true understanding
of the molecular processes at play in the SANC response to ANS drive, we must continue to include new
data and mechanisms as they are made available, focusing our efforts by addressing the major model
limitations first. As with most models, the reward of such work would not be an improvement in the
"what," since relatively simple phenomenological models can reproduce input-output relationships very
well, but rather in the "how," as we would gain a rigorous mechanistic explanation for how cells function.
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5 PHOSPHOKINASE-A (EC 2.7.11.11)
5.1 Overview
This chapter describes the activation of phosphokinase-A by cAMP, as highlighted in Figure 79.
OPKA
% 0
Figure 79. High level illustration of phosphokinase-A activation by cAMP in the context of the entire model
originally shown in Figure 4 (see original figure for key).
Model
e Phosphokinase A is composed of two identical regulatory subunits and two identical catalytic
subunits. Binding of 2 cAMP molecules per regulatory subunit releases the associated catalytic
subunit which can then phosphorylate target proteins
e Phosphokinase A is a very complicated molecule, we present a minimal model
e Activation of phosphokinase A catalytic subunits by cAMP is modeled using a standard Hill
function to describe steady-state activation. Total phosphokinase A abundance, half-activation
cAMP concentration and Hill coefficient based on experimental measurements.
e The rate of phosphokinase A catalytic subunit activation is based on experimental values
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* The phosphokinase A model reproduces experimental data on PKA activation/inactivation due to
time-varying cAMP concentration (see Figure 85)
Results
e A wide range of phosphokinase A parameters are published; we summarize the data and provide
a theoretical explanation for this variance as a function of the phosphokinase A concentration
used in individual experiments
e Phosphokinase A activation is rate-limiting for parasympathetic stimulation, slowing down the
time required to reach 95% of steady-state value to ~10 s. See Figure 86
" Phosphokinase A activation reflects the effects of sympathetic and parasympathetic activity (see
Figure 87)
5.2 Introduction
Protein kinases phosphorylate a vast array of molecular targets and thereby modulate their function (for
reviews see (112, 321, 325, 326, 332, 365)). In the heart, phosphorylation has been shown to influence
membrane currents (3, 60, 129, 141, 270) and Ca2 cycling machinery (341). It is therefore important to
include protein kinase in our SANC model.
Over 60 different protein kinases have been identified (325), and have varying regulatory mechanisms,
phosphorylation targets, and cell type as well as cell compartment specificity (112, 321). The protein
kinase family most prevalent in heart tissue is cAMP-dependent protein kinase (cAPK, or protein kinase
A, PKA). In its inactive state, PKA exists as R2C2, comprising two identical regulatory (R) subunits and
two identical catalytic (C) subunits. Upon binding 4 molecules of cAMP (two per R), the C subunits are
released and available to phosphorylate targets: R2C2 + 4cAMP <-+ R2cAMP 4 + 2C ((75), (112, 321) for
review).
The R subunits interact with cAMP and structural proteins in the cell (202, 321, 332, 362) and can
undergo phosphorylation themselves (113, 152). There are two types of R subunit (each one with an a and
P subtype, (321, 332)): RI and RII, which define two functionally distinct forms of PKA: PKA I and PKA
II. RI and RII differ in affinity for cAMP (152, 321) and structural proteins (144). Because RII has a
much higher affinity than RI for structural proteins (144), PKA II can be localized in specific cellular
compartments whereas PKA I is soluble (74, 321). It has also been shown that cardiac myocytes contain
mostly PKA II whereas skeletal muscle contains PKA I (152). Finally, R subunits can be phosphorylated
leading to changes in apparent cAMP affinity (152) and kinetics of reassociation with C (279, 280). Since
the rate of R-C reassociation is decreased by phosphorylation, Buxbaum and Dudai have shown that it is a
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possible mechanism for long-term PKA activation/memory through autophosphorylation of RII (50). On
the other hand, RI does not undergo autophosphorylation (112, 152).
A number of C subunit forms exist, but "have similar chemical, physical, catalytic, and immunological
properties, as well as similar Km for ATP, protein substrate specificity, and the ability to interact with
either type I or type II R subunit" (112). C binds ATP with high affinity (Km=3-18 pM (4, 112)) and
various phosphorylation targets with similar affinity (Km=30-66 pM (4) or 200 pM (126)). The
phosphorylation reaction involves the transfer of a phosphate from ATP to the target (fast, >80 /s - 500 /s
depending on target, (4, 126, 371)), followed by the rate-limiting release of ADP (24-35/s (371)) that sets
overall phosphorylation turnover rate to ~20 /s (4, 371).
The activity of PKA is counterbalanced by protein phosphatases (PPs) that remove the phosphate groups
added by PKA. We implicitly model PP activity as playing a role in determining the steady-state
phosphorylation state of various protein targets.
5.3 Model
A thorough model of PKA regulation in Drosophila has been developed (50); however, brain RII in that
model is different from heart RII that we are modeling (351). Also, detailed models for catalytic subunit
activity exist (4, 126, 371). While we appreciate the importance of PKA in modulating SANC function, a
review of experimental data makes apparent the great complexity of this molecule and its sensitivity to
experimental conditions: for example, the concentration of enzyme used in experiments can shift the
apparent half-activation concentration of cAMP (Ka) by orders of magnitude ((18), Table 17),
phosphorylation and the presence of ATP significantly affect R-C reassociation kinetics (279, 280), and
Mg2 (73) and NaCl (249) affect maximal catalytic velocity. A complete PKA model would therefore be
overly complicated and would require many assumptions due to the lack of comprehensive experimental
data. We also note that other models of SANC modulation by the ANS do not include PKA explicitly (81,
96). We are concerned with the dynamics of SANC modulation, so to capture the contribution of PKA in
the second messenger cascade, we include only a minimal model featuring activation of C subunit by
cAMP. In defining this model, we use data to estimate physiologic PKA concentration, the physiological
Ka, and the rate of the activation reaction for the phosphorylated RII subunit (x). A model of
phosphorylation is also presented wherein the balance of phosphorylated and dephosphorylated protein
targets is a function of C and PP activity. We assume that PP is constant, so steady-state phosphorylation
is modeled as a function of C only (see section 6.5 for phosphorylation specification; here we focus on
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catalytic subunit activation). Our PKA activation model is shown on the right in Figure 80 and is
described by equation (14).
dC
= (2R2T- C)-'[cAMP] -xC (14)
dt K,
Activation
K, ror x/KR2C2+cAMP - 'R 2C2 cAMP4  - R2cAMP4 +2C R C+cAMP "' R cAMP+Cro/K
Phosphorylation
_. K r -~
C- T - CT ' C+TP| f(C)
T 'PP) TP
rD K p(PP)P+PP+IT: PP TP=- ' PP+ TP.
Figure 80 Model of PKA activation by cAMP and balance of phosphorylation by the C subunit and
dephosphorylation by PP. Activation: The R subunits are in rapid equilibrium with cAMP described by dissociation
constant KD. It is assumed that C cannot dissociate when cAMP is not bound to R; when R is saturated by cAMP, the
C subunits are released with Michaelis-Menten coefficient K and dissociation rate ro. The minimal model of C
subunit activation is shown to the right of the empty arrow: cAMP liberates C with an apparent activation constant
Ka; the overall rate of the reaction is limited by x, the reassociation rate of R and C. Phosphorylation: The
phosphorylation and dephosphorylation of target proteins (T) are diagrammed in detail on the left, and a simplified
model is shown on the right. We encapsulate phosphorylation with the functional changes it causes, so the modeling
aspects are discussed in section 6.5; we provide this diagram to illustrate the mechanism of
phosphorylation/dephosphorylation. The C subunits bind T with rapid equilibrium constant KT, followed by a
phosphorylation reaction with rate rp. The reverse reaction proceeds similarly, with the phosphorylated protein
target (TP) binding PP with Michaelis-Menten constant Kp, followed by the dephosphorylation reaction with rate rD.
In the simplified model, the phosphorylation reaction rate is a function of C,f(C), and the dephosphorylation rate is
a function of protein phosphatase p(PP).
The assumptions in our model are similar to those used by Buxbaum and Dudai (50): RII is treated as a
monomer that binds a single cAMP molecule and releases a single C. This contrasts the fact that the
regulatory unit exists as a dimer (R 2 C2), each R binds 2 molecules of cAMP, and releases 2 C subunits
upon dissociation, but this simplified model captures the necessary functionality with the benefit of a
reduced number of states and rate constants. We further assume that PKA does not dissociate in the
absence of cAMP; this is supported by the very high affinity of the RII and C subunits (<0.1 nM in the
presence of Mg2 + (143)). Finally, we assume that all regulatory subunits exist in a phosphorylated form
(see reasoning below), so we only model the phosphorylated kinetics. The model for C subunit activity is
also simplified compared to (4, 126, 371) by not modeling specific affinities and phosphorylation rates for
the various targets, but rather using just the concentration of activated C subunit to define the steady-state
phosphorylation balance for various protein targets (see section 6.5). The use of steady-state functions is
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justified by the presence of multiple phosphorylation sites on a single target protein, and complex effects
of phosphorylated sites on target protein conformation and function as well as interaction with other
cellular machinery that relies on phosphorylation as a signal for removal or up-regulation of specific
proteins. The PKA activation model parameters are summarized in Table 15 along with a brief description
of how they were obtained. A more thorough explanation can be found in the text.
Table 15 PKA model parameters for rabbit SANC model at 37 'C.
Parameter Source
R 2T-0.5 pM Measurements of kinase activity (correlated to abundance of C subunit), as well as
measurements of cAMP binding (correlated to abundance of R subunit) conducted in
rabbit heart tissue homogenate both indicate ~0.9-1 gM for each subunit (74). PKA is a
homodimer with two regulatory and two catalytic subunits (R2C2), so R2r-0.5 pM.
Ka=5 pM Apparent half-activation concentrations of cAMP from a number of studies were used to
infer the dependence of Ka on experimental PKA concentration (see Table 17) and this
linear relationship was evaluated at physiologic [PKA] to yield Ka. A similar analysis
yielded a Hill coefficient of unity, implying that the binding reaction is not cooperative.
x=0.2/min Obtained by fitting the R-C reassociation time course from (280) (see Figure 85). A rate
of 0.07/min fit the experimental data which were collected at 23 'C; this value was
converted to 0.2/min at 37 'C using a Qio of 1.7.
We calculate the abundance of PKA in rabbit SANCs from data published by Corbin et al. (74) and
reproduced in Table 16. Using either the activity of the C subunit or the amount of cAMP binding protein,
the total R subunit concentration in rabbit SANC is -0.9-1 pM giving a PKA holoenzyme concentration
of 0.5 pM (PKA holoenzyme is R2C2). This value is greater than that estimated in rabbit skeletal muscle
(0.23 pM (18)) but lower than that in rat and cow heart (0.55 and 0.8, respectively (74)). Furthermore,
this concentration lies in the middle of the PKA concentration range generally thought to exist in cells
(0.2-0.7 pM (112)).
Table 16 also shows that the total PKA activity is split equally between the membrane/protein bound
(particulate) and soluble (supernatant) portions. The distribution of RI and RII in these fractions is shown
in more detail in Figure 81. This figure shows that the membrane/protein associated PKA is exclusively
type II, whereas the soluble fraction contains both types. From the areas under the RI and RII peaks in
Figure 81, we compute that roughly 1/3 of the supernatant PKA is type I, whereas the entire particulate
fraction and 2/3 of the supernatant are type II. This means that PKA II is about 5x more abundant than
PKA I in rabbit heart; an observation supported by other studies (152). We therefore assume that all PKA
in rabbit SANC is type II and do not include a model of PKA I. Table 16 also shows the PKA activity
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ratio in the presence (+cAMP) and absence (base) of saturating cAMP; these values were used in
conjunction with Figure 81 to compute the relative abundances of RI and RII discussed above.
Table 16 Measurements of R and C subunit concentrations and PKA activation in rabbit SANC, reproduced from
(74).
PKA Activity cAMP binding protein PKA activity
(C subunit) (R subunit) ratio
U/g tissue M* nmol/ g tissue pMf base/+cAMP
Homogenate 53,500 0.97 0.42 0.91 0.15
Supernatant 33,100 0.60 0.21 0.46 0.09
Particulate 26,100 0.47 0.19 0.41 0.24
* converted from U/g tissue using 3x10 6 U/mg C, 40,000 g/mol C, 3.5x10-6 mg/cell, 1.6x10- 2 L cytoplasm/cell. 7
converted from nmol/ g tissue using the weight of the cell and volume of cytoplasm as above
300-
200-
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90-
0-
0
4
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Figure 81 Separation of RI and RII in rabbit heart particulate and supernatant fractions shows that the particulate
(membrane/organelle bound) PKA activity is entirely due to RII (second peak) while the supernatant fraction
(soluble PKA) is a mixture of RI (first peak) and RII. Figure taken from (74). The protein kinase activity in the
absence of cAMP (o) and in the presence of 2 pM cAMP (o) (this concentration is saturating at the low [PKA] in
the experiment) are also shown.
The apparent half-activation cAMP concentration Ka depends on the concentration of PKA (18). This is
so because standard binding assays assume total enzyme concentration « KD, but this is not always the
case experimentally, especially for high-affinity interactions like that between R and cAMP. The PKA-
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specific apparent activation constants and experimental enzyme concentrations are shown in Table 17 and
plotted in Figure 82. The Ka data are well fit by a linear relationship with slope 10, allowing us to
estimate Ka at 0.5 ptM PKA to be 5 pM. The effect of [PKA] on the Hill coefficient for the cAMP
activation is more complicated, as shown in Figure 82B. The three values of PKA I are all ~1, but we
were unable to find any data in the range where PKA II exhibited strong cooperative binding. Therefore,
it is unclear whether the Hill coefficients for PKA I and II peak around 0.1 pM. From this figure, we
conclude that the activation of PKA II by cAMP is not cooperative at physiological [PKA] and has Hill
coefficient 1. This observation is in line with the detailed PKA model of Buxbaum and Dudai (50). In
Figure 83, we offer a simple illustration of the phenomena of apparent half-activation concentration shift
and Hill coefficient increase with total enzyme concentration.
Table 17 Experimental PKA concentration affects apparent Ka and Hill coefficient for activation by cAMP.
[PKA] 12activation [cAMP] Hill coefficient PKA sourcejiM piM
0.009 0.3 1.1Rabbit skeletal PKAI0.15 1.3 1.2*
0.18 2.8 0.85 Bovine cardiac PKA II
0.03 0.1 2*
0.075 0.3* 4.4* Bovine cardiac PKA II
0.140 0.4* 2.8*
2.3 25 1* Bovine cardiac PKA II
0.02 0.105 1.5-1.7 Recombinant RI
not explicitly reported in papers; calculated by digitizing figures and fitting with Hill functions, see Figu
Figure 85.
Ref.
(18)
(152)
(279)
(280)
(143)
re 84 and
30- 5-
A B
10 4
01 -2 .2 3
0
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Figure 82 Plots of the data in Table 17. A. Ka for cAMP activation of PKAI (o) and PKAII (e); the equation of the
plotted best fit line is shown on the figure (fit to PKA I and II data using polyf it in Matlab). B. Hill coefficient as
a function of [PKA]; trend is illustrated by a line connecting all the data points.
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Effect of enzyme concentration on Kapp, KD=1
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Figure 83 The simple binding reaction shown on the right, with enzyme-ligand dissociation constant KD and
conditions specifying the conservation of the total amount of ligand and enzyme, is solved for bound complex EL.
The figure shows the EL/Er for the indicated amounts of ET. The actual KD=l, indicated by o, but we see that for
ET>KD, the apparent binding curve shifts right and becomes steeper. Cooperative binding of multiple ligand
molecules may make these phenomena more pronounced (the figure uses a Hill coefficient of 1, implying non-
cooperative binding). The solution is EL=1/2(ET+LT+KD-[(Er+LT+KD)2-4EL] 2
RII can (but RI cannot) undergo autophosphorylation by C (112, 152, 279) via an intramolecular
mechanism (108). A number of studies have explored the effect of phosphorylation on RII function (113,
152, 279, 280) and the conclusion is that phosphorylation does not affect affinity for cAMP (279, 280),
but does decrease the rate of reassociation of the R and C subunits (which causes the apparent shifts in Ka,
as explained by Buxbaum and Dudai (50)). Furthermore, as argued by Rangel-Aldao and Rosen (279)
based on the high physiological ATP concentration in cells and the selective action of PP on dissociated
R2 (rather than PKA holoenzyme R2C2), the majority of PKA in SANCs is likely phosphorylated. We
adopt this idea in our model, obtaining the R-C dissociation rate x-0.2/min for the phosphorylated R
subunit. This was done by choosing parameters to reproduce an experiment done by Rangel-Aldao and
Rosen shown in Figure 85. In this experiment, PKA was incubated with a high [cAMP] (4 mM) to steady
state, and then cAMP was hydrolyzed by the addition of PDE (280). As [cAMP] decreases with time,
PKA holoenzyme reassociates as quantified through measurement of the catalytic rate of the sample. The
data and model reproduction are shown in Figure 85. This figure shows that the rate of R-C dissociation is
~0.07/min for phosphorylated R at 23 'C (0.2/min at 37 C), and is at least 6 times faster for
unphosphorylated R (0.4/min is shown in the figure at 23 'C, but faster rates yielded similar curves). This
decrease in R-C reassociation rate due to phosphorylation is similar to the >5x decrease reported in
another experiment, where the ratio is again a lower bound due to experimental limitations (279).
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Figure 84 Reproduction of figures from reference papers (18, 279) to estimate the value of Hill coefficient and Ka
shown in Table 17. A. fraction of dissociated PKA for phosphorylated (9) and unphosphorylated (o) protein. B.
PKA activity in arbitrary units (AU) as a function of cAMP for 0.009 tM (m) and 0.15 RM (A) PKA.
5.4 Results
Our simple PKA model reproduces data showing dynamic catalytic subunit dissociation from regulatory
subunits in response to a changing cAMP concentration (Figure 85). In reproducing this data, we also
considered more complicated models, where cAMP-binding and R-C dissociation were separate steps.
The more complicated models did not provide a better fit than what is shown in Figure 85, where we
considered only a single-step in which cAMP binds and R-C dissociates, and they had the drawback that
best fit parameters were not unique.
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Figure 85 Model reproduction of data from Fig. 1 in (280). cAMP concentration (A), reassociated
unphosphorylated kinase (o), and reassociated phosphorylated kinase (e) are shown relative to their maximum
values. Model reproduction is plotted with lines. The rate of cAMP decay was fit to the data (r-0.35 /min). A
Ka=25ptM and R2r-2.3 p.M were reported in the paper. The only free variables were the R-C dissociation rates x,
which were fit as indicated next to each curve (units of /min). The model solved the following differential equations:
d[cAMP]/dt-r[cAMP], and dC/dt = (2R 2 r-CX/Ka[CAMP] - xC, with [RC]=2R2rC, and initial condition
[cAMP]=400p.M, and C= 2x2.3x400/(400+25)= 4.33 pM. For unphosphorylated PKA (curve labeled RC), the
minimum rate is shown because all faster rates yielded good fits to the data. For phosphorylated PKA (RpC), the
best fit was obtained with rate 0.07/min. Experiment was conducted at a temperature of 23 0C.
The peak and steady-state C concentration as a function of vagal or sympathetic stimulation follow the
expected trends, increasing with sympathetic stimulation, with a slight peak vs. steady-state difference
caused by neurotransmitter depletion above 10 Hz, and decreasing with vagal stimulation, with almost no
depletion effects (Figure 86). An interesting disparity starts to become visible here as well, in that
maximal sympathetic stimulation increases C concentration by less than a factor of 2, whereas vagal
stimulation reduces C concentration by almost a factor of 7. The kinetic data for C subunit activation
continues to emphasize the difference between sympathetic and vagal rates, with vagal effects being
faster than sympathetic. While the sympathetic times for half- and 95%- activation remain about the same
as they were for p-AR activation, the vagal effect experiences more slowing down, now with a half-time
of ~3 s, and a 95%-time between 5 and 10 s. The time courses are still not purely exponential, as the ratio
of 0.95-time/0.5-time is closer to 3 rather than the 4.3 one would expect for a single-exponential approach
to steady state.
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Figure 86 PKA catalytic subunit sensitivity and rate of activation/inactivation (model simulation). A. Steady-state
(SS) and peak C concentrations are shown as functions of sympathetic (S) and vagal (V) stimulation frequency,
respectively. B. The rates of activation from a baseline level (~0.38 pM) to the peak/min values indicated in A. did
not follow an exponential time course, so we show the time required to reach 0.5 and 0.95 of peak value. Missing
values indicate frequencies where the first stimulus surpassed the 0.5point.
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The joint effects of adrenergic and cholinergic stimulation are shown in Figure 87. We again see the large
changes effected by cholinergic stimulation (about twice as great as that of adrenergic stimulation), and
the effective elimination of an adrenergic effect at high ACh concentrations. At low ACh concentrations
however, the adrenergic effect is strong, with 10 Hz sympathetic stimulation raising the C concentration
to almost the same level as maximal independent adrenergic stimulation. The effect of vagal stimulation
during simultaneous adrenergic activation strongly inhibits C activation, and the effect becomes more
powerful with greater rates of vagal stimulation: in the presence of 5 Hz vagal stimulation, the greatest
physiological sympathetic stimulation (~10 Hz, equivalent to about 0.1piM NE) barely raises C above the
baseline level.
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Figure 87 PKA catalytic subunit concentration is modulated by both sympathetic and parasympathetic activity
(model simulation). Note the reverse ACh scale; showing maximal cholinergic effect on the left and maximal
adrenergic effect on the right. In the ACh regime, four sets of simulations were done, with simultaneous sympathetic
stimulation (SS) at 0, 2, 5, and 10 Hz as labeled. In the NE regime, simultaneous vagal stimulation (VS) frequencies
are similarly indicated. The baseline panel shows the cAMP concentration in the absence of neurotransmitter.
neurotransmitter concentrations were clamped in the neuroeffector junction and EJS (no effect of reuptake /
absorption / hydrolysis).
5.5 Discussion
We present a very simple model of a very complicated molecule. Even as such, our PKA activation model
reproduces in-vitro experimental data (see Figure 84) as well as the following observations made in rabbit
SANC. Application of Iso and PDE inhibitor caused a 3 and 9-fold increase in cAMP level, respectively,
and resulted in a 1.5 and 2.5-fold increase in PKA-dependent phosphorylation, respectively (342). The
baseline [cAMP] in these experiments was -2 pM, which using our model predicts 1.9x and 2.7x increase
in activated C subunit concentration. At baseline (concentration of 3 pM cAMP), our model indicates
PKA is 38% activated. This is higher than the 20% baseline activity estimated in skeletal muscle (18), but
we argue is reasonable given the strong effect of PKA inhibition on SANC rate (341).
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We also quantified the dependence of the apparent half-activation cAMP concentration on experimental
conditions; a phenomenon that had been previously noted (18), but not described mathematically using
published data from various experiments (18, 143, 152, 279, 280). We described this dependence with a
linear relationship that fits the data well on the range 0.01-3pM cAMP, and used this relationship to
determine the value of Ka at the estimated cellular concentration of PKA in the SANC.
The effects of adrenergic and cholinergic stimulation on PKA catalytic subunit activation produced by our
model are qualitatively correct, with the expected sigmoidal increases with adrenergic activation, and
decreases with cholinergic activation. We have been unable to find direct measurements of PKA activity
in response to such stimulation, so we cannot definitively state that the values shown in Figure 86 and
Figure 87 are accurate. Furthermore, the Demir and Dokos models of SANC rate modulation by vagal
stimulation do not include explicit PKA activation, so we cannot compare performance against these
models either. However, we constructed our PKA model bottom-up, using a reasonable mechanism and
experimentally measured parameters which gives us a fair amount of certainty about its accuracy.
A number of limitations exist in the model due to its simplicity. For example, the model presents no
intrinsic mechanism to explain the observed dependence of half-activating cAMP concentration on total
PKA concentration, although we do provide a plausible experimental methodology-based explanation for
these results. While this exclusion limits our understanding of the system, it does not impair the function
of the model in predicting the phenomena of interest. Another limitation is that we do not model PKA I.
This molecule may have a different affinity to cAMP and a different rate of activation, which could lead
to more complex downstream effects. On the other hand, given its low abundance relative to PKA II, and
that we were able to reproduce high-level data using the present PKA II model, we argue that this
omission is forgivable.
The biggest limitation is that we do not model subcellular compartmentalization of PKA. It has been
shown that compartmentalization may be critical to targeted PKA function ((55, 74, 144), for review see
(60, 233, 272, 298, 362, 365)). The consequences of a compartmentalized model would be to allow higher
concentrations of PKA in the vicinity of selected structures , which would allow faster phosphorylation
and possibly independent dynamics from the rest of the cell. Coupled with localized cAMP pools, the
rates of C activation, and the magnitude of the activation could be much greater than in our whole-cell
model. In fact, we found it necessary to include an abstract feature of PKA/cAMP compartmentalization
in our model, through the use of a speedup factor Cs,=100 (see section 6.7 for more detail). Enough data
does not exist to formulate a complete compartmental model at this time, but recent advances in
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measurement of localized cAMP pools (for review see (176)) and a growing understanding of PKA
localization (233, 298, 362) may make the necessary data available in the near future.
5.6 Conclusion
We presented a simple model of PKA catalytic subunit activation, along with simplifying assumptions
that would allow the use of C concentration as a determinant of target protein phosphorylation. The model
parameters were based on direct measurements of cAMP affinity and deactivation rate. In determining
model parameters, we provided an explanation for the large variance in reported Ka values and were able
to deduce the value of this parameter in a way consistent with all the data rather than picking an arbitrary
value on the observed range.
The model reproduces data collected in cell-free experiments as well as in experiments on rabbit SANCs.
However, it is not without its limitations, as it is largely a phenomenological model that ignores the
complexity of the interaction between the regulatory and catalytic subunits. The largest limitation of the
model presented here is that we consider PKA concentration to be uniform throughout the SANC,
ignoring any local differences. Given the structure of PKA regulatory subunits, in particular those of PKA
II which are known to contain residues that can anchor it to the cell membrane or other cellular
organelles, this is a limitation that will have to be addressed in any mechanistically-correct model of PKA
activation and function in the cell.
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6 MODIFICATION OF ION CHANNELS AND CALCIUM-CYCLING MACHINERY BY SECOND
MESSENGERS
6.1 Overview
This chapter describes the interaction of all the second-messengers with the sinoatrial node cell
components that they affect. These interactions are illustrated in Figure 88. Elements A and B in this
figure were fit using explicit data; 1-6 used implicit data and a global optimization algorithm (details in
bullets below). This chapter also includes a thorough comparison of the experimental data and functions
used by other models and explores/eliminates an unexpected instability we discovered in the Maltsev
model.
Cell
membrane
ICaL C K ACh3
NPKA 2U4
qP 5-,6
Cj
SERCA II
1Kr
Figure 88. High level illustration of second messenger-mediated effects on sinoatrial node cell components in the
context of the entire model originally shown in Figure 4 (see original figure for key). 1: modulation of adenylate
cyclase (AC) by stimulatory and inhibitory G-proteins; 2: shift of "funny" current If activation gate by
phosphokinase A; 3: stimulation of L-type Ca2" current ICa,L by phosphokinase A; 4: phosphokinase A mediated
increase in Ca2 uptake flux jp through SERCA 1I pump; 5 and 6: stimulation of rapid delayed rectifier K* current
1Kr conductance and kinetics. A: activation of acetylcholine-sensitive K* current IKACh by inhibitory G-protein py
subunit. B: shift of "funny" current If activation gate by cAMP.
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Second messenger effects on sinoatrial node cell components
" Many (likely, all) of the ion channels are modified by second messengers released through
sympathetic and parasympathetic stimulation of the sinoatrial node cell, see Table 18. We follow
the example of previous models and change the properties of the major "pacemaking currents"
e py 1-mediated activation of IKACh (A in Figure 88) and cAMP-mediated shift of If activation gate
(B in Figure 88) are based on explicit data for these reactions. Data for A showed IK,ACh current in
response to acetylcholine concentration (we used our G-protein model to compute the py,
concentration corresponding to each acetylcholine concentration, see Figure 89). Data for B
showed the shift in If activation as a function of experimentally-controlled cAMP concentration
(see Figure 91).
e The effect of G-proteins on adenylate cyclase (1 in Figure 88), and the cAMP and phosphokinase
A-mediated effects (2-6 in Figure 88) are based on implicit data. For example, the effects of
acetylcholine and norepinephrine on ICaL were measured rather than the explicit effect of
experimentally-controlled phosphokinase A concentration. The parameters for all these functions
were chosen simultaneously using a global optimization procedure to best-fit all the experimental
data at once. The obtained fits are very good; see Figure 105. Our model reproduces experimental
data better than other models: see Figure 89, Figure 91-Figure 93, Figure 95, and Figure 96.
" Speedup factors representing rate increases due to subcellular compartmentalization of second
messengers were chosen to reproduce dynamic heart rate data (see Figure 106)
Maltsev model instability/limitations
" We use the Maltsev model as the baseline sinoatrial cell model. This model reported heart rates as
low as Ill bpm due to acetylcholine. The heart rate data we wanted to reproduce show rates as
low as 65 bpm due to parasympathetic stimulation (33). Pushing the Maltsev model to rates
below -100 bpm produced un-physiologic "chaotic" beating (see Figure 97). We were able to
correct this aberrant behavior, simulate the full range of experimentally observed heart rates, and
improve the shape of the model-generated action potential (compare Figure 97C with Figure 98)
by modeling changes in rapid delayed rectifier K+ channel (IKr) kinetics. These changes were not
explored in the Maltsev model but are supported by experimental data.
" A component contributing to the instability is a fixed-frequency subthreshold oscillation due to
the L-type Ca2 current (ICaL). We identify necessary and sufficient conditions for the existence of
this oscillation (Figure 100) but do not eliminate it from the model because this behavior has been
experimentally observed (Figure 101)
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* Our model can reproduce the full range of sympathetically-mediated heart rates (Figure 102) and
has a more correct action potential shape than that produced by the Maltsev model (compare
Figure 102B to Figure 103)
6.2 Introduction
The second messengers described in Chapters 3-5 modulate target proteins (ion channels and
phospholamban), which in turn affect maximal current densities, ion channel kinetics, and Ca 2 cycling.
In Table 18, we summarize the known modulation mechanisms and the magnitude of adrenergic and
cholinergic effects on the ionic currents known to exist in the rabbit SANC. These currents are all
included in the Maltsev SANC model, although the full range of modulations described in the table is
usually not modeled. In fact, the Maltsev model only considered changes in ICaL, IK,ACh, If, 'Kr, and P,, and
were able to reproduce some adrenergic and cholinergic effects on SANC rate. The Demir model included
changes to the most comprehensive number of ionic currents: ICa,L, If, IK, IKACh, INa, and IbNa, but since it
did not include a description of sarcoplasmic reticulum Ca2 ' release (a feature unique to the Maltsev
model), it did not model changes in Ca 2+ cycling. Finally, the Dokos model features changes in only three
ionic currents in response to ACh released by vagal stimulation: If, ICaL, and 'K,ACh-
Our work is an extension of the Maltsev model, so we follow their example and focus on reproducing the
effects on ICaL, IKACh, If, 'Kr, and Pup. We also found it necessary to change the kinetics of IKr, instead of
just its current density as was done by Maltsev et al.. This extra feature allows our model to reproduce the
full range of HR observed in vagal stimulation experiments on perfused rabbit hearts (33), and improves
the shape of the diastolic depolarization in response to ACh stimulation.
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Table 18. Mechanisms and magnitude
review by Mangoni and Nargeot (231).
of the modulation of SANC ionic currents, based largely on the excellent
Current Modulation mechanism Adrenergic effect Cholinergic effect
K, ACh Activated by G-protein py Ch subunit (358)
Increases with ACh and can stop
pacemaking (88, 160, 264, 339)
cAMP (26, 90);
Phosphorylation (3)
PKA phosphorylation
(231, 270). G1-mediatedICa,L cAMP cascade (145),
Nitric oxide-cGMP (111)
PKA phosphorylation
(341)
IKr PKA and PKC (141, 348)
Likely same as IKr, PKA
1Ks and PKC phosphorylation
(348)
PKA phosphorylation
(231). Pharmacologic
I t  sensitivity similar to ICa,L
(129). AC/cAMP cascade
(330)
Coupled with Ca2+ release
through RyR and NCX
'Ca,T (211, 215). Gi-mediated
cAMP cascade (145)
Current identified by
bCa/Na Hagiwara (132), plays a
Activation curve shifts 9.5-
9.6 mV (26), 11 mV (90), or
9.6mV (367). Phosphatase
inhibition increased If
current density by 39.6±
6.4%, and Iso-induced
activation curve shift by a
factor of 1.5 (3)
Enhanced 103±33% (131)
and 54.19% (367) by Iso.
NE increases peak current
108+32% and shifts
activation threshold to left
by 6 mV in mice (230)
Iso enhances amplitude and
frequency of localized Ca 2+
releases (338), 2x increase
to model Iso effect (227)
1.7x increase in 'K due to
adrenaline (44). 47±12%
increase due to Iso in
ventricular myocytes (141).
IK activation speeds up (120)
and deactivation slows down
(347) with Iso.
PKA and PKC dependent
increase in IK (348)
x2 due to Iso (129, 242). Up
100% due to Iso, EC5o= 2.6
nM, also shifts activation to
left (330)
4.8±3.4% increase due to Iso
(131)
Activation curve shifts -9.9 mV
(367), -7mV with ACh (88)
~55% decrease by ACh (270).
31% decrease by ACh (367). No
effect (145). No effect on
baseline, but reverses the effect
of Iso (154)
Localized Ca 2+ releases are
abolished by inhibition of PKA
activity (341). 70% decrease to
produce ACh effect (227)
10.5± 2% decrease from baseline
by 1p M ACh. Can undo
stimulation by Iso with
IC50=133.9 nM (330)
No effect (145)
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role in pacemaking (254),
specific modulation
mechanism not known
Voltage and [Na]; (289);
direct stimulation by Iso
INaK (84); mechanism is
unclear, but modeled as
cAMP effect (81)
Changed passively by
INCX RyR modulation by PKA
(22)
KChIP2 (Ca sensitive
'"o protein) (7); drugs (209)
Current is similar to I,, but
Il with slow kinetics (231);May share similar
modulation
May be linked to If
regulation (231). 27.8±2.4%
increase with Iso (84). 2.6x
max increase to model Iso
effect (81)
KChIP1 and 2 increase it
more than lOx (7)
ACh decreases INaK in sheep
purkinje (158). Up to 20%
increase in K+ uptake with ACh
((216); this K+ movement is
attributed to INaK (158)).
Maximum modeled decrease of
1%(81)
ACh reduced net slow inward
current by 50% (121) which has
a component due to INCX (231)
May be reduced by lower Ca 2
concentration (7)
6.3 IKACh activation by Gk
6.3.1 Background
One of the first observations of an ACh-sensitive potassium current was made in tortoise sinus venosus
by Harris and Hutter who noted that cells loaded with radioactive K' released this isotope much more
rapidly upon application of ACh or in response to vagal stimulation (138). An early phenomenological
model of IKACh was developed by Osterrieder, Noma, and Trautwein (ONT model (264)), where the
activation rate of the IK,ACh channel was treated as a function of ACh concentration. This model was
subsequently modified and used by Demir et al. (81) and Maltsev and Lakatta (227) in their SANC
models. Dokos, Celler, and Lovell (DCL model, (96)) on the other hand, used data from Inomata et al.
(160) to formulate a different IKACh model. As explained by Dokos et al., the difference between the ONT
and DCL models is that the former attributes the lag between ACh application and IKACh activation to
neurotransmitter diffusion, whereas the latter attributes this latency to the gating of the channel itself (96).
A feature that both of these models share is that the channels open as a result of direct interaction with
ACh; however, it was shown that IKACh channels are controlled by binding of G-protein py subunits (220,
358), which in turn are released through ACh-stimulated, M2-muscarinic receptor mediated activation of
G1 (see Chapter 3). Thus, in our model the apparent IKACh latency is due to the delay in activation of the
second messenger Gpy, as well as channel gating. Below, we describe a new model of IKAch activation by
Gpy. Using our model of neurotransmitter release (Chapter 2), we also provide an explanation for some of
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the apparent discrepancies in the experimental data on this channel, which had led different groups to
develop inconsistent models.
6.3.2 Model description
We model IKACh similar to the original ONT model (osterrieder 1980), as an equilibrium between a closed
and open state of the channel, where the opening rate P is a function of $1y (the py subunit liberated from
inhibitory G-protein), and the closing rate a is a function of transmembrane voltage (Vm):
C 'llei O
a(V.)
In contrast to the form used by ONT, Demir, and Maltsev, where P is an instantaneous function of ACh,
we impose a nonzero time constant on the rate of change of P. This modification was necessary in order
to improve the fit to the half-time of activation data (see Figure 89C) and preserve model stability: using
an instantaneous relationship for p results in a 3-4 bpm oscillation in HR for low-frequency vagal
stimulation.
{(py )IKACh
, =12.3 2 aKACh ( y KchLK h n'"^" +K KA1cI
= ra / ( Py, )"lCh
d8 9.p - )6
dt 6,
With aIKch= .47, KdIKAch=1.097 pM, nIKACh 3, and wa=6x 10-9 mSxmM.We used the same formulation
for a(Vn) as was used by Maltsev and Lakatta (227):
a = 17e0.133(V +40)
In defining the parameters of Gpy activation of IKACh, we use experimental data from three studies:
DiFrancesco et al. (88), Inomata et al. (160), and Osterrieder et al. (264). These three sets of experiments
differ in SANC preparation: DiFrancesco et al. and Inomata et al. used cells isolated from the rabbit and
guinea-pig SAN, respectively, whereas Osterrieder et al. used slices of rabbit SAN tissue. These data are
plotted in Figure 89B, and we make two observations: 1) there does not appear to be a large species
difference between steady-state activation of rabbit and guinea pig IKAch, as the data of DiFrancesco and
Inomata are in very close agreement with each other 2) ACh hydrolysis by AChE is significant in whole-
tissue slices, but does not seem significant in isolated cells. The second point is illustrated most clearly by
comparing the Osterrieder "control" data with that of the isolated cell preparations: the Osterrieder data is
shifted to the right, indicating a less potent effect of ACh on IKACh activation. However, when Osterrieder
et al. blocked the activity of AChE using the inhibitor neostigmine, their data shift back to the same range
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observed by DiFrancesco et al. and Inomata et al.. We hypothesize that the effect of AChE is apparent in
tissue slices but not in isolated cells because the cell-isolation procedure either damages AChE activity or
effectively removes all ECM from the cells and therefore allows more accurate control over the ACh
concentration at the cell surface. As we showed in Figure 27, our model produces this effect for both P-
AR and M2 muscarinic receptor activation when neurotransmitter concentration is fixed at the cell surface
(directly in the neuroeffector junction/EJS compartments) versus on the opposite side of the ECM (in the
BS compartment). Although our diffusion and AChE models were not constructed with the Osterrieder
data in mind, Figure 89B shows that we can reproduce at least some of the rightward shift in IKACh by
applying ACh in the BS compartment rather than the neuroeffector junction and EJS.
More specifically, Figure 89 summarizes the performance of our IKACh model with regard to experimental
data and the SANC models of Dokos, Demir, and Maltsev. In panel A, we show the steady-state
concentration of py, subunit in response to ACh concentration applied directly at the cell surface versus in
the BS. Panel B shows the steady-state current (or open probability of the channel). We picked model
parameters nIKACh, Kd,IKACh and aIKACh in order to reproduce the data of DiFrancesco et al. (88), Inomata et
al. (160), and the neostigmine data of Osterrieder at al. (264), as well as the maximal value of P used by
Maltsev and Lakatta (227) and Demir et al. (81). We can see that our steady-state value is very similar to
that of the Dokos model, but produces a more sensitive IKACh than that of the Demir and Maltsev models.
We also see the modeled effect of a physically distant ACh concentration, which more closely matches
the models of Demir and Maltsev, as well as the control data of Osterrieder et al.. Panel C shows the half-
time of IKACh activation in response to a step in ACh concentration (ACh was applied in the neuroeffector
junction/EJS for our model). Our model matches the half-times reported by Inomata et al. and the
function used by Dokos et al., but is roughly one order of magnitude slower than the data of Osterrieder et
al. and the models of Demir and Maltsev. We chose to use the Inomata et al. data because of the issues
with the Osterrieder preparation discussed above. The Inomata et al. kinetic data were collected at 26 'C,
but following the example of Dokos et al., we did not temperature-correct them to 37 'C. We conducted
simulations using an IKACh formulation based on the temperature-corrected data (using the reported Qio of
2.11 (160)), but the slower kinetics shown in Figure 89 produced more physiological HR responses to
low-frequency vagal stimulation.
The final parameter of IKACh is the maximum current density. DiFrancesco et al. (88) show a maximum
IK,ACh of roughly 2 pA/pF at -40 mV. The reversal potential of IKACh in our model is -87 mV, which gives
a driving force of 47 mV and implies a measured maximal conductance of 0.043 nS/pF, which we use in
our model. This value is close to that used by Demir (0.02 nS/pF for bath application of ACh, calculated
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from the values of 1.119 nS and cell capacitance of 55 x 106 pF, (81)) and Dokos (1.3 pA/pF at -75 mV,
from max IKACh of 40.5 pA, cell capacitance of 32 pF). Our IKACh conductance is smaller than the value
used by Maltsev and Lakatta (0.14241818 nS/pF, (227)), which we suspect they chose to offset their less-
sensitive IK,ACh activation profile.
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Figure 89 IKACh steady-state activation and half-time are reproduced by our model, as well as the rightward shift that
most likely occurs due to differences in experimental preparation. A. Concentration of py as a function of ACh
concentration in the neuroeffector junction and EJS (solid line) versus in the BS (dashed line). B. Experimental data
and model reproductions by our model (thick lines, solid is for ACh in the neuroeffector junction and EJS, dashed is
for ACh in the BS) the Dokos model (line labeled "Do"), and the Maltsev ("Ma") and Demir ("De") models. The
model lines show the steady-state open probability of the IKACh channel scaled by the maximum value. Steady-state
IKACh data from DiFrancesco et al. (88) (A), Inomata et al. (160) (o), and Osterrieder et al. (264) (o control, o
neostigmine) were individually fit by Hill functions and scaled down by the amplitude of the Hill function fit. C.
Time to half-activation of IKACh in response to steps in ACh concentration. Our model is shown with a thick line for
a G-protein speedup factor G,=20. The Dokos model curve "Do", was computed as t112=-log(1-0.51 4 )/(a,+p3l) using
the equations for a, and #32 in (96). The Maltsev and Demir model curve "Ma, De" was computed as log(2)/(a+p)
using the equations for a and P in (81, 227) at -40 mV because the rates were based on (264), which was collected at
-40 mV. As mentioned in the text of (8 1), the a rate was sped up relative to what was reported by Osterrieder et al.;
this is why the curve does not lie on top of the Osterrieder et al. data. The Osterrieder et al. half-times (9) were
computed from the a and P values from Fig. 7 in (264) as tv2=log(2)/(a+). The Inomata et al. (160) data and error
bars (n) are shown as reported in the paper, without a temperature correction.
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6.3.3 Discussion
We model activation of IKACh by only the py subunits derived from inhibitory G protein (py1). This is at
odds with the observation that the py subunits are identical between inhibitory and stimulatory G-proteins
(178), but was necessary in order to make IKACh activation only sensitive to ACh. Using the total py
concentration derived from both Gs and G1 results in NE-induced activation of IKACh due to the py
subunits liberated in the process of Gs activation. We could not find any reports of adrenergic activation
of IKACh, so we specified its activation by only the py subunits from G1. This approach is reasonable
because there may be physical co-localization of IKACh channels and M2-muscarinic receptors, which
would imply mainly G1-derived py concentration in the vicinity of the channels.
We obtained the value of Kd,IKAch= .097 pM by fitting the data shown in Figure 89B. This value is higher
than the Py-IKACh dissociation constants directly measured by Wickman et al. (3-30 nM (358)). This
discrepancy may be due to a number of factors: Wickman et al. used recombinant Gpy subunits from rat
brain and the IKACh channels were from rat atrial myocytes rather than rabbit SANC. Furthermore,
Wickman et al. showed that GiaGDP has an inhibitory effect on IKACh channels; since our model predicts
relatively high GiaGDP levels in the presence of ACh, this may explain the need for higher GPY
concentrations to activate IKACh (358).
In describing the kinetics of IKACh activation by pyi, we used the same half-time data used by Dokos et al.
(96), although these data were collected at 26 'C rather than the physiologic temperature of 370C. Our
model is capable of reproducing the temperature-corrected data, by increasing the G-protein speedup
factor Gg and decreasing the P time constant scalar #m. The temperature-corrected data and our model fit
are shown in Figure 90A. This figure also shows the global effect of these fast IK,ACh kinetics on the
model: for slow vagal stimulation frequencies, the HR develops an oscillation, as shown in Figure 90B.
The amplitude of this oscillation is greatly reduced by using the slower 1KACh kinetics we described above.
Furthermore, the IKACh formulation we use produces virtually the same temporal effect on HR as the faster
formulation when the latter is stimulated by an ACh clamp rather than pulsatile vagal stimulation. The
origin of the HR oscillation is illustrated in Figure 90C. The top line shows the value of p (the 'K,ACh
channel's opening rate constant). Due to the very fast response of M2-muscarinic receptors, and the
greater Gg needed to reproduce the temperature-corrected IKACh half-times, P undergoes a rapid rise and
decay with each vagal stimulus, thus the frequency of the p waveform isfi=2 Hz. The membrane potential
(Vm) shows the SANC AP. As we can see in panel B, the HR oscillates between 122 and 128 bpm, so the
frequency of the V. signal is aboutf 2=2.03-2.17 Hz. The IK,ACh trace is a function of these two processes:
the open probability of the channel (determined by P) and the driving force for the current through the
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channel (determined by V,). Thus, IKACh exhibits a beat pattern, depending on whether P and V,. are
constructively or destructively interfering. Given the frequencies of p and V,,, the expected frequency of
this beat is Jfi-f2|=0.03-0.17 Hz, which corresponds to periods of 6-30 seconds. The actual period of the
1K,ACh envelope is roughly in the middle of this range, at about 11 s. Finally, because IKACh influences the
rate of depolarization and therefore the HR, the HR signal reflects the frequency of the IK,Ach envelope,
oscillating with a period of about 11 s. The HR oscillation is significantly reduced when IKACh kinetics are
slower because the slower kinetics eliminate much of the p oscillation, as can be seen in the thin line p
trace in panel C.
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Figure 90. The combination of fast IKACh kinetics and uniform-frequency, pulsatile ACh release induces a non-
physiologic HR oscillation (model simulation). A. Same as Figure 89C, but includes temperature-corrected half-time
data from (160) (m) and shows the model reproduction of that data using Gg and pmt values shown on the figure. B.
HR as a function of time for 2 Hz vagal stimulation using the fast kinetics from panel A (fast IKACh), the slower
kinetics from Figure 89 (slow IKACh), and fast kinetics but ACh concentration clamp in the neuroeffector
junction/EJS instead of 2 Hz vagal stimulation (fast IKACh, ACh clamp). In the last simulation, ACh concentration
was stepped from the baseline level to 0.0082x21 188 ptM at time 0, according to the stimulation-frequency -- ACh
function in Figure 26. C. Thick lines show the value of p, Vn, 1K,ACh, and HR from the 'fast IKACh' simulation in panel
B. The thin line shows the P value from the 'slow IKACh' simulation. The y-axis is arbitrary; each trace was scaled to
have a similar relative range and shifted vertically for clarity.
The preceding analysis brings into question our early assumption that we can lump all cholinergic
varicosities into one. This was done in order to reduce the number of ODEs we would have to solve: ACh
release from a single varicosity is described by 6 equations, and there are 14.5 cholinergic varicosities per
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SANC, so treating each varicosity individually would mean solving 90 simultaneous equations for ACh
release alone! Lumping all the varicosities into one allowed us to gain computational feasibility, but
removed the ability to model inhomogeneities that doubtless exist in the system. For example, the
distance from the brain to each varicosity is different, so a finite neural conduction rate implies that some
varicosities would release neurotransmitter before others. Also, we model the release of multiple
varicosities as an instantaneous process, but some temporal jitter likely exists there as well. If we were
able to include these effects in the model of ACh release, it would result in a more gradual M2-muscarinic
activation profile with each stimulus and a more gradual G-protein activation even with the high Gs.
required to reproduce the temperature-corrected IKACh half-times. Thus, a more accurate ACh release
model would have allowed us to more accurately model IK,ACh without running into the HR oscillation we
see in Figure 90. However, we made the simplifying assumption at the level of ACh release, and therefore
must use slower IKACh kinetics in order to avoid the non-physiologic HR oscillation. However, although
our IK,ACh formulation does not exactly reproduce the most accurate kinetic data, the effect on HR appears
to be negligible, as we can see by the close agreement between the 'slow IK,ACh', and 'fast 1K,ACh, ACh
clamp' data in Figure 90B.
In all, our IKACh model is mechanistically correct as it is activated by Gpy, it reproduces the steady-state
activation profile recorded in a number of studies (86, 160, 264), has similar activation kinetics as used by
Dokos et al. (96), and has a maximum conductance based on a measured value (88) and close to the
values used in the Dokos (96) and Demir (81) models. The process we followed in developing this model
also led to a plausible explanation for the lower ACh sensitivity reported by Osterrieder et al. (264), and
brought to our attention the need for explicitly modeling ACh release from individual varicosities or even
vesicles (or some approximate way of temporally-smearing ACh release).
6.4 If activation curve shift by cAMP (IfjshiftC)
The hyperpolarization-activated Na' current, or "funny" current If, is known to be affected by adrenergic
and cholinergic agonists (88, 91, 92, 367). The effect that is most well-characterized is the shift in the If
activation curve, which is known to be directly controlled by cAMP concentration (90). The data showing
the I shift due to cAMP are reproduced in Figure 91. Our model uses the fit published by DiFrancesco
and Tortora (90):
I',ShiftC S [cAMP]' / ([CAMP|"' + Kon)
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with sfm=1I1I mV, Ko sg=0.21 I1pM, and n=O.85. This function is shown in Figure 91, as well as the function
used in the Demir model. The function used by Demir differs from the experimental data in two ways: the
steepness of the curve is much greater, and the range is roughly twice as large. The Dokos and Maltsev
models did not explicitly model cAMP, so we cannot plot their functions here for comparison. We
assume that cAMP is in rapid equilibrium with I, channels, and that the binding reaction produces an
immediate effect on the channels so the above relationship is instantaneous. The models of Demir and
Maltsev used a similar instantaneous formulation, whereas Dokos used fourth-order kinetics to relate ACh
concentration to IfShift. Dokos et al. mention that their choice of fourth-order kinetics was arbitrary; also, it
is pertinent to note that their formulation treats the whole cascade from ACh to IfShift as a single process,
whereas the latency and delay in our model arise from the intermediate steps of receptor and G-protein
activation, and cAMP synthesis.
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Figure 91. The If activation curve shifts with cAMP. Data (o) from (90) are reproduced along with the function used
in our model (thick line) and the function used by Demir et al. (thin line labeled 'De') (81).
The function used by Demir deserves further discussion, as it illustrates an attempt to deal with an
inconsistency in the experimental data. As we can see from the data in Figure 91, cAMP accounts for a
maximal shift of 11 mV; however, experiments have shown that If activation shifts maximally by 9.5 to
11 mV (26, 90, 367) upon adrenergic stimulation and -7 to -9.9 mV (88, 367) with cholinergic stimulation
(see Table 18 for details), implying a -20 mV range of shifts. Demir et al. dealt with this inconsistency by
expanding the range of their cAMP-+Jfshifc function to 21 mV. We considered this approach as well, but
upon a further review of the literature we found data showing that the If channels are also modified by
phosphorylation (3), which affects both If current density and the shift in the activation curve (see Table
18 for details). We therefore express the total activation curve shift as a sum of a cAMP- and a PKA-
mediated effect: Ifshift-Ifshific+Ifship. We use the exact cAMP-IfShftc relationship reported by
DiFrancesco and Tortora (90), and we fit the parameters of the PKA-/S,hifp function in order to
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reproduce the full range of Ijhshi data in response to adrenergic and cholinergic stimulation (367). We
present the details in the following section, since we used a consistent framework to represent all the PKA
effects.
6.5 PKA Effects
PKA phosphorylates various target proteins and in this way affects their function. In our model, we
developed mechanistically-motivated descriptions of the signal transduction cascade from autonomic
nerve impulses to the activation of PKA catalytic subunit C. In describing how C affects the properties of
various ion channels and other functionally-important proteins in the SANC, we step away from
mechanisms and focus on the important phenomena instead. This abstraction is necessary because the
effects of phosphorylation are very complex, and therefore require more data than are currently
unavailable. For example, phosphorylation involves a number of steps: binding of C to the
phosphorylation sites (likely a plurality of sites per protein), the phosphorylation reaction itself wherein a
phosphate is transferred from a donor ATP to the target site, the concurrent dephosphorylation of these
same sites by a number of protein phosphatases (PPs), and the final change in protein function as a
consequence of phosphorylation, which can either be a direct effect due to a conformational change in the
protein or the result of interaction with other cellular machinery that relies on phosphorylation as a signal
for removal or up-regulation of specific proteins. Thus, to describe all these reactions, we would need
information regarding the number of phosphorylation sites on each protein of interest, the affinities and
rates of phosphate transfer for each of these sites, the affinities and rates of dephosphorylation by PPs, a
description of other regulatory proteins that interact with these sites, and the final quantitative
measurement of the effect of phosphorylation on the function of the target protein.
Given that an explicit mechanistic model of PKA effects on SANC function is too complicated to
parameterize confidently, we adopt the simplest model that is still based on the above mechanisms and
can reproduce the high-level data of interest. We define steady-state functions to describe the change
(either relative or absolute) in the phosphorylation-modulated model parameters. Based on the
mechanisms mentioned above, these steady-state functions are expected to be monotonic with C, and can
be arbitrarily complicated given the number of steps involved. We use the sum of Hill functions to
describe each steady-state relationship; in most cases only two functions were necessary:
C "is Cn2s
IJShitP,SS as + a1 Cns + Knis + a2s C2S + K2n2S
Is 2S
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Given the complexity of the system, some delay is expected so we include a single time constant rp to
define the differential equations:
dl 
=ShiftP IfnShifPSS 
- JshitP) I Vp
dR gCaL = (RgCaL,SS 
- RgCaL /P
dR
dRPU
dRgKr 
=(RgKrss 
- R gKr P
dpa
dt (pafSS - pa) /rP
We describe the meaning of each of these variables below, and discuss the experimental data that justify
each variable's dependence on PKA phosphorylation. The optimization method we used to compute the
best-fit parameters for the above equations is discussed in section 6.6.
6.5.1 Shift in If activation (If shirtP)
As we discussed above, the I activation function is known to shift with adrenergic and cholinergic
stimulation. We modeled the direct cAMP effect to reproduce the pertinent data (Figure 91), and we
include a PKA-mediated shift based on the observations of Accili et al. that phosphorylation also
contributes to a shift in if activation (3). We use data from a study by Zaza et al. (367), where Ifshft was
directly measured in isolated rabbit SANC cells in response to the adrenergic agonist Iso, and the
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cholinergic neurotransmitter ACh. To convert the Iso data to equivalent NE concentrations, we shifted the
data one order of magnitude to the right (see Figure 32).
The Demir, Dokos, and Maltsev models do not explicitly include a phosphorylation-mediated change in
I,. Demir et al. ascribe the full effect to cAMP, at the expense of not reproducing the cAMP data of
DiFrancesco and Tortora (90). On the positive side however, the Demir model provides smooth IfShip with
both ACh and Iso application (81). Maltsev and Dokos use functions that directly translate ACh
concentration to If;Ship, so they neither espouse not denounce a PKA-mediated mechanism. They also do
not provide functions for adrenergically-mediated changes: Dokos does not include an adrenergic model
at all, and Maltsev simply uses a constant shift of 7.8 mV to simulate a maximal p-adrenergic effect
(227). The experimental data from (367), our model reproduction of that data, and the models of Demir,
Dokos, and Maltsev are summarized in Figure 92.
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Figure 92. Our model reproduces experimental data on the shift in If activation due to adrenergic and cholinergic
stimulation. Data from Zaza et al. (o) (367) are shown with the decreasing points showing the ACh effect and the
increasing points showing adrenergic effect. The study used the adrenergic agonist Iso, which is about 10 x as potent
as NE, so the original Iso data are shifted by a factor of 10 to the right to correspond to the NE scale. Thick lines
show our model reproduction of the data when the neuroeffector junction and EJS concentrations are clamped to the
corresponding ACh or NE concentrations. The If shipf model of Demir et al. (81) for both ACh and Iso is labeled 'De'
and the Iso curve is shifted to the right by a factor of 10 as we did with the Zaza et al. data. The Dokos steady-state
ACh response is labeled 'Do' (96), and the Maltsev model relationships are labeled 'Ma' (227). Maltsev and Lakatta
only modeled a maximal adrenergic effect using a constant Ishif; this value is shown as a line between 10 and 100
piM.
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6.5.2 ICa,L Conductance (RgcaL)
The L-type Ca2 channel is modulated by PKA-dependent phosphorylation (for review, see (231)). This
mechanism agrees with the observations that ACh reduces peak ICaL (270, 367), while Iso enhances it
(367). As discussed by Maltsev and Lakatta (227), a wide range of ICa,L sensitivities to ACh have been
reported (154, 270, 367), also see Table 18 for details. We follow their example in reproducing the data of
Zaza et al. (zaza 1996). Although this study reported a 31% decrease in ICa,L due to high ACh (300 pM), a
minimal effect is seen for concentrations below 10 pM, which is in agreement with the observation of
Honjo et al. that 10 pM ACh had no effect on ICa,L (154). These figures contrast the strong inhibition
observed by Petit-Jacques et al.: 56% at lOpM ACh (270). We did not use the Petit-Jacques et al. data
because strong ICa,L inhibition of this magnitude caused cessation of spontaneous SANC activity at
moderate ACh concentrations in our model, which is at odds with the commonly accepted mechanism
(that SANCs stop beating due to an increased potassium conductance). Zaza et al. also provide data on the
effect of Iso in stimulating ICa,L-
The Zaza et al. and Petit-Jacques et al. data on the relative change in L-type channel conductance (RgCaL)
are summarized in Figure 93, along with our model reproduction of the data, and the models used by
Maltsev, Dokos, and Demir. As is the case for Irshir, Demir used a function of cAMP to directly modulate
the L-type calcium current conductance, although they note that the actual mechanism involves PKA.
Their description matches the Petit-Jacques data for applications of ACh, and the amplitude of their Iso-
stimulated function is similar to the Zaza et al. Iso data, but shifted to the right. Maltsev and Dokos model
changes in ICa,L as direct ACh effects: Maltsev uses an instantaneous function of ACh that appears to have
a half-activation similar to the Petit-Jacques data, but a maximum value from the Zaza data, whereas
Dokos used a first-order reaction (again, introducing some delay between ACh application and ICa,L
change) with steady-state value that matches the Petit-Jacques data. To simulate a p-adrenergic effect,
Maltsev used a constant value of 1.75x baseline. Our model fits the Zaza data very well for
concentrations below 10 pM, but deviates from the high-ACh data points. We do not consider this
deviation important for two reasons: 1) physiological ACh concentrations are below 0.1 pM ACh
(corresponding to 10 Hz maximal vagal spike rate), and 2) SANC cells stop spontaneously depolarizing at
ACh>10 pM, so these measurements were recorded on essentially dysfunctional cells and may not be
valid.
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Figure 93. Data and models of the relative change in L-type calcium current conductance. ACh and Iso data from
Zaza et al. (o) (367), Iso data is increasing and has been shifted to the right by a factor of 10 to convert Iso
concentration to equivalent NE concentration, ACh data is decreasing. ACh data from Petit-Jacques et al. (Ei) (270).
Thick lines show our model reproduction of the data when the neuroeffector junction and EJS concentrations are
clamped to the corresponding ACh or NE concentrations. Functions used by the Maltsev ('Ma'), Dokos ('Do'), and
Demir ('De') models are shown with thin lines. The Demir Iso curve is shifted to the right by a factor of 10 in order
to convert it to equivalent NE concentration, as was done with the Zaza et al. Iso data.
6.5.3 PLB Phosphorylation and SERCA Pumping rate (Rpup)
Phospholamban (PLB) is a protein that inhibits the activity of the sarcoplasmic reticulum Ca2 pump
(SERCAII). The inhibitory activity of PLB is a function of its own phosphorylated state: phosphorylated
PLB is not an effective inhibitor of SERCAII function, whereas unphosphorylated PLB is. Therefore,
adrenergic stimulation increases PKA activation, increasing PLB phosphorylation, decreasing the
effectiveness of PLB, and increasing the Ca2 pumping rate by SERCAII. The opposite is true for
cholinergic stimulation. The effect of cholinergic agonist carbachol (CCh) on PLB phosphorylation was
quantified by Lyashkov et al. (222), who showed that cholinergic activation reduces the amount of
phosphorylated PLB and that this reduction happens in concert with the observed reduction in SANC
oscillation rate (see Figure 94). Maltsev et al. include this effect in their SANC model by modifying the
parameter Pup, which is a measure of SERCAIl pumping rate (227). They also show that this change in
PUP and the resulting effect on spontaneous Ca2 release in their SANC model is a major contributor to
changes in SANC spontaneous oscillation rate. Given its potentially important role in HR regulation by
the autonomic nervous system, we included modulation of Pup in our model as well. The Dokos and
Demir models on the other hand, were developed before the role of the "calcium clock" was fully
understood so they do not include these effects.
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Figure 94. Effect of CCh on PLB phosphorylation and SANC beating rate, figure taken from (222). A.
Phosphorylated PLB (PLB-Ser- 16) as a fraction of total PLB is shown for a range of CCh concentrations. B. The
effect of CCh on PLB phosphorylation overlaps its effect on SANC beating rate reduction, implying an important
functional role of PLB regulation.
We model adrenergic and cholinergic effects on P, through the relative change in this parameter's value
Rp,,. In defining the cholinergic effect, we follow the example of Maltsev et al. and use the Lyashkov et
al. PLB data (222). In doing this, we are making two assumptions: 1) that the effectiveness of CCh is not
vastly different from that of ACh, and 2) that the fraction of phosphorylated PLB is directly proportional
to SERCAII function. The first assumption appears to be justified, judging by the similar effect of CCh
and ACh on HR (see Figure 105k). The latter assumption is the more questionable of the two, since it
does not consider the affinity of the PLB-SERCAII interaction. Different affinities would effectively shift
the PLB curve left or right along the ACh/CCh axis; on the other hand, the close agreement of PLB
phosphorylation reduction and HR reduction (Figure 94B) imply that no such shift is necessary.
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We were unable to find detailed data relating adrenergic stimulation to PLB phosphorylation. For the p-
adrenergic effect in their model, Maltsev and Lakatta used a constant value of 2x the baseline value of
PUp. This value was chosen in order to produce a desired increase in HR with p-adrenergic stimulation
(227). We followed this example and computed the necessary Rpu, values that would yield HRs measured
under sympathetic nerve stimulation in rabbit heart by Brack et al. (33). This procedure is detailed in
section 6.5.6. These data, the fits achieved by our model and the function used by Maltsev are shown in
Figure 95. The ACh functions are very similar, but our NE function rises to about 3.5x baseline, whereas
Maltsev et al. used a value of 2x baseline (227). This difference is mainly due to the larger HR range we
were reproduced: in the Maltsev model, maximal p-adrenergic stimulation causes a 25.8% increase in HR
(from a baseline of 184 bpm to a maximum 226 bpm), whereas in our model, maximal p-adrenergic
stimulation causes a 73% increase in HR (baseline 156 bpm, maximum 270 bpm).
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Figure 95. Our Rp,, formulation (thick lines) fits the ACh data of Lyashkov et al. (o) (222) and the NE values
required to reproduce the HR data from Brack et al. (o) (33). The Lyashkov et al. data were collected using CCh,
and are plotted here as a function of ACh without any modification. The Maltsev model (thin lines) uses a function
of ACh directly fit to the Lyashkov et al. data as indicated ('Ma'), and the maximal adrenergic effect is simulated
using a value 2x baseline.
6.5.4 IKr Conductance (RgKr)
The rapid delayed rectifier potassium current IKr is known to be modulated by PKA and PKC (141, 348),
with 47-70% increase in peak current due to adrenergic stimulation (44, 141) (see Table 18 for details).
We were unable to find data showing the specific dependence of the relative change in IKr conductance
(RgKr) on NE or ACh, so we computed RgKr values in order to reproduce the HR data of Brack et al. (33)
(see section 6.5.6). The Maltsev model includes a p-adrenergically mediated increase in 'Kr of 50% above
baseline, and did not change it with ACh. The Demir model also includes a change in the potassium
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current IK, which they modeled as a direct effect of cAMP concentration, but note that this change is
PKA-mediated. Demir et al. (81) do not cite any specific data used for defining their IK modulation
equations, so we assume they chose the function in order to reproduce some desired phenomena. The
Dokos model did not modulate the potassium current. Figure 96 summarizes the data points we used to fit
our RgKr function, and the functions used by Maltsev and Demir. The functions used to describe
adrenergic modulation of RgKr vary between 35%-67% maximal increase over baseline value, with our
model being much more sensitive to NE than the Demir model. We believe that our model is valid
because it fits the values required to reproduce HR changes due to sympathetic stimulation (33), has a
sensitivity to NE that is similar to that of If and Ica,L (see Figure 92 and Figure 93), and has a maximum
increase close to that reported by Brown and DiFrancesco in rabbit SANC (44). Our RgKr function for
ACh modulation lies between the 0 effect used in the Maltsev model, and the 40% maximal decrease in
the Demir model. The sensitivity of our formulation to ACh is slightly greater than that of the Demir
model, but closely mirrors the sensitivity to NE, and fits the values required to reproduce the vagal
stimulation HR data from Brack et al. (33). The RgKr functions we used also help maintain the maximum
diastolic potential of our model around the baseline value of -60 mV for a wide range of adrenergic and
cholinergic stimulations, in line with experimental observations (see Fig 3 in (88), Fig 6A in (44), Fig lE
in (64), Fig 3 in (328), Fig 1 in (352), Fig 3 in (53)).
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Figure 96 We model the relative conductance change of the rapid delayed rectifier potassium channel by fitting it to
values required in order to reproduce the HR data of Brack et al. (o) (33). Our model reproduction of the data is
shown with thick lines. The Demir model change in IK conductance is shown with thin lines ('De') for ACh and Iso
effects, with the Iso line shifted to the right by a factor of 10 to convert to equivalent NE concentration. The Maltsev
model did not change gKr with ACh ('Ma' line at 1), and increased it by 50% to model a maximal p-adrenergic effect.
166
6.5.5 IKr Kinetics (pas)
We initially attempted to reproduce the effects of ANS stimulation on HR by following the example of
the Maltsev model and only modifying the parameters described above(IKACh, IfShift, RgcaL, Rpp, and RgKr)-
The Maltsev model showed that these four parameters were sufficient to reproduce HRs between 111
bpm and 226 bpm (227). We aimed to reproduce the wider HR range obtained in response to vagus and
sympathetic nerve stimulation in perfused rabbit heart, which showed minimum and maximum HRs of 67
bpm and 250 bpm, respectively (33). After updating the IK,ACh model (see Figure 89), and adjusting the
baseline PUP value to reproduce the baseline HR of 156 bpm (33) (see section 6.5.6 for details), we were
confronted by a major limitation of the Maltsev model illustrated in Figure 97.
As shown in Figure 97B, the Maltsev model was only explored up to 0.1 pM ACh, at which point it
reaches 111 bpm (227). A version of our model in which we do not change IKr kinetics (pasf=1 in Figure
97) crosses this threshold however, at which point the HR "bifurcates" into a slow rate and a fast rate.
Maltsev and Lakatta did not encounter the bifurcation because the higher baseline HR in their model (184
bpm) and less sensitive IKACh formulation did not push their ACh-stimulated HR below 111 bpm, were the
HR bifurcation occurs. However, the existence of what they termed "chaotic firing" was noted in their
earlier paper (see Figs 10 and 11 in (228)), and is the same phenomenon we observe here. We stress that
this phenomenon is a function of the SANC oscillation rate rather than a pathologic setting of particular
parameter values. In our attempts to reproduce the low HRs reported by Brack et al., we explored all the
currents listed in Table 18 and were able to increase the sensitivity of the HR to ACh, essentially shifting
the HR curve in Figure 97B left. However, as soon as the HR dropped below ~100 bpm in these
simulations, a bifurcation occurred. We do not show these simulations because they involved manual
changes in many parameters and are difficult to describe in enough detail to allow reproduction; by
simply clamping pag to 1 in our model, we can study the bifurcation behavior, albeit at relatively high
ACh. The consequence of the bifurcation is that the set of ACh-modulated changes used in the Maltsev
model is incapable of producing uniform HRs between ~50 bpm and 110 bpm. As Figure 97B also shows
however, by including changes in 'Kr kinetics via pa, our full model reproduces the complete range of
HR data reported by Brack et al. without encountering this bifurcation. The full model also reproduces the
data of Lyashkov et al. (222), although these data were not explicitly used to fit/train the model. Finally,
Campbell et al. (53) showed that 20Hz vagal stimulation causes guinea-pig SANCs to stop beating, and
this phenomenon is replicated by all three models (however the mechanism is different: our model stops
beating due to a high IKACh, whereas the Maltsev model stops due to a decrease in ICaL).
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Figure 97. Illustration of HR bifurcation and insufficient change in early DD without pag modification. 40-second
simulations were run at 50 logarithmically distributed ACh concentrations (0 pM and 49 values between 0.003-0.4
pM) using three SANC models: the Maltsev and Lakatta model ('Ma'), our new model with pag clamped to 1
('paf=l '), and our full model ('full model'). A. Membrane potential in the pasf=1 model during the last 8 seconds for
three simulations: immediately before the HR bifurcation (bottom), the first simulation exhibiting bifurcated HR
(middle, 0.1063 pM ACh), and the second simulation with a bifurcated HR (top, 0.1177 pM ACh). The numbers
between the last two APs indicate the HR between those two beats in bpm. Dashed lines show 0 mV. B. HR is
plotted as a function of ACh concentration for each model as labeled. The HR computed between each adjacent pair
of APs during the last 10 seconds of simulation is plotted (-). The solid lines are drawn for each model, one
connecting the maximum HRs at each concentration, and another connecting the minimum HRs to emphasize the
bifurcation. The Maltsev model was only explored up to 0.1 pM ACh, so we do not plot behavior beyond this point.
HR data from Brack et al. (o) (33) at 0, 2, 5, and 7 Hz vagal stimulation are plotted as a function of equivalent ACh
concentration, labeled with arrows. Data from Lyashkov et al. (o), which were collected using CCh as the
cholinergic agonist are plotted as a function of ACh assuming equal potency of CCh and ACh. The data were
provided as normalized HR, so we scaled them by the baseline HR from Brack et al.. A data point from Campbell et
al. (A) (53) shows that 20Hz vagal stimulation caused cessation of spontaneous activity in guinea pig SANC. This
point is plotted at the ACh concentration equivalent to 20 Hz stimulation. C. The last AP from each simulation is
shown for the three models as labeled. Waveforms are lined up so that they begin at the most negative diastolic
potential. No trace is shown for simulations that lacked spontaneous activity.
Figure 97A shows the actual membrane voltage traces for simulations immediately preceding and during
the bifurcation. Note that in all the traces, there appears to be a ripple at approximately -40 mV with a
fixed period of ~0.61 s. When APs successfully fire from each ripple (bottom trace), we see a HR of
approximately 60/0.61=98 bpm. If one or two successive ripples fail to cross the AP threshold however,
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we observe the bifurcated HRs at approximately % and M the ripple frequency. This phenomenon is quite
apparent upon a fine-grained exploration of the bifurcated range, producing alternating HR periods that
are integer multiples of each other (data not shown). Since the ripples occur around -40 mV, the rate at
which the cell rises from the maximum diastolic potential (MDP) of -60 mV to this level determines
whether the cell has had enough time to reset so that it can fire an AP at the peak of the ripple. This rate
of early diastolic depolarization (DD) is shown in Figure 97C.
Panel C shows detail on the AP shape produced by the three models. All three maintain a fairly
unchanged MDP, around -60 mV. The major difference between our full model and the two models that
lack pasf is that the slope of the early DD changes in our model, whereas it is relatively constant in the
other two. If early DD does not change with ACh (as in the Maltsev model), then HR can only be
controlled by prolonging late DD. However, as we can see in the top two traces in Figure 97A and the
"pas= " model in panel C, prolonging late DD too much causes the AP to "fall off' the ripple caused by
the rapid early DD. To eliminate the HR instability described above, we use the pasr parameter to
appropriately slow down early DD (details below). The type of early DD change produced by the full
model is also supported by experimental recordings in mammalian SANC in response to both bath-
applied and vagally-released ACh, see Figure 98.
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Figure 98. The slope of early DD decreases with bath applied ACh as well as vagal stimulation. A. Membrane
potential recordings in isolated rabbit SANCs under control conditions (c) and with 0.01 pM ACh as labeled. Figure
taken from Fig 3 in (88). B. the effect of 10Hz vagal stimulation on the APs recorded in guinea-pig SANC. C.
Expanded view of APs in A before vagal stimulation (a), and at two points during stimulation (b, c). B and C taken
from Fig 3 in (53).
The process though which we identified pay as a determinant of early DD is shown in Figure 99. Panel A
shows the major time-varying currents active during the first 0.1 s of depolarization: IKr, If, and ICa,L. Note
that the total time-varying current is positive, and it is balanced by a negative total instantaneous current
(not shown), which changes linearly with cell membrane potential in this range. Due to the sign
convention, negative currents depolarize the cell, so early DD occurs when IKr becomes less positive
(termed potassium current decay) from its high value immediately following an AP. Panel B shows a
series of experiments aimed at slowing early DD by either increasing IKr, decreasing If, or both. These
APs show that negative shift in the IKr activation gate or a positive shift in the inactivation gate to boost
IKr during DD were ineffective in changing early DD, as was complete blockage of If. Changes in ICa,L
were also without effect on early DD, and caused cessation of spontaneous activity (not shown). The rate
of early DD was only affected by the kinetics of IKr activation, wherein a paf value of 0.3 significantly
slowed early DD. In this scenario, the additional elimination of If was synergistic. Because the decay in
K' conductance has long been thought to be the initiator of DD (253), we view its regulation by paf a
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reasonable modification of the model that is also minimal in the sense that the desired behavior is
obtained through a change in a single parameter (we could alter early DD by changing other currents as
well, but these changes always required more than one parameter). Also, there is some experimental
evidence showing changes in 1Kr kinetics with adrenergic agonists through the PKA/PKC pathway (see
Table 18), so changes with cholinergic stimulation can reasonably be expected.
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Figure 99. The rate of decay of IKr determines early DD slope. A. The major time-varying currents during the first
0.ls of diastolic depolarization are IKr, If, and ICa,L. The total time-varying current (thick line) during this period is
approximately equal to the sum of these three currents, as indicated. B. Simulated APs under various interventions.
In all simulations, PU, was reduced to 0.3x baseline in order to prolong late DD and emphasize early DD; this and
the parameters specifically listed below were the only changes from baseline values. The baseline simulation is
shown with a thick line. The indicated interventions are: a shift in 'Kr activation gate pa 5 mV to the left ('pa'), a shift
in IKr inactivation gate pi 10 mV to the right ('pi'), complete blockade of If by setting conductance gf =0 ('gif), a
slowing of IKr activation gate kinetics by clamping pasf to 0.3 ('pasf), and the combined effect of I blockade and IKr
activation gate slowing ('pasf & gij'). For the simulations involving pasf, we also decreased gKr to 0.8x baseline in
order to elevate the MDP to the same level as in the baseline simulation and make it easier to compare early DD.
The dashed line indicates 0 mV.
We also explored the nature of the fixed-frequency oscillation to determine its origin and properties,
results shown in Figure 100. We show that the oscillation is produced by the L-type Ca2+ current ICa,L, and
that the necessary and sufficient conditions for the oscillation are a functional activation gate (dL) and at
least one of the two inactivation gates (voltage-sensitive gatefL, or submembrane Ca2+-sensitive gate fa).
The "base" trace shows the membrane voltage oscillation at baseline, with a period of 0.61 s. "P,,p=k=0"
illustrates that the oscillation is not caused by the Maltsev "Calcium clock", since setting the rate of Ca2+
uptake into the SR (Pap) and the rate of spontaneous release (k,) to 0 did not eliminate the oscillation nor
significantly change its frequency. The next two traces ("clamp all except dL and fL", and "clamp all
except dL, fa, Casub") show sufficient conditions for the existence of this oscillator: the activation gate dL
and one of the two inactivation mechanisms (f, or fCa and Casub) are enough to cause the oscillation. In
these simulations, all the other SANC variables are clamped to their baseline values and do not change
with time. These two cases differ in one interesting aspect however: if Ca2+ is not involved, the
oscillations tend to decrease over time (increasing gCa,L did not make the waves grow in amplitude)
whereas when Ca2 is involved, the oscillations amplify over time and eventually cause an AP.
The necessity of dL and one of the inactivation mechanisms is shown by the next four lines: Clamping
only Casub orfL does not eliminate the oscillation, but clamping both does. Similarly, clamping only dL
also eliminates the oscillation. In both simulations where no oscillation was seen, we tried increasing gCa,L
up to 100-fold to bring the oscillations back, but this was ineffective. The amplitude of the oscillations
seems to depend strongly on fL, since the fL clamp trace had to be amplified 1,000-fold to have an
amplitude comparable to the other traces. Eliminating the fL gate also had the largest effect on changing
the period of the oscillation. The only way to smoothly modulate the period of the oscillation over a large
range is to slow down the kinetics of the ICaL gates (the top trace shows the effect of slowing dL andfL by
a factor of 10; slowing dL alone was enough to produce some change in the oscillation frequency).
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Figure 100. The necessary and sufficient components for the fixed-frequency oscillation are the ICa,L activation gate
dL and one of the inactivation gatesfL orfca. Each line shows transmembrane potential V,,, and was simulated using
different conditions, as indicated by the labels on the left. The time bar refers to all the traces; the voltage bar refers
to the baseline case. Some of the traces were amplitude-scaled around their mean as indicated by the multiplier at
the end of each label. The numbers on the left show the voltage of the leftmost point in each trace. The numbers
above the traces show the period (in seconds) between the two nearest peaks. The simulation conditions were: base:
ACh=O. 144 pM in the neuroeffector junction and EJS, NE=0 in neuroeffector junction and EJS, pa,=1. One of the
points from this simulation was used when clamping the other variables. The variables clamped in the baseline
simulation were also set to the same values in all the other simulations. Pp,=ks=0: Pup and k, both set to 0. Clamp all
except dL and fL: all variables were clamped to a single value from the baseline simulation, except dL and fL. The
other labels are interpreted in a similar way. The two flat lines are scaled by 10,000 to verify the absence of
oscillations. Slow dL andfL: these gates were slowed by a factor of 10; all other parameters were allowed to change.
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This oscillation, whose properties had not previously been characterized, does not appear to be an artifact
of the simulated system. In fact, a growing, subthreshold oscillation has been observed in rabbit SANC
cells whose automaticity had been pharmacologically stunted as we show in Figure 101.
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Figure 101. The membrane voltage oscillation is physiological. A. high ACh concentration (0.144 tM) and pag
clamped at 1 allows our model to produce subthreshold oscillations that grow in amplitude until the threshold is
reached. If we do not clamp pag at 1, but let it change with ACh, the same behavior is seen at higher ACh, with a
slower oscillation frequency. B. A rescaled version of the region shown by a dotted box in A. C. Figure taken from
Zhang and Vassalle (370). The traces show the membrane voltage of a guinea-pig SANC cell that was made
quiescent using the potassium channel blocker indapimide as indicated at the top. The subsequent addition of NE
restored spontaneous activity (NE applied during the box shown at top), and washout of NE made the cell quiescent
again. b is an enlarged version of a, showing more detail around the threshold, and the inset is enlarged similar to
our model in B.
In the setting of adrenergic stimulation, we did not encounter any unexpected behavior from the Maltsev
model. Modulating the Ifshif, RgCaL, Rp1,, and RgKr as described above produced the expected saturating
increase in SANC oscillation rate. However, the Maltsev model has two undesirable features: 1) the
maximal HR is below that measured in perfused rabbit heart in response to sympathetic stimulation, and
2) the MDP becomes more negative with increasing adrenergic stimulation. These phenomena are
reproduced by our model when pajf is clamped to 1, as shown in Figure 102. By including paf changes of
the kind discussed for cholinergic modulation however, we were able to remedy both limitations. Figure
102A shows that our full model reproduces experimental HR data whereas the pa/= 1 version falls short
173
by achieving a maximum rate of-230 bpm. Figure 102B shows detail on the AP shape in the two models:
without changes in pa, the MDP becomes -10 mV more negative at maximal [NE] and AP duration
increases marginally, whereas the full model shows virtually no change in MDP and the AP duration
actually decreases somewhat. The behavior of the full model more closely resembles experimental data,
some of which are reproduced in Figure 103. In this figure we see that adrenergic stimulation has virtually
no effect on MDP; Choate et al. even report that sympathetic stimulation made the MDP less negative,
but only by about 1-2 mV (64). Regarding the AP peak voltage (APP), the traces show conflicting
information, with panel A showing an increase in APP with adrenaline, but panel C showing a decrease,
however both changes are slight. The AP duration was reported to decrease with sympathetic stimulation
(~ 2-3% (328), panel C), and tighter adrenergic APs are also seen in panel A and B.
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Figure 102. pay allows the full model to attain higher HRs and maintain MDP close to the baseline level for a wide
[NE] range. A Steady-state HR as a function of NE for full model and a version wherein paf is clamped to I, as
labeled. Maltsev model is not shown because it only simulated a maximal adrenergic effect, but the AP shape and
maximal HR are similar to that of the pasj=1 version of our model. 50-second simulations were run for 0 pM NE and
49 logarithmically distributed concentrations between 0.003 and 0.4 pM NE. Each simulation was 50s in duration,
and the HR during the last 3 seconds are all plotted (-), and the minimum and maximum rates are connected by
lines. Data o are from (33) for sympathetic stimulation frequencies as indicated. B. The last AP in each simulation is
shown, shifted so the MDPs are lined up. Dashed line shows 0 mV.
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Figure 103 Adrenergic stimulation via neurotransmitter bath application or neural release causes minimal changes in
AP shape and MDP. A. Effect of adrenaline applied to rabbit SANC, control and adrenaline (Adr) voltage traces are
shown. Taken from Fig 6A in (44). B. Sympathetic stimulation on guinea pig SANC, showing APs before (a), and
-3s (b) and ~-10s (c) after 5 Hz stimulation, taken from Fig lE in (64). C. Sympathetic stimulation on rabbit SANC,
before (A) and at maximal effect (C) after 20 Hz stimulation, taken from Fig 5 in (328).
In light of the above cholinergic and adrenergic explorations, we concluded that it was necessary to
modulate IKr kinetics with adrenergic and cholinergic stimulation. This change allowed us to slow early
DD and avoid "chaotic" beating in the setting of cholinergic drive, and to reach high HRs and correct
subtle changes in the AP with adrenergic drive. We also concluded that the Ca2 current oscillation is not
a pathologic consequence of the Maltsev "Calcium clock", but rather a phenomenon that had been
observed experimentally. We therefore did not attempt to explicitly change the properties of this
oscillation with ACh. We obtained pag data points to describe the steady-state function by using the HR
data of Brack et al. (33) as described in the next section. Since the Dokos, Demir, and Maltsev models did
not alter IKr kinetics, we cannot compare our formulations beyond what is shown in Figure 97and Figure
102. Our pag function and the data it fits can be found in Figure 105i.
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6.5.6 Determining P,, Rp,,, RgKr, and paf to fit HR data
The baseline Maltsev model (in the absence of ACh and NE), generates a beating rate of about 184 bpm.
Brack et al. showed that for a perfused rabbit heart with no sympathetic or vagus stimulation, the baseline
HR is 156 bpm. To achieve this HR, we lowered the value of PP. from 12 to 6.5 mM/s. This parameter
was originally treated as a means of setting baseline HR by Maltsev and Lakatta (228), so our lowered
value does not conflict with any experimental measurements (there are no direct measurements of Pp
(227)).
The SANC model parameters that change with adrenergic and cholinergic stimulation are: I/shift, RgcaL,
Rp,,, RgKr, and pagf. The I/shif, and RgcaL values with ACh and NE were fully specified by the experimental
data from Zaza et al. (367). The R,,, function was specified for various ACh concentrations using the data
of Lyashkov et al. (222). Thus, to be able to simulate the cholinergic effect on HR, we needed to specify
only two functions: RgKr and pa. Furthermore, since our ultimate modeling objective was to reproduce
the HR data from Brack et al. (33), we computed values of RgKr and pasf that would accomplish this goal.
The Brack et al. data shows HRs of 125, 96 and 66 bpm with 2, 5, and 7 Hz stimulation, respectively. In
these experiments, the right vagus was stimulated; Brack et al. also provide HRs for left vagus
stimulation, but since this nerve synapses primarily on the AV node rather than the SAN and it produced
less extreme changes in HR, we chose to use the right vagus data. We used our neurotransmitter release
model to convert these stimulation frequencies to equivalent ACh concentrations and then interpolated the
IfShift, RgCaL, and R,,, data and set those parameters accordingly (each data set was individually fit with a
Hill function in a least squares sense and then evaluated at the desired ACh concentrations). For each data
point, we then found RgKr and pag values to produce the desired HR to within 0.5 bpm. Since these two
parameters also altered the MDP, we were able to find unique solutions by requiring that the MDP be no
greater than the baseline MDP, and no lower than 1 mV below the baseline MDP (baseline MDP is
around -61 mV).
We followed a similar procedure for defining the parameters for NE. We used data from Brack et al.
where the sympathetic nerves were stimulated at 2, 5, and 10 Hz, giving HRs of 193, 226, and 249 bpm.
In this case however, there were three unknowns: Rpp,, RgKr, and pa. We first directly fit the three HR
points using a Hill function which we evaluated at 10 pM NE as an estimate of the maximum
adrenergically-stimulated HR. We then interpolated the '[shft and RgcaL data at 10 gM NE and set these
parameters accordingly. We also set RgKr to 1.7, based on the measurement showing 70% maximal
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increase in IKr with adrenergic stimulation (44). With the other variables fixed, we found the pag and Rp,,
that reproduced the maximal HR while maintaining the MDP at the baseline level. We defined functions
for RgKr and paf by scaling and shifting the Hill function that was directly fit to the HRs such that they
had value 1 at 0 NE and the computed maximum values at infinity. Since these functions were related by
a constant, they ensured that pay and RgKr moved in concert and therefore also fixed the MDP. These
functions were evaluated at the equivalent NE concentrations of the Brack et al. data, and Rppu was chosen
to produce the desired HR at each point.
6.6 Parameter Fitting
6.6.1 Steady-state function parameters
The model parameters (42 total) for which explicit experimental data were unavailable are:
1. AC modulation by Gs and G1: KsAc, nsAc, KIAC, nIAC
2. If shiip modulation by C: aos, als, a2S, n1s, n2S, K1s, K2s
3. RgcaL modulation by C: aoc, aic, a2C, n1C, n2C, Kjc, K 2C
4. Rpu, modulation by C: aop, alp, a2P, nip, n2P, K 1p, K 2P
5. RgKr modulation by C: aoK, a1K, a2K, n1K, n2K, K 1K, K2K
6. pas1 modulation by C: ap, aip, a2,, a3 , ni,, n2,, n3 ,, Kip, K 2,, K3
We would like to point out that despite the large number of free parameters we listed above, the functions
that they parameterize are not arbitrary, but were mechanistically motivated. In fact, they are all Hill
functions with amplitudes (a), binding affinities (K), and measures of cooperative binding (n). This
insistence on appropriate functions increases the number of parameters (for example, good fits for all the
C-functions were obtainable using polynomials with a smaller number of parameters), but ensures
desirable properties like monotonicity, gives parameter values that have intuitive meanings, and from a
practical standpoint, allows us to manually set good initial guesses for the parameters before they are
optimized by a numerical error minimization algorithm. The model is also over-determined in the sense
that the number of parameters, while large, does not allow perfect fits to the data and therefore does not
allow us to fit noise. In all, we fit 60 data points and satisfied 12 equality constraints.
Since our model is sequential (see "Actual cascade used for parameter fitting" in Figure 104), it is not
optimal to fit each function individually. For example, the AC function influences all downstream
functions so a suboptimal fit to the local AC data may still be globally optimal if it enables better fits
downstream. To enable optimization of all the parameters simultaneously, we constructed an error
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function that took all 42 parameters as input and produced model reproductions of all the data points. For
example, Zaza et al. (367) provide data on RgcaL as a function of NE. To obtain the model reproduction of
each data point, we evaluate all the functions linking NE to RgcaL in Figure 104: NE to p*, p* to Gs*, Gs* to
AC (since AC is a function of both Gs and G1, we also have to specify ACh and follow its cascade down
to G1), etc.
In this way, we compute the sum squared error between data and model reproduction for each data set,
and this total error is minimized by a constrained minimization algorithm in Matlab (fmincon). The
constraints we satisfy with equality are: a baseline cAMP concentration of 3pM, baseline fshir, of 0
(If shir fshitP+IfShiftC), and baseline RgcaL, Rup, RgKr and pag of 1. Since the paf data were calculated in
order to reproduce HR data, we also used the 6 paf data points as equality constraints.
Alternate optimizations: we explored the idea of distributing fitting error along the function cascade as a
way to reduce the number of free parameters. In one attempt ("Alternate cascade 1" in Figure 104), we
parameterized the PKA function (arrow from cAMP to C) as a sum of Hill functions and allowed the
cAMP-4fshirrc function to shift left/right, but reduced the complexity of the five relationships depending
directly on C to single Hill functions. In another attempt ("Alternate cascade 2" in Figure 104), we
parameterized the PDE function (arrow from vAC to cAMP) instead of the PKA function, and left the other
changes mentioned above intact. In a final attempt ("Alternate cascade 3" in Figure 104), we allowed both
PKA and PDE functions to be double Hill functions and left the other changes as in the first alternate
attempt. These alternate formulations were motivated by the uncertainty in our PDE and PKA
formulations, and the possibility of subcellular sequestration of cAMP which would make different
populations of PDE and PKA subject to different cAMP concentrations. The second motivator was the
idea that a more complicated function upstream may be able to reduce the necessary complexity of the
downstream functions. While these attempts did reduce the number of free parameters by ~10, they
produced unacceptable model reproductions of high level data, so the original optimization described
above and shown in Figure 104 was used.
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Figure 104. Summary of the signal flow in the overall model. See text for discussion of alternate cascades for
optimization. The diffusion, hydrolysis, and reuptake functions are not explicitly shown. Arrows represent functions
(simple binding reactions, enzyme kinetics, or more abstract equilibrium functions). Solid lines: functions that are
characterized using direct data. Dashed lines: functions defined by fitting parameters to reproduce high-level
implicit data. Key: SS: sympathetic stimulation, VS: vagal stimulation, NE: norepinephrine, ACh: acetylcholine, p*:
activated P-adrenergic receptor, M2*: activated M2 muscarinic receptor, Gs*: activated stimulatory G-protein; Gi*:
activated inhibitory G-protein, 371: liberated py subunit from inhibitory G-protein, p: opening rate coefficient for
IK,ACh channel, agate: gate of IKACh channel, vAc: cAMP-synthesizing velocity of adenylate cyclase, cAMP: cAMP
concentration in cytosol, JIjshirc: cAMP mediated shift in If activation gate, C: activated catalytic subunit of
phosphokinase A, IfshiP: phosphokinase A mediated shift in If activation gate, IfShf: the total shift of the 4 activation
gate (sum of if ShftC and If shiiP), RgCLaL: relative change in L-type calcium channel conductance, Rpep: relative change
in SERCA pumping rate Pp, RgKr: relative change in rapidly activating potassium channel conductance, pasf
speedup factor for IK, activation gate pa. The arrow connecting vAC and cAMP is the phosphodiesterase (PDE)
function.
A summary of the entire model and the experimental data it reproduces are shown in Figure 105. Various
sub-domains of the model are validated by experimental data, as shown by the bulleted lines in the gray
box. Some experiments controlled vagal and sympathetic stimulation (VS and SS), but most used direct
manipulation of the NTs NE (or Iso) and ACh (or CCh or MCh). Because the data spans various subsets
of the model, we are fairly confident that each component system is accurate. Briefly, our model
reproduces both the direct cAMP effect on ISh (a), and the effects of ACh and NE (b). Data on the actual
cAMP generation rate as a function of NE (c), and the steady-state cAMP concentration as a function of
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ACh are reproduced well. The data shown in panel c were collected in whole SAN tissue, so for reasons
discussed earlier, we fit this data using NE application in the BS compartment of our model (dashed line).
The model reproduces the data on L-type Ca" current sensitivity that we deemed most trustworthy (e) but
we also show the other available data (e, o) for completeness and since other models used that data. The
computed data for RgKr (f), Rpp (h) and pasf (i) are also fit well for both ACh and NE, as well as the
explicitly measured data for Rpp with ACh (h, o). Our IKACh formulation fits the steady-state activation
data (1), and ACh application in the BS compartment can explain some of the rightward shift seen in
whole tissue experiments (1, o). Finally, the model reproduction of the most important data, and our initial
aim, are shown in figures g, j, and k. g shows the effect of sympathetic stimulation in the presence of
varying background vagal stimulation, illustrating the inhibitory effect of VS on SS (note the small HR
increase due to SS for 7 Hz VS line versus the larger effect for the 0 Hz VS line). In j, we see the
opposite: the effect of increasing vagal stimulation in the presence of various background sympathetic
stimulations. Note that regardless of background sympathetic tone, the SANC model stops spontaneous
oscillation at vagal stimulation rates of roughly 15 Hz. The direct effect of neurotransmitter application is
shown in k, where we plot data obtained via direct ACh and NE application as well as the data obtained
from nerve stimulation on the same figure. The close agreement of the data (compare o and o) validate
our neurotransmitter release model but also bring into question the large difference in cell responses to
bath-applied versus neural ACh used in the Demir model (where they assumed neural release is only 2%
as effective at impacting the cAMP cascade as bath-applied ACh). In this figure we also show data that
were not originally used to build the model ("test data", A), but are fairly well reproduced nevertheless.
These data were collected in whole SAN tissue, and application of neurotransmitter in the BS
compartment of our model reproduces the observed rightward shift in HR sensitivity to neurotransmitter.
6.6.2 Phosphorylation rate parameter
The value of rp was chosen to be fast enough to allow the reproduction of dynamic HR data (see Figure
106), while also not conflicting with measured rates. We chose a value of Tp= Is, which is on the (rather
wide) range of observed values: on the fast side is the PKA catalytic subunit with a turnover rate of 20/s
(time constant of 0.05s), and on the slow side is the observation by Accili et al., who report that PP
inhibition causes a change in the If current conductance with a time constant of 466 seconds (3).
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Figure 105. Model reproduction of experimental measurements. The gray box shows the complete cascade-view of
our model, with each state variable on a unique vertical level. The bulleted lines on either side illustrate available
experimental data which are shown, along with the model reproduction in the panels corresponding to the letter
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above each bulleted line. For example the rightmost line shows experimental data where vagal stimulation (VS) was
controlled and HR was measured, and the data is shown in panel j. All the panels show model behavior. Solid lines
show model responses when ACh or NE is applied directly in the neuroeffector junction/EJS; dashed lines show the
responses for neurotransmitter application in the BS. The BS application is more appropriate for experiments done
on whole tissue as opposed to isolated cells. The rightmost two columns of figures have a joint [ACh] and [NE] axis;
coincidentally, ACh always caused a decrease in the plotted values and NE caused an increase, so they are not
individually labeled. Some experiments used Iso instead of NE; these data are shifted by a factor of 10 to the right to
show equivalent NE data. Data sources are: a. Fig 3 in (90); b. Fig 2 and 3 in (367); c. Fig 4B in (320) scaled
vertically to produce a baseline vACThta that gives 3pM cAMP; d. Fig 2D in (336) scaled to have a baseline cAMP of
3pM, original data is collected in response to metacholine (MCh) which we assume is equivalent to ACh; e. o Fig 2
and 3 in (367), D Fig 2A in (270) f, h, i. o calculated to reproduce HR data from Fig 2B in (33); h. o Fig 6A in
(222); g. data from Fig 2B in (33), x-axis is sympathetic stimulation (SS) frequency for various amounts of
concurrent vagal stimulation (VS) as indicated next to each curve. 0 Hz SS is shown by the arrow on the left; j. same
data as panel g, but with VS on x axis and different lines corresponding to concurrent SS rate; k. o from Fig 2B in
(33) when only SS or VS is nonzero, stimulation frequency converted to neurotransmitter concentration using our
neurotransmitter release model, m Fig IA in (222) scaled to have a baseline HR of 156 bpm, A Fig 4A in (318) and
Fig4A in (319) with ACh data scaled to a baseline rate of 156 bpm, NE data scaled to have the same HR range as the
model and shifted to a baseline of 156 bpm. these data were collected in whole SAN tissue so are more appropriate
for BS application of neurotransmitter; 1. A Fig 2C in (88), E Fig lB in (160), in the presence of neostigmine e and
control o from Fig 1A in (264), all data scaled relative to max value.
6.7 Speedup Factors
Our models of G-protein activation, cAMP equilibrium, and PKA activation are built using kinetic
information from experimental data. Thus, each component system obeys the published rates. However,
once we combined these individual components into the full cascaded system, we found a need to
introduce empirical speedup factors to allow the reproduction of high-level data. The speedup factors are
multipliers that change the rates of the differential equations. The use of these empirical scalars is
justified for two reasons. First, the vast majority of the experimental data from which we determined the
initial rate constants were collected in cell-free systems. This is commonly done as an experimental
convenience, to allow more systematic control of the experimental environment. However, this also
means that potentially important interactions that happen in-vivo are excluded. For example, regulators of
G-protein signaling (RGS) or GTPase activating proteins (GAPs) have been shown to bind G subunits
and cause a significant increase (over 50x) in GTP hydrolysis rate (23, 327). If auxiliary molecules such
as these are not included in experimental solutions, kinetic constants would be underestimated.
Furthermore, the addition of components that do not exist in the natural system can also retard kinetic
rates; for example, the detergent Lubrol PX decreases the catalytic rate of G-proteins (35), but is
commonly used in many of the classic G-protein experiments. Finally, the concentrations of certain ions
such as Mg 2+ and Na* may not be at physiologic levels, and even the type of buffer used can affect kinetic
rates (see discussion of G-GDP dissociation rates in section 3.4.1).
Secondly, we assumed that all the molecules are dissolved in the entire cytoplasmic volume, whereas it is
known that second messengers are often localized to spatially-segregated pools. This subcellular
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compartmentalization has been noted for G-proteins (166, 250), cAMP (188, 251, 272, 321, 365), PDE
(13, 14, 72, 365), and PKA (55, 74, 144, 233, 272, 298, 362). The Kurata model (198) moved toward
modeling compartmentalization effect by including an explicit "submembrane space" located adjacent to
the sarcolemma and comprising 115 0 th of the full cytoplasmic volume. The consequence of chemical
reactions occurring in smaller volumes is that less time is required to reach a specific concentration. Thus,
if the localized pools of G-protein, cAMP and PKA are on the order of the Kurata submembrane space
(likely they are even smaller), speedup factors on the order of 50 or greater would be expected.
The G-protein speedup factor G#=20, was chosen in order to allow the reproduction of IKACh half-time
data (see Figure 89). Although this data directly pertains only to the inhibitory G-protein, we assume that
similar experimental underestimation or spatial effects occur for the stimulatory G-protein. The cAMP
(cAMPs=10) and PKA (Cs,=100) speedup factors were set to the minimum values that allowed the
reproduction of HR changes in response to vagal and sympathetic stimulation, as shown in Figure 106.
The model reproduction of the HR dynamics are excellent for the vagal stimulation data, as well as low
and high sympathetic stimulation. The 5 Hz sympathetic stimulation data appears to have a faster initial
rise, followed by a slower approach to steady-state which our model does not capture perfectly. However,
the good fits to the low and high stimulation frequencies imply that this is not a fundamental flaw of the
model, and also that it cannot be fixed using the simple speedup factors described here. We reason that
the good fits to the extreme stimulation frequencies and the possibility of some variance in experimental
method when obtaining the 5 Hz data are valid reasons for avoiding more complex speedup functions.
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Figure 106. Model reproduction of dynamic HR data from Brack et al. (33). Model HRs in response to 2, 5, and 10
Hz sympathetic stimulation (SS) and 2, 5, and 7 Hz vagal stimulation (VS) starting at Os, with the medium and high
stimulation rates shifted by 20 and 40 bpm up (SS) or down (VS) for clarity. Digitized data from Fig 1 B (VS) and
Fig 5B (SS) in Brack et al. are shown by symbols for low (o), medium (E), and high (A) stimulation frequencies.
Symbols have been shifted and scaled to best overlap the model lines.
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7 MODEL PROPERTIES
7.1 Overview
In this chapter, we explore high-level model behavior which arises as a consequence of the individual
sub-systems we describe in the preceding chapters but which cannot be modeled explicitly. In standard
modeling parlance, the previous chapters can be seen as the "training data" for our model and this chapter
contains "test data."
Pacemaking currents
" The "classic" pacemaking currents If and Ica,L do not have as large an effect as previously
believed on changing the beating rate of sinoatrial node cells in response to sympathetic and
parasympathetic stimulation (Figure 107 and Figure 108)
* Changes in Ca 2 cycling through the sarcoplasmic reticulum (parameters PU, and Rpup) have a
large effect on heart rate changes, as shown by Maltsev and Lakatta (227)
* Changes in rapid delayed rectifier Kt current kinetics (parameter pasg) cause only subtle changes
in 1Kr shape, but have a very important effect on sinoatrial node cell beating rate. Classically,
much attention has been paid to measuring changes in ion channel conductances; our results
imply that more effort needs to be expended on also quantifying ion channel kinetics.
Response to sympathetic and parasympathetic stimulus trains
* Stimulation of sympathetic and parasympathetic nerves at low, moderate, and high frequencies
reproduce quantitative and qualitative aspects of analogous experimental data (compare Figure
109 and Figure 110)
Phase response curves
* It has been shown that the timing of parasympathetic nerve stimulation with respect to the
sinoatrial node cell action potential affects the "gain" of the stimulus on prolonging cycle period.
We generate simulated phase response curves for both parasympathetic and sympathetic stimuli
that are similar to those reported in other models and experiments (see Figure 111 and Figure
112).
* We identify the rate of IKAch activation as an important factor in determining the shape and
amplitude of vagal phase response curves
" Sympathetic phase response curves are fairly flat, as is expected from the slow rate of
sympathetically-mediated heart rate changes. The sympathetic phase response is amplified by the
presence of background acetylcholine
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Vagal and Sympathetic Impulse response functions
" We reproduce experiments conducted in dogs wherein random stimulation (Gaussian white noise)
of sympathetic and parasympathetic nerves are converted to heart rate impulse response functions
* Our model produces functions that are similar both qualitatively and quantitatively to the
experimental data (see Figure 113 and Figure 114)
* We identify one difference between our simulations and the experimental data: a low frequency
component in the vagal impulse response function. We hypothesize that this feature may be
absent in the experimental data because of inadvertent sympathetic stimulation during the vagal
stimulation protocol (due to physical proximity of some sympathetic nerve fibers and the vagus).
7.2 Results
The detailed approach we took to constructing each sub-system of our overall model (Chapters 2-6), and
the final reproduction of steady-state (Figure 105) as well as dynamic (Figure 106) HR data validate our
model. In this chapter, we explore some high-level behaviors.
First, we look at the changes in ionic currents during adrenergic and cholinergic stimulation. Figure 107
summarizes the effect of adrenergic and cholinergic stimulation, at NE and ACh concentrations chosen to
provide a similar relative increase and decrease from basal as what was shown in the Maltsev model and
is shown in Figure 108. With NE application, the main mechanisms of rate increase are increased Ca2
release from the SR (jSRCarel) which stimulates the depolarizing Na*/Ca2+ exchanger INCX. This effect was
also noted by Maltsev and Lakatta and can be seen in Figure 108A. The jSRCareI curves are qualitatively
different in the two models however, with a less extreme effect seen in our model. This is so because
Maltsev and Lakatta only simulated "maximal" adrenergic stimulation, so they use a PUP value of 24
mM/s whereas our functional representation of Pup and the fact that we reduced the baseline value in
order to reproduce baseline HR only give a value of 10.4 mM/s at the NE concentration used in Figure
107. Similarly, ICaL, is only slightly larger compared to baseline in our model, whereas the difference in
ICa,L is large in the Maltsev model. Because our ICa,L formulation is based on experimental data, as is our
model's HR behavior, we argue that our model's representation of the ICaL change is more appropriate. If
is another current that experienced a large increase with NE in the Maltsev model, but we actually see a
NE-mediated decrease in our model. This is so despite the shift in If activation with NE: at this
concentration, a shift of only 2.25 mV occurs in our model, which appears to be outweighed by the
increase in SANC oscillation frequency, which tends to cause more If inactivation. IK,ACh plays no part in
NE-mediated rate acceleration, so it is about the same as at baseline. Finally, IKr is slightly larger and has
a faster decay during early diastole in our model. This is due to the combined effect of RgKr and paf, and
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we point out that the effect ofpag is rather subtle when looking at just the current traces. This implies that
the paf modification, which is new in our model, is not obviously un-physiologic and may have been
present but overlooked experimentally. The Maltsev model shows a similar larger IKr peak and faster
decay, but the greater relative decay rate of our IKr allows it to fall to a below-baseline value during early
diastole, whereas in the Maltsev model the diastolic IKr is larger with Iso than at baseline. To summarize,
our model shows a similar increase in SANC oscillation rate as the Maltsev model, but the major
mechanisms shift from being a drastic SR Ca2+ release, increases in If and ICaL, to a more moderate SR
Ca 2+ release and a more rapid IKr decay, with the effect of If and I'Ca,L being almost negligible.
Heart Rates: 159 (basal), 199 (NE), 92 (ACh) bpm
v M 60 mv 
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Figure 107. Effect of adrenergic and cholinergic stimulation on the major ionic currents and SR calcium release.
Dashed horizontal lines show 0 for each current and V., The basal simulation was in the absence of vagal or
sympathetic stimulation (but nonzero AChBS and NEBS); 0.02 gM NE and 0.06 pM ACh (in the neuroeffector
junction/EJS) were used for the adrenergic and cholinergic simulations, respectively, which are labeled in the V,
traces. Negative currents are entering the cell (depolarizing), positive flux (JSRCarel) is exiting the SR (depolarizing).
Time bar corresponds to all traces, which were lined up such that V,=O at t=O (vertical dashed line).
The most apparent means of ACh-mediated rate slowing is the drastic increase in IK,ACh., which was also
reported to be a key mechanism by Zhang et al. (369). The other changes are opposite to those we
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discussed above: SR Ca2+ release and INCX decrease, ICa,L decreases almost imperceptibly, If paradoxically
increases, and the rate of IKr decay slows slightly. The effect of ACh on Rpup, RgCaL, RgKr, and pasf can
explain the associated changes, and the paradoxical increase in If is again explained by the prolonged
diastolic period, which provides If channels more time to open despite increasing deactivation and the
negative shift in the activation curve due to ACh. The features of an increased IKACh and decreased SR
Ca 2+ release are shared by the Maltsev model, but their model also has a significant decrease in ICa,L and 4
(see Figure 108B), which are responsible for some of the rate slowing in their model. They also do not
even consider the effect of IKr, since their model did not model changes in Kr conductance or kinetics, but
these were major players in our model (see section 6.5.5).
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Figure 108. Membrane voltage and currents during adrenergic (A) and cholinergic
Maltsev and Lakatta (227) Fig 3A and Fig 6A.
Next, we illustrate the effect of a train of vagal or sympathetic stimuli on beating rate, shown in Figure
109 and compare to experimental data presented in Figure 110. In model simulations and experiments, 2
Hz vagal causes gradual slowing and no change in AP peak or MDP. 10 Hz vagal stimulation causes a
drastic slowing of HR and erratic beating. In our model, beating actually stops shortly after start of
stimulation, but then starts up again and approaches a steady-state rate (see last beat during stimulation in
Figure 109B). In the analogous experiment, HR slows more gradually during this stimulation protocol.
Both model and experiment show a decrease in AP peak during stimulation and an increase after. In the
experimental data, MDP hyperpolarizes during stimulation and then recovers monotonically, in our model
MDP hyperpolarizes slightly during stimulation but recovers to a more positive value before settling to
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(B) simulations taken from
baseline. 20 Hz vagal stimulation stops beating in both model and experiment, but the recovery is
different: the MDP in our model is more positive than at baseline, whereas it is more negative in the
experiment. The decrease in AP height during stimulation and its increase afterwards is also more
extreme in the experimental data than our model. In terms of HR, recovery starts immediately after stop
of stimulation and completes by 30 sec.
The disparity in HR response and AP morphology in response to 10 Hz stimulation may be due to species
differences, since the experimental data were collected in guinea-pig. They may also be due to the fact
that the experiments were done on intact atria rather than single cells, allowing the coupling between
adjacent cells to influence the response of the cell in which the data were collected. We built our single-
cell model to reproduce the HR response of the entire SAN; however, the more detailed changes may be
different from those seen in whole tissue.
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Figure 109. Effect of vagal and sympathetic stimulation on SANC model APs. A-C show the membrane voltage for
a 10-s period of vagal stimulation starting at 5s, at the frequencies indicated in the figure. D shows the HR as a
function of time for each simulation. E-H are the analogous plots for sympathetic stimulation.
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Sympathetic stimulation at 2, 10 and 20 Hz causes no perceptible change in MDP or AP peak in
simulation and data. Interestingly, HR continues to increase after cessation of stimulation, reaching a peak
about 5 seconds after cessation. The HR recovery is also slow, not reaching steady state within 30
seconds. Both of these observations are similar in the experimental data.
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Figure 110. Effect of vagal and sympathetic stimulation, experimental data. A-C above the dashed line are from Fig
2 in (53), showing the effect of right vagus stimulation on guinea-pig SANC membrane voltage. A-B below the
dashed line show an experiment from Fig 2 in (64), showing the effect of sympathetic nerve stimulation in guinea-
pig SANC; A shows the membrane voltage and B the corresponding HR.
Another interesting phenomenon is the importance of sympathetic/parasympathetic spike timing in
altering HR. We produced phase response curves (PRCs) in Figure 111 (see figure caption for explanation
of PRC construction) and the figures from other models and experiments are shown in Figure 112. A fast
IK,ACh (greater Gg and smaller pm, see Figure 90) is needed for a peaked PRC similar to those of the Demir
and Dokos models. The slower IKACh that we use in our model produces less potent (lower magnitude) and
less phase-sensitive rate inhibition. The peaked PRCs all have a max around <D = 0.6, which is similar to
the PRCs of the Dokos and Demir models, as well as the experimental data from Slenter et al. (296). The
slow IKACh PRCs in our model peak around -0.2, meaning that vagal stimulation during the preceding beat
is most potent in influencing the current beat; this quantitative observation is not seen in the other models
or the data. In our model, the effect of background NE is to reduce the amplitude and phase-sensitivity of
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the vagal PRCs when using slow IKACh. This effect is most likely due to the shortening of the period,
which means that a stimulus has less time to have an effect. With fast IKACh, low dose NE actually
increases the PRC amplitude - an example of accentuated antagonism, but high dose NE decreases
amplitude and phase dependence significantly. A qualitatively similar effect was seen by Demir, but they
did not see accentuated antagonism, which is an interesting feature of our model with fast IK,ACh/ G-
protein dynamics.
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Figure 111. Vagal and sympathetic PRCs. Trains of 1, 5, or 10 vagal or sympathetic stimulations at 200 Hz were
delivered at various phases of the AP waveform and the effect on SANC period is quantified as AP=(Pi-Po)/Po,
where Po is the baseline period in the absence of stimulation and P1 is the SANC period with stimulation (plotted as
a percent rather than fraction of 1). Phase CD is defined to be 0 at the point where Vm=0, 1 at the end of that cycle, and
negative during the preceding cycle. These definitions are consistent with what was used by Demir et al. (81). A.
vagal PRC for standard IKACh model (solid line) magnified by 10, and for the fast IKACh model (dashed line) for 1, 5,
and 10 vagal spikes as labeled. B. Effect of simultaneous adrenergic stimulation on vagal PRC. NE concentrations
of 0, 0.01, and 0.1 pM were applied to the neuroeffector junction/EJS during the vagal PRC determination protocol.
Dashed and solid lines are as in A, [NE] for each line as labeled. C. The control AP showing the phase range tested.
D-F. Analogous plots to A-C, except with sympathetic stimulation and background ACh in E. Note the zoomed y-
scale in D and E.
The experimental data show about 30% slowing in response to 10 vagal pulses and 70% with 20 pulses,
and it has a fairly flat shape to the left of the PRC peak, which is around 0.5-0.6. This is different from the
very tall and peaked PRC shapes shown by Demir and Dokos: in the Demir model, 9 pulses cause 90%
maximal rate slowing, and in Dokos, 10 pulses cause an even greater 125% rate slowing. The 10-pulse
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PRCs in our model straddle the experimental range, with the slow and fast IKACh producing ~10% and
80% maximal slowing, respectively. The qualitative shape-of the experimental PRC curves is also less
extreme than the shapes produced by the Demir and Dokos models, and lies between the peaked and blunt
PRCs produced by fast and slow IKACh in our model.
For completeness, we also studied the sympathetic PRC using our model, although we cannot compare
the results with other models or experimental data. Sympathetic PRCs are barely existent, being very
close to zero and fairly insensitive to phase (Figure 11 D). This is expected given the slow rate of p-AR
activation. The addition of background ACh increases PRC amplitude (Figure 111 E), presumably due to
lengthened period which allows the slow NE response to have a greater effect; however, the effect is still
very small at <1%.
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Figure 112. Vagal PRCs from the Demir (A-C to the left of dashed line, from Fig 12 from (81)) and Dokos (top right
figure, from Fig 13 in (96)) models, as well as experimental data from Slenter et al. (A-B in bottom right, from Fig 5
in (296)). A-C on left: Figures analogous to Figure Il1A-C, with 1-9 vagal stimuli delivered at 200Hz and
background Iso concentrations as indicated in B. Top right: Similar PRC curve, but showing phase in seconds (not
normalized to cycle length) and actual cycle length instead of AP. Vagal stimulation was at 100 Hz for 100 ms.
Bottom right: * with dashed lines show AP (labeled as A<D) for 10 (A) and 20 (B) vagal pulses at 200 Hz in rabbit
SAN.
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Finally, we consider the "impulse response" of the HR to individual sympathetic and parasympathetic
spikes. We follow the procedure described by Berger et al. (20). In this study, the autonomic nerves in a
canine preparation were stimulated according to a Gaussian White Noise (GWN) process and the
resulting HR analyzed to produce nerve stimulation -- HR impulse responses. The summary figure from
our model study is shown in Figure 113 with the analogous figure from Berger et al. in Figure 114.
The results are qualitatively very similar, with the vagal impulse response being a sharp downward spike
symmetric around 0, and the sympathetic one being a causal slow rise and fall about 20-30 seconds in
duration. The Berger parasympathetic impulse response is slightly wider than ours, but that is likely due
to the slower HR in their data (-70 bpm compared to -110 bpm) which limits how tight the impulse
response can be in the time-domain. Our vagal impulse response also contains a small low-frequency
component which likely reflects the longer-lasting effect of the G-protein cascade on HR. This feature
appears to be absent from the Berger data, although the area immediately to the right of the peak in their
plot is also a bit more noisy. Another explanation for this is that sympathetic nerves have been observed
to travel in close physical proximity to the vagus (324), so the Berger vagal stimulation data may suffer
from contamination by partial activation of sympathetic fibers. If the system is fairly linear, this would
have the effect of cancelling out the low-frequency hump in the vagal impulse response, since the
sympathetic impulse response is about the same amplitude and shape, but opposite in sign. The difference
could also be a rabbit vs. dog species effect, or it could imply that the effect of vagal stimulation on the
cAMP cascade is not as large as we modeled, which would be in agreement with the model of Demir.
More microanatomical data on the distribution of M2 muscarinic receptors in the neuroeffector junction
and EJS spaces and their coupling to G-proteins and AC would be necessary to clear up this issue
definitively. Alternatively, experiments similar to those of Berger could be re-run using a p-blocker while
collecting the parasympathetic data to ensure no unwanted stimulation of the sympathetic branch. The
sympathetic functions are also qualitatively very similar.
One thing that is quite surprising is how similar the experimental and model-generated transfer functions
are quantitatively: both show about -2 bpm/Hz vagal stimulation peak and about 0.4 bpm/Hz sympathetic
stimulation peak. A difference between the two systems is the amount of nonlinearity (the initial change
in HR before it settles around the new set-point), which is fairly large in our model and almost
nonexistent in the Berger data. This may again be because of species differences or due to the possibility
of simultaneous stimulation of vagus and sympathetic nerves because of their anatomic proximity.
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Figure 113. Transfer function analysis of SANC model responses to vagal and sympathetic stimulation, modeled
after experiments by Berger et al. (20), see reference for experimental details. Briefly, A. GWN vagal stimulation
low-pass filtered to 0.7 Hz, B. SANC model oscillation rate in response to stimulus in A. C. Power spectra of vagal
stimulation rate (Para Rate) and SANC oscillation rate (Sinus Rate), normalized to peak value; arbitrary y-scale. D
and D. Magnitude and phase of transfer function describing SANC input-output relationship for vagal stimulation.
F. Computed coherence function (measure of system linearity). G. Vagal stimulation -> HR impulse response in
time, computed by averaging 8 experiments. H-N are analogous figures for sympathetic stimulation.
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8 CONCLUSION AND FUTURE WORK
The work described in this thesis is the next natural step in the evolution of mathematical models of
SANCs. The very first models applied the HH formalism to spontaneously active cells and provided a
plausible mechanism of diastolic depolarization (the idea of potassium current decay in (253)). Next,
more physiological realism was added in the form of SANC-specific ionic currents based on voltage
clamp studies (82, 89, 95, 360, 368) and subcellular compartmentalization and cycling of Ca2+ (198, 228).
The effects of adrenergic and cholinergic stimulation were also modeled (81, 96, 227, 369, 370), usually
aimed at reproducing specific changes in AP shape or probing the ionic mechanisms of SANC oscillatory
rate change. These models were incomplete however, because they described only very specific vagal
stimulation protocols, and did not model neutrally-released NE, nor the dynamics of SANC rate change.
Our main objective was to build a complete model of dynamic HR modulation by the ANS; we achieved
this goal by developing models of the individual component systems in the signaling cascade and
assembling them to produce the desired high-level phenomenon of dynamic HR change. The model
reproduces numerous experimental data sets and measured values, as well as high-level behaviors
classically associated with ANS control of HR. Below we summarize the unique features of our model,
what the model allows us to learn about the system, and future expansions of the model in terms of
addressing its limitations and exploring other applications.
8.1 Model summary
Our model is fundamentally different from previous SANC models in our adherence to appropriate
molecular mechanisms whenever possible. For example, models that explicitly include ACh release (81,
96) use a single parameter to describe the rate of ACh hydrolysis by AChE; in contrast, our model of ACh
hydrolysis is based on experimentally measured AChE abundance, and the accepted catalytic mechanism
wherein ACh binds AChE with a certain affinity and is then hydrolyzed at a specific rate. As a
consequence, our model has more parameters. This may at first seem a disadvantage; however, these
parameters describe real chemical processes and have been measured experimentally. This means that we
have more confidence about the particular parameter values and therefore the overall function of various
model components. The other components of our model are specified in a similarly detailed manner, and
parameter values are supported by numerous experimental measurements. The explicit nature of our
model also enables future refinements because more current measurements/estimates of particular
parameters can easily be updated without having to change the overall model framework.
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A second consequence of our focus on mechanisms is that our model features novel descriptions of a
number of sub-systems that are absent in other models. We model 1) neurotransmitter release from the
adrenergic and cholinergic varicosities, as well as the ACh- and NE-specific clearance mechanisms 2) the
activation of p-AR and M2 muscarinic receptors 3) the activation of G-proteins and their effect on AC 4)
the function of PDE in establishing an equilibrium cAMP concentration 5) the activation of PKA by
cAMP 6) the effect of second messengers on SANC function, and 7) direct inhibition of adrenergic
activity by high levels of ACh. Some of these sub-systems are useful independently of the whole cascade:
for example, we used the neurotransmitter release model to combine data from experiments that used
neural stimulation and those that used bath applications of NTs. The explicit nature of the entire cascade
is also useful: if experimental data on SANC changes resulting from PDE or PKA inhibition, or cAMP
application are available, the experimental conditions can be easily reproduced using our model in order
to evaluate the simulated responses against the actual data and update the model if necessary.
To summarize each novel component:
1) Neurotransmitter release and clearance are based on first principles of
binding/unbinding/catalysis reactions, diffusion, and SANC/autonomic varicosity geometry. The same
basic framework is used for cholinergic and adrenergic stimulation, and allows simultaneous activation of
both branches of the ANS, conversion from stimulation rate to neurotransmitter concentration, and
neurotransmitter application directly at the cell's surface as well as on the far side of the ECM (in the BS).
2) The activation of p-AR and M2 muscarinic receptors by binding the appropriate
neurotransmitter is modeled using measured rate constants and affinities, and includes two receptor
populations (neuroeffector junction and EJS), with receptor abundances and distribution deduced from
experimental measurements.
3) The G-protein model has independent sets of reactions for Gs and G1, based on direct
experimental data. The intrinsic GTP turnover cycle of each species is modeled, as well as GPCR-
mediated facilitation of guanine nucleotide exchange and subunit dissociation. The activated Gs and G1 a
subunits competitively bind AC and enhance or inhibit its rate of cAMP production according to the
measured AC abundance and experimentally documented effects of adrenergic/cholinergic stimulation.
4) The complete PDE model features the two PDE subtypes most abundant in the SANC and their
modulation by Ca-CaM and cGMP, and is based on experimental data. A reduced model appropriate for
the particular Ca-CaM and cGMP concentrations in the SANC is also presented.
5) The catalytic subunit of PKA is liberated by binding cAMP according to a specific affinity and
rate deduced from a number of experimental measurements appropriate for the SANC environment.
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6) Second messengers cause a number of changes in ion channel parameters and SERCA
function: a) our novel IKACh model is activated by Gp,1, has a correct ACh sensitivity, and can reproduce
correct kinetics (we use slower kinetics to compensate for the simplified nature of our neurotransmitter
release model); b) the shift in the I. activation gate is attributed to both a direct cAMP mechanism and a
phosphorylation-dependent mechanism and allows the reproduction of explicit cAMP data as well as the
overall adrenergic/cholinergic effects; c) changes in ICa,L conductance are mediated by PKA and
reproduce overall cholinergic/adrenergic data; d) SERCA pumping rate parameter PU, is mediated by
PKA (through the implicit inactivation of PLB) and reproduces experimental data on PLB
dephosphorylation by cholinergic agonists; e) IKr conductance and kinetics are PKA mediated, and change
in accordance with maximal measured values and allow the reproduction of the full range of HRs using
the baseline Maltsev model.
7) Adrenergic activity is directly inhibited by high levels of cholinergic agonists via a
postsynaptic process.
The model fits all of the experimental data used in its construction, as well as some phenomena that we
did not explicitly try to fit: the rightward shifts in IK,ACh and HR changes in response to NTs applied to
whole-tissue preparations, the general shape and amplitude of vagal PRCs, and vagal and sympathetic
impulse response functions. By incorporating changes in the kinetics of IKr, our model also eliminates a
major limitation of the Maltsev model and enables smooth HR changes below 100 bpm without eliciting
"chaotic" behavior. The use of pag to modulate IKr kinetics also allows our model to generate more correct
AP shapes than those produced by the Maltsev model.
8.2 Model implications
Our model allows us to draw multiple conclusions about the mechanisms of HR control by the ANS.
Because the model is very detailed, the inferences we make can be equally specific and can be tested
through targeted experiments. For example, it is generally understood that parasympathetically-mediated
HR changes happen more quickly than sympathetically-mediated ones (5). Our model provides evidence
regarding the mechanism responsible for this unique feature of the system: the rate-limiting step in
adrenergic modulation of SANC properties occurs very early in the signal transduction cascade, in the
slow activation of f-ARs. On the other hand, the rate limiting steps for cholinergically-mediated changes
only occur downstream of cAMP, but still remain faster than the maximal adrenergic rate. To test this
explanation, experiments comparing the rate of HR change in response to step application of NE versus
step application of intracellular cAMP can be conducted. The hypothesis supported by our model is that
direct application of cAMP would result in a faster approach to steady-state. The mechanistic explanation
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offered by our model may also have clinical implications: since adrenergic changes are limited at the level
of the receptors, the p-ARs are good drug targets. Conversely, drugs targeting M2 muscarinic receptors
may not be as effective as ones targeting downstream systems such as PDE and PKA.
Along the same lines, the impulse response of our model to vagal and sympathetic stimulation matches
that recorded in dog: the vagal response has the classic peaked shape whereas the sympathetic response is
much more gradual increase followed by a decrease. However, the parasympathetic response from our
model also contains a slow component. This difference may imply that the model overstates the slower
cAMP-mediated mechanisms. It may also be due to differences between the rabbit and canine SANCs.
However, the phenomenon could also be real, arising from contamination of the vagal stimuli by
inadvertent activation of sympathetic fibers traveling in close proximity to the vagus ((171), reviewed by
(324)). It would also imply that there is a greater low-frequency component to parasympathetic
stimulation than previously believed, and would call into question heart rate variability (HRV) methods
that rely on spectral separation of parasympathetic and sympathetic activity. To test these hypotheses,
experiments like those done by Berger et al. (20) in dog should be repeated in rabbit to eliminate possible
species differences. To test the hypothesis that electric stimulation of the vagus also causes stimulation of
sympathetic fibers, the vagal stimulation experiments can be done in the presence and absence of p-
blockers.
The disparity in the speed of vagally versus sympathetically mediated HR changes was also studied in
terms of PRCs. The slow effect of sympathetic activity was manifested as the very small (<0.02%)
maximal change in cycle length for stimuli applied during the preceding beat. On the other hand, vagal
PRCs produced by the model had much larger maximum cycle length effects (10-80%) and the peak
value was observed either during the current or preceding cycle. The model implies that the mechanism
underlying peaked vagal PRC is primarily the rate of IKACh activation, with faster channel kinetics causing
sharper and taller PRCs. Comparing the shape of the PRCs produced by our model to experimental data
also implies that the appropriate rate of IKACh activation lies between the "fast" and "slow" kinetics we
tested. The fast and slow kinetics were based on data from guinea-pig atrial IK,ACh (160), similar
experiments should be conducted in rabbit SANCs to better determine the activation rate; from our model
results, we would expect times between 200-800 ms for half-maximal IKACh activation in response to step
applications of ACh.
Our model also allows us to critically evaluate data on the sensitivity of IKACh to ACh. Due to the explicit
nature of our neurotransmitter release model, we are able to reconcile the disparate IK,ACh activation data
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of Osterrieder et al. (264) versus those of Inomata et al. (160) and DiFrancesco et al. (88) and attribute the
differences to experimental technique (whole SAN tissue vs. isolated cells) and the effect of AChE. We
were able to further support this hypothesis by reproducing the rightward shifts in HR curves observed in
whole SAN tissue experiments versus those on isolated cells (see Figure 105k). Previous models with less
specific descriptions of the extracellular space and neurotransmitter diffusion were unable to
systematically deduce the more appropriate data set, and this led to a number of unique descriptions of
IK,ACh (see Figure 89B, Dokos vs. Maltsev and Demir models). To completely resolve this issue, our
hypothesis should be tested experimentally: by quantifying the IKACh sensitivity to ACh in an isolated cell
versus whole SAN tissue in the presence and absence of AChE inhibitors (the effect of AChE inhibitors
was tested by Osterrieder et al. (264) and the result is in agreement with our hypothesis).
Because of the thorough, description of both adrenergic and cholinergic systems, our model allows us to
deduce how they interact when simultaneously activated. In the literature, both direct and indirect
mechanisms have been proposed; our model shows that both are necessary, but active under different
regimes. In the setting of low and moderate vagal activity, the sympathetic/parasympathetic interaction
occurs indirectly, via competitive inhibition or activation of AC. At high vagal rates however, a direct
inhibition of adrenergic stimulation was necessary to reproduce experimental data. The mechanism of this
direct inhibition is modeled abstractly due to a lack of data. We chose an intracellular mechanism wherein
activated M2 muscarinic receptors effectively reduce the number of active p-ARs. However, presynaptic
mechanisms that result in diminished release of NE are also possible. To differentiate these two
mechanisms, studies of direct NE release or spillover in the setting of constant sympathetic stimulation
and varying levels of simultaneous vagal stimulation would need to be conducted. Also, to verify that
such a direct mechanism exists, experiments in recombinant cells lacking functional G1 could be
conducted to explore whether a cholinergic effect can be elicited at high vagal rates and nonzero
sympathetic rates; our model predicts that an effect would be observed.
Our model uses a unified framework to change SANC parameter values in response to ANS stimulation.
This allows us to assess the importance of various pacemaker mechanisms relative to each other in a way
that was previously not possible. The major conclusions we make are that the classically considered
"pacemaker currents" If and ICaL exert a smaller effect on the rate of SANC depolarization than previously
believed, and that more subtle changes like those in IKr kinetics can have a significant impact. This is so
largely because the experimentally measured changes in If and IcaL (Figure 105 b and e) only reach about
half of their maximal values at neurotransmitter concentrations that elicit near-maximal HR changes
(Figure 105k). Thus, models such as the Maltsev model, which assume the maximal change in If and IcaL
201
parameters to simulate moderate HR changes overestimate their effect. In our model, the modification of
IKr kinetics was necessary in order to allow reproduction of the full experimentally observed HR range,
and is therefore of critical importance. However, its importance is not obvious from the subtle changes in
IKr current traces over the course of an AP (compare 'Kr in Figure 107 versus Figure 108A). While the
particular changes in IKr kinetics may be somewhat arbitrary in our model, it illustrates the importance of
kinetics over conductances. Most other models do not include any changes in channel kinetics due to
adrenergic or cholinergic activity (81, 96, 227); this may be because these changes are more difficult to
measure than those in maximum current. However, our model suggests that more experimental efforts
gathering channel kinetic data would be very valuable for understanding the mechanisms of ANS control
of HR.
Our model shows a diminished importance of ICa,L in altering SANC depolarization rate; however, further
exploration identified it as necessary and sufficient for maintaining a growing membrane voltage
oscillation at very low HRs. This oscillation appears to be physiologic since it has been observed
experimentally, and it points to a new function of ICaL, as a possible mechanism to prevent complete
cessation of pacemaking. From a clinical perspective, this same mechanism could have the negative
consequence of acting as a proarrhythmic. In this case, Ca2+ channel blockers may be of clinical value not
only as methods of rate- but also rhythm-control and more testing of such applications could be called for.
Finally, we identified processes that need to be modeled in detail and are therefore likely to be critical for
SANC function. Our neurotransmitter release model assumes that a number of vesicles are released from
all varicosities at the same instant. By studying the effect of this assumption on the behavior of IKAch and
HR (see section 6.3.3), we concluded that it would be necessary to model a more stochastic vesicle
release process. The dynamics of vesicle release can be studied experimentally to determine the
distribution of lag times between neural stimulus and the fusion of a number of vesicles in a single
varicosity. Also, the effect of stimulus conduction delays as a function of distance to individual
varicosities should be experimentally explored. Another aspect that requires a more explicit treatment is
that of subcellular localization of second messengers. Our detailed models of G-proteins, cAMP and PKA
do not allow the reproduction of appropriate HR dynamics without the use of empirical speedup factors.
The same effect could be achieved by modeling second messenger localization to smaller volumes; the
spatial localization and dimensions of these pools would have to be determined through direct
experimentation or to reproduce the same phenomenon achieved by our speedup factors.
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8.3 Future work: model limitations and applications
A considerable amount of effort was expended to develop our model in adherence to the known
mechanisms and experimental data. As with all models however, ours has a number of limitations that
should be addressed. Below is a list of suggestions for best remedying these limitations:
1. Add stochastic element to neurotransmitter release. This can be done by either modeling each
varicosity separately, or using a temporally-smeared function. Modeling each varicosity
independently would be easiest from a functional point of view since all the same equations could
be used. It would however be much more computationally intensive because this would add
almost 100 more state variables to the ODE system. The second option would be computationally
simpler since we would maintain a "single" adrenergic and cholinergic varicosity, but the
equations describing release would have to change. A good choice for vesicle release function
would have the shape of a Poisson distribution, under the assumption that the signal for vesicle
fusion arrives instantaneously, but N different vesicles fuse with the varicosity membrane and
release neurotransmitter in a random manner (Poisson arrivals). The parameters for this
distribution can be obtained empirically to eliminate the HR oscillation when using fast IKACh,
theoretically by looking at the spatial distribution of vesicles within a varicosity and estimating
the variance of their fusion lags, or experimentally by actually measuring neurotransmitter
concentration in a neuroeffector junction as a function of time in response to a stimulus. The
improved model should allow for fast IK,ACh kinetics without causing the HR oscillation/beat
pattern we observed with the model presented here.
2. Improve IKACh model to reflect actual kinetics. Inomata et al. data (160) or more appropriate
rabbit data can be used to pick appropriate Gg and Pma. Speeding up Gg- may require slowing down
some of the downstream speedup factors to maintain overall vagal HR dynamics Figure 106. The
faster IK,ACh kinetics should also produce PRCs that are more similar to the experimental data of
Slenter et al. (296).
3. Add compartmentalization of cAMP, PKA, and PDE based on experimental data to replace the
empiric speedup factors we used. Some data are available (see references in section 6.7), and it
seems that more will become available in the near future as experimental methods improve and
the scientific community gains a greater appreciation for the importance of compartmentalization
in cell function. Initial modeling attempts will have to be rudimentary due to the computational
complexity they would otherwise introduce; a reasonable first attempt would be to introduce local
volumes (based on experimental data) specific to G-proteins, cAMP, PDE, and PKA, to allow
faster kinetics similar to what we modeled with our speedup factors.
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4. Describe alternate and interacting second messenger systems that are known to exist in the
SANC, like cGMP, PKC, and NO.
5. Obtain more data to better describe and test our model representation of: a) the direct pathway of
ACh-induced inhibition of adrenergic activity, b) IfShift phenomena due to cAMP and PKA, c) the
parameters for which we did not have explicit data and instead fit to HR data (gKr, Rap, pag)
Despite the above limitations, we showed that our model reproduces some high-level phenomena, and
there are many other studies for which the model could be used. For example, it would be interesting to
study the mechanisms responsible for the AP refractory period and its dependence on cycle length as
experimentally measured by Mendez et al. (238); to evaluate the appropriateness of modeling the SAN as
an integrate-and-fire model (integral pulse frequency modulation/IPFM) with regard to incoming
sympathetic and parasympathetic impulses (59, 63, 246); to study in more detail the contribution of
individual second messengers and membrane currents on AP shape and SANC beating rate; or to evaluate
the effect of sympathetic and parasympathetic stimulation rates and individual spike statistics on the
variability in heart rate. As an extension of the last point, our model could also be used to generate a
synthetic data set with explicit sympathetic and parasympathetic inputs for the systematic evaluation and
comparison of the numerous HRV estimation methods, all of which aim to solve the inverse problem of
deducing ANS tone from an observation of HR or other physiological signals (a number of HRV methods
that could be studied in this way are described in (1)). Also along the lines of ANS tone estimation, the
forward model that we describe here can be used to systematically design an optimal (in some well-
defined mathematical sense) algorithm for the inference problem of estimating sympathetic and
parasympathetic rates from an observation of heart beat times.
One way to approach this goal of designing an estimation algorithm is to first reduce the model to a
collection of functions that describe steady-state values and the time constants for approaching those
values. These functions could eliminate many "unnecessary" components of the system; for example, all
the neurotransmitter reuptake, diffusion, and hydrolysis functions, and the explicit P-adrenergic and M2-
muscarinic binding reactions could be replaced by a two steady-state functions (that express steady-state
fraction of each bound receptor as a function of sympathetic or parasympathetic nerve stimulation
frequency) and two time constant functions (to express the lag between nerve stimulation and receptor
activation; it may be necessary to use more than one time constant since the approaches to steady-state
were not single-exponential). These functions could be obtained in a straightforward manner by running
the full model with various inputs, and fitting functions of necessary complexity to the generated data.
Once the system is reduced to a smaller number of equations and a consistent equation format
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(essentially, the differential equation for each variable v would look like dv/dt-(vss(u)-v)/rv(u), with v
being the particular variable, vss(u) being the steady state function as a function of upstream variables u,
and r,(u) being the time constant function), it should be easier to define the relationship between the
inputs (sympathetic and parasympathetic stimulation frequency) and the resulting heart rates. Certain
components of the system could even be removed at this point, if their time constants are fast relative to
those of the other variables. This reduced and simplified form may have a well-defined estimation
approach already defined (I am not familiar with any specific algorithms, but it seems reasonable that a
few may exist to solve the inverse problem for a cascaded system of steady-state functions and lags), or a
specific algorithm can be derived for this purpose.
In developing this model, we encountered many interesting experimental data which it would be
interesting to reproduce. We reproduced many of them (see Figure 105); below, we list others that should
be reproduced to either verify the correct functioning of the model ("test data") or to provide improved
estimates of certain model parameters ("training data"):
1. Acetylcholinesterase function in a quiescent cell (Fig. 10 in (192))
2. Adenylate cyclase activation by Iso, can be converted to NE by shifting an order of magnitude to
the right (Fig 2 in (41))
3. Phosphodiesterase and G-protein effects on If, (various figures in (92))
4. Phosphokinase A inhibition (Fig 2 in (341))
5. To estimate baseline parasympathetic rate in rabbits, reproduce the observation that in rabbits,
atropoine (which can be modeled by setting parasympathetic stimulation rate to 0) caused a
39.6% increase in HR (193)
6. cAMP dynamics and effect on rabbit heart rate, and simultaneous acetylcholine and
norepinephrine effects on heart rate (various figures in (317-320))
7. cGMP dynamics (cGMP is not included in the present model; if it is added, these data could be
used to formulate its behavior: (318, 319))
8. Desensitization to acetylcholine (the current model does not include desensitization to
acetylcholine, data in Fig 2 in (154) could be used to formulate it)
9. cAMP effect on heart rate (Fig 1 in (363))
10. Sympathetic stimulation and NE effect on heart rate (Fig 2 in (328))
11. Time course of ACh and NE effects on heart rate and AP shape (Fig 2-4 and 6-7 in (352))
12. Dynamics of sympathetic stimulation on HR in guinea pig (Fig 4 in (64))
205

9 APPENDIX
9.1 Temperature correction
We aim to reproduce SANC activity in-vivo, at a temperature of 37 'C. However, many of the available
experimental data were collected at other temperatures, most commonly room temperature (20-25 'C). To
compensate measured kinetic values (time constants and rates) for temperature effects, the concept of a
Qio is frequently used ((reference)-Qio used: (368)-1.7, (76)-3, (212)-1.7, (198)-1.7, (69)-2.3):
r2= r.1( .0) 1o
Where r1 is the measured rate at temperature T1, and r2 is the rate corrected to temperature T2. In essence,
the rate is Qio times faster for each 10 'C increase in temperature. A wide range of Qio values have been
measured for various systems, ranging from ~1.2 for diffusion of small molecules (196) to 2.3 for
movement of sodium channel activation gates (69), and values as high as 3 have been assumed by
modelers for certain ion channels (76). For the present model, we use an intermediate Qio of 1.7 as used
in a number of other models (198, 212, 368) unless a specific Qio value for the reaction of interest is
reported in an experimental paper.
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9.2 Unit conversions
We gathered experimental data from a large number of studies. This section provides the numerical
details on how units were converted to allow comparison across these disparate sources. Table 19
contains the conversion factors we used; when computing concentrations of intracellular molecules, the
volume of the cytosol was used (not whole cell volume, which includes the nucleus and other organelles).
Table 19. Conversion factors for translating experimental results to SANC-specific values
Value
169.18
146.21
6x1023
1
3.5 x 10-12
1.6 x 10-12
1760
52.5
13,000
Units
g /mol NE
g /mol ACh
molecules/mol
g /mL wet tissue
L wet tissue/SANC
L cytosol/SANC
ptm 2/SANC
mg protein/g wet tissue
ACh molecules/s/AChE
Source (if anolicable)
(186, 357)
Volume of cell calculated using
cell dimensions
Cytosol occupies 46% of cell
volume (82)
Surface area of cell calculated
using cell dimensions
*
AChE catalytic rate constant, see
section 2.3.4
* The "total protein" in certain experiments refers to mostly membrane protein, after cells have been homogenized
and sarcoplasmic, nuclear, and contractile protein has been removed (39, 123). We estimate the membrane protein
content of cardiac cells to be 2x10-7 mg/cell. This figure was obtained from a measurement of protein fractions in
mouse ventricular muscle by Medugorac (237). This study reports 52.5 mg stromal protein per 1 g wet weight of
myocardium (237). For comparison, a study on human cardiac patients without ventricular dysfunction reported 11-
16 mg protein/gram wet weight (115), and a study by Delforge et al. quotes 10% protein per tissue weight (100 mg
protein/g wet weight) as a standard value (80). On this range from 11-100 mg protein/gram wet weight, we choose
the intermediate value of 52.5 mg protein/g wet weight.
The values in the above table are used to convert units using standard dimensional analysis; for example
to convert ptg NE/g wet tissue to molecules of NE/SANC:
pg NE 1xI 10-6 g mol NE g wet tissue x mL wet tissue 103 molecules NE
xgts Xp x 3.518 x 10 ts p 1.S x6xm
g wet tissue P9g 169.1 8g NE mL wet tissue SANC mol NE
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9.3 Summary ofprevious neurotransmitter diffusion models
In this section, we summarize each previous model pointing out their unique assumptions and differences
from our model. In the figures used to summarize each model, [ACh]ms is the "main store" of
neurotransmitter (the varicosity), [ACh]ceii is the concentration at the cell membrane, and [ACh]ex is the
concentration in the extrajunctional space.
Among the earliest models is that developed by Warner and Cox (349) to explain changes in canine HR in
response to vagal and sympathetic stimulation.
[ACh]ms
i|L
| .................[Ahe, [ACh]
[ACh]celi [Ch]
Figure 115 Warner 1962 model (349).
This model features vagus nerves containing a number of vesicles which are released into the
neuroeffector junction at a rate proportional to the frequency of vagus nerve spiking or external
stimulation (349)). ACh is diluted in the volume of the neuroeffector junction and hydrolyzed by AChE
(349). The neuronal store of vesicles is replenished through a diffusion-like process from a constant
vesicle store (349), a feature that we also included in our model. As shown above, the model does not
explicitly define diffusion through the neuroeffector junction, and instead considers the nerve end and cell
end of the junction as a single compartment. The model also does not include washout from the
neuroeffector junction, so hydrolysis is the only method for removing ACh. This model can accurately
reproduce changes in HR that result from step inputs; however, model parameters were chosen in order to
fit every recording independently and not all are reported in the paper (349). This implies that the model
is rich enough to explain a particular phenomenon, but not a general class of phenomena across multiple
experiments, which in turn implies that it may be an oversimplification.
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In 1971, Chess and Calaresu (61) published a model of HR changes in response to left and right vagus
stimulation.
no
FR jw K1 XR Ft I>ye
1 JWT2  LXRFIG. 2. Block diagram of frequency response model
L FL KeW7Td of vagus-heart period system. FL and FR are variations
in rate of left and right vagal stimulation, Xi, and Xn
are interaction terms, and HP is variation in heart
period. For bilateral stimulation, parallel first-order
HP systems for left and right vagi are mutually connected
by rate-sensitive elements whose outputs (XL and
K1RejwTd X) are routed to contralateral paths. For unilateral
+ Tstimulation of either vagus, both XL and Xn are zero
and model reduces to a simple first-order system.
Figure 116. Model of Chess and Calaresu 1971, figure taken from (61). See original caption for abbreviations.
The model contains transfer functions from vagus stimulation frequency to change in HR, but does not
explicitly model the ACh concentration (61). It is mentioned here for completeness and to emphasize the
fact that the dynamics of HR in response to ACh are better modeled as a third order system. This implies
that models with simple ACh removal dynamics (such as the Warner model) cannot account for HR
changes observed experimentally (see page 25 in (96) for discussion).
In 1977, Purves published a collection of equations describing the diffusion of molecules away from a
point source as a function of time and distance (276). For ACh in particular, several equations are given,
which include passive diffusion as well as hydrolysis by AChE (276). Despite being an idealization that
does not fit the physical description of the neuroeffector junction (the diffusion model assumes a point
source diffusing through an infinite, homogeneous space), the Purves model has been used by Osterrieder
et al. (265), Pott (274), and Demir (81). Interestingly, all of these groups used equation 38 from Purves,
which assumes that hydrolysis occurs in the medium (276):
M2
C = 8( n )M . exp -k t - 4 t
As Loffelholz and Pappano point out however, only cell membrane-bound AChEs participate in
hydrolysis (219). Purves 1977 also provides a solution for this case (Equation 40 in (276)), however it is
more complicated and involves computing the error function compliment at each time or distance point:
xp(-x|4D) kex kx+ k' 2  x
M (nDt)* D D 2 erfc 0t+ kh DS
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The Osterrieder et al. and Pott models were used to reproduce membrane voltage hyperpolarizations of
rabbit (Osterrieder) and guinea pig (Pott) SA node cells in response to pipette-administered ACh, so the
models do not include replenishment of the main ACh store (265, 274). As shown in the diagram below,
these two models feature a diffusion distance of 30-100 microns, which may have accurately described
the distance between the ACh pipette tip and the cells, but is orders of magnitude larger than
neuroeffector junction widths measured with electron microscopy, which are less than 0.1 pim (65, 219).
[ACh]ms
[ACh]
30-100 pm
|.................[ACh]ce [Ch]
................... .................
Figure 117 Osterrieder 1981 and Pott 1983 models
In his 1989 paper, Celler used an ACh release and hydrolysis model similar to that of Warner, which
included release of a fraction of the sequestered ACh with each vagal stimulus pulse, and hydrolysis of
the free ACh in the neuroeffector junction (56). As with the Warner model, diffusion and washout were
not considered. The major difference between these two models however, is that the Celler model made
explicit that the total amount of ACh was constant (hydrolyzed ACh replenished the sequestered store)
rather than being withdrawn from a limitless pool as in the Warner model (56, 349). We incorporated this
feature in our model as well; however, we did not limit the model to the local ACh supply only, and also
included the Warner-like term for ACh synthesis from the blood stream.
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[ACh]ms
[ACh]
........... ................
[ACh]ce [Ch]
Figure 118 Celler 1989 model (56).
Also in 1989, Dexter et al. analyzed a detailed model of ACh hydrolysis by AChE, washout, and binding
to receptors to conclude that ACh concentration would decay with a single exponential time course,
where the time constant is a function of all three ACh removal processes (86).
[ACh]ms
[ACh]ex [ACh]
[ACh]R [ACh]cei [Ch]
Figure 119 Dexter 1989 model (86).
Dokos developed a fairly comprehensive ACh model, for the first time introducing an explicit
extrajunctional third compartment (96). The rationale behind their model description and comparisons
with previous models is thoroughly described in the paper; to summarize, the three compartment model
was chosen in order to reproduce 1) the observed fast and slow components of HR recovery after vagal
stimulation and 2) the differing effects produced by the timing of vagal stimulation relative to the
beginning of the heart period (96). The model contains three compartments: the main ACh store [ACh]ms,
ACh released into the neuroeffector junction [ACh], and ACh in the extrajunctional space [ACh]ex. Each
vagal stimulus instantaneously releases a fraction of ACh from the main store, with a fraction being
released into the neuroeffector junction and EJS simultaneously. The ACh in the neuroeffector junction is
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hydrolyzed with a rate 14/s and is reabsorbed and synthesized into ACh in the main store. ACh diffuses
between the neuroeffector junction and EJS with rate 0.5/s. Finally, ACh from the extrajunctional space
"escapes" unhydrolized and returns to the main store with rate 0.5/s. This is the most thorough
compartmental model, capturing the three important processes (synthesis, diffusion, hydrolysis). Similar
to our model, it shares the undesirable (but in our opinion, physiologic) feature of discontinuous jumps in
concentration with each stimulus (release and diffusion from the varicosity to the cell is assumed to be
instantaneous).
[ACh]ms
|.................[ACh]ex [ACh]
[ACh],eJIJ [Ch]
Figure 120. Dokos 1996 model (96).
The most recent SANC model with explicit ACh dynamics was published by Demir (81). This model
used the Purves equation for diffusion within the neuroeffector junction and hydrolysis, but it also
modeled depletion of ACh from the nerve varicosity such that after the first three releases (which release
a constant amount of ACh), the amount of ACh released per stimulus decays exponentially (81). While
some amount of depletion may occur, this model does not include any mechanisms for ACh
synthesis/replenishment, so once all the ACh stores are depleted (which happens after about 10 releases),
further vagal stimulation has no effect on ACh concentration in the neuroeffector junction. This is a
serious drawback of this model, which makes it inappropriate for the type of prolonged vagal stimulations
that occur in-vivo. This model is similar to those of Osterrieder and Pott, however Demir uses a much
more physiological neuroeffector junction distance of 75nm. The diffusivity constant Demir assumes
however, is 5 orders of magnitude smaller than those used by Osterrieder and Pott, who used the more
reasonable value of 8 x 10-6 cm2/s.
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[ACh]ms
[ACh]
1I 175 nm
|.................[A~ceIE[Ch]
Figure 121. Demir 1999 model (81)
Table 20. A list of parameters assumed or measured in previous studies.
Hydrolysis Synthesis (/s)
(/s)
Warner 1962 (349)
Osterrieder
(264)
1980
Osterrieder 1981
(265)
Nilsson 1970 (252),
Trautwein 1963 (331)
Lindmar 1982 (214)
Pott 1983 (274)
Celler 1989 (56)
Dexter 1989 (86)
Celler 1991 (57)
Dokos 1996 (96)
Demir 1999 (81)
* experimentally measured
0.87*
D (cm2/s) Distance to cell
(nm)
Peak ACh after
1 pulse (mM)
2.75
2.5
8 x 10-6 30,000-100,000
<60
0.2773*
1
0.57*
0.2567*
0.2260*
14
50
8 x 106
0.5 EJS-+ms
14 NJ-+ms
0
100,000
4x10-4
2x10-35.1469x 10-
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9.4 Diffusion within the SANC
The second messengers in our model are either synthesized at the cell membrane (cAMP generation by
AC) or are tethered to the membrane by anchoring proteins prior to release (catalytic subunit of PKA, G-
protein a subunits). Thus, we explored the rate of diffusion from submembrane space (defined as a space
0.02 ptm immediately inside the cell membrane (198)) into the general cytosol. Molecular Monte-Carlo
simulations of a cell cross section Figure 122 illustrate that unhindered diffusion within the cell is very
rapid over a large range of assumed diffusivities. We initially modeled all second messengers as being
instantly diffused within the entire SANC vo-lume; however, G-proteins, cAMP, and PKA appear to be
localized to cell compartments by the action of PDEs or membrane anchoring proteins. Subcellular
localization is expected to result in faster rates of change compared to a system where the second
messengers instantly fill the entire cell volume. To model this feature, we included speed-up factors for
G-proteins, cAMP, and PKA, whose values were set in order to reproduce HR time courses in response to
vagus and sympathetic nerve stimulation in an isolated rabbit heart preparation (see section 6.7).
t = 0 mns t= 10 ms Subspace Concentration
E 0.8
:4 0.6 =10~
0.4
21) ?D=10~-5 -2 2
0.2 D=10~7
0 0
-4 -2 0 2 4 -4 -2 0 2 4 0 0.5 1
Distance (gm) Distance (gm) Time (ms)
Figure 122 Monte-Carlo simulation of unhindered diffusion from cell membrane. The panels on the left illustrate the
initial condition (all molecules in submembrane space) and the location of the molecules at 10 ms for the
intermediate diffusivity of 10-6 cm2/s. The right panel shows the normalized number of molecules within the
submembrane space as a function of time for the three diffusivities indicated on the figure (in cm2/s).
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9.5 Model specification
9.5.1 State variables
Table 21. Model state variables and initial values suitable for 0 Hz sympathetic and parasympathetic stimulation.
Order Variable Initial value Units Description
1 Nv,ACh 6075 number Number of ACh-filled vesicles
2 [ACh]JNJ 1.404E-07 mM ACh concentration in neuroeffector junction
3 [A ChM] NJ 4.646E-05 mM M2 muscarinic receptors bound to ACh in the NJ
4 [A Ch]EJS 1 .640E-07 mM ACh concentration in extrajunctional space
5 [AChM]EJS 2.278E-06 mM M2 muscarinic receptors bound to ACh in the EJS
6 [ACh]ECM 8.575E-07 mM ACh concentration in the extracellular matrix
7 X 3.625E-07 mM Activated M2 muscarinic receptor concentration in
cytosol
8 NNE 675 number Number of NE-filled vesicles
9 [NEINJ 3.097E-08 mM NE concentration in neuroeffector junction
10 [NEpB]NAJ .284E-05 mM p-adrenergic receptors bound to NE in the NJ
I1 [NE]EJS 3.018E-07 mM NE concentration in extrajunctional space
12 [NEp3]EJS 5.234E-07 mM p-adrenergic receptors bound to NE in the EJS
13 [NE]ECM 9.616E-07 mM NE concentration in the extracellular matrix
14 [Gsaly GDP] 1.824E-03 mM Un-dissociated Gs bound to GDP (concentration in
cytosol)
15 [Gsapy GTP] 7.264E-05 mM Un-dissociated Gs bound to GTP (concentration in
cytosol)
16 [Gsa GTP] 3.394E-05 mM Dissociated Gsa subunit bound to GTP (concentrationin cytosol)
17 [Gra, GDP] 9.53 1 E-03 mM Un-dissociated G1 bound to GDP (concentration in
cytosol)
18 [Grapy GTP] 3.466E-04 mM Un-dissociated G1 bound to GTP (concentration in
cytosol)
19 [Gr, GTP] 4.072E-05 mM Dissociated Gia subunit bound to GTP (concentrationin cytosol)
20 [cAMP] 3.105E-03 mM cAMP concentration in cytosol
21 C 3.831E-04 mM Activated PKA catalytic subunit concentration in
cytosol
22 If;ShiftP -9.812 mV Shift in If activation gate due to phosphorylation
23 RgCaL 1.006 scalar Relative change in Ca> L-type channel conductance
24 Rpup 1.012 scalar Relative change in SERCA pumping rate P,
25 RgKr Iscalar Relative change in rapidly activating delayed rectifierK+ channel conductance
26 pasf 1.084 scalar Speedup factor for IKr activation gate Pa
27 Ca, 2.644E-04 mM Ca2+ concentration in cytosol
28 Casub 1.581E-04 mM Ca> concentration in submembrane space
29 CajSR 0.102 mM Ca2 concentration in junctional SR
30 CanSR 0.9886 mM Ca2+ concentration in network SR
Fractional occupancy of the troponin Ca2 site by
31 frc 0.0506 1 fraction Ca2 in cytosol
fraction Fractional occupancy of the troponin Mg> site by32 CTMC 0.5687 a in cytosol
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fTM
fcMi
fCMs
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Fractional occupancy of the troponin Mg2> site by0.3809 fraction Mg2 in cytosol
0.100 fration Fractional occupancy of calmodulin by Ca>2 in0.1008 fractioncytosol
0.0627 fration Fractional occupancy of calmodulin by Ca>2 in06267 fractionsubmembrane space
0.106 fration Fractional occupancy of calsequestrin by Ca>2 in0.1063 fractionSR
0.5981 fraction Ryanodine receptor (RyR) reactivated (closed) state
.758E-07 fraction RyR open state
.853E-07 fraction RyR inactivated state
0.4019 fraction RyR RI state (described in (294, 304))
-60.92 mV Transmembrane voltage
.0003702 fraction ICaL activation gate
0.6014 fraction IC,,L voltage-dependent inactivation gate
0.6126 fraction ICaL Ca>-dependent inactivation gate
0.3349 fraction 'Kr fast activation gate
0.5871 fraction 'Kr slow activation gate
0.8687 fraction 'Kr inactivation gate
0.04394 fraction IK, activation gate
0.065 fraction If activation gate
.003112 fraction 'CTactivation gate
0.2976 fraction 'CaTinactivation gate
0.5671 fraction I,, inactivation gate
.004759 fraction ,, and , activation gate
0.3186 fraction It activation gate
0.4066 fraction J, inactivation gate
00002503 /ms 'KAChactivation rate
0.00145 fraction FAch activation gate (function of)
fcQ
R
0
I
RI
V,
dL
fL
fca
PaF
Pas
n
y
dT
fT
q
r
qa
qi
agate
2
1
0
0
0.
9.5.2 Model equations
ACh release, clearance, and activation of M2 muscarinic receptors. In these equations, Is,,n is the
impulse (Dirac delta function) corresponding to each stimulus.
M2* =([AChM]NJ VNJACh + [AChM]EJS VEJS ) yto
khNJ = VmaNJ,AChE
NJ,A Ch ([A Ch]NJ +Kapp, AChE
kS = .VmaEJSAChE
VEs([A Ch] EJS + KaPpAChE
konM,NJ NJACh], / KMM) nk
kOnM,EJS EJSACh]Ej / KMM) nko
khNJ [ACh]NJ VNJACh6 X 105
QACh
N MACh -Nv, ACh +
+ +
TACh
khEJs [ACh]EJS VEJS6 x 105
QEJS ACh
Nv,rACh ]- arACh'tin
d [ACh]N QA NvA/ kr
dt 6 NJ 5ACh va,ACh Nvar,ACh sfim + kdNJ, ACh [ACh] EJS + koff [AChML]Ndt 6X 1 O'NJ,ACh [va,,ACh
-(kdNJACh + khNJ )[ACh]NJ 
-konM,NJ tM ]NJ - [AChM]NJ
d[AChM]Nj
dt NJ onM,NJ ([t ]NJ - [AChM]NJ kof AhMN
d[ACh]Ej
dt
kdNJ Ch [ACh] NJ kdEJS[A ECM +k[ M
EJS NJ,ACh
dNJ ACh + kdEJS + hEJS [ AChEJS konM,EJS
\EJS NJ,ACh
( t EJS -[AChM]EJS)
d[AChM]EJS 
= konM,EJS ([ M,|EJS 
-[AChM]EJS k0  [A ChM]EJS
d[ACh]C - dJk kdJ )Ahdtl ECM _ dES [ACh]EJS + kdECM [ACh]BS - dECM dEJS ECMdt VECM /VEJS VECM / EJS J
dX M2* -X
dt rx
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dNv,ACh 
_
dt
NE release, clearance, and activation of p-AR
(=[NE ]NJ NJNE + [ NEQ ]EJS VEJS yto x - max XnM nM'*
NJ,NE ([ NE ]NJ + KDn
kN VmaxNJa
a NJ ,NE ([NE ]NJ + KDa
kEJS VmaxEJS,a
VEJS( [ NE]EJS + KD)
kon,JNJ = ([NE]NJ / KMP )"" kf
konpEJS =([NE]EJS / Ki "" kff8
dNv,NE NvMax,NE -Nv,NE +n [ NE r NJ NJ,E 5N rx10
+ ~Nvar, NE Istimdt rNE QNE [Nvar,NE
d[NE]NJ QNE NvNEkr 1+
dt N 6xJ 6 Vx 0 N N var,NE stim kdNJ,NE[NE ] EJS +kOff [NEQ]NJNNE Nvar,NE
-(kdNJNE+ k + kaNJ )[NE]NJoflNJ t NJ -[NEQ]NJ)
d [NEQ|]N E8 )- o ,dtNNJ konfNIJ ([t ]NJ -[ NE INJ ) [ NE I]NJ
d[NE]EJS kdNJ, NE NE NJ + kdEJS [ NEECM + k NEq] EJSdt VEJS / VNJNE
kdNJ NE +kdEJS +kEJS [NE]EJS 
-konflEJS(fl]EJS [NE3 ] EJS
VEJS NJ,NE
d[ NE S ]EJ  k JS ([t ]EJS 
- [NEQ ]EJS ) - kofffl [NEQ8]EJS
d[ NEECM kdEJS [NE|EJS + dECM [ NE Bs kdEJS + dECM [NE]ECM
ECM EJS \ECM EJS
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G-Protein activation, modulation of AC, and cAMP generation
Instantaneous relationships
vPD PE ,ax nPDE nPDE + KjDDEVPDE =VPDEm..[CAMP]PD/ ([cAMP]D + M )
6 *(] IGSa,6rGDP] [GSap8yGDP]
Rma=( /ivDPK +(fr [-8*])max pio
' (G sapGDP]+]KGS [GSairGDP]+KGSO
=[M2*]v . G [GIafyGDP]
'mM (GGDP]+ KGI
[GsaGDP] [Gs T - [Gsa,, GDP] - [GsarGTP] - [GsaGTP]
[GaGDP] [GI ]T - [GIa6 GDP] - [Gaor GTP] - [G,, GTP]
[y], = [ G,,GTP] + [G,,GDP]
[ly8] = [GSaGTP] + [GsaGDP] + [)6y],
kaSD= kSax f
[PY] + KM,aSD
k kaID,maxID + e 
_([Pr] K,'aD )saID
k - kaS [6][y] + KMaST
k s r = k s ,m ax [ p y ] ) 7 + M s[fl~y] ± K MdST
AC= ACT [GaGTP]SAC
[GsaGTP]" + K7s 1i + [ GGTP|"'A
JAC
AC- = ACT [GIaGTP]AC
[G,,GTP]AC + K,j I + [GSaGTP]"^"
SAC
AC = ACT - AC* - AC-
VACTotal =v AC. [AC*] + VAC [AC] + VAC [AC-]
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Differential equations
d(GsaprGDP]
dt = G (kaSD [Gsa GDP] + kat, Sb (Gsair GTP] - ksb (GsaprGDP] - Rf6)
darTP= Gf ( ksb (GsaprGDP] + kasr [GsaGTP) 
-(kca,'sb + kdST )(Gsap6yGTP])
d[Gs aGTP]
dat = Gs (kdST [Gsapr GTP] + k, [GsGDP] + R,- (kcat,sf + kaST)[GSaGTP])
d (GiGDP] = Gsf (kaID [GiaGDP] + kai [G,,,,GTP] 
-k, [G,,,,GDP]- RM
d [GIayGTP]
dt Gs,' (kb[GafiYGDP] + kIT [GjaGTP] - ( kcat~i + kdlT )LGafiYGTP])
dtG ] Gs (kdT [ Ga,,,GTP] + k,, [ G, GDP] + RM -(kaa,I + kair)[ GGTP])
d[cAMP] AM1~J (VACTotal VPDE
dt
The py equations above ignore the subunits that may be involved in the hypothesized intermediate states,
for simplicity. Otherwise, the py concentration is the solution to the following implicit form that arises
because of the hypothesized Gss(p)(py)GTP state shown in Figure 52. The implicit equation and solution
are:
[Gs ] +[G]T-[GsapryGDP]- 1+ (Gsa] GTP)
[A Iy = [J671 + KM,dsr
-( G,,,,GDP] - LGiaj, GTP]
X = [Gs ]T + [G, ]T - [Gsapr GDP] - [Gsay GTP] - [GayGDP] - Gaa,,GTP]
a=1, b=KM,dST -X+[GsapiGTP], c=-KM,dSTX
-b+-b 2 -4ac
2a
[GsaGDP] and [GiaGDP] are not expressed as differential equations but rather reflect conservation of G-
protein. These functions were chosen to ensure that numerical errors do not lead to drift in the abundance
of Gs and G1.
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cAMP-mediated If shift If shifec
If,ShiftC = s., [cAMP]"f / ([cAMP"f + Ko",f
PKA
Cns Cn2S
I fa,ShiftP,SS a0S S nl s + K is + a2S C "" + K2S
C"'c Cnsc
RgCaLSS =a +a c n c +a c 2C
gaS OC 1C (nic + K, 2 C C + 2bC K Cn~ + K2 C
C"np Cn2P
= P 1 P nip + Kn1"' + a 2 P + K2Pc CK2P ± K2 P
C" nKC"n2K
RgKr,SS = aOK ±alK n + KK C2K n2K + KCnI KkK Cn2K +
1p 2 p 3p
dCx
dC, (2R2 -C) [cAMP]-xCdt Ka
dShfP i SS - If,ShiftP )/P
dRgCaL (R RgCaL )P
Ri gCaL,SS Rga,-
dR
A Pu- ( R p, ,Ss - R g,, ) / rP
d'd par
dt =(K, p ,SS -RPa,) /r,
Integration with Maltsev SANC model
gCa,L new = RgCa,LgCa,L
f,Shift - f,ShiftC f,ShiftP
If,1/2 = If,1/2,basal f,Shift
up,new =Rp up
gKr,new =RgKrgKr
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The rest of the Maltsev and Lakatta equations are as specified in the supplement to (227). Note that the
differential equations in the original paper are /ms, whereas our equations are /s. For consistency with the
original model, we multiply all the Maltsev and Lakatta differential equations by 1000 to convert the time
to /s rather than changing each rate or time constant individually. This allows for easier comparison
against the original equations to ensure proper implementation.
L-Type Ca 2 current (ICa,L)
ICa, ,L new (Vm - ECaL )dL fL fCa
d~+ e-(,n+13.5)/6
f =1 / ( + 3)"'
adL 0.028 39(V +35)/(e (v +35)/2.5 1) - 0.0849V /(e - 4.8 -)
pdL 0.01 143(V 5) /(e (V 5)12.5
TdL =1/ (adL +f#dL)
r, = 257.le- ((v +32.s)13.9)2 +44.3
fe,, = KC / ( Kma + Caub
TjCa ~fCs2 / aca
-dL =1000x(dL- dL )/dL
dt
dt
dfca =00x(f 
_~Dfa)fa
dt
T-type Ca 2 current (ICa,T)
ICa,T = C (C,,VmF. EcaT )dT fT
dT, =1 /(1+e "(V26.3)/6
fT, =1 / (i+ e ('" 1.7 )/5.6)
TdT I / (1.068e(v-'±26.3)/31 + 1.068e (v '+26.3)/30)
r1J. = 1 / 0.0 153e (v,,+61.7)/83.3 + 0.0 15e (V+61.7)/15.38)
d- = 1000 X(d, dJ)/TdT
dt
dfT =1000 x(fT, - fT /rT
dt
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Rapidly activating delayed rectifier K* current (IKr)
IKr n Vm n EK )(0.6paF + 0 '4 pa ) pi
pOc = 1 / (1+ e-(vr,+23.2)/10.6
p , =1 / (1+ e-(v,,,+28.6)/17.1
rpaF =0.84655354 / (0.0372e '/15.9 + 0.00096e-' /22.5)
rpas =0.84655354 /(0.0042e'/17 + 0.00015e-' '/21.6
r . =1 / (0. le- "'54.645 + 0.656e 106.157
dp a
da = paf x 1000 x (pa,o PaF "paF
dp" = p a x 1000 x Pao - Pas pas
d - 1000x(p,'-p,)IrA
Slowly activating delayed rectifier K+ current (IKs)
IKs CngKs (V EKs)n 2
an =0.014 /(1+ e- (v 40)/9)
p8, = 0.00 1/(1 + e-v '/45
n.= a,, /(a, +, )
dn=
=1000 x (n - n) / rdt
4-aminopyridine-sensitive currents (Io and I,,)
I =C, go(V-EKqr
I =Cmgsus(Vm -EK)r
q 1, / (I + e(v- +49)/13 )
= +(1±e +(v 19.3)/i5
rq =39.102 / (0.57e oO8(v- +44) + 0.065e"(V "4593) +6.06
Tr =14.40516 / (1.037e09(v-+3061) + 0.369e-o.12(Vr,+23.84))+ 2.75352
d= 1000 x(q. -q)/ rq
drdr1000 x(r, 
-r) /r,.
dt
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Hyperpolarization-activated, "funny" current
IJN, = C,O.3833gj (V,, ENa)Y 2
IK= C,,0.6167g, (V-EKy 2
If' I, + I1
Y. =1 / 1+ eOv -'f,/)'
r, 0.7166529 / (e-(v,-+386.9)/45.302 + e(V -73.08) 19.231
dy =1000 x(y, 
-y)/ r,dt - xy-~r
Sustained inward current (I,,)
I,, = C,,g, (V,, - E,, ) q,q,
q,,. =1I / (1 + e-(v'"+57)/' )
aqa =1/(0.15e-'''" +0.2e-' 700)
8qa =1/ (16ev'18 +15e"' 50)
'ca =1 / (a, + pqa )
aq =1 / (3100e""13 + 700ev /70)
qj =1/ (95e- +50e-v' '700 )+ 0.000229 / (1+ e- '"')
Tqi =6.65/ (aqi +qi)
q, =aq /(aqi +8qi)
dqa= 1000x(qa 
-qa)/rq,dt
dq 1 I000x(qi, 
-qj)/qi
Na*-dependent background current (IbNa)
Ibla = CgbNa (Vm ENa
Na*/K+ pump current (INaK)
INaK = NaK,max / +( KmKp / K 0 ) 1)(1 +( KmNap / Nai )1.3 )(1 + e-(V, ENa+120) 
30
Ca2+-dependent background current (Ibca)
IbCa =Cg8 ( - ECa,L)
225
Na*/Ca2 + exchanger current (INCX)
do = l+(Ca, /K,)(1I+ e,-"-/ET )+ (Na, / K,,,)(1+(Na / K 2 no)(1+ Na /K 3 no
k43 =Na, / (K3 ,0 + Na,)
k4 = e- Q"'" ( 2 Er
k34 =Nao / (K3 n + Na0 )
k2 =( CaO / K,, ) eQ,"' / ET d
k23 (Na / K1,0 ) Na / K2no)(1 + Na / K300 e-Q"V/(2ET) / d
k 3 =e '''"(2Er )
x, = k34k4l (k 23 + k2 ) +k 2Ik32 (k43 + k4 )
d, =1+(Cab / K, )(1 + e-Qiv/ ET + Na, / KC0,) + (Na / K 10 )(I +(Na / K 2 ni )(1+ Na, / K3
k = (Casub / K, )e- QV1FT / Er
k,4 =(Na / Klni)(Na, I K 20 )(1-+ Na, / K3nje"V /(2Er I d
E2= k43k32 (kl4 + k 2 )+k 4 k2 (k34 +k 32 )
X =k 43k14 (k 23 +k 2I ) +k 12k23 (k43 +k4l )
X4=k 34k23 (kl4 +k 2 )+k 21k 4 (k34 +k32 )
IN = CmkNCX (k2 X2 -1c 12 X)/(x1  2 +X3  4INCX +nNXx G1 2  3 4 )
Acetylcholine-activated K+ current (IK,ACh)
IK,ACh =CnagategKACh,mzax m(- EK
#8= 0.001 x 12.32 x aI[ACh )iK-ch * different from Maltsev equation
([3y8], )"LKACh + KI'YJCh
Q,=Q,,' IK[Q ],"IAh
/ /([/Jr]1 )no~Ch * different from Maltsev equation
= -* * different from Maltsev equation
dt 8,
a 0.00 1x 17e 133(V +40)
agte,,,, = /(a+)
r*a gate =1/ (a + /3)
dagate aga,, - agate
dt rgate
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Ca2+ release flux (jSRCarel) from SR via RyRs
ISRCarel s O( Ca -jCSsub
kCaSR =MaxSR - (MaxSR - MinSR) / (I + (EC50 _SR / CajSR )HSR
koSRCa koCa /CSR
kiSRCa kiCa kCaSR
dR ximRkS Ca2 , R -komO))
=_ 1000 x{kiRI-kSRCa JsbR)-(koSRCa sub
d 1000 x ((koSRCa sub R - koO) - (kiSRCa subO - kimI))
d= 1000 x ((kiSRCa Casub0 kI )-(kO, 
- koSRCa C2ubRJ))
dRI
d = 1000 x ((ko, I - koSRCa subRI) - (k.RJ - kiSRCaCasubR))
dt'
Ca2+ diffusion flux (iCadif)
'Ca di f Casub -Ca, 1 daiCa
The rate of Ca2+ uptake (ja) by pumping into the SR
jup = fp,new /(1+ K, /Ca,)
Ca2+ flux between network and junctional SR compartments (jir)
jr = (CanSR - CajSR) Tr
Ca2+ buffering
d =000 x (kjTCCa, (1 - fTC) - kbTCfTC)
dftC =1000 x ( kITCCa, (1 - fTmC - fTM ) - kbTMCfTMC)
dtM = 1000 x (kfTMMMg, (1 - fTmC - fTMM) - kbTMMfTMM)
dfCm 1000 x ( kCmCai (1 - fC) 
- kbcMfcM,)
d'
d = 1000 x (kCmCasub 
- fCMs -kbCM fCMS)
d 1000 x ( kcQCaJSR (I - fcQ) kbCQ fCQ
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Dynamics of Ca concentrations in cell compartments. The derivatives that appear in these equations
are divided by 1000 to convert back to original Maltsev units of /ms, and the whole expression is then
scaled back to /s)
= 1000 x (Ca du dfi 1000 + TC, dfTc /1000 + TMC fTC /1000
dt - fsubJupnSRViK dt dt dt
d a = 100 0 O jSRCareI jSR ub CaL CaT bCa 21NCX (/ su{ b 2 - ( Ca _dsi + C Mdi C /1000
dCaS dfK C
=0jSR = t- ]SRCarel ot CQ 1000
dt dt
dCa0 ~=O~~
dtnSR i 1000 X up tr VjSR / VnSR
Transmembrane voltage (Vm)
dV/
=- 1000 X ( ICa,L + Ca,T f st Kr Ks to sus NaK NCX bCa bNa K,ACh Cndt
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9.5.3 Parameter values and descriptions
Table 22. Model parameters
Parameter
[A Ch]BS
[GI] T
[Gs]T
[M]EJS
[M]NJ
[NE]BS
[pt]EJS
[#,8]NJ
aoc
aoK
aop
ao,
aos
aic
alK
alp
alp
ais
asc
a2K
as,
asp
a2s
as,
ACT
aIIKACh
cAMPg1
Cs'
Gg
0.9 unitless
0.00000186
0.000288
0.0002
0.000172
0.0003
mM
mM
mM
mM
mM
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IM*,max
Kic
KIK
Kip
Kip
Kis
Value
3 E-6
0.01
2 E-3
4.4 E-4
0.010
3 E-6
2 E-4
0.024
-7.59
0.8
0.319
0.05
-15.7
8.56
0.167
0.72
0.5476
5.78
0.75
0.79
2.83
0.776
28.25
3.4
6.25 E-6
1.47
10
100
20
Units
mM
mM
mM
mM
mM
mM
mM
mM
unitless
unitless
unitless
unitless
unitless
unitless
unitless
unitless
unitless
unitless
unitless
unitless
unitless
unitless
unitless
unitless
mM
unitless
unitless
unitless
unitless
Description
ACh concentration in the blood stream
Total concentration of GI in cytosol
Total concentration of Gs in cytosol
Total M2 muscarinic receptor concentration in the EJS
Total M2 muscarinic receptor concentration in the cholinergic
NJ
NE concentration in the blood stream
Total P-adrenergic receptor concentration in the EJS
Total j-adrenergic receptor concentration in the NJ
Offset for RgcaL function
Offset for RgKr function
Offset for Rpp function
Offset for pay, function
Offset for If ShiftP function
Amplitude 1 for RgcaL function
Amplitude 1 for RgKr function
Amplitude 1 for Rpp function
Amplitude 1 for pag function
Amplitude 1 for ]ShiftP function
Amplitude 2 for RgCaL function
Amplitude 2 for RgKr function
Amplitude 2 for Rpp function
Amplitude 2 for pag function
Amplitude 2 for If ShiftP function
Amplitude 3 for pag function
Total concentration of AC in cytosol
Amplitude scale for maximum P rate
Factor by which the cAMP reactions are accelerated
Factor by which the activation of C is accelerated
Factor by which the G-protein reactions are accelerated
Maximum inhibition of p-adrenergic activity by direct
pathway (X)
Michaelis-Menten coefficient 1 for RgCaL function
Michaelis-Menten coefficient 1 for RgKr function
Michaelis-Menten-coefficient 1 for Rppu function
Michaelis-Menten coefficient 1 for pay function
Michaelis-Menten coefficient 1 for fshifiP function
K2C 0.000657 mM Michaelis-Menten coefficient 2 for RgCaL function
K2K 0.000573 mM Michaelis-Menten coefficient 2 for RgKr function
K2P 0.0006 mM Michaelis-Menten coefficient 2 for Rpp function
K2, 0.000379 mM Michaelis-Menten-coefficient 2 for pay function
K2s 0.001 mM Michaelis-Menten coefficient 2 for IfshifP function
Ks, 0.000578 mM Michaelis-Menten coefficient 3 forpag function
Ka 0.005 mM cAMP concentration that causes half-maximal activation ofPKA
kaIDmax 0.367 /sec Maximum rate of association for GjiGDP with py
kalT 0 /see Maximum rate of association for GiaGTP with py
Kapp,AChE 0.10 mM Apparent Michaelis-Menten coefficient for AChE
kaSD,max 0.0617 /sec Maximum rate of association for GsaGDP with Py
kaSTmax 3.33 E-4 /sec Maximum rate of association for GsQGTP with py
kcatIb 0.167 /sec GTPase rate constant of G1apy
kcat,g 0.167 /sec GTPase rate of free Gic
kcatrSb 0.167 /sec GTPase rate constant of Gsapy
kcat, s 0.167 /sec GTPase rate constant of free Gsa
Kd,IKACh 0.001097 mM Dissociation constant for pyr and IKACh
KDa 0.252 mM Michaelis-Menten coefficient for cellular absorption of NE
kdECM 0.4 /S Rate constant for diffusion between the ECM and blood
stream
kdEJS 20 /s Rate constant for diffusion between the EJS and ECM
kdIT 0.0167 /sec Maximum rate constant of dissociation for GiapyGTP intoGiQGTP and Py
KDn 0.00027 mM Michaelis-Menten coefficient for neuronal reuptake of NE
kdNJACh 7800 / Rate constant for diffusion between the cholinergic NJ andEJS
kdNJNE 8800 S Rate constant for diffusion between the adrenergic NJ andEJS
kdSTmax 3.83 E-3 /sec Maximum rate of dissociation for GspyGTP into GsaGTP and
py
KGI 0.03 mM Michaelis-Menten coefficient for liganded M2 muscarinic
receptor and GiaOyGDP
KGS 6 E-3 mM Michaelis-Menten coefficient for liganded P-adrenergic
receptor and GsapyGDP
KGSO 0.026 mM Michaelis-Menten coefficient for unliganded beta adrenergic
receptor and GsapyGDP
KIAC 2.14 E-4 mM Dissociation constant for GiUGTP and AC
kb 6.67 E-3 /sec GDP dissociation rate constant for Gicpy
kg 1.67 E-3 /sec GDP dissociation rate constant for free Gia
Km* 2 E-5 mM Michaelis-Menten coefficient for direct inhibition of p-
adrenergic activity by direct pathway (X)
KMaID 2.76 E-4 mM Michaelis-Menten coefficient for association of GiaGDP with
fry
KmaSD 3 B-5 mM Michaelis-Menten coefficient for association of GscGDP with
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PrY
KMaST 1 E-4 mM Michaelis-Menten coefficient for association of GsaGTP with
mM Michaelis-Menten coefficient for binding of GsapyGTP with
another Py (slows down dissociation rate)
KMPDE 0.00695 mM Michaelis-Menten coefficient for hydrolysis of cAMP byPDE
Kmm 0.0003 mM Michaelis-Menten coefficient for M2 muscarinic receptor andACh
Kmp 0.0015 mM Michaelis-Menten coefficient for P-adrenergic receptor andNE
kofjy 2100 /S Dissociation rate constant for ACh bound to M2 muscarinic
receptor
k0.15 Dissociation rate constant for NE bound to p-adrenergic
receptors
kr 0.01 unitless Fraction of available vesicles that are released per stimulus
KSAC 4.59 E-5 mM Dissociation constant for GsaGTP and AC
ksb 6.67 E-3 /sec GDP dissociation rate constant for Gsap7
ks 0.0267 /sec GDP dissociation rate for free Gsa
niC 1.57 unitless Hill coefficient 1 for RgcaL function
nIK 9.64 unitless Hill coefficient 1 for RgKr function
nip 3.67 unitless Hill coefficient 1 for Rppu function
ni, 5.11 unitless Hill coefficient 1 for pay. function
nis 10.27 unitless Hill coefficient 1 for IShiftP function
n2C 5.437 unitless Hill coefficient 2 for RgcaL function
n2K 7.06 unitless Hill coefficient 2 for RgKr function
np 9.86 unitless Hill coefficient 2 for Rp, function
n2, 16.57 unitless Hill coefficient 2 for paj function
n2S 4.1 unitless Hill coefficient 2 for IShiftP function
ns, 9.294 unitless Hill coefficient 3 forpag function
nAC 1.74 Hill coefficient for GiaGTP and AC
nIKA Ch 3 unitless Hill coefficient for py3 and IK,A Ch
nm 0.7 unitless Hill Coefficient for M2 muscarinic receptor and ACh
Hill coefficient for direct inhibition of p-adrenergic activity
flM. 16 unitless by direct pathway (X)
nPDE 0.9 unitless Hill coefficient for cAMP hydrolysis by PDE
nsAC 1 Hill coefficient for GsaGTP and AC
Nvar,ACh 13.5 unitless Number of cholinergic varicosities per cell
Nvar,NE 4.5 number Number of adrenergic varicosities per cell
NvMax,ACh 6075 number Maximum number of ACh-containing vesicles in all
cholinergic varicosities
Maximum number of NE-containing vesicles in all adrenergic
NvMax,NE 675 number vrcstevaricosities
n13 0.7 unitless Hill Coefficient for P-adrenergic receptor and NE
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QA Ch 5000 molecules Number of ACh molecules in a cholinergic vesicle
QNE 20000 molecules Number of NE molecules in an adrenergic vesicle
Total concentration of R2 subunit concentration
R27 0.0005 mM (equivalently, one half of maximal C concentration)
slope factor for logistic function for association of GJQGDP
sa/D 4 B-5 mM with py
UEJS 0.5 unitless Fraction of Ch hydrolyzed in EJS that is restored to varicosity
VAC 1 /sec Baseline rate of cAMP production by AC
Rate constant of cAMP production for inhibited (GiaGTP-
vaC- 0.5 /sec bound) AC
Rate constant of cAMP production for activated (GsaGTP-
vaC* 100 /sec bound) AC
VYa 1600 fL Volume of cytosol inside sinoatrial node cell
VECM 2800 fL Volume of ECM
VEJS 173 fL Volume of EJS
Maximum activation velocity of GI by liganded M2
Vmax,M 10 /sec muscarinic receptor
Maximum activation velocity of Gs by liganded p-adrenergic
vmaxfp 10 /sec receptor
Maximum activation velocity of Gs by unliganded beta
vmax,flO 1.54 /sec adrenergic receptor
VmaxEJS,a 115.566 amol/s Maximum velocity of cellular absorption of NE from the EJS
VmaxEJSAChE 1014 amol/s Maximum AChE velocity in the EJS
Vmax, 18.7 amol/s Maximum velocity of neuronal reuptake of NE per cell
Maximum velocity of cellular absorption of NE from the NJ
vmaxNJ,a 0.374 amol/s (all varicosities together)
VmaxNJ,AChE 525 amol/s Maximum AChE velocity in the NJ (all varicosities together)
VNJACh 4 fL Total volume of cholinergic NJ
VMINE 0.9 fL Total volume of adrenergic NJ
VPDE,max 0.0008 mM/sec Maximum cAMP hydrolysis rate constant by PDE
x 0.00333 /sec Rate of PKA catalytic+regulatory subunit reassociation
Pr 3.57 E-5 mM Total p-adrenergic receptor concentration in the cytosol
p-a 6 E-9 ms mM 3  Scale for P time constant
TACh 5 s Time constant for ACh synthesis in cholinergic nerves
TNE 30 s Time constant for synthesis of NE in sympathetic nerves
P I sec Time constant for phosphorylation by C
TX 3 s Time constant by which X lags M2*
Maltsev model parameters:
Ca, 2 mM Extracellular Ca2+ concentration
K, 5.4 mM Extracellular K+ concentration
Na0  140 mM Extracellular Na* concentration
Na, 10 mM Intracellular Na+ concentration
Mg, 2.5 mM Intracellular Mg2+ concentration
Cm 32 pF Cell membrane electric capacitance
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jSR
Vi
VnSR
ET
F
ENa
EK
EKs
ECa,L
Eca, T
Es,
gCa,L
gca, T
gg
V;1/2,basal
gs,
gKr
gKs
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0.0351
0.0042
1.58
0.04
26.72655
96485
70.5329
-87.0014
-49.4464
45
45
37.4
0.58
0.1832
0.15
-64
0.003
0.08113973
0.0259
0.252
0.02
2.88
187.5
0.0006
0.00486
0.043
0.00035
1.4
14
0.021
11
0.85
2.11 E-4
395.3
2.289
26.44
1628
561.4
gsus
INaK,max
kNCX
gbca
gbNa
gK Ch,max
Kmjca
KmKp
KmNap
arca
Smax
1Y/
Ko5,f
K3n
Kino
K2no
pL Volume of submembrane space
pL Volume of junctional SR (Ca2+ release store)
pL Volume of the cytosol excluding submembrane space
pL Volume of network SR (Ca2+ uptake store)
mV (RT/F) factor in calculating Nernst potentials
C/mol Faraday constant
mV Equilibrium potential for Na'
mV Equilibrium potential for K+
mV Reversal potential for IKs
mV Apparent reversal potential Of ICa,L
mV Apparent reversal potential Of ICa,T
mV Apparent reversal potential of Is,
nS/pF Maximum L-type Ca2+ current conductance
nS/pF Maximum T-type Ca2+ current conductance
nS/pF Maximum "funny" current conductance
mV Baseline half-activation voltage for Ij.
nS/pF Maximum sustained non-selective current conductance
nS/pF Maximum conductance of rapid delayed rectifier K' current
nS/pF Maximum conductance of slow delayed rectifier K' current
nS/pF Maximum conductance of 4-aminopyridine sensitive transientKt current
nS/pF Maximum conductance of 4-aminopyridine sensitive
sustained K' current
pA/pF Maximum Na/K t pump current
pA/pF Maximum Na±/Ca 2+ exchanger current
nS/pF Maximum conductance of background Ca 2+ current
nS/pF Maximum conductance of background Nat current
nS/pF Maximum conductance of acetylcholine-activated K' current
mM Dissociation constant of Ca 2+-dependent ICaL inactivation
mM Extracellular K' concentration for half-maximal INaK
mM Intracellular Nat concentration for half-maximal INaK
/ms Ca 2+ dissociation rate constant for ICa,L
mV Maximal shift in If activation gate due to cAMP
unitless Hill coefficient for cAMP-dependent shift in I activation gate
mM cAMP concentration needed for half-maximal shift in If
activation gate
mM Intracellular Na' dissociation constant for first site on NCX
mM Intracellular Na+ dissociation constant for second site onNCX
mM Intracellular Nat dissociation constant for third site on NCX
mM Extracellular Na+ dissociation constant for first site on NCX
mM Extracellular Na' dissociation constant for second site onNCX
K3170
Kc;
Kco
K -
Qcn
QcO
Q,
rdifCa
mMIVI
0.0065 mM/ms
10 /mM 2/ms
0.06 /ms
0.5 /mM/ms
0.005 /ms
0.45 mM
250000 /ms
15 unitless
1 unitless
2.5 unitless
0.542 /ms
0.445 /ms
0.446 /ms
0.00751 /ms
0.751 /ms
227.7 /mM/ms
0.534 /mM/ms
88.8 /mM/ms
227.7 /mM/ms
2.277 /mM/ms
0.031 mM
0.062 mM
10 mM
0.045 mM
SR
Rate constant for Ca2+ uptake by the Ca2+ pump in the
network SR
RyR parameter
RyR parameter
RyR parameter
RyR parameter
RyR parameter
RyR parameter
RyR parameter
RyR parameter
RyR parameter
Ca> dissociation constant for calmodulin
Ca> dissociation constant for calsequestrin
Ca> dissociation constant for the troponin-Ca2 site
Ca2 dissociation constant for the troponin-Mg2+ site
Mg2+ dissociation constant for the troponin-Mg> site
Ca> association constant for calmodulin
Ca> association constant for calsequestrin
Ca2 association constant for troponin
Ca 2+ association constant for the troponin-Mg2 site
Mg association constant for the troponin-Mg> site
Total concentration of the troponin-Ca2 site
Total concentration of the troponin-Mg2 site
Total calsequestrin concentration
Total calmodulin concentration
Table 23. Low-level model parameters that are used to calculate some higher-level parameters in table Table 22.
Parameter Value Units Description
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4.663
0.0207
3.663
26.44
0.1369
0
0.4315
mM Extracellular Na' dissociation constant for third site on NCX
mM Intracellular Ca 2+ dissociation constant for NCX
mM Extracellular Ca2' dissociation constant for NCX
Intracellular dissociation constant for simultaneous Nat and
mM Ca2+ binding to NCX
unitless Intracellular Ca2 occlusion reaction of NCX
unitless Extracellular Ca2+ occlusion reaction of NCX
unitless Na* occlusion reactions of NCX
Time constant of Ca2+ diffusion from the submembrane space
mS to cytosol
Time constant for Ca> transfer from the network to
ms junctional SR
Half-maximal intracellular Cai for Ca2+ uptake in the network
0.04
6 E-4
P UP
koca
komn
kica
kim
EC 5 saR
k,
MaxSR
MinSR
HSR
kbCM
kbc
kb TMC
kbTMM
kfCAM
k/cuQ
kfcg
CITC
kffMM
TMCIO,
CQo,
CM10,
LCeII 70 Im Length of sinoatrial node cell
dCeI 8 pim Diameter of sinoatrial node cell
majorDChol 1.38 pim Major diameter of cholinergic varicosities
minorDchoi 0.48 pm Minor diameter of cholinergic varicosities
majorDAdr 1.26 pm Major diameter of adrenergic varicosities
minorDAdr 0.38 gm Minor diameter of adrenergic varicosities
Height of cholinergic NJ (distance from cell surface to
HNJ,ACh 0.195 pim bottom of varicosity)
166 gim Height of adrenergic NJ (distance from cell surface to bottom
HNJ,NE 0. pof varicosity)
NVesicles,ACh 450 number Number of ACh-containing vesicles per varicosity
NVesicles,NE 150 number Number of NE-containing vesicles per varicosity
HEJS 0.1 gM Height of EJS (distance from cell membrane to ECM)
Height of ECM (distance from edge of EJS to blood stream
compartment)
NCels 8 number Number of cells in a cross-section of sinoatrial node
DNJ 0.000007 cm 2/s ACh and NE diffusivity in the NJ
DEjS 0.000007 cm 2/s ACh and NE diffusivity in the EJS
DECM 0.0000008 cm 2/s ACh and NE diffusivity in the ECM
235
9.6 Basic chemical reactions
Our model explicitly describes chemical reactions between various molecules. Because the model is fairly
low-level, the equations that describe these reactions are fairly simple. In this section, we cover three
elementary reactions which form the basis for almost all of the functions that appear in the body of this
thesis. The elementary reactions are: 1) simple binding, 2) enzyme kinetics, and 3) cooperative binding.
9.6.1 Steady-state binding reaction
Given the reaction
R+L RL (15)
And the total amounts of receptor and ligand R+RL=RT, L+RL=LT, what is the steady state concentration
of RL?
We can rewrite equation (15) using Rr and LT
(RT -RL) + (LT -RL) aRL (16)
At steady state, the rate of creation of RL and its rate of destruction is equal:
a(RT - RL)(LT-RL)=bRL (17)
Solving equation (17) with a straightforward application of the quadratic formula gives:
RL =I R,+Lr +-- RT +Lr +- -4RTLT2 a a
R + L1  + 
4 R L (18)
2 aTTb )2
±Rr + Lr +-j
If LT>> RT or RT >> LT, the second term in the square root becomes small, so we can use the first term of
the Taylor expansion for the square root around 1 to obtain:
RT + LT + b 4R LRL a T T
2 RT+LT2+
2 +RTLT
RTL b
Rr + Lr +-b
a
If LT>> RT, we obtain the standard equation:
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LT
RL i Rr b
a
If, on the other hand, RT >> LT, we obtain:
RL LT RT b
a
If RT and LT are on the same order: Rr~z L7-X, and b/a is small, the expression under the radical in
equation (18) approaches 0, so we get:
Rr +LT
2
If b/a is large, we get:
RL ; 0
And if b/az RT LT = X, we get:
RL 3 RT +LT +-
6 a
+L + b
a
8
9.6.2 Enzyme Kinetics
Given a typical enzyme reaction:
E+S ,"ES > E+P (19)
7'b
Where E is the enzyme, S is the substrate, ES is the enzyme-substrate complex, P is the product of the
catalytic reaction. For a fixed concentration of enzyme ET= E + ES, equation (19) can be written as
(ET- ES + S a ' ES " > (-ET ES)+ P
The differential equations are:
dES
d =a(ET -ES)S -(b+c)ESdt
dS
_=-a(E -ES)S+bES (20)
dt
dP
= cES
dt
If S is maintained at a constant level, or if it is abundant relative to the time course of the
binding/unbinding reaction, we can easily solve for the steady-state concentration of ES by solving the
dESfirst equation with = 0:
dt
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0=a(ET-ES)S-(b+c)ES
ES = aETS
aS + b +c
S
ET S + Kpp
The last equation is in the familiar Michaelis-Menten form, where Ka,, b + c
a
(21)
is the apparent
dissociation constant. From (21), it follows that the steady-state rate of P generation, or velocity (v) is:
dP
v =-
dt
cE S
S+ Kpp
If the product is itself an enzyme and reverts back to the substrate and some byproduct B with some rate
constant d:
E+ S N " 'ES c >E+p d >S+Bb (22)
If we assume that the amount of substrate and product is a constant S+ P = SPT, and similarly for the total
amount of enzyme as before E + Es = ET equation (22) becomes:
(ET -ES)+(SP -P) " 'ES > E+p d TP)+B
Which gives the following differential equations:
dES
d = a(E - ES)(SP -P)-(b+c)ESdt
dP
= cES - dP
dt
dB
= dP
dt
Setting the derivatives of ES and P equal to 0 and solving gives:
P = -ES
d
ES =
(23)
(24)
(25)
dSP +cEr +d - dSP +cET +d 2 -4dSPcET
a a )
In deriving the above, we used the quadratic equation, which has a ± preceding the radical; we chose the
minus because when SPT = 0, we expect the concentration of ES to be 0.
Equation (25) lets us calculate the overall rate of production of B:
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dB
= dP =cES
dt
=- dSPT+cEr+ d bc- dSP cET+ d b+c 2 4dSPcET2 a a
9.6.3 Cooperative Binding
When one molecule can bind two ligands, the opportunity for cooperative binding exists. The simplest
case is shown below, where the molecule of interest (X) has two binding sites for ligand (Y). When no
ligand is bound, the affinity is KD, and when one ligand is bound, the affinity is increased by a factor f
(KD/f). The two binding sites are assumed to be identical.
XOO +Y XYO+YY
KD XOY + Y KD</
Figure 123 Reaction diagram for binding of 2 ligands (Y) to a molecule X with two binding sites (0). The empty
binding sites are shown as 0 in order to differentiate the two intermediate states. The dissociation constant is KD
when no ligand is bound, and changes to KD/f after one ligand has bound.
The above diagram can be reduced to the following form by grouping the intermediate states:
2Ya/Kp, Yaf/Kp,A N a B ' a c
Figure 124 Simplified form of the diagram in Figure 123. The states are named A, B, and C for simplicity, where B
is the sum of the two intermediate states. This simplification causes the rate constants entering state B to double. The
arbitrary dissociation rate a was introduced to allow writing of differential equations; it is assumed not to change
when the affinity changes. The association rate is expressed in terms of a and KD to ensure that the dissociation
constant is KD-
If the total amount of molecule X is T, then A+B+C=T. We can also write the differential equations for A
and B:
dA
-- 2Ya / KD A+aB
dt
dBB-(a+Yaf KD)B+2YaKDA+2aC
dt
Solving the two differential equations at steady state, and using the equation for T, we can solve for A, B,
and C at steady state:
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A=T 1 2
1+2-+ f
KD KD
2
B=T KD 2(26)
1+2 -+f
KD KD
C=T KD 2
1+2-+ f(
KD KD
The functions forf= 1 are shown in
Steady state occupancy, f=1
T
.4-- A
B
C
(D T/2
E
0
1/100 1/10 1 10 100
Y amount (relative to KD)
Figure 125 Steady state occupancy of each state in Figure 124.
For cooperative binding, the amount of bound ligand (relative to the total possible amount) is expressed
using the Hill equation with an apparent dissociation constant Kapp and a Hill coefficient n:
bound nY (27)Y" + K
app
Using equations (26) and normalizing by 2T since that's the total possible amount of Y that can be bound,
we obtain:
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1
Ybound (B + 2C)2T
Y +f Y ) (28)
KD KD
Y (Y )1+2 +f
KD KD
Note that if-1, equation (28) reduces to Y/(Y+KD), which is exactly the Hill equation with coefficient
n=1, and Kapp=KD. This makes sense since a Hill coefficient of 1 implies independent binding, which is
exactly the condition off=l. To convert equation (28) into a form like equation (27) for any value off, we
can first calculate the apparent dissociation constant (ie. value of Y that gives Ybo0 Fn=1/ 2 ):
K app ap [
KD D KKI 2 > K KD (29)
1+2 +fapp 
KD KD
We can use the slope of the Ybound function at Y=Kapp to calculate n. The slope of Ybound at Y=Kapp is
dYbound (30)
dY YK 4Kapp
Therefore, taking the derivative of equation (28) with respect to Y, evaluating at Y=Kapp, and multiplying
by 4Ka,,, we obtain:
dY 1 2 + 2j K D(
n =4Kp 
-4' -> n = (31)dY Y=K app KD (2+2 ±2j7
Interestingly for the cooperative binding of two molecules as in this model, the asymptotic value of n as
fl-oo is 2.
To verify that equations (29) and (31) are correct, we plot the Ybound ratio using equation (28) as well as
equation (27) using Kap, and n as defined in (29) and (31) forf-O.1,frl, andf-10. As we can see, the
calculations are correct at the intended point (around Ybound=0.5), but deviate away from that point,
especially forf<1 (negatively cooperative binding).
241
Ybound
1
E
0
/.51 1 1 1
0
.0
Y amount (relative to KD)
Figure 126. Plots of Ybou.d for three values of f (indicated next to each curve). The solid lines show the actual amount
of Y bound using equation (28), and the dashed lines are the Hill equation approximations using equations (29) and
(31) to calculate Kapp and n.
To conclude, the Hill equation is pretty good for positively cooperative binding, but for negatively
cooperative binding, it may be better to just use equation (28) and fit thef and KD parameters to data. The
advantage of the Hill equation is a cleaner form however, and the parameters Kapp and n can just as easily
be fit to data.
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